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Outstanding steps forward were made in the last decades in terms of identification of 
endogenous pacemakers and the exploration of their controllability. New “artifical” 
devices were developed and are now able to do much more than solely pacemaking of 
the heart. In this book different aspects of pacemaker - functions and interactions, in 
various organ systems were examined. In addition, various areas of application and the 
potential side effects and complications of the devices were discussed.
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Pacemakers play an important role in our body homeostasis. The identification of 
endogenous pacemakers and the exploration of their controllability lead to a 
remarkable progress in human medicine. On cellular basis proliferation and 
orientation are regulated, and contraction and organ interactions were modulated by 
pacemaking cells. Dysfunctions lead to acute and chronic organ damage and can be 
life-threatening.  In this respect, overactive as well as underactive pacemaking can 
bring a person in a very dangerous situation. 
In the last decades, “artificial” pacemakers made outstanding steps forward, in 
particular in cardiovascular science. The devices are now able to do much more than 
solely pacemaking of the heart. Sensing, pacing, resynchronization, overstimulation 
and defibrillation are just some of the functions that actual devices can cover.  And not 
only is the heart dependant on pacemaking cells; the urinary tract, the central nervous 
system and the blood pressure is controlled to a certain extent by endogenous 
pacemakers.  
However, one has to be careful to find the correct indication before device 
implantation. In addition, complications such as infections need to be minimised. It 
should be noted that some diagnostic or therapeutic procedures cannot be performed 
when a person carries an electrical device. Taken together, a correctly functioning 
device can improve the quality of life substantially.  
New devices, beside cardiac pacemakers, are currently under investigation. In order to 
treat arterial hypertension various strategies were developed. Besides renal nerve 
ablation, baroreceptor stimulation is one approach to reduce the sympathetic nerve 
activity. Similar to a cardiac pacemaker, an electrical device stimulates the glomus 
caroticus to feed back to the central nervous system in order to re-adjust the elevated 




In this book, through eleven chapters different aspects of pacemakers –functions and 
interactions were reviewed. In addition, various areas of application and the potential 
side effects and complications of the devices were discussed. 
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Novel Approaches in Hypertension Treatment - 
Modulation of the Sympathetic Overactivity 
Sebastian A. Potthoff, Lars-Christian Rump and Oliver Vonend 
Department of Internal Medicine / Nephrology, Medical Faculty,  
Heinrich-Heine-University Duesseldorf,  
Germany 
1. Introduction 
Arterial hypertension is the leading cause of mortality in the world [1]. It is estimated that 25 
to 35 % of modern populations suffer from this condition [2-4]. Hypertension is the major 
risk factor for the most common cardio vascular diseases which are a major cause for 
morbidity and mortality. Depending on the stage of hypertension, it dramatically increases 
the individual risk for heart failure, heart attack, stroke or chronic kidney failure if not 
treated adequately [5]. Since hypertension is usually not directly linked to specific 
symptoms, it is one of the most insufficiently treated diseases in the population with only 
10-20 % of patients with controlled blood pressure levels [4]. It is estimated that the 
prevalence of hypertension is going to increase within the next decades. Aging populations 
contribute significantly to this trend [6]. Due to its impact on public health, it already is a 
major burden for modern societies [7].  
New strategies and treatment options have to be evaluated in order to slow or prevent the 
rise in hypertension related morbidity and mortality. This chapter focuses on the role of the 
sympathetic nervous system in the pathogenesis of hypertension. After almost half a decade 
with only minor advancements in this field, sympathetic overactivity has been recognized as 
a major contributor to hypertension [8]. Many secondary causes can increase sympathetic 
activity which can lead to hypertension. Beyond the initial contribution, sympathetic 
overactivity can sustain hypertension. Therefore the sympathetic nervous system plays a 
role in the acute and chronic pathogenesis of hypertension. Understanding the mechanisms 
involved in the regulation of the sympathetic nervous system is currently leading to novel 
approaches in hypertension treatment.  
2. Anatomy of the sympathetic nervous system 
2.1 Efferent sympathetic neurons 
Sympathetic innervation origins from the intermediolateral cell column of the spinal cord. 
Preganglionic neurons range from the thoracic to the lumbar parts (T1-L2). These short 
neurons usually travel to the paravertebral ganglia where they connect to the postganglionic 
neurons. Those postganglionic neurons sympathetically innervate most organs such as 
heart, kidney and blood vessels (Fig. 1). Sympathetic nerve endings release a variety of 
neurotransmitters notably norepinephrine, neuropeptide Y (NPY) and adenosine 
triphosphate (ATP) [9, 10]. 
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Sympathetic overactivity is a major contributor to arterial hypertension which is one of the 




Fig. 1. Schematic of sensory, afferent and sympathetic efferent neurons and target organ 
innervation.   
One of the distinct features of the sympathetic nervous system is the immediate regulation 
of peripheral vascular resistance through adaptation of the vascular tone. Besides this 
immediate action on blood pressure control through vasoconstriction, release of sympathetic 
neurotransmitters contribute to adaptive mechanisms through regulation of cell 
proliferation, transformation and apoptosis which are blood pressure independent [11-14].   
2.2 Afferent sympathetic nerve activity 
Besides the efferent innervation, sensory afferent neurons travel from target organs to the 
sympathetic nuclei of the central nervous system (CNS). These afferent nerves have been 
extensively described for the kidney but can also be found in the heart [15]. The pathogenesis 
of this sympathetic activation was elucidated in several animal models [16]. Afferent nerves 
are activated by baro- or chemoreceptors in ischemia or inflammation [17]. They travel along 
the renal artery and insert the posterior horn of the spinal cord at the level of TH6-L3 from 
where they travel to the sympathetic nuclei of the CNS (Fig.1). Neurotransmitters of these 
afferent neurons are ATP, substance P and calcitonin-gene related peptide (CGRP)[18].  
The renin-angiotensin-aldosterone system (RAAS) contributes to the central nervous 
feedback in sympathetic activation. Especially angiotensin II and nitric oxide (NO) are 
important effectors of this system [19]. Inhibition of the RAAS leads to a decrease in efferent 
sympathetic activity in chronic kidney disease patients [18]. Not all inhibitors of the RAAS 
can penetrate through the blood-brain barrier, therefore peripheral actions of angiotensin II 
are likely to affect afferent signal transduction.  
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Renal ischemia leads to a release of adenosine as a paracrine transmitter. This leads to a 
potent activation of afferent neurons [17]. Interestingly, in an animal model, already minor 
kidney injury through local injection of phenol leads to a permanent neurogenic 
hypertension [20]. Severing afferent and efferent sympathetic nerve fibers prevents 
hypertension in an animal model of chronic kidney injury [21]. Independent from CNS-
effects, chronic kidney injury leads to an increase of presynaptic norepinephrine release in 
the heart and kidney. This might be due to an increase in angiotensin II through RAAS 
activation [22-24]. However, it is still unclear which renal mechanisms contribute to a 
sustained activation of renal afferent neurons. 
3. Detection of increased neuronal activity 
3.1 Microneurography 
Microneurography has been established at the university of Uppsala (Sweden) by Karl-
Erik Habbarth und Åke Vallbo [25]. The sympathetic nerve activity can be measured by 
insertion of a micro electrode into a peripheral nerve (mostly peroneal nerve) [26].  
 
 
Fig. 2. Multiunit activity sympathetic nerve activity (MSNA) of the sural nerve.  Kidney 
transplant patients show an increased sympathetic nerve activity despite normal serum 
creatinine levels. Only nephrectomy of the native kidneys is able to normalize the activity 
compared to healthy controls (modified from [28] ). 
 
Aspects of Pacemakers – Functions and Interactions in Cardiac and Non-Cardiac Indications 
 
4 
Sympathetic overactivity is a major contributor to arterial hypertension which is one of the 




Fig. 1. Schematic of sensory, afferent and sympathetic efferent neurons and target organ 
innervation.   
One of the distinct features of the sympathetic nervous system is the immediate regulation 
of peripheral vascular resistance through adaptation of the vascular tone. Besides this 
immediate action on blood pressure control through vasoconstriction, release of sympathetic 
neurotransmitters contribute to adaptive mechanisms through regulation of cell 
proliferation, transformation and apoptosis which are blood pressure independent [11-14].   
2.2 Afferent sympathetic nerve activity 
Besides the efferent innervation, sensory afferent neurons travel from target organs to the 
sympathetic nuclei of the central nervous system (CNS). These afferent nerves have been 
extensively described for the kidney but can also be found in the heart [15]. The pathogenesis 
of this sympathetic activation was elucidated in several animal models [16]. Afferent nerves 
are activated by baro- or chemoreceptors in ischemia or inflammation [17]. They travel along 
the renal artery and insert the posterior horn of the spinal cord at the level of TH6-L3 from 
where they travel to the sympathetic nuclei of the CNS (Fig.1). Neurotransmitters of these 
afferent neurons are ATP, substance P and calcitonin-gene related peptide (CGRP)[18].  
The renin-angiotensin-aldosterone system (RAAS) contributes to the central nervous 
feedback in sympathetic activation. Especially angiotensin II and nitric oxide (NO) are 
important effectors of this system [19]. Inhibition of the RAAS leads to a decrease in efferent 
sympathetic activity in chronic kidney disease patients [18]. Not all inhibitors of the RAAS 
can penetrate through the blood-brain barrier, therefore peripheral actions of angiotensin II 
are likely to affect afferent signal transduction.  
 
Novel Approaches in Hypertension Treatment - Modulation of the Sympathetic Overactivity 
 
5 
Renal ischemia leads to a release of adenosine as a paracrine transmitter. This leads to a 
potent activation of afferent neurons [17]. Interestingly, in an animal model, already minor 
kidney injury through local injection of phenol leads to a permanent neurogenic 
hypertension [20]. Severing afferent and efferent sympathetic nerve fibers prevents 
hypertension in an animal model of chronic kidney injury [21]. Independent from CNS-
effects, chronic kidney injury leads to an increase of presynaptic norepinephrine release in 
the heart and kidney. This might be due to an increase in angiotensin II through RAAS 
activation [22-24]. However, it is still unclear which renal mechanisms contribute to a 
sustained activation of renal afferent neurons. 
3. Detection of increased neuronal activity 
3.1 Microneurography 
Microneurography has been established at the university of Uppsala (Sweden) by Karl-
Erik Habbarth und Åke Vallbo [25]. The sympathetic nerve activity can be measured by 
insertion of a micro electrode into a peripheral nerve (mostly peroneal nerve) [26].  
 
 
Fig. 2. Multiunit activity sympathetic nerve activity (MSNA) of the sural nerve.  Kidney 
transplant patients show an increased sympathetic nerve activity despite normal serum 
creatinine levels. Only nephrectomy of the native kidneys is able to normalize the activity 
compared to healthy controls (modified from [28] ). 
 
Aspects of Pacemakers – Functions and Interactions in Cardiac and Non-Cardiac Indications 
 
6 
Multiunit activity sympathic nerve activity (MSNA) is equivalent to the sympathetic 
activity. This activity is measured as “bursts” per minute. Using this method, the concept 
of the kidney as a pacemaker of sympathetic activity could be very well established. 
Converse et al. analyzed the sympathetic activity in dialysis patients vs. healthy controls 
[27]. Interestingly, in kidney transplant patients with normal serum levels of creatinine 
and urea, the sympathetic overactivity persisted. Only bilateral nephrectomy was able to 
abolish the pathologic sympathetic overactivity (Fig. 2) [28]. 
3.2 Norepinephrine release 
Besides microneurography, norepinephrine release can be used to estimate the activity of 
the sympathetic nervous system. This concept has been established by Murray Esler from 
Melbourne, Australia [29]. Norepinephrine can be measured in blood samples. Also local 
norepinephrine release can be quantified in tissue samples from kidney and heart.  
The heart is an important target organ of sympathetic activity. Especially patients with end 
stage renal disease show a dramatic and early increase of cardiovascular events. Zocalli et 
al. could demonstrate that norepinephrine and NPY serum levels correlate with the patient 




Fig. 3. Serum norepinephrine levels correlate well with the incidence of cardiovascular 
events in end stage renal disease patients (n = 228 patients on haemodialysis). Kaplan-Meier 
survival curves for cardiovascular events (fatal and nonfatal) in patients below and above 
75th percentile of serum norepinephrine (5.57 nmol/L) (from [30]). 
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3.3 Modulation of sympathetic activity 
The sympathetic nervous system allows for rapid adaptation of the body to current events. 
Orthostatic reaction is a well examined example of immediate activation of the sympathetic 
nervous system [32]. Besides pain, stress and urgency, changes in temperature, blood 
oxygenation and ambient sound level lead to a change in sympathetic activity [15, 32]. 
Instead of immediate alterations of sympathetic activity, it appears feasible that long-term 
change in sympathetic activity is the underlying mechanism which contributes to the 
development of hypertension. Aging people show an increase in sympathetic activity with 
an increase of MSNA of 1 burst/min per year [33]. Although female subjects are 
characterized by a lower MSNA, they exhibit a more significant annual increase [34]. It is 
likely that the increase in MSNA contributes to the development of hypertension in the 
aging population, since the prevalence of hypertension increases with age. There is a tight 
correlation between blood pressure and MSNA in subjects older than 40 which does not 
occur in younger patients (Fig. 4.) [34]. This might be due to diminished compensatory 
mechanisms in the elderly population (endothelial dysfunction, diminished baroreflex, etc.).     
Sympathetic overactivity is the pathogenic link between hear failure, sleep apnea, metabolic 




Fig. 4. Correlation between MSNA and mean arterial blood pressure in female subjects <40 
and ≥ 40 years of age. A correlation between blood pressure and MSNA cannot be found 
until the age of 40 (modified from [34]). 
3.4 Sympathic overactivity in chronic heart failure   
Chronic heart failure is associated with an increased sympathetic activity [35]. There is a 
tight correlation between severity of heart failure and MSNA. However, MSNA does not 
allow direct conclusion on the degree of heart failure. Due to different mechanisms of 
sympathetic activation, high MSNA can also be found in patients with only mild to 
moderate heart failure [36].  
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The rise in MSNA causes an increase of norepinephrine release in the myocardium. The 
increased release of norepinephrine contributes to the increased risk of arrhythmogenic 
cardiac events and left ventricular hypertrophy.  
In an animal model with genetically determined sympathetic overactivity (α2-adrenoceptor 
knockout - decreased adrenergic auto inhibition), increase of left ventricular mass and heart 
failure can be observed [37]. 
Hypernatremia is a common finding in severe chronic heart failure. This leads to an 
activation of the RAAS and sympathetic nervous system.  However, the increase in 
sympathetic activity can already be observed in mild to moderate chronic heart failure. The 
underlying cause is not well understood. This might be linked to a change in baroreflex 
sensitivity or a maladaptation of the cardiopulmonary reflex [35]. 
A left ventricular systolic dysfunction with an increase of cardiopulmonary filling pressure 
can trigger sympathetic activity. Obesity and sleep apnea add to this condition.  
Therefore, a goal in chronic heart failure has to be the inhibition of the self-sustaining pacing 
of sympathetic activity, in order to reduce the cardiovascular mortality.  
3.5 Sympathetic overactivity in sleep apnea 
Sleep related respiratory dysfunction is much more common in patients with hypertension 
compared to the common population [18]. Some authors estimate that every second patient 
with hypertension is prone to sleep related respiratory dysfunction [38]. An increase in 
blood pressure is almost always observable in sleep apnea patients. Apnea causes an 
immediate increase in sympathetic activity which is the underlying cause of the increase in 
blood pressure [39]. Chemo-receptors within the carotid body (glomus caroticum) are 
activated due to hypoxia. Those chemo-receptors can directly activate the sympathetic 
nervous system. [18]. 
In chronic sleep apnea, this activation of the sympathetic nervous system persists during 
daytime which results in increased MSNA and norepinephrine release [40]. Intermittent 
hypoxia leads to a sustained increase in blood pressure in an animal model. Denervation of the 
carotid body abolishes the blood pressure increase after hypoxia [41]. Desensitizing chemo-
receptors through respiration of 100 % oxygen leads to a decrease in sympathetic activity, 
heart rate and blood pressure in wake sleep apnea patients but not in healthy controls [42]. 
Apparently, a sustained activity of chemo receptors contributes to the stimulation of the 
sympathetic nervous system while awake which is leading to hypertension.  
Despite chemoreceptors, baroreceptors play a central role in regulation of the cardiovascular 
system. A dysfunction of baroreceptors can be observed in sleep apnea patients similar to 
chronic heart failure patients. In a canine animal model of sleep apnea, the baroreflex is 
adjusted to higher blood pressure levels [43]. Obstruction of the respiration at night leads to 
a sustained hypertension at daytime [44]. Continuous Positive Airway Pressure (CPAP) 
therapy  is able to abolish or reduce sleep apnea. Night- and day-time sympathetic 
overactivity can be significantly reduced through this therapy [40]. 
3.6 Sympathic overactivity in metabolic syndrome 
The increased sympathetic activity in metabolic syndrome patients contributes to the 
increased cardiovascular risk in this patient group [45]. In overweight patients, sympathetic 
overactivity appears to be linked to a dysfunction of the baroreflex [46]. This is also linked to 
the distribution of body fat mass. Accumulation of visceral fat is characterized by an 
increase in MSNA and cardiovascular risk [45]. 
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Compared to healthy individuals, overweight people suffer significantly more often from 
hypertension and show an increased risk for the development of type 2 diabetes. An 
increased MSNA can also be observed in patients with type II diabetes  [47].  
The underlying cause for this interacting pathogenesis is unknown. Hyperinsulinemia 
appears to play an important role. For instance, administration of insulin in an increasing 
dose was able to increase MSNA in euglycemic individuals [48]. 
3.7 Sympathic overactivity in hypertension 
Almost all studies measuring microneurographic sympathetic nerve activity in hypertensive 
patients could demonstrate the central role of sympathetic overactivity [49]. Smith et al. was 
able to show that especially in patients with observable target organ damage MSNA 
increase is more pronounced [50] (Fig. 5). 
 
 
Fig. 5. Microneurographic measurements confirm a significant increase in sympathetic nerve 
activity (MSNA) in patients with hypertension (HT) compared to healthy individuals. An 
increased MSNA can already be found in high-normal blood pressure patients (130-139/85-
89 mmHg) (modified from [50]). 
The underlying conditions of sympathetic overactivity in hypertension are often linked and 
cannot be distinguished from each other. These conditions among others include chronic 
kidney disease, heart failure, obesity and sleep apnea. However, there is evidence that 
sympathetic reactivity might be genetically determined. Children of hypertensive 
individuals show normal MSNA-levels. When subjected to mental stress these children 
show a significantly increased MSNA if compared to children of non-affected parents [51].  
Other hypertensive conditions such as preeclampsia [52] or pulmonary arterial hypertension 
[52] show an increased burst activity in microneurography. 
Today, we have a distinct understanding of the pathogenesis of hypertension induced by 
chronic kidney injury. As seen in figure 1, activation of afferent neurons in the injured 
kidney leads to an increased sympathetic activity through central nervous mechanisms. It is 
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well established that increase of serum norepinephrine levels can indicate chronic kidney 
failure [53]. However, this finding is mostly based on reduced norepinephrine clearance in 
the kidney. Recently, it has been discovered that the kidney also releases a soluble 
monoamine-oxidase (Renalse) which degrades circulating catecholamines and thereby 
might regulate blood pressure [54]. Renalase serum levels are significantly decreased in 
chronic kidney failure. If Renalase actually plays a significant role in hypertension in chronic 
kidney failure patients has not been proven yet.  
As stated above, bilateral nephrectomy is able to normalize MSNA. This can be reproduced 
in an animal model by renal denervation or selective dorsal rhizotomy [55]. Beside increased 
catecholamine levels, increased MSNA is an additional finding in renovascular hypertension 
[56]. The underlying mechanism for renovascular hypertension in renal artery stenosis is 
increased renin release which is dependent on renal innervation. Increase in blood pressure 
can be abolished in a Goldblatt-hypertension animal model (“2 kidney 1 clip”) if the affected 
kidney is denervated [57]. Interestingly, denervation of the non-affected contralateral kidney 
also abolishes hypertension in this model  [58].  
4. Therapeutic approach in sympathetic overactivity  
4.1 Pharmaceutical approach 
In patients with chronic renal failure, the degree of the disease correlates very well with the 
sympathetic activity [59]. An increase of MSNA of 10 burts/min increases the event rate by 60 
%. Concordantly, adverse cardiovascular events are also increased in these patients (Fig. 6.).  
 
 
Fig. 6. Kaplan-Meier curve for adverse cardiovascular events in dependence of MSNA above 
(≥ 36 bursts/min) and below (< 36 bursts/min) the 75th percentile (modified from [59] ).  
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RAAS blockade, through ACE-inhibitors or AT1-blockers, leads to a reduction in the efferent 
sympathetic activity [60, 61]. However, normalization of sympathetic activity can only be 
achieved if a central sympatholytic drug (moxonidine) is added to this treatment [62]. 
Moxonidine has been shown to have renoprotective properties in chronic renal failure and to 
reduce MSNA [63, 64]. This effect was independent from blood pressure reduction. In an 
animal model of chronic kidney failure, monoxidine is able to significantly improve 
histomorphologic and functional renal outcome. It is able to reduce albuminuria and the 
degree of glomerulosclerosis [65]. This might be dependent on an alteration of gene expression 
[14]. Adrenergic receptor activation (α- and β-receptors) is involved in this pathogenesis [66]. 
Therefore it appears feasible that adrenergic receptor inhibitors might be beneficial.   
In patients with resistant hypertension, the suggested blood pressure goal of below 140/90 
mmHg cannot always be achieved using oral antihypertensive medication. Therefore, there 
has been extensive research on alternative approaches for blood pressure control. Due to the 
pivotal role of sympathetic activity in the pathogenesis of hypertension, novel treatment 
strategies have focused on the alteration of sympathetic overactivity in order to control 
blood pressure and reduce overall cardiovascular risk.  
There have been two major advancements in the field of non-pharmaceutical intervention: 
baroreflex activation therapy at the caroid body and catheter-based renal denervation. Each 
of these strategies significantly reduces sympathetic activity and controls blood pressure 
beyond pharmaceutical intervention.  
4.2 Baroreflex activation therapy  
As described above, dysfunction of the baroreceptor reflex causes an increase in sympathetic 
activity in a variety of diseases such as sleep apnea and chronic heart failure. In a canine 
animal model, Lohmeier et al. could demonstrate that activation of the baroreflex at the 
carotid artery by implanted pacemaker was able to reduce blood pressure as well as serum 
catecholamine levels [67, 68]. This approach is currently in clinical evaluation for resistant 
hypertension [69].  Promising data from a clinical trial for baroreflex activation therapy has 
been published recently. In this study, baseline mean blood pressure was 179/105 mmHg 
and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months 
of device therapy, mean blood pressure was reduced by 21/12 mmHg. This result was 
sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 
33/22 mm Hg. The device exhibited a favorable safety profile [70]. 
In the Rheos Pivotal Trial, preliminary results (2010) also show similar results in blood 
pressure control [71]. In this study, subjects were enrolled if systolic blood pressure (SBP) 
was > 160 mmHg, 24-hour ambulatory SBP > 135 mmHg and they were on at least 3 
antihypertensive drugs at maximum doses including a diuretic. 2010, 45 of 55 roll-in 
subjects have reached 6 months follow-up: Prior to baroreflex activation therapy mean 
blood pressure was 178/102 mmHg and post baroreflex activation therapy mean blood 
pressure was 144/87 (p<0.001). A reduction of > 20 mmHg was achieved in 69 % and  
> 30 mmHg in 58 % of subjects. In this study, antihypertensive medication remained 
unchanged during the follow-up period.  
There are some issues of concern regarding this intervention. Previously, baroreflex 
activation therapy required bilateral carotid preparation and implantation of electrodes and 
the corresponding pacemaker aggregate. Due to the approach of bilateral activation, battery 
power of pacemakers lasts only for two years with the need of replacement after this period. 
However, advancements regarding baroreflex activation therapy are made. Recently, a 
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single side baroreflex activation device has been introduced which is currently investigated 
in clinical trials.  
4.3 Renal denervation therapy  
As stated above, renal denervation in animals leads to a reduction of MSNA and blood 
pressure. In 1923, sympathectomy was performed for the first time in order to treat 
hypertension with stenocardia [72]. In 1935, Page and Heuer at the Rockefeller institute 
published data on surgical sympathectomy on blood pressure and renal function [73].   
In 1953, a large study of 1266 cases was published on lumbal sympathectomy. However, this 
procedure was linked with severe side effects such as voiding dysfunction, intestinal 
dysfunction, impotence and orthostatic dysregulation [74]. Due to pharmaceutical 
alternatives, surgical sympathicolysis was replaced by antihypertensive drugs.  
Recently, a novel, minimal-invasive, catheter-based approach is available which selectively 
severs renal nerve fibers at the site of the renal artery [75]. This renal denervation strategy 
can significantly reduce blood pressure in resistant hypertension (Fig. 7) [76]. In a 
multicentre, prospective, randomized trial, patients who had a baseline systolic blood 
pressure of 160 mmHg or more (≥150 mmHg for patients with type 2 diabetes) and were 
treated with at least 3 antihypertensive drugs were enrolled. After a 6-month follow-up 
period after renal denervation, office-based blood pressure measurements in the renal 
denervation group reduced by 32/12 mmHg (SD 23/11, baseline of 178/96 mmHg, 
p<0.0001) without significant side effects. Patients with a glomerular filtration rate of  
< 45 ml/Min/1.73 m2 (MDRD) or renal artery abnormalities were excluded from the study.  
Due to the pathogenesis of sympathetic overactivity in chronic kidney failure, it is feasible 
that this novel approach might also be beneficial in this patient group.  
 
 
Fig. 7. Schematic of renal nerve fibres along the renal artery. Renal denervation is achieved 
by ablation using a catheter which is connected to a radiofrequency generator (picture by 
Ardian/Medtronic). 
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In a preliminary study, renal norepinephrine release was measured. There was a significant 
mean reduction of 47 %. Exemplary, MSNA was measured in a patient before and after 




Fig. 8. Exemplary blood pressure and MSNA in a patient before and after renal denervation. 
There is a significant reduction in blood pressure and burst activity (modified from [77] ). 
5. Summary 
Hypertension is the most significant health burden in modern societies. 25 to 35 % of the 
population suffers from this condition. Due to increasing age, the incidence of hypertension 
will increase in the future.  
Overactivity of the sympathetic nervous system is a striking feature of a variety of 
cardiovascular and renal diseases. There is a distinct correlation between sympathetic 
activity, stage of disease and hypertension. Almost every hypertensive subject shows 
sympathetic overactivity. It correlates well with the cardiovascular event rate (heart failure, 
myocardial infarction, and stroke).  
The kidney plays a pivotal role in the control of sympathetic nerve activity. Baro- and 
chemoreceptors which activate afferent sensory nerves travel from the kidney to the 
sympathetic nuclei of the central nervous system. This can lead to an increase in 
sympathetic activity which leads to an increase of neurotransmitter release in the target 
organs. This axis is especially pronounced in patients with chronic kidney disease. But also 
chronic heart failure, sleep apnea and obesity increase sympathetic nerve activity which can 
be measured by microneurography.  
Pharmaceutical intervention can be achieved with RAAS-blockade (Renin- or ACE-
inhibitors, or AT1-blockers) and peripheral adrenergic receptor antagonists and centrally 
acting sympatholytic drugs.  
If pharmaceutical therapy fails in achieving target blood pressure levels, novel approaches 
in hypertension treatment such as baroreflex activation or renal denervation therapy are 
promising strategies for future treatment which directly inhibit the pacing of sympathetic 
activity.  
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1. Introduction  
MicroRNAs (miRNAs) are endogenously expressed, small (approx. 22 nucleotides long) 
non-coding RNA molecules that regulate gene expression at the post-transcriptional level. 
They are encoded in almost all organisms, from viruses to humans (Soifer et al., 2007). 
Bioinformatic studies of the genomes of multiple organisms suggest that this short length 
maximizes target-gene specificity and minimizes non-specific effects. Generally, by targeting 
the 3'-untranslated region (UTR) of mRNAs in a sequence specific manner, they influence 
the translation (protein synthesis repression) or stability of the transcripts (mRNA 
degradation) (Ying et al., 2008). The role of endogenously expressed miRNA (the first 
miRNA to be discovered was lin-4) in down-regulating gene expression was first described 
by Victor Ambros and his colleagues in 1993 for C. Elegans, although the term microRNA 
was only introduced in 2001 (Lagos-Quintana et al., 2001; Lau, et al., 2001; Lee et al., 2001; 
Ruvkun, 2001). In humans, approx. 1700 mature miRNA have been cloned and sequenced 
(miRBase v17.0 database, release April 2011, http://www.mirbase.org). It is estimated that 
there could be as many as thousands of miRNAs in humans, thought to regulate approx. 30 
% of genes within the human genome (Pillai et al., 2007).  
1.1 MicroRNA biology  
MicroRNAs are genome encoded, derived from the intergenic regions, exon sequences of 
non-coding transcription units or intronic sequences of either protein coding or non-coding 
transcription units. They are encoded as a single gene or gene clusters. It has been predicted 
that miRNAs constitute more than 3 % of human genes (Pillai, 2005). Intergenic miRNAs are 
transcribed as an independent transcription unit, as a monocistronic, bicistronic or 
polycistronic primary transcript (Bartel, 2004). Intronic miRNA are usually part of introns of 
pre-mRNA, preferentially transcribed in the same orientation as the mRNA, probably not 
transcribed from their own promoters but instead processed from introns, as are many 
snoRNA. Intronic miRNAs and their host transcripts are co-regulated and co-transcribed 
from the same promoter (Kim & Kim, 2007). Within the genome, there might be more than 
one copy of particular miRNAs. The suggestion has been made that some miRNAs are also 
encoded in antisense DNA, which is not transcribed to the mRNA (Bartel, 2004).  
1.1.1 MicroRNA processing 
Regulation of miRNA expression depends on transcription factors and epigenetic 
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region. Over the course of their lifecycle, miRNAs must undergo extensive post-
transcriptional modifications. Genes encoding miRNAs are transcribed with RNA-
polymerase II or RNA-polymerase III (Pol II or Pol III) into a primary transcript, 200 
nucleotides (nt) to several kilobases (kb) long, known as a pri-miRNA. Mature miRNA 
sequences are usually localized to regions of imperfect stem-loop. The resulting pri-
miRNA (with poly-A tail and 7-methylguanosine cap) is processed by an RNase III 
enzyme called Drosha and a double-stranded RNA-binding protein, DGCR8 (DiGeorge 
syndrome critical region) in the cell nucleus, into a 70-nt stem-loop structure called a pre-
miRNA. The resulting stem-loop structure, with a monophosphate at the 5' terminus and a 
2-nt overhang with a hydroxyl group at the 3' terminus, is imported into the cytoplasm by 
a transporter protein, Exportin 5. After GTP hydrolysis, with consequent release of the 
pre-miRNA, the double-stranded RNA portion of pre-miRNA is bound and cleaved by 
Dicer (RNase III enzyme) together with co-factor TRBP (transactivating region binding 
protein). The action of these proteins removes the terminal loop and produces a 
miRNA:miRNA* duplex, which is a transient intermediate in miRNA biogenesis (20–25 
nt), with a 2-nt overhanging its 3' UTR. One of the two strands of each fragment, known 
as the guide strand (miRNA), together with proteins argonaute (Ago 1-4), helicases, 
nucleases and RNA binding proteins, is incorporated into a complex called the miRNA-
containing ribonucleoprotein complex (miRNP) or RNA-induced silencing complex 
(RISC). The resulting complex is responsible for base-pairing with complementary mRNA 
sequences. The other strand, miRNA* or passenger strand, is presumably degraded, 
although there are increasing prospects that either or both strands may be functional. It is 
believed that the guide strand is determined on the basis of the less energetically stable 5' 
end (Bartel, 2004; Pillai, 2005; Pillai et al., 2007; Ying et al., 2008). Intronic miRNAs bypass 
Drosha cleavage and rely on the action of the pre-mRNA splicing/debranching machinery 
to produce an approx. 60 nt precursor miRNA hairpin (pre-miRNA) (Kim & Kim, 2007). 
The miRNA processing is summarized in Figure 1. 
1.1.2 MicroRNAs mechanism  
The functional role of miRNA varies, depending on the organism, but the primary 
mechanism of miRNA action in mammals is to inhibit mRNA translation. The catalytic 
components of miRNP/RISC complex are Ago proteins. After base pairing between the 
miRNA and target mRNA, degradation of the target mRNA results when complementarity 
is perfect, or suppression of the translation occurs when base pairing between these two 
molecules is incomplete. Especially in animals, each miRNA can inhibit the translation of 
many different mRNAs (as many as 200 predicted target genes) without degrading the 
target mRNA. In addition, mRNA can be regulated by more than one miRNA. The 
cooperative action of multiple identical or different miRNP/RISCs appears to provide the 
most efficient translational inhibition. This explains the presence of multiple miRNA 
complementary sites in most genetically identified targets, and the cooperative action of 
miRNA:UTR interactions would provide an additional mechanism to increase the specificity 
of miRNAs. Proteins or mRNA secondary structures could restrict miRNP/RISC 
accessibility to the UTRs, or may facilitate recognition of the authentic mRNA targets 
(Bartel, 2004; Pillai, 2005; Pillai et al., 2007; Ying et al., 2008). It has been suggested that 
miRNAs may also be involved in regulation by binding to the 5' UTR of the target genes 
(Liu z. Et al, 2008). There is still the prospect that some miRNA might specify more than just 
post-transcriptional repression; some might in addition target DNA for transcriptional 
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silencing. Each of the examples (DNA methylation and silencing in plants, heterochromatin 
formation in fungi, DNA rearrangements in ciliates) suggests the existence of a nuclear 
RISC-like complex (Bartel, 2004). 
 
 
Legend: Pol II/PolIII, RNA-polymerase II and III; poly-A, poly-A tail; 7mGpppG, 7-methylguanosine 
cap; Drosha, RNase III enzyme; DGCR8, double stranded RNA-binding protein; Exportin 5,  transporter 
protein; Dicer, RNase III enzyme.   
Fig. 1. Schematic overview of the miRNA biogenesis pathway 
1.2 MicroRNA annotation in humans 
After the small isolated RNAs are annotated as miRNAs, based on expression and 
biogenesis criteria, they need to be named (Ambros et al., 2003; Berezikov et al., 2006). 
Perhaps the best examples of naming annotated miRNA in this context are those of muscle-
specific hsa-miR-133a-1, hsa-miR-133a-2 and hsa-miR-133b, and heart associated hsa-miR-199a-
3p and hsa-miR-199a-5p. The prefix hsa is designated for human miRNA (Homo sapiens), the 
term miR is designated for miRNA gene; the numbers 133 and 199 are unique identifying 
numbers that characterize the exact miRNA sequence; the letters a and b are used for 
paralogous miRNAs; numbers after the miRNA gene name, e.g., hsa-miR-133a numbers  
1 and 2, are used for one copy of genes encoded within the genome; 3p or 5p, in this case for 
hsa-miR-199a, is used when none of the miRNA duplex is degraded, or it has not yet been 
determined from which pre-miRNA arm the miRNA is degraded and from which pre-miRNA 
arm the miRNA is incorporated in the miRNP/RISC (Griffiths-Jones et al., 2008). 
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1.3 Target prediction and bioinformatics 
MicroRNAs are generally conserved in evolution, some quite broadly, others only in more 
closely related species (Bartel, 2004). Many computational methods have recently been 
developed for identifying potential miRNA targets (Ioshikes et al., 2007). Most of these 
methods search for multiple conserved regions of miRNA complementarities within 3' UTR; 
the most important parameters are therefore evolutionary conservation with regard to the 
quality and stability of base pairing. The interaction between seven consecutive nucleotides in 
the target mRNAs 3' UTR and the 2-8 nt (“seed sequence”) at the 5' miRNA end is believed to 
be important for base pairing. The majority of prediction programmes use pairing with the 
seed sequence as one of the major criteria. There are several available programs for predicting 
mRNA targets for specific miRNA or for predicting possible miRNA binding sites for specific 
mRNA, but none of these programs can be used as a means of independently validating the 
targets, and all predicted targets must be validated in vitro and in vivo (Kuhn et al., 2008). 
Further complicating target site prediction in mammals is the fact that not all 3' UTR sites with 
perfect complementarities to the miRNA seed nucleotides are functional. Moreover, mRNAs 
sites with imperfect seed complementarities can themselves be very good miRNA targets. In 
animals, there are far fewer mRNAs with near perfect complementarities to miRNAs. 
Bioinformatic analysis is therefore much noisier and more prone to false positives (Barnes et 
al., 2007). The most often used target prediction programs are perhaps TargetScan and PicTar, 
although others are often used, such as miRanda, microrna.org, miRBase etc. There is also a 
database available containing dysregulated miRNAs in different diseases or their profiling in 
various tissues (HMDD, Human MicroRNA Disease Database; Lu et al., 2008). Another useful 
database is Tarbase, in which all experimentally validated targets for all organisms and 
miRNAs are incorporated (Sethupathy et al., 2006).  
2. MicroRNA in regulating physiological functions 
Importance of miRNA processing pathway components. MicroRNAs and their associated 
proteins appear to be one of the more abundant ribonucleoprotein complexes within cells. 
Perhaps the best evidence of miRNAs being important for normal physiological functions is 
provided by experiments in which the components of the miRNA biogenesis pathway are 
depleted or over-expressed. Biochemical experiments in several eukaryotes have shown that 
DGCR8 is an essential co-factor of the RNAse II enzyme Drosha. In addition, the reduced 
enzymes Dicer and Drosha have been demonstrated in several diseases, as well as over-
expression of Dicer, Ago 2 and exportin-5 (Soifer et al., 2007).  
Outcomes of translational repression. By translational repression, miRNAs, in normal cell 
conditions can function in different ways. Firstly, for mRNAs that should not be expressed 
in a particular cell type, miRNAs reduce protein production to inconsequential levels 
(switch off the targets). Secondly, miRNAs can adjust protein output in a manner that allows 
for customized expression in different cell types but a more uniform level within each cell 
type (fine-tuning target expression). Thirdly, some miRNAs act as bystanders, for which 
down-regulation by miRNAs is tolerated or is negated by feedback processes (neutral target 
expression). MicroRNA functions have mainly been determined by in vivo experiments, by 
the phenotypic consequences of a mutated miRNA or an altered mRNA complementarity 
site, either of which can disrupt miRNA regulation. In some cases, function has been 
inferred from the effects of transgenic constructs that lead to ectopic expression of the 
miRNA (Bartel, 2004).  
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Physiological functions. Many miRNAs are expressed in a tissue-specific manner, e.g., miR-
208 is cardiac specific (van Rooij et al., 2007), miR-122 is liver specific (Girard et al., 2008), 
and/or cell-type specific manner (e.g. miR-223 is primarily expressed in granulocytes); they 
are important at distinct stages of development and have been found to regulate a variety of 
developmental and physiological processes (Williams, 2008). In terms of development, 
miRNAs are important in regulating morphogenesis and the maintenance of 
undifferentiated or incompletely differentiated cell types, such as stem cell differentiation, 
cardiac and skeletal muscle development, neurogenesis, hematopoiesis etc. Recently 
discovered miRNA functions include control of cell-fate decision, cell proliferation, cell 
death, neuronal patterning, modulation of hematopoietic lineage differentiation and 
controlling the timing of developmental transitions (Callis et al., 2007; Fazi & Nervi, 2008; Li 
& Gregory, 2008). In physiological conditions, miRNAs are involved in metabolism, 
regulation of insulin secretion, cholesterol metabolism, resistance to viral infection and 
oxidative stress, immune response etc (Lodish et al., 2007; Williams, 2008). With all different 
genes and expression patterns, it is reasonable to propose that every cell type at each 
developmental stage might have a distinct miRNA expression profile. MicroRNA biogenesis 
and activity is now regarded as a key regulatory mechanism in maintenance tissue identity 
during embryogenesis and adult life. 
3. MicroRNAs and disease 
Presence of SNPs. Disruption of miRNA target interaction in the form of single-nucleotide 
polymorphisms (SNPs), either in the miRNA gene or its target site (3′ UTR mRNA), can lead 
to complete gain or loss of the miRNA function and thus account for a diseased state (e.g.  
AT1R and miR-155, Martin et al., 2007). In contrast to the miRNA target sites in mRNA 
transcripts, in which the potential of variation is huge, variants identified in miRNA 
precursor sequences tend to be extremely rare, usually restricted to one individual. The 
presence of SNPs in pri-miRNA or pre-miRNA can also affect the processing of miRNAs and 
their expression, which can also result in different disease outcomes (Barnes et al., 2007).  
Aberrant expression of miRNAs. Recent advances in miRNA research have provided evidence 
of an miRNA association with various pathological conditions. These can be due to 
abnormal miRNA expression profiles, genomic rearrangements or epigenetic mechanisms 
activated in diseased human tissues. Aberrant miRNAs expression and processing is 
associated with genetic disorders, cancer, autoimmune and inflammatory diseases, and 
neurodegenerative and cardiovascular disorders (Perera & Ray, 2007). It is estimated that 50 
% of miRNA genes are located at fragile chromosome sites and associated with the 
development of cancer. MicroRNAs can in addition act as tumour suppressors or proto-
oncogens during the course of carcinogenesis (Cho, 2009).  
4. MicroRNAs in heart physiology and disease 
Cardiac specific Dicer deletion. One of the most important studies showing that miRNAs are 
important in heart physiology, as well as in heart disease, concerned the cardiac specific 
knockout of Dicer in prenatal mice. Dicer deletion resulted in rapidly progressive dilated 
cardiomyopathy, heart failure and postnatal mortality; early mortality was due to heart 
defects, such as pericardial edema and underdevelopment of the ventricular myocardium. 
Dicer mutant mice showed a severe decrease in heart contractile function, due to aberrant 
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expression and loss of cardiac contractile proteins, and profound sarcomere disarray, 
resulting in reduced heart rates. Decreased Dicer expression has consistently been detected 
in end-stage human cardiomyopathy and heart failure. In contrast, increased expression has 
been observed after left ventricular assist device support in humans, which is used to 
improve cardiac function (Chen et al., 2008). Furthermore, postnatal experiments of Dicer 
loss in cardiomyocytes of young mice resulted in sudden cardiac death, probably due to 
arrhythmias. Loss of Dicer in adult myocardium induces rapid and dramatic biventricular 
enlargement, accompanied by myocyte hypertrophy, myofiber disarray, ventricular fibrosis 
and strong induction of foetal gene transcripts (da Costa Martins et al, 2008). These results 
clearly demonstrated that components of miRNA processing are important for cardiac 
contractility, suggesting one of the crucial roles of miRNAs in normal and pathological 
functions of the heart. Changes in miRNA biogenesis affect both juvenile and adult 
myocardial morphology, suggesting a huge biological impact of miRNAs in the postnatal 
heart. It can therefore be concluded that Dicer down-regulation probably affects the 
expression of hundreds of miRNAs, which results in a severe disease outcome.  
Heart disease. MicroRNA research in cardiovascular diseases has only just started. There is 
growing evidence to suggest that miRNAs are involved in the regulation of developmental, 
physiologic and pathologic conditions of the heart. Cardiac diseases, including those with 
progressive degeneration, might involve abnormal miRNA regulation leading to loss of 
renewal of the cardiac muscle cells. The majority of studies have been concerned with 
development, conduct and pathology, focusing on hypertrophy, end-stage heart failure, 
cardiomyopathy and myocardial infarction (Schipper et al., 2008; Thum et al., 2007; Xiao et 
al., 2008; Yin et al, 2008). Stress, associated with cardiac diseases, contributes to miRNA 
expression patterns in the heart, suggesting that miRNAs might function in stress-related 
factors affecting cardiac structure and function. Previous studies of cardiac disease have 
focused on miRNAs that are primarily expressed in cardiomyocytes; however, there is 
mounting evidence that other miRNAs expressed in the human heart have an impact on 
cardiovascular disease (Cordes et al., 2009; Rane et al., 2009; Roy et al., 2009; Song et al., 
2010). In several studies, miRNA microarray analysis has been performed using cell lines 
and an animal model of hypertrophy (Cheng et al., 2007; Sayed et al., 2007; van Rooij et al., 
2006; Tatsuguchi et al., 2007; Thum et al., 2008), human cardiomyopathies and aortic 
stenosis (Ikeda et al., 2007; Sucharov et al., 2008), end-stage heart failure (Matkovich et al., 
2009; Thum et al., 2007), fibrosis (van Rooij et al., 2008), myocardial infarction (Roy et al., 
2009) and development (Niu et al., 2008) and animal model of remodelling and reverse 
remodelling of the heart (Wang et al., 2009) and all other forms of myocardial ischemia. 
Among the genes activated by oxidative stress are the transcription factors that orchestrate 
the expression of a wide variety of responses affecting metabolism, angiogenesis, cell 
survival and oxygen delivery and, in addition, miRNA expression, thought to be critical for 
adaptation to low oxygen. In response to low oxygen, a number of miRNAs are up- or 
down-regulated, with several of these dependent on hypoxia-inducible-factor, a 
transcription factor that plays essential role in the homeostatic response to hypoxia 
(Kulshreshtha et al., 2007; Kulshreshtha et al., 2008).  
Heart development. The heart is the first organ to form and to function during development. It 
has been established that miRNAs represent developmental expression patterns, important 
for timing developmental decisions and pattern formation (Morton et al., 2008). In addition, 
it has been shown that some miRNA patterns are similar in diseased and foetal hearts, 
supporting the concept of reactivation of the foetal gene program in cardiovascular diseases. 
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MicroRNA expression in failing hearts has an increased similarity to that of foetal cardiac 
tissue, suggesting that foetal gene expression in diseased hearts is a hallmark of cardiac 
stress (Thum et al., 2007).  
4.1 Cardiac and muscle specific microRNAs in heart 
MicroRNAs miR-1, miR-133, miR-206 and miR-208, are considered to be muscle and/or 
cardiac specific because they are preferentially but not exclusively expressed in muscle 
and/or cardiac tissue. Among mammalian miRNAs identified so far, miR-1 and miR-133 are 
believed to have a muscle specific expression pattern, with an impact on the regulation of 
heart development. Cardiac expression of miR-1 is controlled by SRF (serum response 
factor) and myocardin; similar to miR-1, miR-133 expression in the heart is controlled by SRF 
(Niu et al., 2008). Currently, a number of miRNAs have been described as enriched or 
muscle specific, but, to the best of our knowledge, only miR-208 has been described as 
cardiac specific. 
4.1.1 Cardiac specific miR-208  
As an identified cardiac specific miRNA, miR-208 is believed to play an important role in 
response to stress, such as pressure overload, activated calcineurin or hypothyroidism. 
MicroRNA miR-208 is encoded by an intron of Myh6, a gene encoding human and mouse α-
cardiac muscle myosin heavy chain (αMHC). By targeting THRAP1, a co-factor of the thyroid 
hormone nuclear receptor, it mediates down-regulation of αMHC and up-regulation of β-
cardiac muscle myosin heavy chain (βMHC) in mice, the primary contractile proteins of the 
heart. Changes in contractile proteins are accompanied by hypertrophy and fibrosis, 
resulting eventually in the diminution of contractility; these changes are also referred to as 
remodelling. Experimental models of miR-208 null animals (mice), which failed to undergo 
stress-induced remodelling and hypertrophic growth in response to activated calcineurin 
signalling or pressure-overload-induced stress, and failed to induce βMHC up-regulation in 
response to hypothyroidism, support the suggested role of miR-208 in remodelling (van 
Rooij et al, 2007). It was recently determined that this miR-208 gene corresponds to miR-208a 
and that it is a member of a family that also includes miR-208b, which is encoded within an 
intron of Myh7 (gene coding ßMHC). These two miRNAs (miR-208a and miR-208b) are 
differentially expressed in mice heart during development, paralleling the expression of 
their host genes (Callis et al., 2009).  
4.1.2 Muscle specific miR-1 and miR-133 
Development. Muscle miRNAs are mainly controlled by myogenic transcription factors; 
through cardiac development they fine-tune regulatory protein levels in a spatiotemporal 
manner. MicroRNAs miR-1 and miR-133 are clustered on the same chromosome loci (miR-1-
1 and miR-133a-2 on chromosome 20, and miR-1-2 and miR-133a-1 on chromosome 18) and 
are transcribed together in a tissue specific manner. Using cell culture and animal model 
experiments, it has recently been shown that miR-1 and miR-133 have opposite roles in 
muscle development, with miR-1 promoting myoblast differentiation and miR-133 
promoting myoblast proliferation; both miR-1 and miR-133 target SRF, with miR-1 also 
targeting transcription repressor, histone deacteylase HDAC4 thus promoting myogenesis 
(Chen et al., 2006; Niu et al., 2008). Over-expression of miR-1 in developing mouse hearts 
results in decreased cardiomyocyte proliferation and premature differentiation through 
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expression and loss of cardiac contractile proteins, and profound sarcomere disarray, 
resulting in reduced heart rates. Decreased Dicer expression has consistently been detected 
in end-stage human cardiomyopathy and heart failure. In contrast, increased expression has 
been observed after left ventricular assist device support in humans, which is used to 
improve cardiac function (Chen et al., 2008). Furthermore, postnatal experiments of Dicer 
loss in cardiomyocytes of young mice resulted in sudden cardiac death, probably due to 
arrhythmias. Loss of Dicer in adult myocardium induces rapid and dramatic biventricular 
enlargement, accompanied by myocyte hypertrophy, myofiber disarray, ventricular fibrosis 
and strong induction of foetal gene transcripts (da Costa Martins et al, 2008). These results 
clearly demonstrated that components of miRNA processing are important for cardiac 
contractility, suggesting one of the crucial roles of miRNAs in normal and pathological 
functions of the heart. Changes in miRNA biogenesis affect both juvenile and adult 
myocardial morphology, suggesting a huge biological impact of miRNAs in the postnatal 
heart. It can therefore be concluded that Dicer down-regulation probably affects the 
expression of hundreds of miRNAs, which results in a severe disease outcome.  
Heart disease. MicroRNA research in cardiovascular diseases has only just started. There is 
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2010). In several studies, miRNA microarray analysis has been performed using cell lines 
and an animal model of hypertrophy (Cheng et al., 2007; Sayed et al., 2007; van Rooij et al., 
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transcription factor that plays essential role in the homeostatic response to hypoxia 
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Heart development. The heart is the first organ to form and to function during development. It 
has been established that miRNAs represent developmental expression patterns, important 
for timing developmental decisions and pattern formation (Morton et al., 2008). In addition, 
it has been shown that some miRNA patterns are similar in diseased and foetal hearts, 
supporting the concept of reactivation of the foetal gene program in cardiovascular diseases. 
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down-regulation of transcription factor Hand2. Target deletion of miR-1 causes death in utero 
of the majority of offspring, due to defects in cardiac morphogenesis. The surviving ones die 
later due to conductivity problems. It is suggested that a precise dosage of Hand2 is essential 
for normal cardiomyocyte development and morphogenesis (Zhao et al., 2005). Experiments 
using mouse models of an miR-1-2 null animal suggest that miR-1-2 has a non-redundant 
role with miR-1-1 in the heart, despite their apparent overlapping expression patterns. Half 
of the miR-1-2 null animals died, others suffered from incomplete ventricular septation, 
indicating abnormal cardiogenesis. It would be useful to know whether deletion of miR-1-1 
invokes a similar phenotype, and whether deletion of both copies causes a more severe 
phenotype (Zhao et al., 2007). Finally, it has been shown that, during development, miR-133 
regulates cardiogenesis by targeting nuclear factor Nelf-A/Whsc2 (Care et al., 2007).  
Apoptosis. Loss of cardiac muscle cells due to apoptotic cell death is a common process in 
heart development, as well as in myocardial ischemia, cardiac hypertrophy and heart 
failure. MicroRNAs are also implicated in cardiovascular disease as regulators of apoptosis. 
Opposite effects of miR-1 and miR-133 regulating cardiomyocyte apoptosis induced by 
oxidative stress have been described, with a pro-apoptotic role of miR-1 (targeting HSP60 
and HSP70, heat-shock proteins) and anti-apoptotic role of miR-133 (targeting caspase-9) (Xu 
et al., 2007).  
Hypertrophy. Both miR-1 and miR-133 have been demonstrated to be dysregulated in 
hypertrophic and failing hearts and in myocardial infarction in both animals and humans. 
MicroRNA miR-133 showed down-regulation in patients with hypertrophic 
cardiomyopathy and in mouse models of cardiac hypertrophy. The predicted targets for 
miR-133 are Rhoa, a GDP-GTP exchange protein regulating cardiac hypertrophy, and Cdc42, 
a signal transduction kinase implicated in hypertrophy; both miRNAs are involved in cell 
growth, myofibrillar rearrangements and regulation of contractility. Another target was 
determined, Nelf-A/Whsc2, a nuclear factor involved in cardiogenesis but the role of Nelf-
A/Whsc2 in cardiac hypertrophy has not yet been defined (Care et al., 2007). Although it is 
also believed that miR-1 expression is down-regulated during cardiac hypertrophy, results 
are somewhat controversial; additional genetic studies are therefore needed to demonstrate 
clearly a direct role of miR-1 in the regulation of cardiac hypertrophy. However, miR-1 
targets in the context of cell growth, contractility and extracellular matrix have been 
determined, including RasGAP, Cdk9, Rheb and fibronectin (Care et al., 2007). 
4.2 MicroRNAs controlling cardiac excitability 
The electrical-conduction system, which maintains proper heart rhythmicity, has been 
shown to be regulated by miRNAs that regulate the expression of its components and 
therefore possess the potential to induce arrhythmia. Dysregulated miRNA expression 
might affect the expression of ion channel genes, leading to arrhythmogenesis; it has been 
postulated that miRNAs control cardiac excitability through this regulation. Using 
bioinformatics and experimental approaches, a number of miRNAs have recently been 
proposed as having the potential to regulate human ion channel genes. The matrix of 
miRNAs that are expressed in cardiac myocytes has been established, with the potential to 
regulate genes encoding cardiac ion channels and transporters. The author proposed that 
multiple miRNAs might be critically involved in the electrical/ionic remodelling process in 
heart disease through altering the expression of the genes in cardiac myocytes (Luo et al., 
2010). MicroRNAs known up to date to target cardiac excitability are listet in Table 1 with 
corresponding target genes and their functions.  
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4.2.1 Cardiac specific miR-208 
As previously reported, the expression of miR-208a and miR-208b is not just 
developmentally regulated in the heart, but also pathologically. In a recent study, it was 
postulated that miR-208a expression was sufficient to induce arrhythmias; furthermore, 
experiments on genetic deletion of miR-208a in mice revealed that miR-208a is required for 
proper cardiac conduction and expression of the transcription factor GATA4 and gap 
junction protein connexin 40 (Cx 40). MicroRNA miR-208 is therefore required for 
maintaining the expression of cardiac transcription factors known to be important for the 
development of the conduction system. Over-expression of miR-208a results in cardiac 
conduction abnormalities and suggests that miR-208a regulates cardiac conduction system 
components. Studies on mice lacking miR-208a suggest that these mice suffer atrial 
fibrillation. Furthermore, Cx 40 expression is restricted to the atria, more precisely in the His 
bundle and Purkinje fibres. Consistent with the phenotype of mice lacking miR-208a, mice 
lacking Cx 40 also suffer from first-degree AV block. It can be concluded, therefore, that 
miR-208a gain- and lost-of-function are associated with arrhythmias (Callis et al., 2009). 
4.2.2. Muscle specific miR-1 and miR-133 
MicroRNAs miR-1 and miR-133. The slow delayed rectifier current Iks, is constituted of 
channel complex, which is formed from KCNQI and KCNEI. Their expression is regionally 
heterogeneous; it is also changed by the pathological state of the heart. It has been 
experimentally established that the two genes, KCNQI and KCNEI, are targets for miR-133 
and miR-1, respectively. It was shown that expressions of miR-1 and miR-133 in the heart are 
spatially heterogeneous and that this may contribute to regional differences in the 
distribution of KCNQI and KCNE1. To confirm the hypothesis, it was shown that KCNQI has 
the opposite patterns of transmural and apical-basal gradients to those of miR-133, whereas 
the characteristic regional distribution of miR-1 may be one of the causal factors for the 
converse transmural and apical-base gradients of KCNEI. Thus, in areas in which miR-1 and 
miR-133 are less abundant, Iks are more densely expressed (Luo et al., 2007). In one of the 
first studies of miRNA influence on the cardiac conduction system, it was suggested that 
down-regulation of miR-1 and miR-133 contributes to arrhythmogenesis in hypertrophic and 
failing hearts, and that miR-1 and miR-133 play an important role in determining cardiac 
automaticity, possibly by re-expression of the pacemaker channel genes HCN2 and HCN4. 
Both miRNAs are involved in hypertrophy, with miR-133 believed to be a negative regulator 
of hypertrophic growth of heart muscle. By undergoing a remodelling process and 
hypertrophic growth, the heart adapts to impaired cardiac function. The remodelling 
process in the heart also includes electrical remodelling, which increases the risk of 
arrhythmogenesis by re-expression of the pacemaker channel HCN genes 
(hyperpolarization–activated cyclic-nucleotide-gated channels). The HCN2 gene has been 
shown to be a target of miR-133. In addition, pacemaker channels HCN2 and HCN4 have 
both been shown to be targets for miR-1, so its down-regulation may also lead to re-
expression of these pacemaker channels in a diseased heart. To date, these two miRNAs 
have a postulated role in regulating automaticity in the functioning of the If current. This is a 
mixed Na+K+ inward current, which is activated by hyperpolarization and is the main 
current of pacemaker activity in the sinoatrial node. If may therefore be controlled by miR-1 
and miR-133 through the regulation of HCN density (Luo et al., 2008). 
MicroRNA miR-1. Up-regulation of miR-1 has been reported in patients with coronary artery 
disease and in animal models in the border zone of myocardial infarction. Over-expression 
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are somewhat controversial; additional genetic studies are therefore needed to demonstrate 
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of miR-1 in the hearts of adult rats leads to widened QRS complex, indicative of 
intraventricule conduction delay and the development of severe cardiac arrhythmia. Target 
mRNAs for miR-1 have been predicted as ion channel genes GJA1, which encodes gap-
junction protein connexin 43, and KCNJ2, which encodes the K+ channel subunit Kir2.1. 
Knockdown of endogenous miR-1 can inhibit ischemic arrhythmias. Therefore, miR-1 might 
contribute to re-entry through decreased intracellular coupling via the repression of GJA1 
(Yang et al., 2007). In contrast to this research, it was shown that miR-1 levels are greatly 
reduced in the left atrium of patients with persistent atrial fibrillation (AF), possibly 
resulting in up-regulation of Kir2.1 subunits, which leads to increased Ik1. Up-regulation of 
this inward-rectifier current is important for AF maintenance (Girmatsion et al., 2009). A 
further miR-1 target involved in regulation of cardiac conductance is Irx5, a transcription 
factor that regulates cardiac repolarization by repressing Kcnd2. This gene encodes for 
potassium channel Kv4.2, which is responsible for transient outward K+ current. Normal 
expression of all three components, miR-1, Irx5 and Kcnd2, is required for maintaining the 
ventricular repolarisation gradient. Evidence was provided by deletion of the miR-1-2 gene, 
which resulted in the death of half of the mice at birth, and those surviving to adulthood 
showed an aberrant heart rate and repolarization (Zhao et al., 2007). Calcium channels 
account for excitation-contraction coupling and also contribute to pacemaker activities. The 
effect of increased expression of miR-1 on excitation-contraction coupling and Ca2+ cycling 
has been investigated in rat ventricular myocytes. It was shown that miR-1 over-expression 
increased phosphorylation of the ryanodine receptor (RyR2) by selective decrease in 
expression of protein phosphatase PP2A. RyR channels on the sarcoplasmic reticulum (SR) 
are essential for activation of contractile filaments during myocardial contraction; RyR2 is 
regulated by kinases and phosphathases, its activity depends on the phosphorylation state. 
Through translational inhibition, miR-1 causes hyperphosphorylation of RyR2 thus 
enhancing RyR2 activity and promoting arhythmogenic SR Ca2+ release. The author 
concluded that miR-1 enhances cardiac excitation-contraction coupling by selectively 
increasing phosphorylation of the L-type and RyR2 channels via disrupting localization of 
PP2A activity to these channels (Terenteyev et al., 2009).  
MicroRNA miR-133. In vitro studies have identified ERG (ether-a-go-go related gene) as an 
miR-133 target, K+ channel (IKr), in cardiomyocytes; its repression may contribute to 
depression and subsequent QT prolongation in diabetic hearts. ERG protein level was 
decreased in the ventricle of diabetic hearts; in contrast, increased expression of miR-133 and 
SRF was detected in the same diabetic subjects. Down-regulation of ERG is responsible for 
arrhythmias in diabetic hearts caused by QT prolongation (Xiao et al., 2006).  
4.2.3 Other miRNAs regulating cardiac excitability 
Another possible mechanism of miRNA regulating the L-type Ca2+ current, reduction of which 
is associated with atrial electrical remodelling and atrial fibrillation, has recently been 
suggested. In particular, miR-328 level was approx.  4-fold up-regulated, targeting the L-type 
Ca2+ channel genes, CACNA1C and CACNB1. The author therefore concluded that miR-328 
contributes to adverse atrial electric remodelling in AF and was postulated as a novel molecular 
mechanism for AF (Lu et al., 2010). Furthermore, it has been shown that nicotine-induced atrial 
remodelling, which represents an increased risk for atrial fibrillation, results in significant up-
regulation of TGF-ß1 and TGF-ßRII and, remarkably, a decrease in the levels of miR-133 and miR-
590, which at least partly accounts for TGF-ß1 and TGF-ßRII up-regulation. It is suggested that 
the antifibrotic effect of both miR-133 and miR-590 are implicated in AF (Shan et al., 2009). 
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miRNA Target gene Target gene description Regulating process Reference 
miR-1 Hand2 
transcription factor, 







Zhao et al., 
2005 
 Irx5 iroquois homeobox 5 
pattern formation of 
vertebrate embryos, 
heart development 
Zhao et al., 
2007 
 GJA1 gap junction protein, alpha 1, connexin 43 conduction between 
cells and within a 
cell 













Luo et al., 
2007 





pacemaker channels Luo et al., 2007 
 PP2A protein phosphatase 2A regulating RyR2 phosphorylation 
Terenteyev 
et al., 2009 
miR-133 ERG ether-a-go-go-like gene long QT sindrom, diabetes mellitus 















potassium channel 2 
pacemaker channels Luo et al., 2007 
 TGFB1, TGFBRII 
transforming growth 




Shan et al., 
2009 
miR-208 GATA4, Cx 40 
GATA binding protein 4 
and connexin 40 
heart conduction 
and arrhythmia 
Callis et al., 
2009 
miR-590 TGFB1, TGFBRII 
transforming growth 




Shan et al., 
2009 
miR-328 CACNA1/ CACNB1 
voltage-dependent 
calcium channel calcium transport 
Lu et al., 
2010 
Table 1. MicroRNAs regulating cardiac excitation, its target genes and function. 
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mRNAs for miR-1 have been predicted as ion channel genes GJA1, which encodes gap-
junction protein connexin 43, and KCNJ2, which encodes the K+ channel subunit Kir2.1. 
Knockdown of endogenous miR-1 can inhibit ischemic arrhythmias. Therefore, miR-1 might 
contribute to re-entry through decreased intracellular coupling via the repression of GJA1 
(Yang et al., 2007). In contrast to this research, it was shown that miR-1 levels are greatly 
reduced in the left atrium of patients with persistent atrial fibrillation (AF), possibly 
resulting in up-regulation of Kir2.1 subunits, which leads to increased Ik1. Up-regulation of 
this inward-rectifier current is important for AF maintenance (Girmatsion et al., 2009). A 
further miR-1 target involved in regulation of cardiac conductance is Irx5, a transcription 
factor that regulates cardiac repolarization by repressing Kcnd2. This gene encodes for 
potassium channel Kv4.2, which is responsible for transient outward K+ current. Normal 
expression of all three components, miR-1, Irx5 and Kcnd2, is required for maintaining the 
ventricular repolarisation gradient. Evidence was provided by deletion of the miR-1-2 gene, 
which resulted in the death of half of the mice at birth, and those surviving to adulthood 
showed an aberrant heart rate and repolarization (Zhao et al., 2007). Calcium channels 
account for excitation-contraction coupling and also contribute to pacemaker activities. The 
effect of increased expression of miR-1 on excitation-contraction coupling and Ca2+ cycling 
has been investigated in rat ventricular myocytes. It was shown that miR-1 over-expression 
increased phosphorylation of the ryanodine receptor (RyR2) by selective decrease in 
expression of protein phosphatase PP2A. RyR channels on the sarcoplasmic reticulum (SR) 
are essential for activation of contractile filaments during myocardial contraction; RyR2 is 
regulated by kinases and phosphathases, its activity depends on the phosphorylation state. 
Through translational inhibition, miR-1 causes hyperphosphorylation of RyR2 thus 
enhancing RyR2 activity and promoting arhythmogenic SR Ca2+ release. The author 
concluded that miR-1 enhances cardiac excitation-contraction coupling by selectively 
increasing phosphorylation of the L-type and RyR2 channels via disrupting localization of 
PP2A activity to these channels (Terenteyev et al., 2009).  
MicroRNA miR-133. In vitro studies have identified ERG (ether-a-go-go related gene) as an 
miR-133 target, K+ channel (IKr), in cardiomyocytes; its repression may contribute to 
depression and subsequent QT prolongation in diabetic hearts. ERG protein level was 
decreased in the ventricle of diabetic hearts; in contrast, increased expression of miR-133 and 
SRF was detected in the same diabetic subjects. Down-regulation of ERG is responsible for 
arrhythmias in diabetic hearts caused by QT prolongation (Xiao et al., 2006).  
4.2.3 Other miRNAs regulating cardiac excitability 
Another possible mechanism of miRNA regulating the L-type Ca2+ current, reduction of which 
is associated with atrial electrical remodelling and atrial fibrillation, has recently been 
suggested. In particular, miR-328 level was approx.  4-fold up-regulated, targeting the L-type 
Ca2+ channel genes, CACNA1C and CACNB1. The author therefore concluded that miR-328 
contributes to adverse atrial electric remodelling in AF and was postulated as a novel molecular 
mechanism for AF (Lu et al., 2010). Furthermore, it has been shown that nicotine-induced atrial 
remodelling, which represents an increased risk for atrial fibrillation, results in significant up-
regulation of TGF-ß1 and TGF-ßRII and, remarkably, a decrease in the levels of miR-133 and miR-
590, which at least partly accounts for TGF-ß1 and TGF-ßRII up-regulation. It is suggested that 
the antifibrotic effect of both miR-133 and miR-590 are implicated in AF (Shan et al., 2009). 
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miRNA Target gene Target gene description Regulating process Reference 
miR-1 Hand2 
transcription factor, 







Zhao et al., 
2005 
 Irx5 iroquois homeobox 5 
pattern formation of 
vertebrate embryos, 
heart development 
Zhao et al., 
2007 
 GJA1 gap junction protein, alpha 1, connexin 43 conduction between 
cells and within a 
cell 













Luo et al., 
2007 





pacemaker channels Luo et al., 2007 
 PP2A protein phosphatase 2A regulating RyR2 phosphorylation 
Terenteyev 
et al., 2009 
miR-133 ERG ether-a-go-go-like gene long QT sindrom, diabetes mellitus 















potassium channel 2 
pacemaker channels Luo et al., 2007 
 TGFB1, TGFBRII 
transforming growth 




Shan et al., 
2009 
miR-208 GATA4, Cx 40 
GATA binding protein 4 
and connexin 40 
heart conduction 
and arrhythmia 
Callis et al., 
2009 
miR-590 TGFB1, TGFBRII 
transforming growth 




Shan et al., 
2009 
miR-328 CACNA1/ CACNB1 
voltage-dependent 
calcium channel calcium transport 
Lu et al., 
2010 
Table 1. MicroRNAs regulating cardiac excitation, its target genes and function. 
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5. Therapeutic potentials of microRNAs 
MicroRNA expression patterns are dynamically regulated during various diseases, thus 
providing an opportunity to use them as biomarkers or diagnosis indicators and for 
prognosis. MicroRNAs are small molecules, making their in vivo delivery feasible. The use 
of chemically modified oligonucleotides either to target a specific miRNA or disrupt 
miRNA-mRNA binding may lead to inactivation of pathological miRNA. MicroRNAs may 
therefore serve as therapeutic targets in the future (Liu Z. et al, 2008; Soifer et al., 2008).  
5.1 Replenishing small RNAs  
For an miRNA that is under-expressed, re-introduction of the mature miRNA into the 
affected tissue would restore regulation of the target gene. For this purpose, artificial 
miRNA have been developed (miRNA mimic) to enhance the expression of beneficial 
miRNAs or the introduction of short hairpin duplex, similar to pre-miRNA, into the cell. 
These findings raise the hope that re-introduction of certain miRNAs (e.g., miR-1, miR-133 or 
miR-208), depending on the disease outcome, might reduce life threatening arrhythmias, a 
frequent cause of death in patients with cardiovascular disease, or heart remodelling 
associated with prolonged ischemia, which often results in end-stage heart failure and poor 
prognosis (Liu Z. et al, 2008; Soifer et al., 2008). In vivo over-expression of miR-133 protected 
animals from agonist induced cardiac hypertrophy, whereas reduction in wild-type mice 
(anti-miRNA antisense antagomir molecules secreted by implanted osmotic pumps) caused 
an increase in hypertrophic markers. This suggests that individual miRNAs are potential 
therapeutic agents, provided that their expression or delivery can be targeted to appropriate 
tissue. However, care should be taken, since over-production of miR-133 induces 
arrhythmias (Care et al., 2007). Most of the developed protocols have used local 
administration in easily accessible tissue; systemic delivery has also some promising results; 
the major challenge remains tissue and cell-type specific targeting (Liu Z. et al, 2008; Soifer 
et al., 2008). 
5.2 Inhibiting small RNAs  
ASOs are short and single-stranded antisense oligonucleotides and, in the context of miRNA 
inhibition, are called AMOs, anti-miRNA oligonucleotides. Over-expressed miRNA can be 
down-regulated by reducing the mature miRNA level through direct targeting (mature 
miRNA, pri-miRNA or pre-miRNA) or by reducing the components of miRNA biogenesis. 
Chemically engineered oligonucleotides, termed “antagomirs”, have been developed and 
proven to be efficient and specific silencers of endogenous miRNAs in mice. Chemical 
modifications and cholesterol conjugations stabilize and facilitate intravenous delivery of 
antagomirs. They interact with miRNAs in the cytoplasm and lead to specific miRNA down-
regulation when injected systemically or locally (Liu Z. et al, 2008; Soifer et al., 2008). Direct 
injection of lipid-complexed antagomir oligonucleotides against miR-1 into rat hearts 
protected the animals from induced arrhythmias, suggesting that transient down-regulation 
of miR-1 could provide therapeutic benefits to those suffering from acute myocardial 
infarctions (Yang et al., 2007). In another approach, miRNA sponges have been developed to 
inhibit several miRNAs; miRNA sponges possess multiple binding sites and could be useful 
for sequestering an miRNA family. Furthermore, miR-masks and miR-erasers have also 
been developed; an miR-mask has been designed for masking the miRNA binding site on 
target mRNA, whereas an miR-eraser is similar to miR-sponges, except that the miR-eraser 
 
MicroRNAs as Possible Molecular Pacemakers 
 
33 
uses only two copies of the antisense sequence. Gene-specific miRNA mimic and miRNA-
masking antisense approaches have been used to test the possibility of using miRNAs and 
their corresponding targets as therapeutic targets. The expression of the cardiac pacemaker 
channel genes, HCN2 and HCN4, has been manipulated via the mentioned approaches. 
MicroRNA mimics repressed protein levels, whereas miRNA masking markedly enhanced 
HCN2/HCN4 expression and function (Xiao et al., 2007). In a recent study, the authors 
proposed that arhhythomgenesis after intracardiac skeletal myoblast (SKM) transplantation, 
a promising therapy for myocardial infarct repair, may be related to the differentiation state 
of (SKM). It was shown that miR-181a plays an important role in myobast differentiation, so 
using lentivirus mediated oligonucleotides against miR-181a, the authors demonstrated 
reduced arrhythmias post SKM transplantation (Li et al., 2009).   
We need more knowledge concerning which miRNAs to target, how to produce and stabilize 
them, how to direct them to the heart and not systemically. The specificity of drug-like 
oligonucleotides is important, because of the off-target effect. The off-target effect is also a 
significant challenge, especially considering that miRNA-mediated repression often requires a 
homology of only six to seven nucleotides in the seed region of the miRNA and mRNA target 
site. Toxicity due to chemical modifications, which is used to facilitate cellular uptake and 
prevent degradation, should be take into account (Liu Z. et al, 2008; Soifer et al., 2008).  
6. Conclusions 
The field of miRNA is largely undiscovered territory, a young, emerging field of research, 
and we are just beginning to understand the role of miRNAs in the cardiovascular context. 
Recent advances in the research of miRNAs suggest that miRNAs modulate a wide variety 
of cardiac functions with developmental, (patho)physiological and clinical implications. The 
miRNA level in the myocardium must be kept within a proper concentration range to 
maintain normal cardiac conduction; excessive either decrease or increase in the level of 
some miRNAs can induce arrhythmia, which supports the central role of some miRNAs in 
fine-tuning the regulation of cardiac electrophysiology in pathological and normal 
conditions. The role of miRNAs in the pathogenesis of the heart and vessels points to the 
possibility of miRNA targets for the treatment of cardiovascular disease in previously 
unconsidered medical therapies. 
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therefore serve as therapeutic targets in the future (Liu Z. et al, 2008; Soifer et al., 2008).  
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For an miRNA that is under-expressed, re-introduction of the mature miRNA into the 
affected tissue would restore regulation of the target gene. For this purpose, artificial 
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miRNAs or the introduction of short hairpin duplex, similar to pre-miRNA, into the cell. 
These findings raise the hope that re-introduction of certain miRNAs (e.g., miR-1, miR-133 or 
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of cardiac functions with developmental, (patho)physiological and clinical implications. The 
miRNA level in the myocardium must be kept within a proper concentration range to 
maintain normal cardiac conduction; excessive either decrease or increase in the level of 
some miRNAs can induce arrhythmia, which supports the central role of some miRNAs in 
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Torsades de pointes is a potentially life threatening form of rapid, polymorphic ventricular 
tachycardia. Literally meaning “twisting of the points”, torsades de pointes is 
electrocardiographically characterized by QRS axis undulations over runs of several beats, 
with a specific twist of the QRS complex around the isoelectric baseline. The definition also 
requires that an abnormal QT-prolongation be present (usually to 600 msec or greater) and / 
or abnormal TU complexes. The arrhythmia usually terminates spontaneously, with the 
exception of rare degeneration into ventricular fibrillation. The episodes are often repetitive 
and frequency dependent. 
In 1966, Dessertenne first described torsades de pointes in a patient with atrio-ventricular 
block (Dessertenne, 1966). Ever since, several reports have associated torsades de pointes 
with bradycardia, especially with atrio-ventricular block (Viskin, 1999). From 5% to 30% of 
patients with atrio-ventricular block have been reported to develop torsades de pointes 
(Motté, 1970, Jensen, 1975,  Guize, 1993) - an observation that suggests the participation of 
yet other intrinsic or extrinsic sensitising factors. 
Most episodes of torsades de pointes are paroxystic, not longer than 5-20 beats, with a very 
elevated heart rate (160-300 bpm). The typical morphology of torsades de pointes includes a 
complete twist at 180° of QRS complexes and a progressive change of the surface ECG. A QT 
interval prolongation to 600 ms or longer is always evident. These episodes are often 
preceded by ventricular bigeminism with fixed and long coupling interval. 
2. Risk factors 
Several studies have proposed different risk factors for torsades de pointes. Among them, 
the most commonly encountered are female gender, advanced age, bradycardia, different 
metabolic disorders, and a number of therapeutic agents (Haverkamp, 2000). The gender-
specific preponderance in females to develop drug-induced torsades de pointes when 
treated with antiarrhythmic drugs or during spontaneous bradyarrhythmias is also well 
documented. In the general population, women have a longer corrected QT interval than 
men. 
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Several endocrine disorders as well as a number of electrolytic imbalances have been 
incriminated as torsades de pointes facilitators (hypothyroidism, mental anorexia, 
hypokalaemia, hypomagnesaemia, hypocalcaemia, acidosis). 
A great number of drugs are currently considered “torsadogenic”. Almost all of these drugs 
have an IKr channel blocking effect, which explains QT interval prolongation. These agents 
belong to both “cardiotropic” and “non-cardiotropic” drugs (an exhaustive list is available 
on Internet at http://www.qtdrugs.org). 
2.1 Atrio-ventricular block – a piece in the puzzle 
The common element between atrio-ventricular block and torsades de pointes seems to be 
the presence of QT interval prolongation. Still, the association between atrio-ventricular 
block and QT interval prolongation is infrequent. Several studies have shown that this exact 
category of patients who present atrio-ventricular block induced – QT prolongation has the 
most elevated risk of developing torsades de pointes. 
 
 
Fig. 1. Holter recording in a patient with post-operative atrio-ventricular block and typical 
torsades de pointes. Note the association of long QT interval, ventricular bigeminism, 
bradycardia, and bradycardia-dependant polymorphic ventricular tachycardia degenerating 
in ventricular fibrillation. 
Kurita et al. have reported that patients with bradycardia-induced torsades de pointes have 
abnormally long QT intervals at slow heart rates, compared with patients with bradycardia 
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but no tachyarrhythmia (Kurita, 1992). Strasberg et al. compared patients with atrio-
ventricular block with torsades de pointes to those without torsades de pointes, and 
mentioned that the QT interval in patients with torsades de pointes was longer than in those 
without torsades de pointes, whereas heart rate and QRS interval during the escape rhythm 
were not significantly different (Strasberg, 1986). Moreover, they reported that QT interval 
above 600 ms and premature ventricular beats on electrocardiogram appear to indicate an 
increased risk for the development of polymorphic ventricular tachycardia in a patient with 
atrio-ventricular block. 
In a retrospective review of 43 young patients with congenital atrio-ventricular block, 
Sholler et al. found QT interval prolongation to be an independent predictor of symptoms, 
including cardiac arrest and syncope. Overall, the outcome was poor with 21% of the 
atrio-ventricular block patients in their symptomatic group with rate-corrected QT 
intervals >0.45 seconds, in contrast with none in the asymptomatic group (Sholler, 1989). 
Marked QT interval prolongation complicated by torsades de pointes, as a sequela of 
acquired atrio-ventricular block, has been convincingly demonstrated in paediatric and 
adult patients. In each of these patients, who ranged in age from 18 months to 80 years on 
initial presentation with torsades de pointes, there was QT interval normalization and 
complete suppression of torsades de pointes after institution of ventricular pacing at age-
appropriate rates. 
Experimental data confirm these observations. In a dog model with chronic atrio-ventricular 
block, the QT interval was prolonged by 20%. 
3. Genetic bases 
3.1 Genetic bases of acquired long QT syndrome 
In contrast to congenital long QT syndrome, the acquired form has been considered a non-
familial disease, which is not transmitted in specific genetic patterns of inheritance. This 
does not automatically exclude genetic components from the pathogenesis of acquired long 
QT syndrome, but it implies that these are only cofactors in the pathogenesis. 
The unpredictability of acquired long QT syndrome, its similarity to the congenital form and 
identification of manifest congenital long QT syndrome in patients with the drug-induced 
form, all suggest a genetic contribution to risk. 
With the identification of mutations in ion channel genes underlying congenital long QT 
syndrome and the investigation of large families, a variable clinical expressivity and 
especially incomplete penetrance have become apparent (Raviña, 2000). In a given family, 
some individuals with a certain mutation have frank long QT intervals, while others with 
the same mutation have normal QT intervals at baseline. In some cases, the latter, who 
represent less than 10% of the patients with acquired long QT syndrome, experience 
torsades de pointes only after intervention of a QT-prolonging stressor. In autosomal 
dominant long QT syndrome (Romano-Ward syndrome), the aspect of incomplete 
penetrance was reported to be approximately 25% in a specific group of families. This raises 
the question of the frequency and importance of silent ion channel gene mutations that may 
become functionally significant in presence of coexisting factors. 
Mutations in KCNE1 and KCNE2, KCNH2, HERG itself, and SCN5A have been identified in 
acquired forms of long QT syndrome (Abbott, 1999). However, the gene in which mutations 
are seen most commonly is KCNQ1, encoding for potassium channel IKs (Donger, 1997, 
Napolitano, 2000, Kubota, 2000). 
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Several frequently occurring polymorphisms have also been described in the long QT 
syndrome population, distributed in nearly all the genes associated with this condition. 
Although these changes are apparently not pathogenic, some can generate individual 
susceptibility to the development of arrhythmia. This is the case of the K897T 
polymorphism in KCNH2 (Crotti, 2005), which is present in up to 15% of the population 
and is linked with susceptibility to certain drugs. Another example is the R1047L 
polymorphism, the second most frequent polymorphism encountered in KCNH2, which 
has been associated with the development of torsades de pointes while using the drug 
dofetilide (Sun, 2004). 
Polymorphisms that confer susceptibility to the development of ventricular arrhythmia have 
also been documented in sodium channel Na1.5. This is the case of the H558R 
polymorphism (Viswanathan, 2003), which is present in up to 30% of the population, or 
S1103Y, found mainly in blacks, with an incidence of nearly 13%, and associated with an 
increased risk of sudden death in childhood (Splawski, 2002, Paulussen, 2004). Most of these 
DNA polymorphisms do not occur in coding regions and may either have no functional 
significance, or modulate expression levels of functionally normal proteins. Other rare 
polymorphisms with minor allele frequencies (1-2%) that have been implicated in drug-
induced torsades de pointes include D85N (KCNE1) (Paulussen, 2004) and T8A (KCNE2) 
(Sesti, 2000). I447 polymorphism in KCR1 was also proposed as potential modulator of the 
risk of drug-induced torsades de pointes (Roden, 2005). The valine variant was seen in 1.1% 
of patients, compared with 7% in controls, suggesting that the presence of valine in this 
position protects against drug-induced torsades de pointes. 
It is not yet clear if all patients with acquired long QT syndrome have a genetic 
predisposition. Systematic evaluation of genes known to be involved in congenital long  
QT syndrome has therefore been recommended in patients with acquired long QT 
syndrome. 
3.2 Genetic bases of atrio-ventricular block-induced torsades de pointes 
A general observation is that only a minority of patients with atrio-ventricular block 
develop torsades de pointes. Moreover, in the early nineties, in patients with atrio-
ventricular block and torsades de pointes compared with those without torsades de 
pointes, it was reported that the QT interval was longer than the bradycardia could 
account for.  These observations suggested a genetic predisposition of the affected 
subjects. Furthermore, common clinical features and the presence of long QT intervals in 
patients with congenital long QT syndrome and in those with atrio-ventricular block–
induced torsades de pointes suggested that patients with atrio-ventricular block-mediated 
QT-related arrhythmia could have latent congenital long QT syndrome or a vulnerable 
genetic polymorphism. 
Moreover, several similarities have been found between experimental models of atrio-
ventricular block–induced torsades de pointes and specific forms of human congenital 
long QT syndrome. Frequent episodes of spontaneous torsades de pointes during day and 
night, abnormal QTU complex, and reduction of both IKr and IKs in a rabbit atrio-
ventricular block model (Tsuji , 2002) closely resemble the clinical characteristics of the 
malignant form of human congenital long QT syndrome caused by double mutation of 
HERG and KCNQ1. An enhanced susceptibility to acquired torsades de pointes, the 
adrenergic dependence of torsades de pointes, the typical T-wave patterns during 
prolonged QT intervals and the reduction of IKs in dog with chronic atrio-ventricular 
 
Atrio-Ventricular Block-Induced Torsades de Pointes: An Update 
 
43 
block closely resemble the clinical characteristics of the LQT1 or LQT5 form of human 
congenital long QT syndrome. 
Using recently introduced molecular biology techniques, these bradycardia-related 
repolarisation abnormalities appear to be allelic variants in the coding region of congenital 
long QT syndrome genes, variants that can be identified in 10–15% of affected subjects. A 
recent retrospective study showed that 14% to 18% of subjects with atrio-ventricular block-
related QT-interval prolongation were carriers of a genetic mutation in genes coding for 
potassium channels. Another study showed that 36% of patients with complete atrio-
ventricular block and torsades de pointes had a genetic mutation involving HERG and 
SCN5A (Yoshida, 2001). In fact, the most commonly encountered mutation in this setting is 
in HERG genes, coding for potassium channel IKr. 
The scarcity of this association in the general population is directly responsible for the 
limited amount of information that we dispose of regarding this issue. Still, much is 
expected from future molecular testing in these patients. 
4. Pathophysiology 
4.1 Pathophysiology of torsades de pointes 
The association between torsades de pointes and a prolonged QT interval has long been 
known, but the underlying mechanisms of torsades de pointes have yet to be satisfactorily 
elucidated. In general, alterations in cardiac ion currents which dictate the normal action 
potential play a major role in arrhythmogenesis. Both early afterdepolarisation - induced 
triggered activity (Cosio, 1991, Shimizu,1995, Burashnikov, 2002) and increased dispersion 
of repolarisation have been suggested as playing a role in the genesis of torsades de pointes. 
Significantly increased transmural dispersion of repolarisation favours re-entrant substrates 
that initiate and maintain torsades de pointes. 
QT intervals in humans are very variable, being strongly influenced by age, sex, heart rate 
or heart diseases. It would appear that subjects with a propensity to develop the syndrome 
have a subclinical abnormality in some of the ion channels dictating repolarisation, and / or 
a reduced repolarisation reserve. 
The latter hypothesis has been suggested by Roden et al (Roden, 1998). They hypothesized 
that the extent of QT lengthening in response to specific environmental triggers depends on 
the ventricular “repolarisation reserve”. This concept proposes that loss of one component 
(e.g. IKs) ordinarily will not lead to failure of repolarisation since multiple other currents 
flow across the myocyte membrane (e.g. IKr) also act to maintain repolarisation in normal 
ranges. However, when a reduction or down regulation in any of the currents involved in 
the repolarisation phase is overlapped by a destabilizing factor, this “reserve” is overcome 
and acquired long QT syndrome may become clinically obvious (Roden, 1998). This issue 
may occur in the female gender, when a factor such as bradycardia or hypokalaemia is 
present, in conditions that predispose to electrical remodelling such as heart failure, 
myocardial ischemia, or ventricular hypertrophy. 
It is well known that local action potential duration of myocardial cells displays 
considerable variability depending on many factors, including, in normal conditions, 
location in the ventricular wall (epicardium, mid-myocardium or endocardium) and rate of 
stimulation. These differences in action potential duration across the ventricular wall 
determine the transmural dispersion of repolarisation. When this transmural dispersion is 
exaggerated, opposite voltage gradients may occur and trigger oscillatory potentials, 
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block closely resemble the clinical characteristics of the LQT1 or LQT5 form of human 
congenital long QT syndrome. 
Using recently introduced molecular biology techniques, these bradycardia-related 
repolarisation abnormalities appear to be allelic variants in the coding region of congenital 
long QT syndrome genes, variants that can be identified in 10–15% of affected subjects. A 
recent retrospective study showed that 14% to 18% of subjects with atrio-ventricular block-
related QT-interval prolongation were carriers of a genetic mutation in genes coding for 
potassium channels. Another study showed that 36% of patients with complete atrio-
ventricular block and torsades de pointes had a genetic mutation involving HERG and 
SCN5A (Yoshida, 2001). In fact, the most commonly encountered mutation in this setting is 
in HERG genes, coding for potassium channel IKr. 
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limited amount of information that we dispose of regarding this issue. Still, much is 
expected from future molecular testing in these patients. 
4. Pathophysiology 
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The association between torsades de pointes and a prolonged QT interval has long been 
known, but the underlying mechanisms of torsades de pointes have yet to be satisfactorily 
elucidated. In general, alterations in cardiac ion currents which dictate the normal action 
potential play a major role in arrhythmogenesis. Both early afterdepolarisation - induced 
triggered activity (Cosio, 1991, Shimizu,1995, Burashnikov, 2002) and increased dispersion 
of repolarisation have been suggested as playing a role in the genesis of torsades de pointes. 
Significantly increased transmural dispersion of repolarisation favours re-entrant substrates 
that initiate and maintain torsades de pointes. 
QT intervals in humans are very variable, being strongly influenced by age, sex, heart rate 
or heart diseases. It would appear that subjects with a propensity to develop the syndrome 
have a subclinical abnormality in some of the ion channels dictating repolarisation, and / or 
a reduced repolarisation reserve. 
The latter hypothesis has been suggested by Roden et al (Roden, 1998). They hypothesized 
that the extent of QT lengthening in response to specific environmental triggers depends on 
the ventricular “repolarisation reserve”. This concept proposes that loss of one component 
(e.g. IKs) ordinarily will not lead to failure of repolarisation since multiple other currents 
flow across the myocyte membrane (e.g. IKr) also act to maintain repolarisation in normal 
ranges. However, when a reduction or down regulation in any of the currents involved in 
the repolarisation phase is overlapped by a destabilizing factor, this “reserve” is overcome 
and acquired long QT syndrome may become clinically obvious (Roden, 1998). This issue 
may occur in the female gender, when a factor such as bradycardia or hypokalaemia is 
present, in conditions that predispose to electrical remodelling such as heart failure, 
myocardial ischemia, or ventricular hypertrophy. 
It is well known that local action potential duration of myocardial cells displays 
considerable variability depending on many factors, including, in normal conditions, 
location in the ventricular wall (epicardium, mid-myocardium or endocardium) and rate of 
stimulation. These differences in action potential duration across the ventricular wall 
determine the transmural dispersion of repolarisation. When this transmural dispersion is 
exaggerated, opposite voltage gradients may occur and trigger oscillatory potentials, 
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namely phase 2 early afterdepolarisations and sustained abnormal electrical activity 
(Dangman, 1981, Brachmann, 1983, Levine, 1985, Roden, 1985, Davidenko, 1989). 
Rarely, a single severe abnormality in a major repolarizing current can elicit an abnormal 
phenotype, as in congenital long QT syndrome (Roden, 1996). More commonly, one or more 
pre-existing minor abnormalities of repolarisation result in a subclinical phenotype. 
Following recent advances in molecular biology and genetics, it has become clear that in 
some clinical instances (e.g. congestive heart failure or cardiac hypertrophy) ion channel 
genes become down-regulated and the consequent reduced ion currents are likely to cause 
prolonged myocardial repolarisation. If, within this framework, an environmental stressor 
able to further destabilize the “repolarisation reserve” interferes, a long QT syndrome may 
be unburied and the arrhythmic consequences may appear. 
Thus, a potentially dangerous stressor may appear completely safe when present in a large 
number of subjects. The risk may only be evident when the factor is present in a certain 
individual under certain circumstances. 
4.2 Pathophysiology of atrio-ventricular block-induced torsades de pointes 
Although a slow ventricular rate may be a major factor for inducing abnormal QT 
prolongation, the mechanism of QT prolongation in patients with bradycardia-related 
torsades de pointes is poorly understood. 
Farkas et al. showed for the first time that bilateral vagotomy can prevent drug-induced 
torsades de pointes in an in vivo rabbit model, demonstrating that vagally-mediated 
reductions in heart rate are necessary for the development of torsades de pointes (Farkas, 
2008). Torsades de pointes has been described in many conditions associated with 
bradycardia, such as atrio-ventricular block, drugs, vagotonia or hypothyroidism. 
Moreover, the occurrence of torsades de pointes in the presence of bradycardia is influenced 
by other factors such as gender, degree of QT prolongation or duration of bradycardia. 
An interesting observation shows that arrhythmogenic bradycardias are most commonly 
chronic, with a slow ventricular escape rhythm – a profile corresponding to atrio-ventricular 
block. Studies have reported that patients with atrio-ventricular block have significantly 
longer QT intervals than those with sinus bradycardia, even at comparable heart rates. This 
relative QT prolongation may be one of the major reasons that torsades de pointes is more 
commonly observed in chronic atrio-ventricular block than in sinus bradycardia. 
Clinical and experimental data show that the duration of atrio-ventricular block is  
an important determinant of the susceptibility to acquired torsades de pointes. Experimental 
studies show that torsades de pointes is rarely inducible at 0 weeks of atrio-ventricular  
block (acute atrio-ventricular block) but is inducible at 5 weeks (chronic atrio-ventricular 
block) in most animals (Vos, 1998). In a series of 64 patients with chronic atrio-ventricular 
block, Yiginer et al. reported a longer duration of bradycardia in the three patients who 
developed torsades de pointes (Yiginer, 2010). Concomitant to the duration of atrio-
ventricular block, the likelihood of structural and electrical alterations in myocardial cells 
may increase. 
4.2.1 Bradycardia-induced cardiac remodelling 
Atrio-ventricular block-induced volume overload initiates a number of adaptative processes 
that are aimed to compensate the decreased cardiac output and the increased end-diastolic 
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pressure. These remodelling processes offer both the “trigger” and “substrate” for the 
occurrence of torsades de pointes. 
Bradycardia-induced volume overload causes the development of a biventricular eccentric 
hypertrophy and consequently a non-homogenous lengthening of the ventricular action 
potential duration. Exact information concerning the sequence and nature of the time-
related electrophysiological process in hypertrophy are lacking, but there seems to be a 
parallelism between the evolutions of the two processes. These adaptations, alone or 
synergistically, increase the risk of early afterdepolarisations and / or delayed 
afterdepolarisation and therefore the risk of torsades de pointes. 
4.2.2 Structural remodelling during atrio-ventricular block 
Ventricular hypertrophy in this setting is a response of the heart to compensate the altered 
hemodynamic load induced by atrio-ventricular block (Vos, 1998). The process is initiated 
by mechanical factors and thereafter amplified by neurohumoral factors, such as adrenergic 
stimuli, the renin-angiotensin system, endothelin, or insulin-like growth factor. 
Autopsy studies have demonstrated increased heart weight to body weight ratios, with 
significant contributions of both the right and left ventricular mass. Morphologically, 
biventricular hypertrophy is characterized by an eccentric expansion with increased right 
and left ventricular diameters, as seen during volume overload (Verduyn, 2001). Photo- and 
electron-micrograph analyses have shown myocardial cell hypertrophy together with the 
parallel increases of collagen fibbers and extracellular space. 
Morphopathological studies have shown larger growth responses in the right than left 
ventricular myocytes, supporting the autopsy finding of a larger relative increase of the 
right than the left ventricular weight, as well as a more significant hypertrophy of right 
ventricular free wall and septal wall than of the left ventricular free wall (Verduyn, 2001, 
Sugiyama, 2002). The preponderance of right ventricular cell growth in atrio-ventricular 
block may reflect a greater impact on this chamber after the transition from sinus rhythm to 
idioventricular rhythm. 
This structural adaptation process is accompanied by electrophysiological remodelling. 
Prolongation of the left ventricular action potential is a consistent observation in myocardial 
hypertrophy of different causes in several species. Many of the sarcolemmal ion channels, 
exchangers, and pumps, as well as intracellular ion transporters, can show functional 
defects leading to delayed repolarisation. 
4.2.3 Electrical remodelling during atrio-ventricular block 
While electrical and structural changes in chronic atrio-ventricular block are aimed to 
maintain cardiac function, they also predispose to QT prolongation, leading to the onset of 
torsades de pointes. This association has been extensively evaluated in animal studies. 
Tsuji et al. reported the results obtained in a rabbit model with atrio-ventricular block 
induced by injection of formaldehyde into the atrio-ventricular node (Tsuji, 2002). These 
rabbits received ventricular pacing support after atrio-ventricular block induction. The 
authors demonstrated significant QT interval prolongation in the same day that they 
discontinued pacing, with further prolongation later on. Seventy % of the animals 
developed spontaneous torsades de pointes, with most episodes occurring during the first 
week of uncompensated bradycardia. Even more information has been offered by a rabbit 
model with atrio-ventricular block induced by transcatheter radiofrequency ablation of 
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namely phase 2 early afterdepolarisations and sustained abnormal electrical activity 
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Moreover, the occurrence of torsades de pointes in the presence of bradycardia is influenced 
by other factors such as gender, degree of QT prolongation or duration of bradycardia. 
An interesting observation shows that arrhythmogenic bradycardias are most commonly 
chronic, with a slow ventricular escape rhythm – a profile corresponding to atrio-ventricular 
block. Studies have reported that patients with atrio-ventricular block have significantly 
longer QT intervals than those with sinus bradycardia, even at comparable heart rates. This 
relative QT prolongation may be one of the major reasons that torsades de pointes is more 
commonly observed in chronic atrio-ventricular block than in sinus bradycardia. 
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an important determinant of the susceptibility to acquired torsades de pointes. Experimental 
studies show that torsades de pointes is rarely inducible at 0 weeks of atrio-ventricular  
block (acute atrio-ventricular block) but is inducible at 5 weeks (chronic atrio-ventricular 
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pressure. These remodelling processes offer both the “trigger” and “substrate” for the 
occurrence of torsades de pointes. 
Bradycardia-induced volume overload causes the development of a biventricular eccentric 
hypertrophy and consequently a non-homogenous lengthening of the ventricular action 
potential duration. Exact information concerning the sequence and nature of the time-
related electrophysiological process in hypertrophy are lacking, but there seems to be a 
parallelism between the evolutions of the two processes. These adaptations, alone or 
synergistically, increase the risk of early afterdepolarisations and / or delayed 
afterdepolarisation and therefore the risk of torsades de pointes. 
4.2.2 Structural remodelling during atrio-ventricular block 
Ventricular hypertrophy in this setting is a response of the heart to compensate the altered 
hemodynamic load induced by atrio-ventricular block (Vos, 1998). The process is initiated 
by mechanical factors and thereafter amplified by neurohumoral factors, such as adrenergic 
stimuli, the renin-angiotensin system, endothelin, or insulin-like growth factor. 
Autopsy studies have demonstrated increased heart weight to body weight ratios, with 
significant contributions of both the right and left ventricular mass. Morphologically, 
biventricular hypertrophy is characterized by an eccentric expansion with increased right 
and left ventricular diameters, as seen during volume overload (Verduyn, 2001). Photo- and 
electron-micrograph analyses have shown myocardial cell hypertrophy together with the 
parallel increases of collagen fibbers and extracellular space. 
Morphopathological studies have shown larger growth responses in the right than left 
ventricular myocytes, supporting the autopsy finding of a larger relative increase of the 
right than the left ventricular weight, as well as a more significant hypertrophy of right 
ventricular free wall and septal wall than of the left ventricular free wall (Verduyn, 2001, 
Sugiyama, 2002). The preponderance of right ventricular cell growth in atrio-ventricular 
block may reflect a greater impact on this chamber after the transition from sinus rhythm to 
idioventricular rhythm. 
This structural adaptation process is accompanied by electrophysiological remodelling. 
Prolongation of the left ventricular action potential is a consistent observation in myocardial 
hypertrophy of different causes in several species. Many of the sarcolemmal ion channels, 
exchangers, and pumps, as well as intracellular ion transporters, can show functional 
defects leading to delayed repolarisation. 
4.2.3 Electrical remodelling during atrio-ventricular block 
While electrical and structural changes in chronic atrio-ventricular block are aimed to 
maintain cardiac function, they also predispose to QT prolongation, leading to the onset of 
torsades de pointes. This association has been extensively evaluated in animal studies. 
Tsuji et al. reported the results obtained in a rabbit model with atrio-ventricular block 
induced by injection of formaldehyde into the atrio-ventricular node (Tsuji, 2002). These 
rabbits received ventricular pacing support after atrio-ventricular block induction. The 
authors demonstrated significant QT interval prolongation in the same day that they 
discontinued pacing, with further prolongation later on. Seventy % of the animals 
developed spontaneous torsades de pointes, with most episodes occurring during the first 
week of uncompensated bradycardia. Even more information has been offered by a rabbit 
model with atrio-ventricular block induced by transcatheter radiofrequency ablation of 
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atrio-ventricular node. Chronic endocardial ventricular pacing at near-physiologic rate was 
installed immediately after the ablation procedure. The authors showed identical 
amplitudes of all repolarizing currents in atrio-ventricular block group and sham-operated 
group. Moreover, they showed a similar down-regulation in the affected currents regardless 
of ventricular cavity stimulation (left or right ventricle) and they concluded that secondary 
electrical remodelling is unrelated to the loss of atrio-ventricular synchrony, suggesting that 
bradycardia alone suffices to turn on the electrical remodelling process. 
In vivo experiments in dogs indicate the importance of bradycardia-dependent early 
afterdepolarisations, increased regional dispersion of repolarisation and multiple ectopic 
beats for the initiation of torsades de pointes. Fast heart rates tend to oppose these actions, 
preventing torsades de pointes. 
Several mechanisms have been proposed for early afterdepolarisations occurrence in this 
setting (Emori, 2001, Yan, 2001). These abnormalities appear to be secondary to both 
bradycardia-dependent depression of electrogenic Na+ pumping and more complete 
inactivation of K+ currents. Vos et al. showed a high incidence of early afterdepolarisations 
in dogs with chronic atrio-ventricular block after d-sotalol administration and proposed 
significant down-regulation of the slow component of the delayed rectifier K+ current (IKs) 
and that of the rapid component (IKr) as potential mechanism (Vos, 1995, 1998). 
Enhanced regional dispersion of repolarisation is considered to be the consequence of 
inhomogeneous prolongation of ventricular action potential (more in the left than the right 
ventricle), probably reflecting the existence of significant repolarisation gradients in closely 
adjacent areas, possibly the septum. Interventricular differences of the action potential are 
known to exist in the normal myocardium of dogs with sinus rhythm. In chronic atrio-
ventricular block, larger action potential durations have been documented in left mid-
myocardial compared with right ventricular myocytes, in contrast to the larger degree of 
hypertrophy in the latter. The observation that a down-regulation of IKs is present in both 
ventricles while IKr down-regulation is mainly expressed in the right ventricle could explain 
these abnormalities. 
Other currents such as It0, ICaL or IK1 have been reported as unchanged in a number of 
studies. 
However, the observations are contradictory. While some suggest that the role of It0  
is unlikely given the fact that the spike-and-dome configuration of the action potential  
is preserved, others suggest that low ventricular rates are associated with submaximal 
activation of It0, which would shift the plateau phase of the action potential to voltage  
levels in which Ca2+ window current availability is increased, predisposing to torsades de 
pointes. 
The fact that the action potential duration to 95% of complete repolarisation and action 
potential duration to 50% of complete repolarisation have been found to be increased to a 
similar extent indicates that the delay of repolarisation is most likely due to a disturbance at 
the plateau level, sustaining the central role of IKr and IKs in this setting. 
Additional insights into the ionic mechanisms of action potential prolongation in chronic 
atrio-ventricular block come from experiments with almokalant. After block of IKr during 
almokalant treatment, the action potential duration was found much larger in chronic atrio-
ventricular block myocytes than in sinus rhythm controls. This suggests that ionic currents 
other than IKr contribute to the abnormal repolarisation in chronic atrio-ventricular block, 
even though the role of IKr can not be excluded. These results have been confirmed by other 
similar studies, which show uniformly distributed IKs down-regulation by 50% in both 
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ventricles, while a similar degree of IKr inhibition was apparent only in the right but not in 
the left ventricle. 
In vivo recordings in dog with chronic atrio-ventricular block demonstrate that another 
important factor involved in the occurrence of torsades de pointes is represented by 
ventricular ectopic beats. However, their origin and mechanisms remain obscure for the 
moment. 
5. Conclusions 
Investigations of the clinical aspects and molecular mechanisms of long QT syndrome have 
provided novel and important insights into the basis of ventricular arrhythmias and shown 
how small perturbations in ion flow can have important consequences in human health. 
Even if molecular diagnosis appears to be an appealing way of integrating contemporary 
genomics with arrhythmia science, several obstacles limit its wide availability. Molecular 
diagnosis is restricted by the very large number of candidate genes and the correspondingly 
huge number of described polymorphisms. Moreover, most association studies have not 
proven to be reproducible, raising the problem of false positives. There is also the issue that, 
owing to its restrictive costs, mutation screening will be limited to a limited number of 
specialized centres for some time. 
Though great progress has been made, many important issues require further clarification. 
A major challenge in the future will be to understand the complex mechanisms of 
repolarisation and to assess the individual risk of malignant arrhythmia more precisely. 
Moreover, mutations in other ion channel genes, still unrecognized, could be responsible for 
different variants of long QT syndrome. 
We recommend systematically genotyping patients with acquired long QT syndrome and 
torsades de pointes. The next step could be represented by case-control studies of gene 
polymorphisms in pace-maker patients to find the possible markers of susceptibility to 
malignant arrhythmias during bradycardia. 
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1. Introduction 
Before discussing rhythms and pacemakers, we would like to begin this chapter by quoting 
Albert Einstein (Einstein, 1934): 
“Our experience hitherto justifies us in trusting that nature is the realization of the 
simplest that is mathematically conceivable. I am convinced that purely mathematical 
construction enables us to find those concepts and those lawlike connections between 
them that provide the key to the understanding of natural phenomena”. 
Indeed, it seems that nature can be described and understood in mathematical terms. In the 
context of physical phenomena nobody can deny the usefulness, applicability and relevance 
of mathematical models. However, as strange and paradoxical as it might appear, the 
importance of mathematics in biology is still questioned. 
In the case of biological systems it is particularly important to discuss whether this 
confidence is based on facts. Among life scientists it is a widespread opinion that 
mathematical models just put in very complicated terms what they already knew.  
On the other hand this is in sharp contrast with what Darwin expresses in a letter, regretting 
not having deepened in some basic mathematical principles (Nowak, 2006). 
Mathematical models incorporate experimental information, both, quantitative and 
qualitative. Models have to mimic the observed behavior, but this is not enough. They have 
to allow for the understanding of the mechanisms underlying the studied phenomenon and 
also have to be able to make predictions (again, both qualitative and quantitative).  
The construction of a mathematical model is not an unidirectional process. The feedback at 
the different stages of the process is one of the most important and useful characteristics (see 
Figure 1).  A mathematical model provides the necessary elements to compare and even 
discard different hypotheses, and, in many cases, to propose new experiments (Fuentes-
Pardo et al., 2005). 
Just to provide a few examples in which the construction of a mathematical model has been 
essential in the understanding of a biological process we mention the work by Hodgkin and 
Huxley in the early fifties,  on the existence of selective ion channels on the membrane of a 
neuron. Their model not only enabled them to test this hypothesis, namely, but also to 
deduce qualitative properties of the transmission of electrical impulses, leading to the notion 
of action potential (Hodkgin et al., 1952a; Hodgkin & Huxley, 1952b, 1952c, 1952d, 1952e). In 
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the past few years, important progress has been made in establishing mathematical models 
at the basis of the understanding of many biological systems: genetic regulatory networks, 
ecological dynamics, morphogenetic process and so on. At the same time, it is important to 
mention the fact that some of these models have been proven efficient tools in the design of 
new treatments or in implementing new therapies (Murray, 2003a, 2003b).   
 
 
Fig. 1. Relationship among experiments, models, and theories. 
As we hope we will make clear in what follows, it is absolutely necessary to incorporate 
modeling tools in the study of circadian rhythms and their pacemakers. We could use the 
title of the famous song by George Gershwin “I’ve got rhythm” to express our conviction 
that without a solid mathematical framework, we will never have rhythms or at least a good 
understanding of them. 
In the rest of this chapter we are going to explain the main characteristics of a circadian 
rhythm and the possible organization of the structures in charge of generating the circadian 
oscillation, i.e. the pacemaker(s). Also we are going to expose the importance of high 
frequency oscillators (ultradian oscillators) in the generation of the circadian oscillation in 
the pacemaker and finally we are going to discuss the development of a mathematical 
model related to the emergence of an oscillation with a period of about 24 hours in a 
circadian pacemaker and the concomitant phenomenon of synchronization.  
The story began a few years ago, when a biologist asked a mathematician to construct a 
mathematical model for the emergence of the crayfish circadian rhythm. The mathematician 
asked her what the goal was.  The reply can be summarized as follows: 
—To understand in depth the observed experimental phenomena in order to explain the 
mechanisms underlying to the emergence of circadian rhythms in the corresponding 
pacemaker.  
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What followed was a close collaboration which involved, among other things, a great deal of 
patience from both, in order to be able to establish a common language and the possibility of 
“translating” questions, problems and assertions phrased in a biological way in the 
mathematical jargon and the other way around. As a result of this collaboration (that still 
continues) an important point was made: 
A focal point to the understanding the generation of the 24 hour oscillation in the circadian 
pacemaker is a more primeval time-base, one that encompasses both biophysics and 
biochemistry, both cellular biology and cell reproduction.  This is a high frequency clock or   
ultradian clock (Lloyd et al., 2008).  
Considering that the physiological basis for the pacemaker function has to be at the cellular 
level, it is a fundamental question how individual cells interact among themselves in order 
to produce a coherent collective behavior that exhibits periodic features. The study of how  
biological systems organize themselves in time (including the study of biological clocks and 
biological rhythms), how time and space-time structures and hierarchies arise in living 
organisms, what we might call space-time morphogenesis, is still far from satisfactory. In 
what follows we present a concrete attempt to provide a mathematical framework in a 
specific example.  
The chapter is organized as follows. In section 2 we briefly discuss the basic features of 
circadian rhythms and the circadian pacemaker(s) organization. Section 3 is devoted to the 
molecular and cellular basis of the circadian pacemaker functioning. In section 4 we provide 
a short review of the presence of ultradian oscillators that are believed to be responsible for 
the emergence of oscillatory behavior in the circadian pacemaker.  Section 5 deals with the 
specific case of the crayfish, presenting both experimental results as well as a mathematical 
model. We present in section 6 a very simple model that might account for the appearance 
of low frequency oscillations in the (circadian) pacemaker as a result of the coupling of 
ultradian (high frequency) nonlinear oscillators. We conclude with some general remarks 
and, more importantly, with open problems and further questions on the subject. 
2. What are circadian rhythms? 
Many physiological variables change according to some temporal signals like the hour of 
the day or the seasons during the year. The study of biological rhythms is centered on the 
understanding of the mechanisms underlying the periodical changes exhibited by the 
functions of the organisms, as well as the relationship they maintain with external signals. 
Among the collection of biological rhythms it can be distinguished those belonging to the 
circa (lit. near) class. These rhythms are designed in that way because when periodical 
signals from the environment are eliminated, the oscillation persists with a period similar, 
but different from that of the external influence. For example, under constant environmental 
conditions, the circatidal, circadian, circalunar, and circannual rhythms show a period of 
approximately 12 hours, 24 hours, 28 days, and 365 days respectively. In natural conditions, 
however, the external perturbations are present, the period of these rhythms is exactly equal 
to the period of the external perturbation. 
A common feature of circa rhythms is that are all the expression of endogenous oscillator 
networks. In circa rhythm there exists a structure, known as the pacemaker, which has the 
ability to oscillate even under constant environmental conditions. This is true under normal 
circumstances, when it is part of the organism and even when it has been removed from it. 
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2. What are circadian rhythms? 
Many physiological variables change according to some temporal signals like the hour of 
the day or the seasons during the year. The study of biological rhythms is centered on the 
understanding of the mechanisms underlying the periodical changes exhibited by the 
functions of the organisms, as well as the relationship they maintain with external signals. 
Among the collection of biological rhythms it can be distinguished those belonging to the 
circa (lit. near) class. These rhythms are designed in that way because when periodical 
signals from the environment are eliminated, the oscillation persists with a period similar, 
but different from that of the external influence. For example, under constant environmental 
conditions, the circatidal, circadian, circalunar, and circannual rhythms show a period of 
approximately 12 hours, 24 hours, 28 days, and 365 days respectively. In natural conditions, 
however, the external perturbations are present, the period of these rhythms is exactly equal 
to the period of the external perturbation. 
A common feature of circa rhythms is that are all the expression of endogenous oscillator 
networks. In circa rhythm there exists a structure, known as the pacemaker, which has the 
ability to oscillate even under constant environmental conditions. This is true under normal 
circumstances, when it is part of the organism and even when it has been removed from it. 
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This structure has also the ability to impose its rhythm to other related units within the 
organism called effectors. 
In this presentation, we discuss circadian rhythms, which are based on a circadian biological 
clock or circadian pacemaker that has a free-running period of 20-28 hour. This clock is able 
to synchronize itself to 24-hour environmental cycles, namely the light-dark cycles from the 
Earth rotation. 
Circadian rhythms are relevant to many processes and have received considerable attention. 
We mention the following two important facts: 
1. Their universality. With the exception of bacteria and simpler organisms, all living 
organisms that have been studied exhibit some kind of rhythm. 
2. Their fundamental role in the temporal organization of the physiological and 
behavioral functions of  living organisms. 
Although circadian rhythms have been well known since antiquity, the existence of the 
corresponding biological clocks has only been, relatively speaking, recently accepted 
(around the sixties). Since then, researchers have gathered evidence in favor of the existence 
of endogenous biological circadian oscillators or circadian pacemakers.  
2.1 Organization of circadian pacemakers  
In the early days of chronobiology the notion of circadian organization was quite simple: 
inside the organism there was a clock (pacemaker) able to be entrained by light via 
photoreceptors and to impose its rhythm to some structures in the body called effector 
organs (Zivkovic B., 2006). 
This model became difficult to sustain because of new experimental evidence. For example, 
it was recognized that other signals as temperature, food, or social cues are able to 
synchronize the pacemaker (Zivkovic B., 2006).  
Moreover, experimental results pointed out to the existence of more than one pacemaker 
inside the organism: in certain environmental conditions circadian rhythms would split into 
two or more components, each with a different endogenous period; every component 
observed corresponds to the dynamics of each pacemaker (Zivkovic B., 2006). 
In some organisms it appeared that the organization between multiple pacemakers was 
hierarchical, i.e., there was a master or central pacemaker whose output affects the phase 
(synchronizes) of the group of peripheral or slaves pacemakers. However in other 
organisms it appeared that the organization was non-hierarchical, i.e., each pacemaker 
influences all the others, and as a group, generates an output that drive all the overt 
rhythms (Zivkovic B., 2006). 
The next step was the recognition that the information does not necessarily flow in just one 
direction: from the environment, via sensory systems, to the pacemakers, to the effector 
organs. The pacemaker(s) also generate(s) a circadian rhythm in sensory sensitivity. For 
example the eye may be more sensitivity to light during the night than during the day. 
Other form of feedback was, for example, the effect of an hormone released from an effector 
organ over the pacemaker dynamics (Zivkovic B., 2006). 
2.2 Synchronization 
Other remarkable characteristic of the circa rhythms is that, although their oscillations are 
due to endogenous mechanisms, they have the ability “to follow” the rhythm coming from 
external signals. An alignment of the period and phase of the circa rhythms to the period 
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and phase of some external rhythms can be observed. This property is known as extrinsic 
synchronization or synchronization by external stimulus. 
In contrast to extrinsic synchronization, in which, as we just mentioned, an external signal 
plays a fundamental role in inducing a coherent collective behavior, there is another kind of 
coordinated in time regime. We could call this intrinsic or spontaneous synchronization. In 
this, there is no distinguished agent.  
In order to have this functionality of external synchronization, it has been postulated that 
the biochronometric system has to possess an internal synchronization system regulating 
the pacemaker functional units and their interactions with an external synchronization 
system. 
3. How does the circadian pacemaker work? 
In several organisms including fungi, plants, worms, crustaceans, insects, mollusca, birds 
and mammals, circadian pacemakers, centrals and peripherals, have been identified by 
performing lesion studies, in vitro and in vivo functional studies, as well as transplant 
studies. However the way the pacemakers work is far from being understood ( Paranjpe & 
Sharma, 2005).   
It is now common to begin from a general assertion the circadian oscillation exhibited by the 
pacemaker will be describable as a circular list of causes and effects that closes within the 
bounds of a single cell, even in the most complicated systems as in mammals (Dunlap, 
1999).  
In an attempt to understand the mechanisms underlying the dynamics of circadian 
pacemaker, molecular models have been proposed. As in any other self-sustaining 
oscillatory process, these molecular models are based on negative and positive feedback 
loops. Clock genes turn on and off because of the proteins they encode. It has been 
suggested that synchronization of the intracellular clock with the geophysical cycles is due 
to the degradation of a substance and formation of another, both induced by light (Harmer 
et al., 2001). 
Now, assuming that there is (and that we reasonably understand) “an intracellular 
synchronizable clock” in each circadian pacemaker cells, it still remains to be elucidated 
how the molecular time arising from the molecular clock is transferred to the cell in order to 
promote changes in its excitability and modify the physiology and behavior of the organism. 
This is a very complicated problem for which, up to the present, there is no adequate model. 
Moreover, it was discovered that every cell in the body contain a molecular clock, i.e. every 
cell is a secondary or slave pacemaker with a molecular machinery very similar to one in the 
central or master pacemaker. However it is known that if we remove a central pacemaker all 
overt rhythms finished, while removal a peripheral pacemaker does not; that 
transplantation of a central pacemaker tissues also transplant the phase and the period of all 
overt rhythms of the donor to the host, while transplantation of peripheral pacemaker does 
not do, i.e., the observed period and phase were that of the host; that the central pacemakers 
cells kept in a dish cycling “indefinitely” while peripheral pacemaker damp into 
arrythmicity after just a few cycles (Zivkovic, 2006). 
Recent results have made  evident the important role of  electrical signaling at the cellular 
level.  It was shown that in order to maintain a robust circadian oscillation, the molecular 
feedback loops are necessary but not sufficient. The rhythmic nature of pacemaker cells was 
traditionally described considering the individual properties of the cells. Nitabatch and cols. 
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and phase of some external rhythms can be observed. This property is known as extrinsic 
synchronization or synchronization by external stimulus. 
In contrast to extrinsic synchronization, in which, as we just mentioned, an external signal 
plays a fundamental role in inducing a coherent collective behavior, there is another kind of 
coordinated in time regime. We could call this intrinsic or spontaneous synchronization. In 
this, there is no distinguished agent.  
In order to have this functionality of external synchronization, it has been postulated that 
the biochronometric system has to possess an internal synchronization system regulating 
the pacemaker functional units and their interactions with an external synchronization 
system. 
3. How does the circadian pacemaker work? 
In several organisms including fungi, plants, worms, crustaceans, insects, mollusca, birds 
and mammals, circadian pacemakers, centrals and peripherals, have been identified by 
performing lesion studies, in vitro and in vivo functional studies, as well as transplant 
studies. However the way the pacemakers work is far from being understood ( Paranjpe & 
Sharma, 2005).   
It is now common to begin from a general assertion the circadian oscillation exhibited by the 
pacemaker will be describable as a circular list of causes and effects that closes within the 
bounds of a single cell, even in the most complicated systems as in mammals (Dunlap, 
1999).  
In an attempt to understand the mechanisms underlying the dynamics of circadian 
pacemaker, molecular models have been proposed. As in any other self-sustaining 
oscillatory process, these molecular models are based on negative and positive feedback 
loops. Clock genes turn on and off because of the proteins they encode. It has been 
suggested that synchronization of the intracellular clock with the geophysical cycles is due 
to the degradation of a substance and formation of another, both induced by light (Harmer 
et al., 2001). 
Now, assuming that there is (and that we reasonably understand) “an intracellular 
synchronizable clock” in each circadian pacemaker cells, it still remains to be elucidated 
how the molecular time arising from the molecular clock is transferred to the cell in order to 
promote changes in its excitability and modify the physiology and behavior of the organism. 
This is a very complicated problem for which, up to the present, there is no adequate model. 
Moreover, it was discovered that every cell in the body contain a molecular clock, i.e. every 
cell is a secondary or slave pacemaker with a molecular machinery very similar to one in the 
central or master pacemaker. However it is known that if we remove a central pacemaker all 
overt rhythms finished, while removal a peripheral pacemaker does not; that 
transplantation of a central pacemaker tissues also transplant the phase and the period of all 
overt rhythms of the donor to the host, while transplantation of peripheral pacemaker does 
not do, i.e., the observed period and phase were that of the host; that the central pacemakers 
cells kept in a dish cycling “indefinitely” while peripheral pacemaker damp into 
arrythmicity after just a few cycles (Zivkovic, 2006). 
Recent results have made  evident the important role of  electrical signaling at the cellular 
level.  It was shown that in order to maintain a robust circadian oscillation, the molecular 
feedback loops are necessary but not sufficient. The rhythmic nature of pacemaker cells was 
traditionally described considering the individual properties of the cells. Nitabatch and cols. 
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questioned this premise showing that interneuronal communication is necessary to sustain 
molecular, cellular and systemic rhythms (Nitabach et al., 2002, 2005, 2006). 
So, as we can see, the panorama is very complicated. 
4. The oscillation in the circadian pacemaker by coupling ultradian 
oscillations 
Research on biological clocks has been centered in the circadian ones. That is why they were 
frequently employed as a reference point, in particular  with respect to the value of its  
frequency: rhythms that have a frequency less than that of the circadian rhythms were called 
infradian and those having a bigger frequency were called ultradian rhythms. 
As we previously noted, organisms possess a pacemaker that matches physiological 
functions to the 24 hour cycle of day and night on the Earth. Since 1971 when R. J. Konopka 
and S. Benzer (Konopka & Benzer, 1971) identified the first clock-gene up to date, there were 
many significant advances in the comprehension about the mechanisms underlying the 
generation of circadian rhythms. However the paradigm that mechanisms generating a 
period of about 24 hours also have a period of 24 hours (that is the fact that every cell in the 
pacemaker is capable of sustaining a 24 hour oscillation individually in its own activity), 
every time is less solid because of new experimental evidences that explore the possibility 
that the circadian pacemaker is an emergent property of circuit interactions. In this section 
we argue that ultradian oscillators are coupled to yield a composite circadian pacemaker.  
As Paetkau and collaborators. pointed out (Paetkau et al., 2006), “the beats” mechanism has 
been largely ignored because of a number of critical arguments, but most of the criticisms 
predated gene regulatory model of circadian oscillation. 
First of all, 24 hours is a long time in terms of the coherent intracellular dynamics of 
organisms. We only have to think, for example, of the temporal scale of energy generation, 
metabolic reactions, transcriptional order, and cell proliferation and development. All these 
processes make evident the presence and ubiquity of ultradian oscillators in biology: with a 
period of about 40 minutes, the oxygen consumption and other metabolic processes in  
Acanthamoeba  castellanii; similar ultradian clocks were observed in other protists (ciliates and 
flagellates) and yeast; a 40 minute cycle in general transcriptional activity in yeast; with a 
period of 69 minutes, respiration in Dictyostelium; 3 hour cycles of expression of the 
mammalian p53 protein; 2 hour periodicity in the expression of the Notch effector Hes1 in 
cultured cells; a 1.5–3  hour periodicity in the expression of NF-κB signaling molecule in 
mouse cells in culture, among many others (Lloyd & Murray, 2007; Paetkau et al., 2006). 
The complex time structure of organisms requires the synchronized operation of multiple 
processes in many time domains. To focus exclusively on one time domain and thereby 
ignoring the full complexity of the system is to risk misconception of underlying 
mechanisms and to oversimplify the whole phenomenon. Several authors have suggested 
that at least some circadian pacemakers comprise coupled ultradian ones. Theodosios 
Pavlidis, in 1969 (Pavlidis, 1969, 1971), proposed the idea of generating slow rhythms from 
relatively fast biochemical processes by weak coupling of ultradian oscillators. Many other 
modes of coupling are possible, and the over all period of the whole may be longer or 
shorter than the free-running period of the longest or shortest component, respectively 
(Winfree, 1967, 2001).  
The presence of 'beats' was noted in several experimental studies and models and it has 
been suggested as a mechanism for producing circadian oscillations. For example, Patekau 
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and collaborators (Paetkau et al., 2006) propose a model in  which two independent 
transcriptional-translational oscillators with periods much shorter than 24 hours are coupled 
to drive a forced oscillator that has a circadian period, using mechanisms and parameters of 
conventional molecular biology. The Drosophila circadian clock can be modeled as a system 
of coupled ultradian ones based on data showing ultradian peaks in the power spectrum 
(Dowse & Ringo, 1987). Barrio and cols. (Barrio et al., 1997) developed a theoretical model of 
ensambles of mutually coupled ultradian oscillators to explain the generation of circadian 
rhythms in mammals. Díez-Noguera (Díez-Noguera, 1994) propose a functional model of 
the circadian system based on the degree of intercommunication in a complex system (the 
circadian pacemaker). The model was conceived to explain previous results concerning the 
maturation of motor activity in young rats. The maturation of the rhythm shows a 
predominance of ultradian components just after weaning, which disappear gradually when 
the circadian rhythm becomes apparent.  
5. Experiments and mathematical models from the pacemaker crayfish 
Crayfish is a nocturnal freshwater crustacean belonging to the Decapoda Order. With 
respect to the study of circadian rhythms crayfish has proved to be an excellent model due 
to its ability to survive in the non-natural conditions of the laboratory. 
In this animal it has been detected a great variety of  circadian rhythms in both behavior and 
physiological activity (Aréchiga et al., 1993). An example is the rest-activity (the motor) 
circadian rhythm and the circadian rhythm of sensitivity to light of retinular cells, (ERG 
circadian rhythm, (see Figure 2). 
 
 
Fig. 2. Crayfish motor circadian rhythm (A) and ERG circadian rhythm (B).  
5.1 Pacemaker organization for crustaceans 
For crustaceans it has been proposed the existence of a multioscillatory pacemaker system 
(Aréchiga, 1993; Rodíguez-Sosa, 2008). To define a circadian system of multiple oscillators, 
identification of its individual components becomes the first task. It must be shown that 
each of these pacemakers is able to maintain a self-sustained circadian rhythmicity in 
isolation as well as being in synchrony within the whole circadian system.  
Circadian rhythmicity has been demonstrated to be expressed in various isolated structures 
such as the isolated eyestalk (Sánchez & Fuentes-Pardo, 1977), the neurosecretory X-organ-
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shorter than the free-running period of the longest or shortest component, respectively 
(Winfree, 1967, 2001).  
The presence of 'beats' was noted in several experimental studies and models and it has 
been suggested as a mechanism for producing circadian oscillations. For example, Patekau 
 
Ultradian Rhythms Underlying the Dynamics of the Circadian Pacemaker 57 
and collaborators (Paetkau et al., 2006) propose a model in  which two independent 
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to its ability to survive in the non-natural conditions of the laboratory. 
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Fig. 2. Crayfish motor circadian rhythm (A) and ERG circadian rhythm (B).  
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For crustaceans it has been proposed the existence of a multioscillatory pacemaker system 
(Aréchiga, 1993; Rodíguez-Sosa, 2008). To define a circadian system of multiple oscillators, 
identification of its individual components becomes the first task. It must be shown that 
each of these pacemakers is able to maintain a self-sustained circadian rhythmicity in 
isolation as well as being in synchrony within the whole circadian system.  
Circadian rhythmicity has been demonstrated to be expressed in various isolated structures 
such as the isolated eyestalk (Sánchez & Fuentes-Pardo, 1977), the neurosecretory X-organ-
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sinus gland system and in the retina-lamina ganlglionaris system (Aréchiga & Rodríguez-
Sosa, 1998, 2002; Rodríguez-Sosa et al., 1994; Uribe et al., 1998, as cited in Rodríguez-Sosa, 
2008). Another possible pacemaker for the crayfish circadian system is the supraesophageal 
ganglion. Its abblation supresses circadian rhythmicity, however, no experiments in vitro 
have been reported and some rhythms persists after the lesion (Hernández & Fuentes-
Pardo, 2001).  The  way  in  which  these  pacemakers interact  to  generate  a  synchronous  
rhythmicity  is still unknown (See Figure 3). 
 
 
Fig. 3. Schematic representation of the crayfish cerebroid ganglion  and eyestalks. A) 
Cerebroid ganglion, B) Eyestalk and C) Retina are the proposed pacemakers (Modified from 
Aréchiga et al., 1993). 
Moreover, at present, there are no conclusive studies about the origin of the circadian 
oscillations in one of the pacemakers. An approach to this problem involves the study of the 
ontogeny of this circadian rhythm. 
For the expression of a circadian pattern it is necessary that the anatomical substrate reaches 
maturity and establishes the necessary structural and physiological relationships between its 
parts. During development, different structures and functions begin to show some temporal 
organization that eventually will acquire circadian characteristics. This implies that 
underlying the sense of time of the organism there are a number of changes in its anatomical 
and functional organization in the pacemaker. Indeed, the organism exhibits successive 
changes in period, relative amplitude and activity level of their circadian rhythms during all 
the ontogeny process. It can be assumed that variation in these parameters involves changes 
in the structures that participate in the generation of the rhythm, namely, the pacemaker 
(Fanjul-Moles et al., 1987). 
5.2 The presence of ultradian and circadian rhythms in the pacemaker emergent 
temporal patterns  
Ultradian and circadian rhythms have been reported in various studies on crustaceans such 
as locomotor activity and the photoresponse amplitude in the crayfish retina or cardiac 
activity (Aguzzi et al.; Fanjul-Moles & Prieto-Sagredo, 2003; Miranda-Anaya et al., 2003b,  as 
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cited in Rodríguez-Sosa, 2008). The mechanisms underlying this interaction have been a 
matter of discussion in several reports. In what follows we are going to present our 
experimental results, interpretation and mathematical modeling. 
Experimental data show that during crayfish ontogeny, before the complete maturation of 
its neuroendocrine system, there are only ultradian frequency oscillators in the pacemaker. 
Because of the influence of some neurosecretions, presumably the pigment dispersing 
hormone (PDH), high frequency oscillations progressively vanish until they completely 
disappear and the circadian oscillation appears (Figure 4). 
 
 
Fig. 4. Ontogeny of the ERG circadian rhythm. In very young crayfish (immediately after 
hatching), the ERG amplitude is very low (~4 V) and shows clear ultradian fluctuations 
with a period ranging from 15 min to 4 h. Four weeks old crayfish express higher ERG 
amplitude (~50 V) and, for the first time, the presence of a circadian oscillation. Older 
animals (around 5 months after hatching) show a progressive increment in ERG amplitude 
and period length, as well as a progressive disappearance of the high frequency cycles. 
The four hour  pattern (ultradian oscillations) found in the youngest crayfish is similar to the 
pattern found in the ERG amplitude recorded from the isolated eyestalk (a presumible 
pacemaker) of an adult crayfish (Sánchez & Fuentes-Pardo, 1976). In this experimental 
design, it could be observed that, superimposed on circadian variations in the ERG 
amplitude, there were high frequency cycles  that seem to be correlated with the circadian 
time, since their amplitude depended on the phase of the circadian rhythm when they 
appeared. 
Another experimental design in which ultradian oscillations appear superimposed to the 
ERG circadian rhythm was recorded from crayfish deprived of the sinus glands. A plausible 
interpretation to these results is that the organization of a circadian rhythm is produced as a 
consequence of the loss of a release from the sinus gland of a neurohormonal substance, 
presumptively PDH (Moreno-Sáenz et al., 1986). 
In addition to the past scenarios, we have observed the presence of ultradian rhythms  in 
experiments in which we used deuterium oxide (D2O) in long term recordings of the ERG 
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sinus gland system and in the retina-lamina ganlglionaris system (Aréchiga & Rodríguez-
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ganglion. Its abblation supresses circadian rhythmicity, however, no experiments in vitro 
have been reported and some rhythms persists after the lesion (Hernández & Fuentes-
Pardo, 2001).  The  way  in  which  these  pacemakers interact  to  generate  a  synchronous  
rhythmicity  is still unknown (See Figure 3). 
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cited in Rodríguez-Sosa, 2008). The mechanisms underlying this interaction have been a 
matter of discussion in several reports. In what follows we are going to present our 
experimental results, interpretation and mathematical modeling. 
Experimental data show that during crayfish ontogeny, before the complete maturation of 
its neuroendocrine system, there are only ultradian frequency oscillators in the pacemaker. 
Because of the influence of some neurosecretions, presumably the pigment dispersing 
hormone (PDH), high frequency oscillations progressively vanish until they completely 
disappear and the circadian oscillation appears (Figure 4). 
 
 
Fig. 4. Ontogeny of the ERG circadian rhythm. In very young crayfish (immediately after 
hatching), the ERG amplitude is very low (~4 V) and shows clear ultradian fluctuations 
with a period ranging from 15 min to 4 h. Four weeks old crayfish express higher ERG 
amplitude (~50 V) and, for the first time, the presence of a circadian oscillation. Older 
animals (around 5 months after hatching) show a progressive increment in ERG amplitude 
and period length, as well as a progressive disappearance of the high frequency cycles. 
The four hour  pattern (ultradian oscillations) found in the youngest crayfish is similar to the 
pattern found in the ERG amplitude recorded from the isolated eyestalk (a presumible 
pacemaker) of an adult crayfish (Sánchez & Fuentes-Pardo, 1976). In this experimental 
design, it could be observed that, superimposed on circadian variations in the ERG 
amplitude, there were high frequency cycles  that seem to be correlated with the circadian 
time, since their amplitude depended on the phase of the circadian rhythm when they 
appeared. 
Another experimental design in which ultradian oscillations appear superimposed to the 
ERG circadian rhythm was recorded from crayfish deprived of the sinus glands. A plausible 
interpretation to these results is that the organization of a circadian rhythm is produced as a 
consequence of the loss of a release from the sinus gland of a neurohormonal substance, 
presumptively PDH (Moreno-Sáenz et al., 1986). 
In addition to the past scenarios, we have observed the presence of ultradian rhythms  in 
experiments in which we used deuterium oxide (D2O) in long term recordings of the ERG 
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(Fuentes-Pardo & Moreno-Sáenz, 1988). The authors analyzed the effect of deuterium oxide 
on the circadian oscillations obtained from both intact animal and isolated eyestalk. Results 
showed a direct relationship between the D2O dose and the lengthen of period in both 
circadian and ultradian cycles.  It was proposed that the lengthening of the circadian period 
is due to the effect of D2O upon the high frequency oscillations. The lengthening produced 
by D2O could result from the diffusion of this substance to all the cells, tissues and organs of 
the organism, particularly to the cells involved in the generation and expression of the ERG 
oscillatory activity. These cells would actually be the oscillators that reduce their oscillation 
frequency produced by the physicochemical changes of D2O. The results allow us to 
propose that D2O affects the oscillatory machinery by its well-established general property 
of slowing biochemical reaction kinetics due to the “heavy isotope effects”. 
Finally, the last scenario in which we have observed circadian and ultradian oscillations is 
when the ERG circadian rhythm recorded from a crayfish kept under constant darkness is 
perturbed by the presence of a light stimulus, this induces a phase change, an advance or a 
delay, that can be detected once the rhythm returns to a steady state. The sense and 
magnitude of change depend on the circadian time of stimulus application. It is worthwhile 
noticing that immediately after the light application, the ERG circadian rhythm shows a 
transitory stage characterized by the presence of irregular high frequency (ultradian) 
oscillations; the characteristics of these, particularly phase as well as the circadian moment 
when the stimulus was applied, seem to determine whether the rhythm will show advance 
or delay in the steady state (Fuentes-Pardo et al., 2008).  
It is natural to conjecture that the ultradian rhythms observed in each and every one of the 
above experimental scenarios (ontogeny, sectioned eyestalk, sinus gland deprivation, D2O 
and application of a light stimulus) appear as a consequence of the failure (or decreased 
velocity in the case of D2O) of the release of PDH. The circadian rhythm in the pacemaker's 
crayfish is generated by weak coupling of ultradian oscillators between cells. Ultradian 
oscillation would become apparent under weak coupling or in absence of coupling. The 
pacemaker period would be a function of the coupling of the ultradian oscillators, 
increasing as the coupling decreasis.  
In the next section we explore this possibility with a simple model. 
6. Circadian behavior in the pacemaker emerging from the coupling of 
ultradian oscillators 
As we saw in the previous section, in the ontogenesis of the crayfish circadian rhythm the 
experiments showed a global ultradian rhythm in very young individuals that evolves into a 
global circadian rhythm with an intermediate stage in which both rhythms are superposed. 
How could one construct a pacemaker model based on the coupling of many ultradian 
oscillators? 
The coupling strength of the oscillators in the pacemaker should vary during the 
development of the rhythm: In the early stages, the coupling should be weak enough to 
preserve the ultradian character of the resulting output, but strong enough to synchronize 
all the oscillators (otherwise the result would be a practically constant signal, being the sum 
of many unsynchronized clocks). At the other end of the process, in the adult stage,  the  
strength  of  the  coupling  should  be  able  to  produce  a global  circadian result. And it 
should also reproduce the intermediate step where both ultradian and circadian rhythms 
coexist! 
 
Ultradian Rhythms Underlying the Dynamics of the Circadian Pacemaker 61 
In a first stage we have taken a different option, without denying that it would be 
interesting to search for a simple model whose individual oscillators and modes of 
coupling evolve naturally in the above manner. Our approach consists in  assuming the  
existence of  a well-defined ultradian  rhythm  in the pacemaker from  the beginning  of  
the ontogenesis and of a circadian rhythm that emerges gradually, but whose circadian 
character  is well  defined from its first appearance. We concentrate on modeling the 
relations between the two. This does not exclude the possibility that the circadian  
oscillator  might  be  the  result  of  the  coupling  of  many  ultradian oscillators (c.f. the 
following section).  
The results of this approach can be found in  (Lara-Aparicio et al., 1993; Fuentes-Pardo et al., 
1995, 2005). The mathematical model has proved useful for the understanding of several 
characteristics of the circadian rhythm. 
At this time we are asking if the pacemaker temporal pattern observed in the crayfish could 
be the result of the coupling of ultradian oscillators. In order to mimic the described 
behavior we have to take into account the maturation (hormonal) effect. So in the next, we 
are going to show how in a simple model, low frequency oscillatory behavior in a 
pacemaker can be obtained from the coupling of its components, each one being a high 
frequency oscillator. 
In order to fix ideas we will consider that the systems consists of four nonlinear oscillators. 
In the absence of any coupling, we will simply assume that the oscillators are identical and 
whose dynamics is determined by the same function f.  
In mathematical terms we have a system of four second order nonlinear differential 
equations in which  xi (i=1,...4) represents the “position” of the  i-th  oscillator: 
 
In other words, even when in principle the fi  could be different, we take them as identical 
for the sake of simplicity. Moreover, the terms involving the coefficients aij  (linear terms) 
represent the coupling among the different oscillators in the pacemaker. The coupling is 
directly related to the PDH presence (see Section 5.2). It is important to point out that in 
many physical systems, such as masses joined by springs or interacting pendulums the 
nature of the coupling is relatively well known. On the other hand, in the case of cells, the 
underlying interactions among cells is due to rather complex communication mechanisms, 
that in fact, constitute the subject of very active research. 
In principle, we don’t impose any specific functional form for f although later on we will 
consider it to be a van der Pol oscillator.  
We now adopt the specific functional form for the terms in the equation responsible for the 
oscillatory dynamics: 
 
In other words, each separate component is a van der Pol  system. 
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In the following pictures (Figure 5), the behavior of a van der Pol oscillator is depicted. The 
illustration is taken from Weiisstein, Eric W. "van der Pol Equation." from MathWorld--A 
Wolfram Web Resource (http://mathworld.wolfram.com/vanderPolEquation.html) and we 
have left the notation as it appears there, i.e. x and y are taken as independent and 
dependent variables respectively instead of t and x, so that the van der Pol equation reads 
 
Moreover, using the language of dynamical systems, each component has the structure of a 
relaxation oscillation which is very robust (a stable limit cycle).  Essentially this means that if 
the system is perturbed it will recover its oscillations. 
After writing the system as a collection of eight equations of first order, rather than four of 
second order we  can plot the positions and velocities of the oscillators 
In Figure 6 we show a simulation for this system in which both velocities and positions are 
represented. Notice that after a transient state, in which individual high frequency 
oscillations are observed, a regime in which low frequency oscillators appears. 
It would be worthwhile, in future to prove if the different perturbations to the pacemaker 
that we observed experimentally can be modeled by our coupled high frequency oscillators.  
 
 
Fig. 5. Van der Pol oscillator. 
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Fig. 6. Coupled oscillators. 
7. Conclusion 
The study of the emergent dynamics of circadian pacemaker illustrates the utility and even 
the necessity to develop mathematical models to understand the biological systems. 
Remarkable also is the interaction that can be observed among a biological theory, the 
experimental results, the mathematical model, and the mathematical theory. 
In our work, mathematical models have been fundamental to understand the mechanism  
underlying  to some phenomena and suggest us new experiments. When we propose and 
study the mathematical model to describe the ontogeny of crayfish circadian rhythm, 
immediately emerged many questions about the origin of circadian rhythms and the 
possible compatibility with the different proposals and explanations  found in the literature. 
At this moment our models have a qualitative character, but it is possible to refine them in 
order to obtain quantitative answers  to some questions.  
It is important to remember that, in spite of we want to make a simple model, the biological 
systems exhibits an extraordinary diversity and complexity. That is because is really hard to 
consider that the modeling process is finished. 
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1. Introduction  
The heart undergoes relentless biophysical oscillations over the course of a life span in order 
to sustain life. The heart’s continuous rhythm of beating consists of sustained, serial 
oscillations in ionic currents, membrane potential, and excitation-contraction coupling. The 
rhythm of its beats expresses a period range of 0.6-1 seconds in healthy adults. These high 
frequency ultradian (< 24 hr period) rhythms are the life blood of the body’s most important 
myogenic oscillator and pump. However, these are not the only rhythms vital to the 
function of cadiac tissue, as the heart and other components of the cardiovascular system are 
under control of the body’s circadian clock. This “clock“ is not a singular entity, but rather 
consists of distributed oscillators which impose numerous biochemical and physiological 
rhythms with a periodicity of approximately 24 hours. Indeed, recent evidence has 
demonstrated that the very cells of the heart are circadian oscillators themselves.      
Numerous studies of animal models, including humans, reveal that multiple processes of 
cardiac physiology are under control by the circadian system. Moreover, circadian control 
by the organismal “clock” encompasses multiple layers of regulation, extending, at its most 
reduced level, to the molecular clockworks residing within individual cardiomyocytes (Bray 
et al., 2008) and other cardiac cell types (Young, 2009). Coupling between cardiomyocytes at 
the tissue level results in a synchronized cardiac organ-clock. The cardiac clock functions in 
a semiautonomous manner in isolation from autonomic and humoral inputs. These 
“exogenous” inputs represent regulatory arms of the larger circadian system to which the 
cardiac clock is subject to control. The neurohumoral arms of the circadian system are 
driven by the neurocephalic circadian axis, the most important component of which (at least 
in mammals) resides in the suprachiasmatic nuclei of the hypothalamus. However, other 
cephalic components, including the eye and pineal, reinforce central and peripheral 
oscillations and maintain coupling between them, as well as with true exogenous factors 
such as light and dietary intake (Bell-Pedersen et al., 2005; Stratmann and Schibler, 2006). 
Together, these multiple systems interact to produce overt rhythms in cardiac physiology 
including rhythms of heart rate, contraction force, blood pressure, metabolism, gene 
expression, and more (Young, 2009). 
Of particular clinical interest is the observation that multiple aspects of cardiac pathology 
fluctuate on a circadian basis. Numerous studies have documented daily oscillations in 
the occurrence of pathologic cardiac events (Elliott, 2001; Mahmoud at al., 2011). The 
collective impact of these time-of-day-dependent phenomena on human welfare and 
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economics is likely enormous, though the etiology of this temporal dependence is not 
fully understood. Elucidation of the mechanisms underlying these time-dependent 
phenomena is no doubt complicated by the complex, hierarchical organization of the 
circadian system and its far-reaching presence across most tissues. In fact, it is not always 
clear what direct role circadian regulation plays in rhythmic features of cardiac 
physiology and pathology compared to indirect effects which may propagate between 
coupled organ systems. Moreover, not all such rhythms may necessarily be attributed to 
endogenous circadian control at all; rather, some rhythms may be driven independently 
by oscillating exposure to environmental factors themselves and not as zeitgebers 
(timekeepers or entrainment cues). 
Understanding the role of the circadian system as a primary regulator of daily changes in 
cardiac physiology and pathophysiology is of both extreme scientific and clinical interest. 
Development of new therapeutic modalities, as well as improving standard ones, will require 
an unraveling of these intertwined regulatory processes, both direct and indirect, internal and 
external. This necessitates a deeper characterization of the role of circadian processes at 
multiple levels of cardiac function, from the cellular and molecular levels to the systems and 
organismal levels. The aim of this chapter, therefore, is to review the ever-increasing wealth of 
data on circadian control of the heart obtained from human and non-human animal models. I 
will explore many of the major findings to date at each hierarchical level of control to provide 
a broad view of how the circadian system regulates the physiology of the heart, contributes to 
its pathology, and adds to our current understanding of cardiovascular health. 
2. The mammalian circadian clock 
Circadian rhythms are defined as entrainable biological rhythms having an intrinsic 
periodicity under constant conditions (e.g. lighting conditions or temperature) of 
approximately 24 hours. Circadian clocks are ubiquitous amongst living organisms, and can 
be found across far-reaching taxa, including mammals, birds, lower vertebrates, 
invertebrates, non-animal multicellular organisms, and unicellular organisms (Bell-Pedersen 
et al., 2005). Among mammals, circadian clocks have been studied in numerous strains (both 
“normal” and pathological) of rodents, primarily in mice, rats, and hamsters, as well as 
other model systems, including humans (Martino and Sole, 2009).  
These studies, along with studies of other vertebrate models (Bell-Pedersen et al., 2005), 
have demonstrated that numerous semi-autonomously operating clocks reside within a 
single mammalian organism. These clocks are distributed amongst most organs and tissues 
of the body, and can be reduced to the level of the individual cell (Stratmann and Schibler, 
2006). These countless cellular clocks are biochemically coupled to produce coherent outputs 
at the tissue and organ levels, and govern a vast array of documented biochemical and 
physiological processes, including sleep-wake cycles, body temperature, metabolism, and 
cardiovascular functions to name a few.  
2.1 Central physiological clocks 
At the organismal level, central neural and peripheral clocks are organized in a hierarchical 
fashion, with intercellular communication being mediated by both neural and humoral 
mechanisms (Stratmann and Schibler, 2006). At the top of this hierarchy is the neurocephalic 
circadian axis, consisting of the hypothalamic suprachiasmatic nuclei (SCN) at its heart, 
along with the optic retinae and the epithalamic pineal gland (Bell-Pedersen et al., 2005).  
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The SCN, at the top of this neurohumoral triumvirate, is regarded as the “master 
pacemaker”, as it synchronizes peripheral oscillators and dictates the appropriate phasing of 
“slave oscillators” subject to the regulatory arms of the central circadian axis. Consistent 
with the SCN’s role as master pacemaker, its ablation abolishes multiple physiological and 
biochemical processes in multiple model species (Turek, 1985), and in rats loss of rhythms 
can be rescued by transplantation of intact SCN from donor rats (Ralph et al., 1990). 
Importantly, the period of host activity rhythms is imposed by the period of the donor 
animal in transplantation studies. Specifically, cardiovascular rhythms are under control of 
the SCN, as ablation of SCN abolishes rhythms in both blood pressure (Weaver, 1998) and 
heart rate (Warren et al., 1994) in rodents. 
In vitro, individual cells of the SCN are capable of sustaining rhythms of multiple clock 
controlled outputs, including action potential firing rate, neuropeptide release, glucose uptake, 
and rhythms of gene expression (Bell-Pedersen et al., 2005; Quintero et al., 2003; Welsh et al., 
1995). Intercellular coupling mechanisms within the SCN are unknown, though pathways 
coupling the SCN with other organs have been described. The SCN is part of a neuroendocrine 
feedback loop between the eyes and pineal gland, and these mutual interactions are necessary 
for entrainment or reinforcement of the hypothalamic clock.  
 
 
Fig. 1. Neuroendocrine pathways involving the SCN 
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As Figure 1 shows, light entrains the SCN via neural connections from the retinohypothalamic 
tract (RHT). In mammals, the SCN (and perhaps the retinae) is the only oscillator that is 
directly entrainable by light, although the pineal gland of many other vertebrate species is 
directly photoreceptive (Bell-Pedersen et al., 2005). The mammalian pineal, while not directly 
photosensitive, influences SCN activity by nightly secretion of the indoleamine hormone 
melatonin. The SCN is rich in melatonin receptors, and its activity is thus inhibited by 
melatonin during the dark period (Cassone et al., 1987). The neurohumoral feedback loop is 
closed by a polysynaptic pathway as follows. First order GABAergic neurons from the SCN 
synapse with neurons in the paraventricular nucleus (PVN) of the hypothalamus. Descending 
tracts from the PVN innervate targets in the intermediolateral cell column of the thoracic 
spinal cord, which in turn project to the superior cervical ganglia (SCG). Finally, sympathetic 
SCG neurons form noradrenergic synapses with the pineal gland, which possesses stimulatory 
2 adrenergic receptors (Moore, 1996). 
The SCN regulates other peripheral organs (including the heart) by way of different 
autonomic efferents. In addition to sympathetic regulation by way of the IML, alternate SCN 
controlled efferent pathways arising from the PVN regulate parasympathetic ganglia by 
projecting to neurons in the dorsal motor nucleus of the vagus (DMV). It appears that 
separate populations of pre-autonomic cells in the SCN provide discreet control over 
symapathetic and parasympathetic pathways (Buijs et al., 2003). 
2.2 Peripheral clocks 
Previously it was believed that the master pacemaker within the SCN drove downstream 
oscillations in other tissues throughout the body, and that the molecular clockworks that 
underlie oscillator function were confined to this tissue. This view was largely based on 
studies which measured disruption of behavioural and physiological outputs of the 
organismal clock, and disruption of molecular rhythms in some tissues. It is now known 
that most tissues possess the same basic molecular machinery (i.e. “clock genes”) as the 
hypothalamic pacemaker, and that many tissues (including the heart) can maintain 
functional oscillations in gene transcription and other processes in a semi-autonomous 
manner (Damiola et al., 2000; Oishi et al., 1998; Stratmann and Schibler, 2006). 
Clock gene oscillations have been maintained in some peripheral tissues for periods of up to 
20 days in culture, indicating a functional molecular clock is preserved ex vivo (Yoo et al., 
2004). Other experiments have demonstrated that clock gene rhythms are not abolished in 
peripheral organs by SCN lesions, but that organs lose synchrony with one another, leading 
to altered phase relationships and disrupted coherent output in vivo (Guo et al. 2005, 2006; 
Yoo et al., 2004). Moreover, implementation of a restricted feeding paradigm (RF) competing 
with light cycles can uncouple rhythms in heart and liver from the SCN, without affecting 
the phase of the SCN itself (Damiola et al., 2000; Hara et al., 2001; Stokkan et al., 2001). As a 
result of these and other studies, the current prevailing view of the SCN as the body’s 
circadian pacemaker is that its role is to synchronize, or entrain, functional peripheral 
oscillators throughout the body, rather than drive them directly. 
2.3 Entrainment of peripheral clocks 
As entrainable oscillators, peripheral tissues may be synchronized by neural or humoral 
signals, or by non-photic exogenous factors such as nutrient intake. Models using parabiosis 
between intact and SCN-lesioned mice demonstrate that some tissues, such as liver, can be 
entrained by humoral (or other non-neural) factors (Guo et al., 2005). Surpisingly, neither 
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implantation of SCN tissue grafts nor non-neural cues from parabiotically linked mice are 
sufficient to rescue clock gene rhythms in other tissues, including cardiac tissue (Guo et al., 
2005, 2006). 
Food intake is a powerful zeitgeber for some peripheral tissues including the heart 
(Balsalobre et al., 2000; Le Minh et al., 2001; Stratmann and Schibler, 2006), and the heart can 
be regulated in discordance with the SCN under a restricted feeding schedule. The 
mechanism of food entrainment likely involves metabolic feedback into the transcriptional 
clock gene cycles, which in turn regulate multiple metabolic processes (Koshaka and Bass, 
2007). Cellular redox state is known to modulate transcriptional clock gene regulation, and 
this may represent one or more pathways by which feeding induced metabolic changes can 
regulate the heart and other clocks (Rutter et al., 2001). 
Plasma glucocorticoid levels are rhythmic in mammals (Stratmann and Schibler, 2006), and 
glucocorticoid signaling interacts with metabolic entrainment (Le Minh et al., 2001). Moreover, 
glucocorticoids are capable of phase shifting molecular rhythms in cardiac tissue and other 
peripheral tissues (Balsalobre, 2000). Plasma levels of epiniphrine and norepinephrine (NE) 
also show diurnal rhythms in humans (Sauerbier et al., 1977), and NE can entrain circadian 
clocks within cultured rat cardiomyocytes  (Durgan et al., 2005). Thus, glucocorticoids, 
especially cortisol in humans, as well as catacholamines, represent other potential zeitgebers 
for peripheral oscillators. These may provide important mechanisms by which the SCN exerts 
control over the heart and other tissues (Stratmann and Schibler, 2006).  
Nightly melatonin secretion by the pineal represents another humoral regulatory arm of the 
circadian system, though extra-pineal contributions to plasma melatonin levels are not fully 
characterized in mammals (Huether, 1993). Interestingly, recent evidence demonstrates 
mammalian cardiac tissue possesses active biosynthetic machinery necessary to produce 
melatonin (Sanchez-Hidalgo et al., 2009), suggesting that extra-pineal melatonin derived 
from cardiac tissue may act as a local autocrine or paracrine signal. 
Numerous beneficial cardioprotective effects have been reported for melatonin (Reiter and 
Tan, 2009). Cardiovascular tissues express both MT1 and MT2 melatonin receptors 
throughout the body, and cardiomyocytes express membrane bound melatonin receptors 
both in vivo and in vitro (Pang et al., 1993; Peliciari-Garcia et al., 2011). The nuclear melatonin 
receptor RORa has been localized to heart as well (Naji et al., 2004), and cardiovascular 
modulation of heart rate in primates may involve activation of intracellular MT3 receptor 
quinone reductase 2 (QR2) (Inui and Hazeki, 2010). Because melatonin exerts non-receptor 
mediated effects on target tissues as well (as a powerful anti-oxidant and scavenger of free 
radicals), it is unclear which cardioprotective mechanisms may involve receptor-dependent 
or receptor-independent regulation.  
2.4 Cellular and molecular clocks 
The mammalian intracellular circadian clock is composed of a finely tuned molecular 
feeback loop (Figure 2). The major components of this feedback loop consist of “clock gene” 
products that either activate expression of other genes (positive elements) or inhibit gene 
expression (negative elements). The primary positive elements are encoded by the genes 
clock and bmal1 (brain and muscle ARNT-like protein 1); these gene products contain a basic 
helix-loop-helix Per-ARNT-Sim (bHLH/PAS) domain, which allow them to heterodimerize 
in the cytoplasm, after which they translocate into the nucleus to activate gene transcription. 
CLOCK:BMAL1 heterodimers activate transcription of target genes (including other “clock 
genes” as well as “clock controlled genes”, or “ccg’s”) by binding to consensus E-box 
sequences in their promoters (Muñoz and Balor, 2003). 
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Fig. 2. Model of the intracellular molecular clock. 
Two important targets of CLOCK:BMAL1 activation are the “negative” clock genes, period 
(per) and cryptochrome (cry). These phylogenetically conserved genes are preserved as core 
clock genes, although multiple mammalian orthologs of these genes have arisen as a result 
of gene duplications (Bell-Pedersen et al., 2005). Indeed, mammalian clock genes include 
three different period genes (per1, per2, and per3) and two cryptochrome genes (cry1 and cry2). 
PER and CRY proteins heterodimerize in the cytoplasm and are then translocated into the 
nucleus, where they inhibit transcriptional activation by the CLOCK:BMAL1 complex. The 
negative elements close the loop, and robustness of the oscillations is enhanced by the 
positive limb. Accurate timekeeping is required to generate a ~24 hour period, and this 
requires precise timing of the feedback loop kinetics. This is mediated in part by the gene 
products of casein kinase 1 epsilon (CK1) and casein kinase 1 delta (CK1), which regulate 
stability and translocation of the PER:CRY complex via modulation of the PER 
phosphorylation state.  
Redundancy is built into the circadian transcriptional loop by the presence of multiple 
functional isoforms of period and cryptochrome genes, as well as the gene for neuronal PAS 
domain protein2 (npas2), whose protein product can substitute for CLOCK as a BMAL1 
dimerization partner in some tissues (Reick et al., 2001). It is unclear what specific roles 
these partially redundant clock genes may have, however, and per3 does not appear to be 
necessary for sustainment of the intracellular transcriptional oscillator (Ko and Takahashi, 
2006). A fascinating study by Qi and Boatang showed that CLOCK protein localizes to the 
Z-disk of the cardiomyocyte sarcomere, and that translocation of CLOCK between the 
nucleus and cytoplasm is influenced by the activity of cross-bridge cycling (Qi and Boateng, 
2006). Thus, cardiomyocyte activity may feed back into the core clock mechanism itself.   
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A secondary feedback loop is formed by activation of CLOCK:BMAL1 targets rev-erb (an 
orphan nuclear receptor member) and rora (retinoic acid-related orphan nuclear receptor). REV-
ERB and RORA proteins competitively bind to retinoic acid-related orphan receptor 
response elements (ROREs) in the promotor of bmal1. These proteins have antagonistic 
functions, such that REV-ERB represses bmal1 transcription while RORA activates it. 
Furthermore, the kinetics of these protein activities differs, such that bmal1 repression by 
REV-ERB occurs more immediately, followed by a delayed activation by RORA (Ko and 
Takahashi, 2006). This secondary feedback loop is thought to stabilize the core 
transcriptional oscillator involving the period and cryptochrome genes (Preitner et al., 2002). 
Importantly, rev-erb and rora genes have been shown to regulate pathways involved in 
cellular metabolism, which may have important consequences for cardiometabolic 
pathologies. These mechanisms are discussed in detail later. A third feedback loop (not 
illustrated) is based on transactivation of the dec1 and dec2 genes by the CLOCK:BMAL1 
complex, followed by inhibition of CLOCK:BMAL1 by DEC1 and DEC2 proteins. 
Most of this ensemble of clock genes has been shown to be rhythmically expressed in hearts 
of mammals and other animals (Cahill, 2002; Chong et al., 2003; Dardente, 2007), and clock 
gene mRNA rhythms have recently been measured in human hearts for per1, per2, and 
bmal1, but not cry1, which appears to be arrhythmic. (Leibetseder et al., 2009). Interestingly, 
the phases of clock gene mRNAs do not necessarily predict the phases of clock controlled 
outputs, and the phase angles between the core oscillator and outputs may be tissue specific 
(Karaganis et al., 2009).  
Because the heart contains multiple cell types, including cardiomyocytes, epithelial cells, 
fibroblasts, and adipocytes, in vivo cardiac clock gene expression could reflect contributions 
of any one (or combinations) of these cell types. Indeed, functional clocks have been 
described in endothelia (Dermot et al., 2007; Takeda et al., 2007), adipose tissue (Zvonik et 
al., 2006), and fibroblasts (Welsh et al., 2004). However, rhythmic clock gene expression 
persists in vitro in isolated rat cardiomyocyte cultures (Durgan et al., 2005; Peliciari-Garcia, 
2011), demonstrating the presence of a functional cardiomyocyte clock.    
Intrerestingly, exogenously administered melatonin alters circadian expression of rev-erb 
mRNA in rat cardiomyocyte cultures (Peliciari-Garcia et al., 2011). In addition to the 
membrane bound melatonin receptors, RORA has been described as a functional nuclear 
melatonin receptor, and may provide an important link between melatonin and regulation 
of peripheral oscillators, including the heart (Peliciari-Garcia et al., 2011). Other ROR 
members, including ROR, may play in important role in peripheral oscillators as well (Ko 
and Takahashi, 2006). 
2.5 The cardiac circadian transcriptome 
Modern technology utilizing high density microarrays to report global gene transcription in 
murine models has tremendously expanded our understanding of the extent to which the 
circadian clock may regulate cellular function. Several laboratories have conducted 
microarray analyses to explore global cardiac gene expression in various normal and 
pathological murine models (Bray et al., 2008; Martino et al., 2007; Storch et al. 2002). The 
first such study to be conducted compared the circadian transcriptome between mouse heart 
and liver, and found that ~8% of cardiac genes (or 462 genes represented on the array) 
exhibited circadian oscillations (Storch et al. 2002). Other studies have yielded similar but 
more extensive estimates (up to 13% of heart genes rhythmic), or lower estimates (2-5% 
heart genes rhythmic) where greater stringencies were imposed on the analysis (Bray et al., 
2008; Martino et al., 2007).   
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Gene ontology analysis from these studies reveals regulation across a wide array of 
molecular pathways, from genes involved in metabolism to cellular trafficking and cell 
death, to name a few. Surprisingly, although ~10% of genes were shown to be rhythmic in 
the liver (Storch et al., 2002), and these included similar functional gene categories as in the 
heart, there was very little overlap between individual genes showing circadian expression 
patterns in both tissues. In fact, only 39 genes showed similar circadian regulation in both 
heart and liver (Storch et al., 2002). This surprising result, along with microarray analyses of 
clock controlled transcriptomes in other tissues and organisms (Bailey et al., 2004, 2007; 
Duffield, 2003; Karaganis et al., 2008), have demonstrated that circadian regulation of gene 
transcription is both extensive and divergent. A key concept which has emerged from these 
studies is that circadian regulation of intracellular pathways is highly specific, and likely 
tuned to the particular demands and functions of a given tissue or organ. As we’ve seen, the 
heart is no exception.   
Subsequent studies of murine cardiovascular tissue have confirmed and extended these 
observations, demonstrating that global regulation of clock controlled genes is divergent 
between closely related tissues or within different functional regions of the same organ (Bray 
et al., 2008; Martino et al., 2007). Separate analysis of rhythmic gene expression in atria and 
ventricles of mouse heart has demonstrated a surprising divergence in the apparent number of 
clock controlled genes expressed within these two tissues (Figure 3). In this study, which 
utilized mutants with cardiomyocyte specific clock disruption to identify intrinsically 
regulated ccg’s (more on this later), 548 genes exhibited circadian transcriptional rhythms in 
the atria, compared to 176 genes in the ventricles (Bray et al., 2008). 
 
 
Fig. 3. Gene ontology of circadian regulated genes from atria and ventricles. From: Bray, et 
al., (2008). Disruption of the Circadian Clock Within the Cardiomyocyte Influences 
Myocardial Contractile Function, Metabolism, and Gene Expression. American Journal of 
Physiology. Heart and Circulatory Physiology,Vol. 294, pp.H1036–H1047, ISSN 1522-1539 
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Many of these genes could be expected to influence normal and pathological aspects of 
cardiophysiology, including genes affecting metabolism, contractile function, and cell 
growth or remodeling. It is worth mentioning a word of caution when interpreting the 
functional significance of these studies, however, since the behaviors of oscillating 
transcripts do not necessarily predict that final gene products will have similar protein 
expression profiles. Posttransciptional and posttranslational regulatory mechanisms, such as 
phosphorylation and ubiquitination may also be under clock control. The final relative 
phasing and amplitudes of protein expression may therefore arise from a complex interplay 
between regulatory pathways involving kinetics of gene transcription and translation, as 
well as mRNA and protein turnover via stability and degradation pathways. This point is 
highlighted by an important study conducted by the Hastings lab, which discovered 
extensive differences between circadian regulated transcription and protein levels in the 
mouse liver (Reddy et al., 2006). For instance, this study revealed that up to 20% of the 
hepatic proteome was rhythmic, while mRNA levels were rhythmic for less than half the 
number of these genes. Clearly, circadian regulation at the transcriptional level is an 
important mechanism of regulation by tissue clocks, but caution must be taken when 
extrapolating these findings to the protein level.  
3. Circadian cardiovascular physiology and pathology 
The circadian system regulates numerous cellular and molecular processes of cardiovascular 
function, including blood pressure, heart rate, contractility, vasomotor tone, blood clotting, 
and cardiovascular metabolism (Sole and Martino, 2009). It is presumed that normal 
function of these processes is necessary to maintain optimal health and longevity, and that 
disruption of circadian regulation of these processes can lead to both acute and chronic 
pathologies, some with potentially disastrous consequences. This section will describe some 
of the major features of cardiovascular function and pathology that may be regulated by the 
circadian clock.  
Because other rhythmic environmental exposures and behaviours may drive physiological 
rhythms with similar periodicities maintained by the circadian clock, it is possible that some 
~24 hour cardiovascular rhythms are not a result of circadian control (i.e., are not 
endogenously maintained rhythms). Moreover, because of the hierarchical organization of 
the organismal circadian system, measurable outputs may reflect different levels of control, 
ranging from local intrinsic oscillator function to systems level control by the neurohumoral 
arms of the SCN and other components of the circadian system.  
Indeed, it is likely that many rhythmic processes of the cardiovascular system reflect 
combinatorial interactions between multiple oscillating systems, both intrinsic and extrinsic. 
For instance, platelet aggregability, a likely predisposing factor for acute ischemic 
cardiovascular incidents, is elevated as a result of morning standing and ambulation, but is 
not increased in the absence of morning activity (Andrews et al., 1996; Brezinski et al., 1988). 
In contrast, other predisposing factors for cardiac ischemia, such as oscillating fibrinolytic 
activity of endolthelial cells, may be regulated by circadian oscillators both intrinsic and 
extrinsic to the heart (Maemura et al, 2000).  
3.1 Temporal variation in the timing of acute cardiovascular events 
Several acute types of pathological cardiovascular events present in a circadian fashion. For 
example, the incidence of myocardial infarction in humans is much higher in the morning 
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combinatorial interactions between multiple oscillating systems, both intrinsic and extrinsic. 
For instance, platelet aggregability, a likely predisposing factor for acute ischemic 
cardiovascular incidents, is elevated as a result of morning standing and ambulation, but is 
not increased in the absence of morning activity (Andrews et al., 1996; Brezinski et al., 1988). 
In contrast, other predisposing factors for cardiac ischemia, such as oscillating fibrinolytic 
activity of endolthelial cells, may be regulated by circadian oscillators both intrinsic and 
extrinsic to the heart (Maemura et al, 2000).  
3.1 Temporal variation in the timing of acute cardiovascular events 
Several acute types of pathological cardiovascular events present in a circadian fashion. For 
example, the incidence of myocardial infarction in humans is much higher in the morning 
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hours, peaking between 06:00-12:00, just as patients arise from bed, or soon before or after 
doing so (Cohen et al., 1997; Muller et al., 1985). In contrast, the incidence of infarcts reaches 
a nightly trough during the hours between 03:00-06:00. Overall, infarcts are approximately 
three fold more likely to occur during the morning than during night. 
Other related cardiovascular events that peak in the early or late morning hours include 
deadly ventricular arrhythmias (Tofler et al., 1995), defibrillation threshold (Venditti et al., 
1996) atrial and ventricular refractoriness (Kong et al., 1995; Simantirakis et al., 2001), 
ischemic stroke (Argentine et al., 1990), rupture of aortic aneurysm or aortic dissection 
(Manfredini et al., 2004; Mehta et al., 2002; Sumiyoshi et al., 2002) and sudden cardiac death 
(Mahmoud at al., 2011; Muller et al., 1987). Some cardiovascular events, such as atrial 
arrhythmias (Deguchi et al., 2009; Sandberg et al., 2010) or thromboembolic stroke (Marshal, 
1977) may peak at other times of day. Comorbid conditions, such as obstructive sleep apnea 
(OSA), may influence the timing of cardiovascular events, and contribute to pathological 
circadian disruption (Kuniyoshi et al., 2008). 
3.2 Circadian regulation of heart rate and blood pressure 
Heart rate (HR) and blood pressure (BP) both exhibit diurnal rhythms in humans, peaking 
the during the day when humans are active, or during the active nocturnal phase in rodent 
models (Mansoor et al., 1994; Millar-Craig et al., 1978; Reilly et al., 2007; Weber et al., 2002). 
HR and BP are lowest during nighttime, but begin to rise in the early morning hours in 
anticipation of waking. These rhythms coincide with rhythms in autonomic tone, with the 
sympathetic system dominating during the day, and the parasympathetic system 
dominating at night. The adaptive value of these daily rhythms is obvious, in that elevated 
HR and BP allow the body to carry out the physical demands associated with daily 
activities, while a nightly reduction in the levels of these processes allows the sleeping body 
to save energy and shift its focus to other important demands, such as cellular upkeep, 
tissue remodelling, or other restorative processes (Sole and Martino, 2009). Importantly, the 
timing of these cardiovascular rhythms is slightly phase advanced relative to the 
sleep/wake cycles (i.e. cardiovascular rhythms anticipate transitions between activity 
phases), allowing for a smooth transition between these alternating states.  
The importance of maintaining these diurnal cardiovascular rhythms is evident when 
comparing variants of hypertensive patients, known as “dippers” and “non-dippers”. In 
some hypertensive patients (“dippers”), normal amplitude circadian rhythms are 
maintained, albeit over an elevated baseline. Other hypertensive patients, so called “non-
dippers”, express a continuously high blood pressure through the active and sleep phases. 
This latter group, having disrupted blood pressure rhythms, are at greater risk for 
developing other cardiovascular diseases and suffering organ damage (Mancia and Parati, 
2000; Verdicchia et al., 1990, 1993). Classification of hypertensive patients as non-dippers is 
based on having less than a 10% decrease in blood pressure at night, since most 
normotensive patients exhibit a >10% change. Some studies, however, have shown that 
blood pressure rhythm amplitudes are distributed normally throughout a given population, 
indicating that a 10% threshold is an arbitrary cutoff value (Mancia and Parati, 2000).  
Other important, related cardiovascular changes exhibit daily rhythms as well, including 
vascular resistance and tone, although studies have produced conflicting results about how 
vascular resistance changes throughout the day (Elherik et al., 2002; Kawano et al., 2002; 
Otto et al., 2004; Shaw et al., 2001), and differential, tissue specific vasomotor control may 
occur throughout the body. 
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4. Evidence linking cardiovascular rhythms and pathology with intrinsic 
oscillators 
It is unclear to what extent daily variations in heart rate and blood pressure are due to 
intrinsic cardiac oscillators or exogenous factors. Because peripheral vascular clocks have 
been described (Dermot et al., 2007), and given the presence of circulating zeitgebers (Guo et 
al., 2004), it is possible that many rhythms of normal and pathological cardiovascular 
function can be attributed to these dispersed signals or to behavioural patterns. Until 
recently, diurnal rhythms in acute cardiovascular events have been attributed solely to the 
stress of awakening and the accompanying morning surge in blood pressure. In light of the 
discoveries of intrinsic cardiovascular clocks, however, these phenomena are currently 
being re-examined, and it is now clear that at least some of these diurnal pathologies result 
from a contribution of local, intrinsic circadian regulation. 
4.1 Lessons from clock mutants 
Several studies have shown disrupted cardiovascular rhythms in animal models possessing 
mutations in core clock gene components. For example, heart rate (HR) and arterial blood 
pressure (BP) rhythms (assayed by radiotelemetry) are abolished in bmal1 knockout mutants 
(bmal1-/-) even a under light:dark (LD) cycle, and bmal1-/- mice are hypotensive (Curtis et al., 
2006). On the other hand, dominant negative clock19 mutants express a less severe 
phenotype, showing partial disruption of HR and BP rhythms (Curtis et al., 2006). 
Disruption of the negative limb of the core molecular clock also disrupts cardiovascular 
rhythms, as baseline rhythms in HR and BP (measured by vascular pressure transducers) 
were lost in both cry1-/- and cry2-/- mice under free-running conditions in constant darkness 
(Masuki et al., 2005). 
Because these mutants have deficient clocks in all tissues, including the SCN, it is impossible 
to determine through these studies whether loss of intrinsic cardiac oscillators contribute to 
these phenotypes. To resolve this issue, ME Young and colleagues have generated mutant 
mice containing a cardiomyocyte-specific clock19 mutation, called CCM mice. By comparing 
various measures of cardiac function and global gene expression between wild type and 
CCM mice in vivo and ex vivo, this group has identified multiple putative pathways through 
which the intrinsic cardiomyocyte clock might regulate cardiovascular function and 
dysfunction (Bray et al., 2008; Durgan et al., 2006).  
For example, in vivo heart function is altered in CCM mice, which show diminished HR 
rhythms, sinus brachycardia, reduced cardiac output, and other functional differences (Bray 
et al., 2008). Experiments utilizing an ex-vivo cardiac perfusion system demonstrate the 
normal heart undergoes circadian rhythms in cellular metabolism and contractile function in 
response to cardiac workload (Durgan et al., 2007). CCM mice show abolished rhythms in 
triglyceride synthesis, reduced cardiac efficiency, and chronically elevated fatty acid 
oxidation (Bray et al., 2008). Additionally, while normal hearts exhibit an increased 
responsiveness to fatty-acids during the active period, which persists in vitro, this rhythm is 
abolished in CCM hearts (Durgan et al., 2006). In agreement with this role of the 
cardiomyocyte clock as a regulator of cellular metabolism, genes regulating both lipid and 
glycogen metabolism where found to be regulated by the cardiomyocyte clock (Bray et al., 
2008), and cardiac responsiveness to a high fat diet is altered in CCM mice (Tsai et al., 2009). 
A working model proposed by Young and colleagues is that the cardiomyocyte circadian 
clock gates lipid metabolic pathways to balance -oxidation rates with fatty acid supply in a 
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being re-examined, and it is now clear that at least some of these diurnal pathologies result 
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which the intrinsic cardiomyocyte clock might regulate cardiovascular function and 
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manner that is appropriate to the time of day. During the active period, when metabolic 
energy requirements are high, transcriptional responsiveness to fatty-acids is increased, 
allowing induction of triglyceride synthesis and fatty acid oxidation. This allows the heart to 
accommodate diurnal changes in circulating fatty-acids levels as a result of feeding or 
fasting status. This elevated transcriptional response at a time of day when fatty acid levels 
are high is necessary, since excess fatty acids can otherwise be shunted into harmful 
“lipotoxic” pathways. Thus, exposing the heart to an excess of lipids at an inappropriate 
time of day (when the transcriptional machinery is not primed for healthy lipid metabolism) 
can cause contractile dysfunction, as in diabetes mellitus (Young et al., 2002).   
Interestingly, rev-erb is known to be an important regulator of lipid metabolism, in 
addition to its role as a core clock gene (Duez and Staels, 2008). It functions to control 
intracellular triglyceride metabolism and -oxidation pathways as well as plasma lipid and 
lipoprotein metabolism. Additionally, rev-erb is implicated as a mediator of vascular 
inflammation, and has been speculated to play a role in the development of metabolic 
disorders, including obesity and diabetes. Rev-erb could therefore contribute to the 
development of cardiovascular pathologies through multiple levels of control    
4.2 Disruption of circadian cycles has cardiovascular consequences 
Shift work has long been hypothesized to be a risk factor for cardiovascular disease and 
other chronic conditions in humans. Shift workers develop a non-dipper blood pressure 
profile and may be at increased risk for hypertension (Mosendane, 2008). Additionally, 
increased risk for metabolic disturbances have been reported for shift workers, including 
dyslipidaemia, metabolic syndrome, and diabetes, although a recent thorough review shows 
epidemiological evidence for metabolic and cardiovascular disease is inconsistent (Wang et 
al., 2011). However, the suggestive evidence warrants further study of these associations.    
The etiology of cardiovascular disease in shift workers, if present, is unknown. While there 
are many confounding factors associated with shift work (such as poor diet and higher 
smoking prevalence), circadian dyssynchrony has logically been proposed as a causative 
factor.  
Several experimental animal studies support the hypothesis that circadian system 
perturbations cause or exacerbate cardiovascular disease and reduce longevity. In one such 
study, cardiomyopathic Syrian hamsters (a model for congestive heart failure) were 
subjected to weekly reversals of LD cycles, resulting in major disruptions of circadian body 
rhythms (Plamen et al., 1998). Rhythm-disturbed animals experienced a median 11% 
decrease in life span compared with controls.  
Hamsters heterozygous for the tau mutation (a point mutation in the CK-1 gene) have 
shortened periods and are unable to entrain properly to a normal 24 hour LD cycle. 
Fascinating studies have revealed that +/tau mutants have reduced longevity under a 
standard photoperiod, and longevity can be rescued in aged hamsters where normal SCN 
tissue has been grafted into the mutant host (Hurd and Ralph, 1998; Ralph and Menaker, 
1988). Interestingly, tau/tau homozygotes are spared these deleterious effects as they cannot 
entrain at all under these conditions and can simply free-run. This observation demonstrates 
that internal desynchronisation of the circadian clock, and not the tau mutation per se, has 
pathological consequences. 
A compelling recent study has demonstrated that mortality in rhythm perturbed +/tau  
hamsters coincides with major cardiomyopathy and renal disease (Martino et al., 2008). 
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Moreover, +/tau animals raised in a shorter photoperiod matching their endogenous period 
phenotype were protected from these deleterious effects, and were clinically no different 
than wild type animals. In addition, this research group showed that lesion of the SCN in 
young mutants protected mice from the onset of pathological cardiac hypertrophy under a 
disruptive light cycle. Collectively, these results provide powerful evidence that internal 
dissonance from the SCN pacemaker is harmful, and indeed worse than complete loss of the 
pacemaker itself.  
Another study by Martino et al. compared global rhythmic gene transcription in heart and 
aorta in normal (sham operated) mice with those in an induced cardiovascular disease state 
(Martino et al., 2007). The rhythmic heart transcriptome was biphasic, as described 
elsewhere (Bray et al., 2008), and was highly similar to the aortic transcriptome, with an 
overall conserved phase angle, but somewhat phase delayed (Figure 4).  
 
 
Fig. 4. Phase plots of circadian transcriptomes in heart and aorta. Reprinted from: Martino, 
et al., (2007). Disturbed Diurnal Rhythm Alters Gene Expression and Exacerbates 
Cardiovascular Disease With Rescue by Resynchronization. Hypertension, Vol.49, pp.1104-
1113, ISSN 1524-4563 
Remarkably, pressure overload induced hypertrophy (via transaortic constriction, or TAC) 
had no apparent effect on global circadian gene transcription in either the heart or aorta. 
However, TAC mice subjected to disruptive photoperiods exhibited abnormal adaptive 
responses to the disease state, such as vascular thinning and muscular atrophy as opposed 
to compensatory hypertrophy in the non-disrupted cohorts. Rhythm disturbed TAC mice 
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also exhibited altered cardiac rhythms of genes important for regulating hypertrophy, blood 
pressure, and fibrosis, as well as altered clock gene rhythms in both the heart and SCN. 
Furthermore, a rescue protocol implementing a restorative photoperiod reversed 
pathological loss of compensatory responses including cardiomyocyte hypertrophy and 
perivascular fibrosis (Martino et al., 2007). Therefore, it must be concluded that the circadian 
clock regulates compensatory cardiac tissue remodeling secondary to the primary 
cardiovascular disease state. 
5. Therapeutic implications and future directions 
5.1 Preventative chronotherapeutic applications 
Our expanding current understanding of the circadian system’s role in regulating 
cardiovascular function should, in principle, open new avenues for chronotherapeutic 
applications. Perhaps the simplest application is chronobiological awareness. All patients, 
and especially those with predisposing health risk factors, may benefit by practicing good 
“sleep hygiene”. This refers to maintaining a regular sleep/wake schedule by going to bed 
and rising at regular times, and ensuring a full night’s sleep. Patients should be screened for 
sleep apnea, which of course should be treated if found.    
Unnecessary phase shifts, for instance due to traveling or late nights out, should be 
minimized. Re-entrainment after disruptive phase shifts, as in jet lag, can be facilitated using 
supplemental melatonin. This may be especially beneficial in frequent travelers. New 
melatonergic agonists, such as, ramelteon and tasimelteon, have different pharmacological 
properties and may provide alternative therapeutic effects. (Singh et al., 2010). The 
availability of alternative treatments offers the promise of individualized chronotherapies.  
If at all possible, shift work should be avoided in patients with cardiovascular disease or 
with strong predisposing factors. If changing hours is not permissible, negative effects 
might be mitigated by chronobiological awareness and focus on making healthy pro-active 
lifestyle choices, such as maintaining proper diet and exercise regimes and undergoing 
regular physical exams. While these are good general preventative recommendations for 
any patient, a greater appreciation for the health benefits of circadian chronosynchrony may 
increase compliance, and can be aided by both an increase in doctor awareness and patient 
education.  
5.2 Chronotherapeutic interventions 
Multiple recent studies have shown a strong time-dependent efficacy for administration of 
anti-hypertensive medications, including beta blockers, calcium channel blockers, 
angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers 
(ARB’s) (Takeda and Maemura, 2010). Chronotherapy was shown to be especially useful in 
patients with resistant hypertension, and more beneficial than changing drug combinations 
(Hermida et al., 2008). Anti-hypertensive chronotherapy, in conjunction with the benefits of 
ambulatory blood pressure monitoring in candidate patients (Mancia and Parati, 2000), 
could provide effective new means of tailoring treatment to subjects with different blood 
pressure profiles.  
Chronic nightly melatonin administration has also been reported to reduce hypertension in 
human male patients (Scheer et al., 2004). In addition to its acute soporific, phase-shifting, 
and anti-hypertensive effects, melatonin has powerful cardioprotective benefits. This may 
be due in part to melatonin’s properties as a potent anti-oxidant, but studies using a 
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perfused rat heart system have demonstrated a possible receptor dependent protection 
against ischemia/reperfusion injury (Genade et al., 2008). Clinical trials are underway to test 
the effectiveness of melatonin in treating human patients with ischemic heart disease 
(Dominguez-Rodriguez, 2007; 2010).  
Mechanisms underlying circadian variation in cardiac arrhythmias are not understood, and 
chronotherapeutic studies for treating cardiac arrhythmias are lacking. However, circadian 
expression of voltage gated K+ channel mRNA and protein levels (for Kkv1.5 and Kv4.2) has 
been detected in rat heart (Yamashita et al., 2003), and more recently for L-type voltage 
gated Ca2+ channels (VGCCα1C and VGCCα1D) in embryonic chick heart (Ko et al., 2010). As 
we gain new understanding of how the cardiomyocyte circadian clock gates 
electrophysiological membrane properties, the way will be paved for the development of 
new chronotherapies targeting cardiac arrhythmias.  
Perhaps the ultimate frontier of circadian chronotherapy lies in gene transfer techniques. 
Although current gene transfer methods are inefficient and risky, the field of gene therapy is 
in its infancy, and should be expected to mature as technical difficulties are resolved. 
Several labs have already employed these methods to treat hypertension in rat models, and 
other models of gene chronotherapy for the treatment of cardiovascular disease are under 
development (Lin et al., 1995, 1998; Murakami et al., 1999; Wang et al., 2004; Yla-Herttuala, 
2000).  
5.3 Future avenues of research 
Much has been learned about the intimate partnership between circadian oscillators and 
cardiovascular health, and much is still to be learned. Fruitful avenues of research have 
employed circadian mutants, animal disease models, and a variety of ex vivo and in vivo 
preparations. Classical circadian research methods, such as surgical grafting, ablation, and 
cycle disruption, have been used to great new effect, in concordance with modern molecular 
tools such as mutant construction, and microarray analysis. This multi-pronged approach 
has revolutionized our understanding of peripheral oscillators, and energized a new 
paradigm for studying systems biology.  
These same approaches and model systems will no doubt continue to produce valuable new 
knowledge, while advanced technologies promise to forge new inroads in the quest to 
unravel cardiovascular clocks. Adaptations of molecular manipulation techniques will allow 
valuable tissue specific knockdown and overexpression experiments to be conducted in 
parallel with genetic knockouts. Tissue and cell specific genetic engineering, side by side 
with improved biological assays, should allow us to continue to dissect the circadian code, 
gene by gene, protein by protein. The circadian proteome must be characterized and 
reconciled with the mosaic of divergent circadian transcriptomes. As new therapies are 
investigated, and epidemiological data are collected, we will continue to bridge the gap 
between laboratory animal and human patient. 
6. Conclusion 
As we’ve seen in this review, circadian rhythms are woven into the dynamic fabric of 
temporal cardiac homeostasis. Governance of this complexly balanced tapestry is shared 
between a synchronous cooperation between distributed, intrinsic oscillators and the master 
pacemaker within the SCN. Discordance between system components can cause 
cardiovascular dysfunction, and exacerbate pre-existing disease. While we continue to 
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also exhibited altered cardiac rhythms of genes important for regulating hypertrophy, blood 
pressure, and fibrosis, as well as altered clock gene rhythms in both the heart and SCN. 
Furthermore, a rescue protocol implementing a restorative photoperiod reversed 
pathological loss of compensatory responses including cardiomyocyte hypertrophy and 
perivascular fibrosis (Martino et al., 2007). Therefore, it must be concluded that the circadian 
clock regulates compensatory cardiac tissue remodeling secondary to the primary 
cardiovascular disease state. 
5. Therapeutic implications and future directions 
5.1 Preventative chronotherapeutic applications 
Our expanding current understanding of the circadian system’s role in regulating 
cardiovascular function should, in principle, open new avenues for chronotherapeutic 
applications. Perhaps the simplest application is chronobiological awareness. All patients, 
and especially those with predisposing health risk factors, may benefit by practicing good 
“sleep hygiene”. This refers to maintaining a regular sleep/wake schedule by going to bed 
and rising at regular times, and ensuring a full night’s sleep. Patients should be screened for 
sleep apnea, which of course should be treated if found.    
Unnecessary phase shifts, for instance due to traveling or late nights out, should be 
minimized. Re-entrainment after disruptive phase shifts, as in jet lag, can be facilitated using 
supplemental melatonin. This may be especially beneficial in frequent travelers. New 
melatonergic agonists, such as, ramelteon and tasimelteon, have different pharmacological 
properties and may provide alternative therapeutic effects. (Singh et al., 2010). The 
availability of alternative treatments offers the promise of individualized chronotherapies.  
If at all possible, shift work should be avoided in patients with cardiovascular disease or 
with strong predisposing factors. If changing hours is not permissible, negative effects 
might be mitigated by chronobiological awareness and focus on making healthy pro-active 
lifestyle choices, such as maintaining proper diet and exercise regimes and undergoing 
regular physical exams. While these are good general preventative recommendations for 
any patient, a greater appreciation for the health benefits of circadian chronosynchrony may 
increase compliance, and can be aided by both an increase in doctor awareness and patient 
education.  
5.2 Chronotherapeutic interventions 
Multiple recent studies have shown a strong time-dependent efficacy for administration of 
anti-hypertensive medications, including beta blockers, calcium channel blockers, 
angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers 
(ARB’s) (Takeda and Maemura, 2010). Chronotherapy was shown to be especially useful in 
patients with resistant hypertension, and more beneficial than changing drug combinations 
(Hermida et al., 2008). Anti-hypertensive chronotherapy, in conjunction with the benefits of 
ambulatory blood pressure monitoring in candidate patients (Mancia and Parati, 2000), 
could provide effective new means of tailoring treatment to subjects with different blood 
pressure profiles.  
Chronic nightly melatonin administration has also been reported to reduce hypertension in 
human male patients (Scheer et al., 2004). In addition to its acute soporific, phase-shifting, 
and anti-hypertensive effects, melatonin has powerful cardioprotective benefits. This may 
be due in part to melatonin’s properties as a potent anti-oxidant, but studies using a 
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perfused rat heart system have demonstrated a possible receptor dependent protection 
against ischemia/reperfusion injury (Genade et al., 2008). Clinical trials are underway to test 
the effectiveness of melatonin in treating human patients with ischemic heart disease 
(Dominguez-Rodriguez, 2007; 2010).  
Mechanisms underlying circadian variation in cardiac arrhythmias are not understood, and 
chronotherapeutic studies for treating cardiac arrhythmias are lacking. However, circadian 
expression of voltage gated K+ channel mRNA and protein levels (for Kkv1.5 and Kv4.2) has 
been detected in rat heart (Yamashita et al., 2003), and more recently for L-type voltage 
gated Ca2+ channels (VGCCα1C and VGCCα1D) in embryonic chick heart (Ko et al., 2010). As 
we gain new understanding of how the cardiomyocyte circadian clock gates 
electrophysiological membrane properties, the way will be paved for the development of 
new chronotherapies targeting cardiac arrhythmias.  
Perhaps the ultimate frontier of circadian chronotherapy lies in gene transfer techniques. 
Although current gene transfer methods are inefficient and risky, the field of gene therapy is 
in its infancy, and should be expected to mature as technical difficulties are resolved. 
Several labs have already employed these methods to treat hypertension in rat models, and 
other models of gene chronotherapy for the treatment of cardiovascular disease are under 
development (Lin et al., 1995, 1998; Murakami et al., 1999; Wang et al., 2004; Yla-Herttuala, 
2000).  
5.3 Future avenues of research 
Much has been learned about the intimate partnership between circadian oscillators and 
cardiovascular health, and much is still to be learned. Fruitful avenues of research have 
employed circadian mutants, animal disease models, and a variety of ex vivo and in vivo 
preparations. Classical circadian research methods, such as surgical grafting, ablation, and 
cycle disruption, have been used to great new effect, in concordance with modern molecular 
tools such as mutant construction, and microarray analysis. This multi-pronged approach 
has revolutionized our understanding of peripheral oscillators, and energized a new 
paradigm for studying systems biology.  
These same approaches and model systems will no doubt continue to produce valuable new 
knowledge, while advanced technologies promise to forge new inroads in the quest to 
unravel cardiovascular clocks. Adaptations of molecular manipulation techniques will allow 
valuable tissue specific knockdown and overexpression experiments to be conducted in 
parallel with genetic knockouts. Tissue and cell specific genetic engineering, side by side 
with improved biological assays, should allow us to continue to dissect the circadian code, 
gene by gene, protein by protein. The circadian proteome must be characterized and 
reconciled with the mosaic of divergent circadian transcriptomes. As new therapies are 
investigated, and epidemiological data are collected, we will continue to bridge the gap 
between laboratory animal and human patient. 
6. Conclusion 
As we’ve seen in this review, circadian rhythms are woven into the dynamic fabric of 
temporal cardiac homeostasis. Governance of this complexly balanced tapestry is shared 
between a synchronous cooperation between distributed, intrinsic oscillators and the master 
pacemaker within the SCN. Discordance between system components can cause 
cardiovascular dysfunction, and exacerbate pre-existing disease. While we continue to 
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unmask the role of circadian rhythms in cardiovascular function, the impetus will increase 
for application of circadian principles into clinical practice. As our fourth dimensional view 
of human medicine matures, we will more clearly see how circadian regulation of the heart 
is an indispensable feature of healthy cardiovascular function.  
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1. Introduction 
Despite advances in detection and therapy heart failure remains a major and growing social 
problem. 
The Framingham Heart Study (Lloyd-Jones et al., 2002) demonstrated that one out of five 40 
year-old adults will develop heart failure symptoms at some point in their lifetime. 
In the United States (Lloyd-Jones et al., 2010), there are 5 million heart failure patients in a 
total population of 294 million and in Europe; there are 10 million heart failure patients in a 
total population of 666 million (Mosterd A et al.,1999). Health-care expenditure for heart 
failure typically accounts for 1% to 2% of total health costs, of which hospitalizations 
constitute 60% to 70% (Berry C et al., 2001; Rydén-Bergsten & Andersson, 1999). 
2. Clinical profiles and prognosis in heart failure 
Heart failure is a syndrome rather than a primary diagnosis and has many potential etiologies, 
various clinical features, and numerous clinical subsets; some patients never develop cardiac 
dysfunction, and others with cardiac dysfunction may or not develop clinical heart failure. 
Heart failure is a progressive disorder that is frequently preceded by asymptomatic left 
ventricular (LV) systolic dysfunction. In the early stages of LV systolic dysfunction 
individuals are typically asymptomatic, partly because of compensatory mechanisms 
involving the autonomic nervous system, neurohormones, and changes in the cardiac 
structure and function. 
Whether the dysfunction is primarily systolic, diastolic or combined, it leads to 
neurohormonal and circulatory abnormalities, usually resulting in characteristic symptoms 
such as fluid retention, shortness of breath, and fatigue, especially on exertion. The severity 
of clinical symptoms may vary substantially during the course of the disease and may not 
correlate with changes in underlying cardiac function. Although the mechanisms 
responsible of heart failure progression to a symptomatic state are not clear, many 
modifiable factors have been identified that predispose or aggravate the remodelling 
process and the development of cardiac dysfunction. Treatment of systemic hypertension, 
with or without LV hypertrophy, reduces the development of heart failure. 
In patients with atherosclerotic cardiovascular disease the prevention of myocardial 
infarction is of crucial importance, since its occurrence confers an 8-to 10-fold increase in the 
risk of subsequent heart failure (Lindenfeld et al., 2010). 
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Others modifiable risk factors include anemia, diabetes, hyperlipidemia, obesity, valvular 
abnormalities, alcohol, certain illicit drugs, some cardiotoxic medications, and diet. 
Cardiac resynchronization therapy by means of cardiac biventricular stimulation has proved 
to be an essential therapy for heart failure, especially in highly symptomatic patients with 
LV systolic dysfunction. 
In fact, current guidelines recommend cardiac resynchronization therapy in patients with 
left ventricular ejection fraction (LVEF) <35%, QRS prolongation (> = 120ms), and New York 
Heart Association (NYHA) class III or IV heart failure. 
These recommendations are consequent to multiple prospective, randomized trials 
demonstrating the benefits of cardiac resynchronization therapy in advanced heart failure: 
symptoms can be reduced and exercise capacity improved, overall mortality decreased and 
LV function increased. In particular cardiac resynchronization therapy was able to slow 
heart failure progression.  
Therefore, it appeared reasonable to test cardiac resynchronization therapy in patients who 
have structural heart disease but have not yet developed severe heart failure symptoms, 
especially considering the relatively high percentage of mortality and hospitalizations in 
mild symptomatic heart failure patients (Zannad et al., 2011). The possibility of using 
cardiac resynchronization therapy in this population justifies an attempt to define and 
identify mild symptomatic patients. 
The current American College of Cardiology/American Heart Association (ACC/AHA) 
practice guidelines for heart failure (Hunt et al., 2009) divide cardiovascular disorders into 
four stages, the first two of which (A and B) do not include symptomatic patients. 
Stage A denotes a high risk for heart failure but without evidence of structural heart 
disease and includes individuals with hypertension, diabetes or known atherosclerotic 
disease. Stage B includes individuals with cardiac abnormalities “structural heart disease 
but without symptoms”. Stage C includes individuals with symptomatic heart failure 
with underlying structural heart disease. Stage D includes individual with advanced 
structural heart disease and refractory symptoms of heart failure requiring specialized 
interventions. 
In a study of a community cohort, Ammar et al. (Ammar et al., 2007) provided information 
regarding the prevalence and the mortality associated with each heart failure stage, giving 
prognostic validation to heart failure staging. 
Participants were classified according to their medical history, symptoms questionnaire, 
physical examination, and echocardiogram. In the cohort, 32% were normal, 22% were stage 
A, 34% were stage B, 12% were stage C, and 0.2% were stage D. Mean B-type natriuretic 
peptide concentrations (pg/ml) increased by stages: stage 0= 26, stage A=32, stage B= 53, 
stage C= 137 and stage D=353. 
Survival at 5 years was 99% in normal subjects, 97% in stage A, 96% in stage B, 75% in stage 
C, and 20% in stage D. 
Before ACC/AHA decided to adopt heart failure stages, classification focused solely on the 
patients’ clinical symptoms, using the NYHA functional classification (class I-IV). In NYHA 
classification all patients had structural heart disease and class I included asymptomatic 
patients, while class II included mildly symptomatic patients.  
Baldassseroni et al. (Baldasseroni et al., 2002) analyzed data from the Italian Network on 
Cardiac HF Registry including 5517 unselected patients with cardiac heart failure due to 
various causes and found that NHHA class I-II was present in 71% of all patients and in 
67,2% of left bundle branch block (LBBB) patients. 
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Moreover the authors indicated that the presence of LBBB is an unfavorable prognostic 
marker in patients with cardiac heart failure and the negative effect does not depend on age, 
cardiac heart failure severity, or drug prescriptions. 
When combining ACC/AHA and NYHA classifications, NYHA class I can be included in 
Stage B and NYHA class II-III in Stage C (see table 1). It should be considered however 
that these stages included both patients with systolic and diastolic LV dysfunction. 
Instead, studies which evaluated the role of cardiac resynchronization therapy in 
asymptomatic or mildly symptomatic heart failure enrolled only patients with systolic LV 
dysfunction. Some previous studies can be analyzed in order to define percentage 
prevalence and characteristics of patients with systolic LV dysfunction in NYHA 
functional class I and II. 
A recent metanalysis (T.J. Wang et al., 2003) reported a prevalence of asymptomatic LV 
systolic dysfunction varying from 0.9% to 12.9%. 
The prevalence of asymptomatic LV systolic dysfunction was twofold to eightfold higher in 
men than in women and higher in the elderly. Moreover the prevalence was highest among 
individuals with known coronary heart disease, ranging from 4.8% to 8.5%.  
In SOLVD study (Studies of LV Dysfunction prevention), the development of heart failure 
was analyzed in patients with asymptomatic LV systolic dysfunction defined by an LVEF < 
35%. Among the total population 30% in the placebo group compared with 21% in the 
enalapril group developed heart failure over a period of 8.3 years. In the Framingham study, 
a mortality rate of 40% in asymptomatic patients with a marginally reduced LVEF (<50%) 
was found over a period of 5 years.  
Iuliano et al. (Iuliano et al., 2002) performed a retrospective analysis to examine the 
association between QRS prolongation (>120 ms) and mortality in patients with a LVEF 
<40% and reported that NYHA I and II classes were present respectively in 1,2 % and 54 % 
of all patients and in 1,4% and 48 % of patients with QRS > 120 ms. Moreover they 
concluded that QRS prolongation is an independent predictor of both increased total 
mortality and sudden death in patients with heart failure.  
Edelmann et al. (Edelmann et al., 2011) evaluated data of 4259 patients with preserved or 
reduced LVEF. NYHA I and II classes were present respectively in about 7-8% and 50% of 
population with reduced LVEF. Moreover the authors underlined how comorbidities can 
condition symptoms appearance.  
De Marco et al. (De Marco et al., 2004) analyzed data of 11804 patients with left ventricular 
dysfunction (LVEF < 40%). Percentages of NYHA I and II classes proved to be respectively 
19, 5 % and 50, 8 %. 
On the basis of these data it can be noted that the number of mildly symptomatic heart 
failure patients with systolic dysfunction is comparable to the number of highly 
symptomatic patients who at present have the widest indication for cardiac 
resynchronization therapy. This is very important considering the influence of heart failure 
therapy on health-care costs in terms of devices and hospitalization. 
3. Therapy of heart failure 
Obviously the first approach in asymptomatic or mildly symptomatic patients is medical 
therapy. In fact angiotensin converting enzyme inhibitors, angiotensin receptor blockers,  
and B- blockers have been proven to provide cardiovascular benefit to patients at any stage 
of heart failure. 
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ACC/AHA Stage NYHA Functional Class 
Stage Description Class Description 
A 
Patients at high risk of developing HF 
because of the presence of conditions that 
are strongly associated with the 
development of HF. Such patients have no 
identified structural or functional 
abnormalities of the pericardium, 
myocardium, or cardiac valves and have 







Patients who have developed structural 
heart disease that is strongly associated 
with the development of HF but who have 
never shown signs or symptoms of HF. 
I (Mild) 
No limitation of physical 
activity. Ordinary physical 
activity does not cause 
undue fatigue, palpitation, 
or dyspnea. 
C 
Patients who have current or prior 
symptoms of HF associated with 
underlying structural heart disease. 
II                  
(Mild) 
Slight limitation of physical 
activity. Comfortable at rest, 
but ordinary physical 
activity results in fatigue, 
palpitation, or dyspnea. 
III       
(Moderate) 
Marked limitation of 
physical activity. 
Comfortable at rest, but less 
than ordinary activity 
causes fatigue, palpitation, 
or dyspnea. 
D 
Patients with advanced structural heart 
disease and marked symptoms of HF at rest 
despite maximal medical therapy and who 
require specialized interventions. 
IV (Severe) 
Unable to carry out any 
physical activity without 
discomfort. Symptoms of 
cardiac insufficiency at rest. 
If any physical activity is 
undertaken, discomfort is 
increased. 
ACC/AHA - American College of Cardiology/American Heart Association; HF - heart failure; NYHA - 
New York Heart Association 
Table 1. ACC/AHA vs NYHA Classification of Heart Failure 
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Even if medical treatment of heart failure improves prognosis and reduces symptoms by 
impeding molecular disease mechanisms, reversing self-propelling neurohormonal 
reactions and reducing afterload burden, drugs cannot abolish electrical dyssynchrony or 
resynchronize mechanical delay. 
Therefore any intervention despite optimal heart failure medication capable of slowing or 
even reversing disease progression, thereby reducing hospitalizations may help to reduce 
healthcare costs in these patients. Cardiac resynchronization therapy can be considered an 
intervention of this type. Some studies have indicated the utility of cardiac 
resynchronization therapy in these patients determining an enlargement of cardiac 
resynchronization therapy indications. A synthesis of these studies is reported in table 2 and 
3 and a more detailed description of them in the following paragraphs. 
4. Cardiac resynchronization therapy 
4.1 Contak CD 
Contak CD was the first study which investigates in NYHA I/II the effect of cardiac 
resynchronization therapy with defibrillator (CRT-D) compared with defibrillator (ICD) 
only to stratify NYHA I/II and NYHA III/IV heart failure patients with or without cardiac 
resynchronization therapy. Enrollment criteria were an LVEF ≤35% and a QRS width ≥ 
120ms. The total population consisted of 490 patients, 32% of whom were in NYHA class II 
at the time of study enrollment, LBBB was present in 55%, and the mean QRS width was 
160ms. During follow-up in patients in NYHA class II at baseline no significant 
symptomatic improvement was achieved in the cardiac resynchronization therapy group 
compared with the control group. Nonetheless in NYHA class II patients, cardiac 
resynchronization therapy was linked to significant improvement in LV dimension but not 
in LVEF over either 3 or 6 months.  
This study was limited by the presence of the patients’ clinical instability (passing from a 
NYHA functional class to another), by the presence of suboptimal medical therapy at 
enrollment, and by a major change in trial design midway through the investigation 
resulting in a combination of the 3- and 6-month control period from two different phases of 
study in the data analysis, and by difficulties inherent in subgroup analysis.  
4.2 Miracle ICD-II 
Miracle ICD-II examines the effect of CRT-D compared with ICD only exclusively in 
NYHA II patients with an indication for ICD therapy. LVEF was ≤35 and QRS ≤ 130 ms. 
Primary end points in this trial were cardiac function tests, NYHA classification and 
quality of life. There was only a 6 months follow up. Results of function tests were not 
significantly different in CRT-D patients compared with those receiving ICD alone. 
However, cardiac resynchronization therapy produced significant improvement in LV 
systolic and diastolic volumes and left ventricular ejection fraction indicating that cardiac 
resynchronization therapy promotes reverse remodelling even in patients with less 
symptomatic heart failure. The fact that these effects did not improve exercise capacity is 
not completely unexpected because patients with mildly symptomatic heart failure 
usually have better-preserved exercise tolerance than those with advanced heart failure. 
Nevertheless, the beneficial impact of cardiac resynchronization therapy on parameters 
that characterize adverse cardiac remodelling is interesting and important and should be 
put into perspective.   
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These findings motivated three studies: the Resynchronization Reverse Remodeling in 
Systolic LV dysfunction (REVERSE), the Multicenter Automatic Defibrillator Implantation 
With cardiac resynchronization therapy (MADIT-CRT), and the Resynchronization 
/defibrillation for Ambulatory heart failure Trial (RAFT) trials which all aimed at assessing 
whether cardiac resynchronization therapy improves the clinical condition and prevents 
disease progression in such heart failure patients.  
4.3 REVERSE 
REVERSE was a multicenter, randomized, double-blind controlled study enrolling  
610 patients during the scheduled  follow-up period of 12 months; 419 with cardiac 
resynchronization therapy (or CRT-D) switched on and 191 with cardiac resynchronization 
therapy switched off. Patients were required to be in sinus rhythm,  in NYHA class I  
(17%) or class II ( 83%) for at least 3 months before enrollment; LVEF had to be ≤ 40%,  
LV end-diastolic dimension ≥ 55mm, and QRS duration ≥120ms. European patients  
(n=261) enrolled in 35 centers had to be followed up for 24 months within their randomized 
group.  
All patients had been receiving optimal medical therapy for heart failure, including stable 
doses of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a 
beta-blocker for at least 3 months. Patients were excluded if they had been classified as 
NYHA functional class III or IV or had been hospitalized for heart failure in the 3 months 
before enrollment.  
The primary end point of this study was defined as a heart failure composite response, with 
response groups classified as “worsened” (death, hospitalization for heart failure, crossover 
because of worsening heart failure, worsening NYHA class, or worsened heart failure 
determined by patient global assessment score), “improved” or unchanged.  
Secondary end points were LV volumes, LVEF, and heart failure hospitalization. Other 
endpoints took into consideration 6-minute walk test, quality-of-life scores, and episodes of 
ventricular tachycardia or ventricular fibrillation. A CRT-D device was implanted in 82% of 
the CRT-ON and 85% of the CRT-OFF group. About 20% were women, 56% had ischemic 
cardiomyopathy, mean QRS duration was 153ms, and mean LVEF was 26%. 
The REVERSE trial showed for the first time that cardiac resynchronization therapy 
improves ventricular structure and function (a significant decrease in LV end-diastolic and 
end-systolic volume indexes, as well as an increase in LVEF) in patients with asymptomatic 
and mildly symptomatic heart failure. In contrast, there was no significant difference 
between the percentage of patients who worsened in the composite primary end point 
compared with the percentage of patients who remained unchanged or improved. In 
addition, REVERSE demonstrates a significant reduction in heart failure morbidity defined 
as the need for hospitalization in patients with worsening heart failure in as much as in 
patients with active cardiac resynchronization therapy  there was a statistically significant 
53% relative risk reduction in time to first heart failure hospitalization.  Finally, REVERSE 
found no significant improvement in quality of life or exercise capacity with cardiac 
resynchronization therapy which is not surprising in a group of patients with little 
functional impairment at baseline.  
Out of the 262 European patients, who remained in their double-blind assignment for 24 
months, 180 were assigned to CRT-ON and 82 to CRT-OFF. In contrast to the main study 
19% patients worsened with CRT-ON compared with 34% with CRT-OFF (p=0.01).  
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However, no difference in 6-minute walk distance, quality of life, or NYHA classification 
was observed between the two groups. LV end-systolic volume index decrease by a mean of 
27.5 ± 31.8 mL/m² in the CRT-ON group compared with 2.7 ± 25.8 mL/m² in the CRT –OFF 
group (p<0.0001). Reverse remodelling by cardiac resynchronization therapy was thus 
progressive, with the greatest effect during the first 6 months and further improvement 
developing over the following 12 months. This progressive reverse remodelling was 
accompanied by a significant delay in time to first heart failure hospitalization or death (HR 
0.38; p= 0.003) with cardiac resynchronization therapy, suggesting that cardiac 
resynchronization therapy prevents the progression of disease in patients with 
asymptomatic or mildly symptomatic LV dysfunction when it is utilized for a period of 1 to 
2 years.   
We have to consider that the baseline characteristics in the European cohort of REVERSE 
had some key differences with respect to the North American subgroup. The European 
group had a lower proportion of ischemic cardiomyopathy, a lower incidence of prior 
myocardial infarction, a lower body mass index and longer average QRS duration.  
4.4 MADIT–CRT 
MADIT–CRT was designed to determine whether CRT-D in high-risk, relatively 
asymptomatic patients with ischemic and nonischemic cardiomyopathy would significantly 
reduce the combined end point of all-cause mortality or heart failure events, whichever of 
the two occurred first, as compared with ICD therapy alone. The secondary objectives were 
measures of reverse remodelling after 12 months and all-cause mortality was one of the 
tertiary end points. 
In order to satisfy inclusion criteria, patients with ischemic causes had to be classified as in 
NYHA class I or II, and those with nonischemic causes had to be classified as in NYHA class 
II. All patients had to have LVEF <30% and sinus rhythm with QRS > 130 ms. MADIT-CRT 
had a group sequential design as in other MADIT trials. Randomization to arms was done 
on a 3:2 basis, and patients were stratified by ischemic or nonischemic cardiomyopathy in 
each study center. 
Secondary endpoint was recurrent heart failure events; tertiary end point was focused 
particularly on LV volume and LVEF changes assessed by echocardiography 1 year after 
enrollment.  
The study population consisted of 1820 patients (1089 in the CRT-D arm and 731 in the ICD-
only arm); 25% were female, 45% had nonischemic cardiomyopathy, the mean LVEF was 
24%, the mean QRS duration was 158 ms, and 70% of the patients had an LBBB 
configuration. The average follow-up for all patients was 2.4 year. 
During follow-up the primary end point occurred in 187 out of 1089 patients in the CRT-D 
group (17.2%) and 185 out of 731 patients in the ICD-only group (25.3%). There was not a 
significant difference in benefit between patients with ischemic cardiomyopathy and those 
with nonischemic cardiomyopathy. The superiority of cardiac resynchronization therapy 
was driven by a 41% reduction in the risk of heart failure events, a finding that was evident 
primarily in a prespecified subgroup of patients with a QRS duration of 150 ms or more. An 
analysis of the Kaplan-Meier estimate of heart failure survival probability shows that there 
was already an early diverging of curves in favour of CRT-D after 2 months. 
The annual mortality rate (3%) was equally low in both arms of randomization. 
Moreover a significant reverse LV remodelling was found at 1 year with a mean increase in 
LVEF of 11%, and a drop in both mean LV end-diastolic volume (52 ml), and in LV end-
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systolic volume (57 ml). These analyses prove that CRT-D can induce a significant reversal 
of the structural remodelling process, even in patients without or with only mild symptoms 
of heart failure (NYHA I/II). A slight but still significant reduction in mitral regurgitation 
was noticed in the CRT-D arm. 
Exercise capacity, measured by a 6-minute walk test, did not improve with CRT-D; both 
quality-of- life scores showed a trend toward improved scores, but the difference before and 
after cardiac resynchronization therapy was not significant. The biomarker brain natriuretic 
peptide was significantly reduced in CRT-D patients (-35 pg/dl) but not in the ICD-only 
arm. 
Therefore MADIT-CRT clearly demonstrated that heart failure progression can be prevented 
within 2.5 years of follow-up in patients with structural heart disease without or with only 
mild symptoms of heart failure at the time of CRT-D. 
Prevention of heart failure progression is combined with reverse ventricular remodelling. 
Since patients in NYHA I/II or stage B heart failure have almost no limitations on their 
exercise capacity and have a relatively low overall mortality rate, it is difficult to 
demonstrate a significant increase in exercise capacity or decrease in overall mortality 
within a relatively short time. 
4.5 RAFT 
In conclusion RAFT study enrolled 1798 patients in NYHA class II or III  heart failure, with 
a LVEF of 30% or less, and an intrinsic QRS duration of 120 ms or more, or a paced QRS 
duration of 200 ms or more, in order to receive either an ICD alone or a CRT-D. The primary 
outcome was death from any cause or hospitalization for heart failure.  
The primary outcome, death or hospitalization for heart failure occurred in 364 out of 904 
patients (40.3%)  in the ICD group, as compared with 297 out of 894 patients ( 33.2 %) in the 
CRT-D group (p<0.001). The time to the occurrence of the primary out-come was 
significantly prolonged in the CRT-D group (p<0.001).  
During the course of the trial the mortality rate in the two groups was 23.5 %( 422 out of the 
1798 patients).  
In the CRT-D group, the 5-year actuarial rate of death was 28.6%, as compared with 34.6% in 
the ICD group. The time until death was significantly prolonged (relative risk reduction, 
25%) in the CRT-D group (p=0.003). 
The number of patients who were hospitalized for heart failure was lower in the CRT-D 
group, with 174 patients hospitalized (19.5%), as compared with 236 (26.1%) in the ICD 
group (p<0.001). 
However, the number of device-related hospitalizations was higher in the CRT-D group, 
with 179 hospitalizations (20%) as compared with 110 (12.25) in the ICD group  
(p<0.001).  
Among patients with NYHA class II heart failure and among those with class III heart 
failure, the two study interventions were associated with similar reductions in the risk of 
death or hospitalization for heart failure, death from any cause, and hospitalization for heart 
failure. 
5. Concluding remarks 
Taking these studies into consideration, cardiac resynchronization therapy in mild systolic 
heart failure results in reverse remodelling and clinical improvements comparable to those 
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we see in advanced heart failure stages. In particular cardiac resynchronization therapy 
proved to be advantageous especially in patients with a prolonged QRS (> 150 ms) which 
probably indicates the existence of ventricular dyssynchrony. This should be considered 
even in the light of a recent study (Bleeker et al., 2006) which demonstrated that the severity 
of baseline LV dyssynchrony, assessed with color-coded tissue Doppler imaging, was 
comparable between patients in NYHA class II and those in NYHA classes III to IV. In their 
study NYHA II class patients showed a significant improvement in LVEF and reduction in 
LV end-systolic volume after cardiac resynchronization therapy, similar to the one in 
patients in NYHA classes III to IV. Cardiac resynchronization therapy should therefore be 
considered in patients with a reduced LVEF, wide QRS (and/or dyssynchrony), and 
minimal or asymptomatic heart failure in addition to optimal medical therapy. All these 
data confirm the pertinence of the recent update on cardiac resynchronization therapy 
guidelines which included indications for mildly symptomatic heart failure patients. Further 
reinforcement of this consideration derives from the fact that cardiac resynchronization 
therapy has been considered a cost-effective intervention for patients with mildly 
symptomatic heart failure and for asymptomatic patients with left ventricular dysfunction 
and previous heart failure symptoms. 
Another aspect that should be analyzed is the rationale for the combined use of cardiac 
resynchronization therapy and ICD in these heart failure patients. This is particularly 
important in as much as sudden death is the leading cause of mortality in mild systolic heart 
failure (MERIT HF, 1999). Therefore, the potentially greatest benefit of ICDs is likely to be 
conferred on patients with mild-to- moderate heart failure. 
The Sudden Cardiac Death in Hearth Failure (SCD-HeFT) trial showed a lowering of  
all-cause mortality by ICD therapy in patients with mild-to-moderate heart failure  
and LVEF <35%. The risk reduction was limited to functional class II patients. No 
treatment benefit was observed among the 30% of patients who were in NYHA functional 
class III. 
EVADEF study demonstrated that ICD implantation effectively reduces sudden cardiac 
death so that mildly symptomatic patients tend to die of progressive heart failure.  
Finally, Gold et al. (Gold et al., 2011.) studied a patient population receiving CRT-D devices 
(83 % out of the entire REVERSE cohort) and concluded that cardiac resynchronization 
therapy did not affect the overall frequency of ventricular tachyarrhythmias even if this 
arrythmia increased in CRT-ON patients without reverse remodelling, whereas it decreased 
in those with reverse remodelling. In their opinion these data could rise the issue of whether 
or not ICD backup is chronically needed in those patients with normalization of LV 
structure and function with cardiac resynchronization therapy. However the incidence of 
ventricular arrhythmias was similar in NYHA I and II patients, and in those with ischemic 
or nonischemic cardiomyopathy as well. Accordingly, neither the etiology nor the severity 
of heart failure was able to predict which patients were more likely to experience 
appropriate ICD therapy thereby benefiting from ICD backup with cardiac 
resynchronization therapy. Thus the authors concluded that further confirmation of their 
results are needed before a strategy of excluding ICD backup in certain mild symptomatic 
cardiac resynchronization therapy patients can be recommended.  
Thus on the basis of these remarks it is difficult to affirm at present, that the use of cardiac 
resynchronization therapy in mildly symptomatic heart failure patients should not be 
combined with ICD. 
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study NYHA II class patients showed a significant improvement in LVEF and reduction in 
LV end-systolic volume after cardiac resynchronization therapy, similar to the one in 
patients in NYHA classes III to IV. Cardiac resynchronization therapy should therefore be 
considered in patients with a reduced LVEF, wide QRS (and/or dyssynchrony), and 
minimal or asymptomatic heart failure in addition to optimal medical therapy. All these 
data confirm the pertinence of the recent update on cardiac resynchronization therapy 
guidelines which included indications for mildly symptomatic heart failure patients. Further 
reinforcement of this consideration derives from the fact that cardiac resynchronization 
therapy has been considered a cost-effective intervention for patients with mildly 
symptomatic heart failure and for asymptomatic patients with left ventricular dysfunction 
and previous heart failure symptoms. 
Another aspect that should be analyzed is the rationale for the combined use of cardiac 
resynchronization therapy and ICD in these heart failure patients. This is particularly 
important in as much as sudden death is the leading cause of mortality in mild systolic heart 
failure (MERIT HF, 1999). Therefore, the potentially greatest benefit of ICDs is likely to be 
conferred on patients with mild-to- moderate heart failure. 
The Sudden Cardiac Death in Hearth Failure (SCD-HeFT) trial showed a lowering of  
all-cause mortality by ICD therapy in patients with mild-to-moderate heart failure  
and LVEF <35%. The risk reduction was limited to functional class II patients. No 
treatment benefit was observed among the 30% of patients who were in NYHA functional 
class III. 
EVADEF study demonstrated that ICD implantation effectively reduces sudden cardiac 
death so that mildly symptomatic patients tend to die of progressive heart failure.  
Finally, Gold et al. (Gold et al., 2011.) studied a patient population receiving CRT-D devices 
(83 % out of the entire REVERSE cohort) and concluded that cardiac resynchronization 
therapy did not affect the overall frequency of ventricular tachyarrhythmias even if this 
arrythmia increased in CRT-ON patients without reverse remodelling, whereas it decreased 
in those with reverse remodelling. In their opinion these data could rise the issue of whether 
or not ICD backup is chronically needed in those patients with normalization of LV 
structure and function with cardiac resynchronization therapy. However the incidence of 
ventricular arrhythmias was similar in NYHA I and II patients, and in those with ischemic 
or nonischemic cardiomyopathy as well. Accordingly, neither the etiology nor the severity 
of heart failure was able to predict which patients were more likely to experience 
appropriate ICD therapy thereby benefiting from ICD backup with cardiac 
resynchronization therapy. Thus the authors concluded that further confirmation of their 
results are needed before a strategy of excluding ICD backup in certain mild symptomatic 
cardiac resynchronization therapy patients can be recommended.  
Thus on the basis of these remarks it is difficult to affirm at present, that the use of cardiac 
resynchronization therapy in mildly symptomatic heart failure patients should not be 
combined with ICD. 
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1. Introduction  
Intracardiac electrostimulation devices have achieved remarkable progresses in the 
treatment of patients with heart disorders, with an increasing number of implants in recent 
years. One of the most relevant complications are device-related infections that are 
increasing significantly; what is more, the rate of increase in device-related infections per 
year has been disproportionally higher than the rate of newly implanted devices. Such 
infections are caused mainly by staphylococci and are associated with the formation of 
biofilms on the device. Diagnosis requires both a well-defined etiology, with the obtainment 
of appropriate samples, and a well-established location (catheter lead and/or endocardium) 
in order to carry out the most appropriate therapeutic strategy, which usually requires both 
a complete device withdrawal and a correct antibiotic treatment. But there is still no 
consensus about the most appropriate antibiotic pattern, particularly in relation to its 
duration, and the best time to reintroduce a new device. 
2. Epidemiology and incidence 
Pacemaker infections are infrequent but there has been an increase over last years, with an 
older population associated to an increment in morbidity and mortality rates and in financial 
cost. In a retrospective analysis of the National Hospital Discharge Survey database (Voigt et 
al., 2010) from 1996 through 2006, a 57% increment in cardiac device-related infections was 
registered. A population-based study in Olmsted County Minnesota calculated an incidence of 
permanent pacemaker and implantable cardioverter defibrillator infection of 1.9 per 1000 
device-years (95% confidence interval (CI) 1.1-3.1). The incidence of pocket infection was 1.37 
per 1000 device-years (95% CI 0.62 - 3.05) and pocket infection with bacteremia or device-
related endocarditis occurred in 1.14 per 1000 devices-year (95% CI 0.47 - 2.74) (Uslam et al, 
2007). Another prospective multicenter study in France observed an incidence of pacemaker 
related infective endocarditis of 0.39 cases per 1000 devices-year (Duval et al, 2004). 
Nowadays, the estimated average cost of medical and surgical treatment of this kind of 
infections is $25,000 (Daouriche, 2004). Treatment of pacemaker-related infections typically 
requires a two-stage surgical approach, with complete removal of the implanted system 
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followed by insertion of a new one; so major costs are derived from hospitalization, 
diagnostic procedures, intravenous antibiotics and commonly two surgical procedures with 
a new device. 
3. Pathogenesis 
Staphylococci are the mean etiological agents (60-80%) and include Staphylococcus aureus and 
coagulase-negative staphylococci with meticillin-resistant strains in some institutions. Gram 
negative bacilli represent 5-10% of cases and another 10% are negatives cultures (Table 1). 
Rarely fungi or mycobacteria are etiological agents. 
Early infections are acquired by contamination of cutaneous microbiota when pacemaker is 
implanted or generator is revised (Da Costa et al., 1998). When microorganisms adhere to 
device's surface, biofilms are formed (Daouriche, 2001). The biofilm is an extraordinarily 
complex structure formed by a community of microorganisms, involved in a molecular 
matrix. Their training begins with the adhesion of the microorganisms to the surface of the 
biomaterial through nonspecific physicochemical forces and bacterial structures called 
adhesins, which are different depending on the microbial agent involved. The bacterial 
inoculum needed to cause infection is several thousand times lower in the presence of 
prosthetic material. Once the organism is attached to the surface it produces a matrix, which 
in the case of Staphylococcus epidermidis is composed of a gelatinous substance called slime, 
which consists mostly of polysaccharides (polysaccharide intercellular adhesion). 
Subsequently, depending on the interaction between the microorganisms and the host 
defense systems, there will be or not a progression in the formation of a mature biofilm. 
Periodically shedding fragments of the biofilm with the more superficially located 
organisms liberated in the cardiovascular system will result in symptoms (Vila et al., 2008). 
The microorganisms located within biofilms are protected from host defense mechanisms and 
are resistant to the action of antimicrobials. This resistance is determined by different 
mechanisms such as reduced diffusion of drugs, altered growth rate of microorganisms, 
resistance mechanisms expressed in planktonic bacteria, genetic elements transfer and 
biomaterial own action. In these circumstances it is common that the antimicrobial minimum 
inhibitory concentration for the organisms inside the biofilm is thousands times higher than 
for the microorganisms located on the surface (Rodríguez-Martínez & Pascual, 2008). 
If pocket infections persist they may progress by catheter leads to a systemic infection with 
bloodstream and/or endocardium affectation. In other cases, this systemic involvement is 
caused by a different focus bacteremia that colonizes the leads, as can occur in health-care 
related procedures like vascular catheter related bacteremia (Uslan et al., 2009; Chamis et al., 
2001). 
There are many risk factors for pacemaker devices infection. One retrospective study 
observed that long-term corticoid use (OR: 13.9; 95%CI 1.44-20.29) and the presence of more 
than two pacing leads (OR: 5.41; 95%CI: 1.44-20.29) were independent risk factors for 
pacemakers infections; in contrast, antimicrobial prophylaxis prior to implantation was a 
protective one (OR: 0.087; 95%CI: 0.016-0.48) (Sohail et al., 2006). Another prospective 
multicenter study observed that the occurrence of infection was positively correlated with 
fever within 24 hours before the implantation procedure (OR: 5.83; 95%CI, 2.00-16.98), use of 
temporary pacing before the implantation procedure (OR: 2.46; 95%CI: 1.09-5.13) and early 
reinterventions (OR: 15.04; 95%CI: 6.7-33.73); however, implantation of a new system (OR: 
0.46; 95%CI 0.24-0.87) and antibiotic prophylaxis (OR: 0.4; 95%CI: 0.18-0.86) were negatively 
correlated with risk of infection (Klug et al., 2006). 
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Microorganism Sohail et alN=189 
Alarcón et al
N=243 
Catanchin et al 
N=39 
Chua et al 
N=123 
Staphylococcus aureus 29% 20% 60% 24% 
Coagulase-negative staphylococci 42% 42% 32% 68% 
Other Gram positive cocci 4% 3% 4% NR 
Gram negative  bacilli 9% 9% 4% 17% 
Fungal 2% 1% - NR 
Polymicrobial 7% 9% - 13% 
Culture negative 7% 13% 36% NR 
Table 1. Etiology of intracardiac electronic devices infections in clinical series. 
4. Clinical manifestations 
There are local and systemic infections. Local infections affect only generator’s pocket and 
are expressed by local inflammatory symptoms like pain, tenderness, erythema and 
purulent drainage. In another cases exteriorization of the device material could be the only 
manifestation. Some patients with localized pocket infection have bacteremia without lead 
affectation. One study observed that local manifestations at the site of pacemaker 
implantation are associated with infection of the intravascular part of the leads in 79% of 
patients, and no clinical observations or laboratory investigations permitted identification of 
these patients with negative lead cultures (Klug et al., 2004). 
Systemic infections affect the intravascular catheter lead and/or endocardium; they are 
manifested by fever, pulmonary embolism, severe sepsis and metastatic infections (Table 2). In 
many cases, local and systemic symptoms coexist, but there can also exist a systemic infection 
without any local symptomatology; which is more frequent in late infections. Sometimes, the 
diagnosis of recurrent pneumonia is made due to recurrent embolisms from catheter's tip or 
tricuspid vegetations. Since this is a bacteriemic infection, metastatic infections are frequent 
such as septic arthritis, osteomyelitis or endophthalmitis. In a recent international cohort of 
2781 episodes of infective endocarditis, 10% of them were device-related endocarditis 
(Murdoch et al., 2009). When endocarditis is present, it is right-sided with tricuspid valve or  
 
Clinical variable Range % 
Fever 80-100 
Murmur on examination 20-43 
Local findings 45 
Pulmonary embolism 29-33 
Anemia 66 
Leukocytosis 59 
High erythrocyte sedimentation rate 59 
Positive blood cultures 77-95 
Positive swab cultures from generator-pocket 61 
Lead vegetation 85-92 
Valve vegetation 90-100 
Table 2. Clinical features in intracardiac device-related endocarditis in different series 
(N=180) (Sohail et al., 2008; Massoure et al., 2006; Duval et al., 2004; Del Río et al., 2003) 
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mural endocardium affected. Only in exceptional cases mitral and/or aortic valves are 
affected. In left-sided endocarditis systemic embolism, stroke, congestive heart-failure and 
metastatic infections are more frequent and have a more severe prognosis. 
Leukocytosis with neutrophilia, elevation of the C-reactive protein or another acute phase 
reactant are the main altered laboratory parameters. 
5. Diagnosis 
The diagnostic must be microbiological and anatomical. The main procedures are blood 
cultures and culture of exudates of the pocket. Any purulent drainage should be properly 
processed for staining and suitable cultures. Bacteremia is present in many patients with 
systemic infections and sometimes in local infections too, so blood cultures are crucial for 
diagnostic, perhaps previous to any antimicrobial treatment. Bacteremia can be detected 
even in patients without fever. The sonication of extracted device can be a useful method 
that allows the recovering of microorganisms that cannot be isolated by conventional 
methods. Despite this, the results obtained with these methods must be interpreted with 
caution in the appropriate clinical context, because they can have an uncertain clinical 
significance or can be the result of a contamination (Mason et al., 2011; Rohacek et al., 
2010). 
Transesophageal echocardiography is a good diagnostic procedure to detect leads 
involvement because it has a higher sensibility to detect vegetations than transthoracic 
echocardiography. These vegetations are usually located on the distal extreme of the lead, 
and/or the endocardium, generally at the level of the tricuspid valve, but in some patients 
they may also exist in the endocardial wall and the mitral or aortic valves (Victor et al., 
1999). The vegetations may be single or multiple and often easily distinguishable from the 
strands that are filamentous structures attached to the electrodes without clinical relevance 
(Kerut et al., 2007). In other occasions the affectation of the lead adopts an aspect of 
thickening or sleeve (Klug et al., 2007).  In patients with cardiac prosthetic valves, the 
involvement of the same should be ruled out by transesophageal echocardiography, 
especially when the causative agent is S aureus (Habib et al., 2010). 
6. Medical treatment 
Antimicrobial agents are one of the main elements of treatment, along with early and 
complete withdrawal of the device. Antibiotic regimen depends on the location of the 
infection and its severity. In local infections may be sufficient to use oral antibiotics for 
several days, while severe and/or systemic infections, as those with bacteremia or 
endocarditis, require intravenous antibiotics for several weeks. 
In critically ill patients empirical use of these drugs is justified, especially in systemic 
infections, in patients with significant comorbidities and when a high risk of complication 
development exists. In these cases antibiotics associations directed against the main 
organisms should be used. Since Staphylococcus aureus and coagulase-negative Staphylococci 
are the main microorganisms involved and, depending on each institution, the number of 
meticillin-resistant strains may be high, it is recommended the use of glycopeptides such as 
vancomycin or teicoplanin associated with a drug active against gram-negative bacilli, 
which depends on the epidemiology of each institution and include cefazidime, cefepime, 
piperacillin + tazobactam or carbapenems (Mermel et al., 2009). 
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Vancomycin should be used according to current recommendations, which means that there 
should be given an initial loading dose adjusted to patient’s weight in seriously ill patients 
(25-30 mg/Kg) and continue with the following doses adjusted to renal function and serum 
trough levels (15-20 µg/ml) (Ryback et al., 2009). 
The association of aminoglycosides is not well established, since we only have evidence of a 
decrease in bacteremia duration in some cases, but it is also associated with more adverse 
effects, especially nephrotoxicity (Cosgrove et al., 2009). 
Once culture results are obtained, treatment should be adjusted depending on the isolated 
organisms and their antimicrobial susceptibility. Thus, in the case of methicillin-sensitive 
Staphylococcus aureus (MSSA) the drug of choice should be cloxacillin or nafcillin in 
appropriate doses. In methicillin-resistant Staphylococcus aureus (MRSA), drug selection 
depends on the minimum inhibitory concentration (MIC) against vancomycin: strains with 
MIC ≤ 1 µg/ml should continue with vancomycin at appropriate doses, whereas strains 
with MIC ≥ 1 µg/ml require an alternative to vancomycin (Soriano et al., 2008). In these 
cases, the most employed drugs are daptomycin and linezolid. Daptomycin is a lipopeptide 
antibiotic rapidly bactericidal on most of gram-positive cocci, including drug-resistant 
strains; a recent clinical trial demonstrated it is not inferior to antistaphylococal penicillin or 
vancomycin in patients with bacteremia and right-sided endocarditis by MSSA and MRSA, 
using a dose of 6 mg/Kg/day (Fowler et al., 2006). However, some therapeutic failures on 
this drug at low doses advise for the use of greater doses between 8 and 10 mg/Kg/day. 
Linezolid an oxazolidinone antibiotics exhibit bacteriostatic activity against many Gram-
positive cocci and provide the advantage of having a high bioavailability which permits an 
oral administration and do not require dose adjustment for renal insufficiency; although 
prolonged treatment may have more side effects such as myelosuppression or neuropathy. 
For patients allergic to beta-lactam antibiotics glycopeptides are the drugs of choice. There 
are other alternatives as dalbavancin, telavancin, ceftobiprole or trimethoprim-
sufametoxazole but the experience is limited. 
Infections caused by coagulase-negative staphylococci should follow a similar attitude. In 
methicillin-sensitive strains, oxacillin or nafcillin are the drugs of choice; whereas in strains 
resistant to methicillin, use of vancomycin is preferred, although it is still not clear which 
role do new drugs play in these cases. New drugs such as daptomycin or linezolid are of 
great interest due to the activity of some of these drugs in bacterial biofilms, and maybe the 
need for device removal could be avoided in the future, at least in selected cases (Parra et al., 
2010). 
The use of rifampicin is controversial since it has not been proven to increase its clinical 
efficacy and, in turn, it is associated with an increased number of adverse reactions and 
interactions with other drugs such as oral anticoagulants, used regularly in this population. 
On the other hand, there is a theoretical advantage in its use when a more intense action on 
microorganisms located inside the biofilm is required. However, device removal is 
necessary in most cases to eradicate the infection and after its extraction, rifampicin benefits 
do not appear to outweigh risks, so its use is discouraged (Perlroth et al., 2008). 
Directed treatment for gram negative microorganisms depends on the characteristics of each 
center. In general quinolones, cotrimoxazole, amoxicilin + clavulanate or cephalosporins, 
could be useful. However there is a gradual increase in infections caused by multidrug 
resistant pathogens as gram-negative bacilli-producing β-lactamases by different mechanisms, 
so it may be necessary to employ more complex treatments (Table 3). Once again, the complete 
removal of the device facilitates eradication (Rodríguez-Baño et al., 2010). 
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that allows the recovering of microorganisms that cannot be isolated by conventional 
methods. Despite this, the results obtained with these methods must be interpreted with 
caution in the appropriate clinical context, because they can have an uncertain clinical 
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Vancomycin should be used according to current recommendations, which means that there 
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There is no consensus on the optimal duration of medical treatment. It is possible that in 
infections involving only the generator pocket, several days treatment duration may be 
sufficient. In systemic infections the antimicrobial regimen depends on the type of organism, 
site of infection (pacemaker lead versus endocardium) and the effective withdrawal of the 
infected device. In the published series, the average treatment duration was of 4-6 weeks, 
although in the series of Dumont et al., they describe 8 patients treated during 8.2 ± 5.4 days 
without recurrence (Dumont et al., 2003). Commonly, 2 weeks of parenteral therapy after 
device removal may be enough if there are no septic complications, whereas when there is 
device-related endocarditis or a complicated Staphylococcus aureus bacteremia, it is necessary 
to prolong this treatment for 4 weeks. In patients who can not remove the system 
completely due to their comorbidity and/or technical difficulties, they may require 
prolonged treatment with antibiotics for several months or even a lifetime (chronic 
suppressive therapy); in these cases the objective would be to keep localized the infection in 
the system, avoiding a possible dissemination. This should be exceptional and restricted to 




Staphylococcus aureus and Coagulase negative 
Staphylococci 
Meticillin sensible 
Cloxacillin or  nafcillin 
Staphylococcus aureus meticillin resistant 
MIC vancomycin > 1 µg/ml 
MIC vancomycin < 1 µg/ml 
 
Daptomycin. Linezolid  
Vancomycin 
Coagulase negative Staphylococii meticilin resistant Vancomycin 
Enterococcus faecalis Penicillin, Ampicillin 
Enterobacter sp, Serratia sp, Citrobacter freundii, 
Morganella sp 
Cefepime,  carbapenems 
Fluorquinolones 
Pseudomonas aeruginosa 
Cefepime, Ceftazidime, aztreonam 
Piperacillin+tazobactam, carbapenems 
(except ertapenem) Fluorquinolones 
Table 3. Directed antimicrobial therapy for systemic infections. Abbreviations: MSSA, 
meticillin-sensible Staphylococcus aureus; MRSA, meticillin-resistant Staphylococcus 
aureus; MIC, minimal inhibitory concentration. 
7. Surgical techniques 
Although randomized trials comparing lead extraction to conservative management are 
lacking, observational studies have clearly demonstrated the role of extraction in case of 
infections of pacemakers; because mortality rates of device-related endocarditis treated only 
with antibiotics are very high, as much as 66% in some series. 
Like in any other surgical procedure, the best way of treating an infectious complication is 
avoiding it with a good prevention, consisting in a strict aseptic manipulation of a patient 
without signs of infection anywhere and employing periprocedural prophylactic antibiotics. 
A standard regimen includes administration of 2 g of cefazolin intravenously one hour 
before the procedure, or vancomycin, 90 to 120 minutes before surgery, if the patient is 
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penicillin allergic or in centers where oxacillin resistance among staphylococci is high 
(Bertaglia et al., 2006). 
Superficial wound infections that do not involve the device do not require extraction and 
can be managed with oral antibiotherapy; but, in general, foreign body infection requires 
removal of the entire system to ensure a complete eradication and to prevent the recurrence 
of infection. When there is a localized pocket infection, there is still controversy with which 
is the best way to approach. The NASPE 2000 guidelines accept a conservative treatment 
consistent in device removal cutting the exposed parts of the leads; an attitude that is 
proving to be unsuccessful and increases the risk of recurrence or spreading of the infection 
and patient’s mortality (Chua et al., 2000). What is more, the recent AHA scientific statement 
and update (Baddour et al., 2010) does not include this approach. 
The first techniques employed for extraction of a transvenous lead were external traction 
with counter weights or open cardiac surgery with inflow occlusion or cardiopulmonary 
bypass. In 1988 Byrd and his colleagues (Smith et al., 1994) incorporated a percutaneous 
technique for lead extraction attempted via the implant vein using locking stylets and 
dilator sheaths or via the femoral vein using snares, retrieval baskets, and sheaths. After this 
introduction, cardiac pacemaker lead extraction techniques have improved and there are 
currently many options to select. 
7.1 Direct traction 
Direct traction techniques consist in lead traction with standard or locking stylets without 
countertraction. Care must be taken not to compromise the integrity of the lead, because this 
difficult the removal and increases the risk of complications or incomplete extraction. To 
avoid this risk, forceful traction is contraindicated and any lead that cannot be freed from 
tissue without distortion or stretching should be extracted with countertraction techniques. 
7.1.1 Simple traction 
Simple traction is the first employed and most basic lead extraction technique. The lead 
exits via the implant vein using standard non-locking stylets and fixation screw retraction 
clips. A modification consists on prolonged graded traction with increasing weights that 
are connected to the proximal end of the lead. Although it can be performed in any case, 
best results are obtained when used with recently implanted leads (less than one or two 
years). 
When removing older leads, excessive traction may result in coil rupture, leaving fragments 
in the cardiovascular system with subsequent thrombotic or infectious complications. 
Unopposed traction can also lead to invagination of the myocardium, myocardial rupture, 
arrhythmia, hypotension or acute severe tricuspid regurgitation secondary to valve leaflet 
avulsion (Farooqi et al., 2010). 
Rosenheck et al. (2002) employed lead rotation during simple traction technique in 89 
patients with 113 lead extractions. Removal was fully completed in 97 (85.8%) leads with a 
6.9% of partial and an 8% of unsuccessful removal rate. The only predictor of successful 
removal was lead age and there was only a small asymptomatic pericardial effusion in one 
patient. 
7.1.2 Locking stylet 
This technique uses a special traction device to assist in the removal of cardiac leads. This 
specialized stylet wire can be inserted through a cardiac lead's conductor lumen once the 
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can be managed with oral antibiotherapy; but, in general, foreign body infection requires 
removal of the entire system to ensure a complete eradication and to prevent the recurrence 
of infection. When there is a localized pocket infection, there is still controversy with which 
is the best way to approach. The NASPE 2000 guidelines accept a conservative treatment 
consistent in device removal cutting the exposed parts of the leads; an attitude that is 
proving to be unsuccessful and increases the risk of recurrence or spreading of the infection 
and patient’s mortality (Chua et al., 2000). What is more, the recent AHA scientific statement 
and update (Baddour et al., 2010) does not include this approach. 
The first techniques employed for extraction of a transvenous lead were external traction 
with counter weights or open cardiac surgery with inflow occlusion or cardiopulmonary 
bypass. In 1988 Byrd and his colleagues (Smith et al., 1994) incorporated a percutaneous 
technique for lead extraction attempted via the implant vein using locking stylets and 
dilator sheaths or via the femoral vein using snares, retrieval baskets, and sheaths. After this 
introduction, cardiac pacemaker lead extraction techniques have improved and there are 
currently many options to select. 
7.1 Direct traction 
Direct traction techniques consist in lead traction with standard or locking stylets without 
countertraction. Care must be taken not to compromise the integrity of the lead, because this 
difficult the removal and increases the risk of complications or incomplete extraction. To 
avoid this risk, forceful traction is contraindicated and any lead that cannot be freed from 
tissue without distortion or stretching should be extracted with countertraction techniques. 
7.1.1 Simple traction 
Simple traction is the first employed and most basic lead extraction technique. The lead 
exits via the implant vein using standard non-locking stylets and fixation screw retraction 
clips. A modification consists on prolonged graded traction with increasing weights that 
are connected to the proximal end of the lead. Although it can be performed in any case, 
best results are obtained when used with recently implanted leads (less than one or two 
years). 
When removing older leads, excessive traction may result in coil rupture, leaving fragments 
in the cardiovascular system with subsequent thrombotic or infectious complications. 
Unopposed traction can also lead to invagination of the myocardium, myocardial rupture, 
arrhythmia, hypotension or acute severe tricuspid regurgitation secondary to valve leaflet 
avulsion (Farooqi et al., 2010). 
Rosenheck et al. (2002) employed lead rotation during simple traction technique in 89 
patients with 113 lead extractions. Removal was fully completed in 97 (85.8%) leads with a 
6.9% of partial and an 8% of unsuccessful removal rate. The only predictor of successful 
removal was lead age and there was only a small asymptomatic pericardial effusion in one 
patient. 
7.1.2 Locking stylet 
This technique uses a special traction device to assist in the removal of cardiac leads. This 
specialized stylet wire can be inserted through a cardiac lead's conductor lumen once the 
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proximal connector has been removed. The stylet can then be locked into position, firmly 
grasping the distal end of the lead or anywhere along the conductor coil. This technique 
prevents the risk of elongation of the lead body and coil during exertion, ensuring that the 
entire lead is removed. Compared to simple traction, the use of a locking stylet results in 
extraction of greater number of intact leads (Kennergren et al., 2000) and a reduced risk of 
rupture. 
The use of a locking stylet is limited when the conductor is broken or central lumen distorted, 
and has similar complications than simple traction such as myocardial invagination or 
rupture. 
Alt et al. (1996) described the experience gathered between 1990 and 1994 by seven 
European centers regarding a locking stylet for removal of 150 leads. Complete removal was 
possible in 122 cases (81%) and in 18 cases (12%) a partial removal was obtained. Failure to 
remove the lead with the extraction stylet was experienced in 10 cases (7%). There were no 
major complications or deaths. 
7.2 Lead extraction sheaths 
7.2.1 Telescoping sheaths 
The function of telescoping sheaths is to mechanically disrupt the fibrosis and provide a 
passage to remove a lead. The use of a sheath is a two-staged process: counterpressure 
and countertraction (Byrd & Wilkoff, 2000). In the first stage, the sheath is pushed along 
the lead while a similar traction is applied to the locking stylet to avoid a tear through the 
vascular wall. The second stage is initiated when the sheath has been advanced to the lead 
tip-myocardial interface and countertraction is employed. In this stage, traction is placed 
on the lead while countertraction is utilized in the sheath to minimize the risk of 
myocardial invagination or rupture. Care must be taken to maintain the sheath angle in 
parallel with the lead to minimize the risk of vascular lesion. Although counter traction 
prevents invagination of the myocardium, perforation of the myocardium is still possible. 
Major risks associated with this technique involve vascular lesion and myocardial 
perforation. 
Results using conventional sheaths are reported in the U.S. Lead Extraction Database (Smith 
et al., 1994; and Byrd et al., 1999), with a complete removal rate of 86.8% and partial removal 
rate of 7.5%. Major complications occurred in 2.5% (haemopericardium, tamponade, 
haemothorax and one death). 
7.2.2 Electrosurgical sheaths 
The electrosurgical sheath (fig. 1) uses radiofrequency energy, similarly to a surgical 
cautery tool. It consists on two electrodes settled on the beveled tip of a sheath and the 
radiofrequency energy is conducted between the bipolar electrodes. It is used to locally 
dissect the binding tissue that surrounds and anchors transvenous leads. The tapered 
distal end of the sheath can also be used to mechanically disrupt these adhesions, like a 
conventional one; and dislocation of the tip is achieved with countertraction. 
In the Excl trial (Farooqi et al., 2010) 287 leads in 166 patients were extracted with bipolar 
electrosurgical sheaths; 96% of leads were completely removed, 4% partially removed and 
only one lead could not be removed (laser sheath as an adjunct was used in 2% of cases). 
Major complications included three cardiac tamponade, one haemothorax and an 
arteriovenous fistula. 
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Fig. 1. Intraoperative image of a lead extraction with an electrosurgical sheath. 
Compared to laser ablation, electrosurgical sheaths are designed to be more supple so that 
may be easier to maneuver. The radiofrequency energy is confined to less than one fourth of 
the circumference of the sheath allowing a directed and careful dissection of the tissue and 
reducing the chance of vascular damage; but in the other hand this directional control 
reduces the cutting efficacy through the fibrosis (Verma & Wilkoff, 2004). 
7.2.3 Laser ablation 
The Excimer laser sheath consists on a circumferential thin layer of optical fibers that run 
along the sheath and finish at the distal tip producing a ring of laser light in pulses to a 
tissue depth of 100 μm, dissolving the nearest fibrous tissue adherent to leads. Thus, fibrous 
tissue encapsulating the lead body is removed in a controlled manner and occluded 
vasculature can be re-canalised (Farooqi et al., 2010). 
The outer layer of the sheath is made of plastic and acts as a support for maneuvering the 
laser but for mechanical countertraction too. Compared to electrosurgical sheaths, the 
circumferencial cutting is more powerful for extraction of multiple leads or with older 
implantation date, and in veins occluded by clot and fibrosis too. On the other hand, this 
circumferential cutting increases the risk of venous laceration, especially at the superior 
vena cava. 
Appropriate sizing of the laser sheath and a proper traction/countertraction technique are 
crucial to prevent complications. A coaxial orientation of the sheath and lead, with the 
leading edge of the sheath oriented away from the wall of the vessel decreases the risk of 
vascular injury; and we must be careful not to advance the outer sheath more deeply than 
the laser sheath to avoid pinching the vascular wall (Henrikson & Brinker, 2008). 
Major complications associated with laser-assisted lead extraction include: major venous 
injury, arrhythmia, myocardial tear, pneumothorax, hemothorax, arteriovenous fistula, 
tricuspid valve injury and pulmonary embolus (Lawton et al., 2006). 
The total initial experience of laser lead extraction in the U.S. (Byrd et al., 2002) was 
reported on 2561 pacing and defibrillator leads from 1684 patients at 89 sites, with a 
procedural success rate of 90%, a major complication rate (tamponade, hemothorax, 
pulmonary embolism, lead migration, and death) of 1.9% and an in-hospital death rate of 
0.8%. The latest report about laser lead extraction is the LExICon study (Wazni et al., 
2010), an observational retrospective study of 2405 consecutive laser-assisted lead 
extractions in 13 sites in the U.S. and Canada. In this study, the most common indication 
 
Aspects of Pacemakers – Functions and Interactions in Cardiac and Non-Cardiac Indications 
 
114 
proximal connector has been removed. The stylet can then be locked into position, firmly 
grasping the distal end of the lead or anywhere along the conductor coil. This technique 
prevents the risk of elongation of the lead body and coil during exertion, ensuring that the 
entire lead is removed. Compared to simple traction, the use of a locking stylet results in 
extraction of greater number of intact leads (Kennergren et al., 2000) and a reduced risk of 
rupture. 
The use of a locking stylet is limited when the conductor is broken or central lumen distorted, 
and has similar complications than simple traction such as myocardial invagination or 
rupture. 
Alt et al. (1996) described the experience gathered between 1990 and 1994 by seven 
European centers regarding a locking stylet for removal of 150 leads. Complete removal was 
possible in 122 cases (81%) and in 18 cases (12%) a partial removal was obtained. Failure to 
remove the lead with the extraction stylet was experienced in 10 cases (7%). There were no 
major complications or deaths. 
7.2 Lead extraction sheaths 
7.2.1 Telescoping sheaths 
The function of telescoping sheaths is to mechanically disrupt the fibrosis and provide a 
passage to remove a lead. The use of a sheath is a two-staged process: counterpressure 
and countertraction (Byrd & Wilkoff, 2000). In the first stage, the sheath is pushed along 
the lead while a similar traction is applied to the locking stylet to avoid a tear through the 
vascular wall. The second stage is initiated when the sheath has been advanced to the lead 
tip-myocardial interface and countertraction is employed. In this stage, traction is placed 
on the lead while countertraction is utilized in the sheath to minimize the risk of 
myocardial invagination or rupture. Care must be taken to maintain the sheath angle in 
parallel with the lead to minimize the risk of vascular lesion. Although counter traction 
prevents invagination of the myocardium, perforation of the myocardium is still possible. 
Major risks associated with this technique involve vascular lesion and myocardial 
perforation. 
Results using conventional sheaths are reported in the U.S. Lead Extraction Database (Smith 
et al., 1994; and Byrd et al., 1999), with a complete removal rate of 86.8% and partial removal 
rate of 7.5%. Major complications occurred in 2.5% (haemopericardium, tamponade, 
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for extraction was infection and a 96.5% of leads were completely removed, with a 
procedural failure rate that statistically increased when leads were implanted for more 
than 10 years. The clinical success rate was of 97.7% (resolution of clinical goals associated 
with the indication for lead removal), and failure to achieve it was associated with body 
mass index <25 kg/m2 and low extraction volume centers. Major adverse events (any 
complication related to the procedure that required procedural intervention or transfusion 
to prevent death, threat to life, or any complication related to the procedure that resulted 
in death or serious harm to bodily function or structure) occurred in 1.4% of procedures, 
with a death rate of 0.28%; and were associated with body mass index <25 kg/m2. 
Indicators of all-cause in-hospital mortality were pocket infections, device-related 
endocarditis, diabetes and creatinine ≥ 2.0; with an overall in-hospital mortality of 1.86%, 
a higher rate than the one presented by Byrd et al in 2002 and that reflects the complex 
comorbid condition of this patient population, especially device-related endocarditis. In 
this study, the all-cause in-hospital mortality rate for the device-related endocarditis 
population was 4.3%, 1.7% for pocket infection and 0.3% for all noninfected patients, 
proving the seriousness of deep advanced and pocket infections. 
Moon et al. (2002), found three independent predictors of the need for laser-assist during 
lead extractions: prolonged implant duration, nonseptic leads and necessary or 
discretionary versus mandatory indications. 
7.3 Femoral and transjugular extraction techniques 
The preferred via for lead extraction is the same transvenous access by which they were 
implanted, usually subclavian, cephalic or axillary veins. However, when removing broken 
or cut leads with free ends and when the primary approach via the implant vein fails, a 
femoral or transjugular access is the procedure of choice. 
The internal jugular transvenous access was described by Mazetti et al. (2008), and, although 
their experience was based only on 18 patients and 22 leads, they achieved a high success 
rate with very few complications. 
Lead extraction using the femoral vein is called “the inferior approach” and probably it is 
the most versatile approach for lead removal. There are two fundamental snaring 
techniques (Belott, 2007): a direct approach in which, once the lead is grabbed with a snare, 
an attempt is made to remove the lead by traction; and a two-step process, by first pulling 
either the proximal or distal end of the lead into the inferior vena cava and secondly, snaring 
the free end and pulling it for its removal. There are many tools for femoral lead extraction; 
the more advanced one is the Byrd Femoral Work Station (Cook Vascular Inc., Leechburg, 
PA). 
Recently (Fischer et al., 2009), it has been described a simple and safe technique of 
transfemoral lead snaring to assist lead extraction and maintain vascular access in the 
setting of venous occlusion, when the distal lead tip pulls free of the myocardium before an 
extraction sheath is passed beyond the point of venous obstruction. 
Finally, both the transjugular and transfemoral approaches have the same potential 
complications of cardiac or vascular perforations. 
7.4 Surgical lead removal and other techniques 
An open heart surgical approach for lead removal should be limited to two scenarios: 
1. Patients with significant retained hardware after percutaneous removal failure. 
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2. Lead vegetations greater than 2 cm in diameter, because of concern of pulmonary 
embolism with percutaneous procedures. This is not a definitive indication because 
there is some experience in transvenous lead extraction with large vegetations without 
precipitating a pulmonary embolism or, even having evidence of it, neither survival nor 
length of hospital stay has been affected by this complication (Meier-Ewert et al., 2003). 
In some cases, a combined technique is the best treatment option. Removal of the distal end 
of the lead by sternotomy and cardiopulmonary bypass due to the presence of large 
vegetations; and a simultaneous percutaneous procedure for extraction of the proximal end, 
due to severe fibrosis around the lead at the venous system, that precluded its traction from 
the atrium. 
Although the currently recommended treatment for pacemaker infection is complete 
removal, both surgery and percutaneous techniques are complex and of very high risk in 
some patients with many comorbidities, in these cases, less invasive techniques have been 
applied at some centers: 
- Closed irrigation system (Hurst et al., 1986), they treated 19 patients for infected or 
eroded permanent pacemaker pockets with local debridement and insertion of a closed 
irrigation system using a solution of tyloxapol and tobramycin. Successful eradication 
of the infection, without complete replacement of the pacemaker system, was achieved 
in all cases. 
- Placement of an antibiotic-releasing envelope to treat an infected pacemaker pocket: only 
one case report has been described in the literature (Lopez, 2010), with good results. 
- Vacuum-assisted system for pacemaker infection: Satsu & Onoe (2010) describe the 
application of vacuum-assisted therapy for treating four patients with infected 
permanent pacemaker with good results. 
7.5 Selection of percutaneous lead extraction technique in permanent transvenous 
pacemaker infections 
Extraction of recently implanted cardiac rhythm devices (less than one year) is commonly a 
safe and easy procedure which consists in pulse generator removal and direct lead traction. 
However, chronically implanted leads become encapsulated by fibrotic attachments along 
any length of the lead where there is contact with the vein, valve or endocardial structures. 
In these cases, percutaneous lead extraction has become the preferred method to remove 
leads with a rate of success in centers with a high-volume case load of 95-97% and high rates 
of resolution of infection. On the other side, these procedures are associated with 
complications rates between 0 and 11% and involve significant risks such as cardiac 
tamponade, hemothorax, pulmonary embolism, lead migration, pneumonia and death. 
Every of these previous described techniques remain useful and its employment depends on 
the indication and the experience of each center, but there are some recent reviews that may 
be of interest in selecting one or another technique. They are summarized in next table 
(Table 4). Anyway, it is important to emphasize that operator experience is vital in 
determining success as familiarity of a wide array of techniques will increase the likelihood 
of uncomplicated extraction. 
Mathur et al. (2003), made a retrospective analysis of various conventional techniques for 
lead extraction, obtaining good results and a low complication rate. They conclude that the 
only independent predictor associated with successful lead extraction with these techniques 
was a shorter dwell time. Success rates for leads in situ for greater than six years 
considerably decreased in their study. 
 
Aspects of Pacemakers – Functions and Interactions in Cardiac and Non-Cardiac Indications 
 
116 
for extraction was infection and a 96.5% of leads were completely removed, with a 
procedural failure rate that statistically increased when leads were implanted for more 
than 10 years. The clinical success rate was of 97.7% (resolution of clinical goals associated 
with the indication for lead removal), and failure to achieve it was associated with body 
mass index <25 kg/m2 and low extraction volume centers. Major adverse events (any 
complication related to the procedure that required procedural intervention or transfusion 
to prevent death, threat to life, or any complication related to the procedure that resulted 
in death or serious harm to bodily function or structure) occurred in 1.4% of procedures, 
with a death rate of 0.28%; and were associated with body mass index <25 kg/m2. 
Indicators of all-cause in-hospital mortality were pocket infections, device-related 
endocarditis, diabetes and creatinine ≥ 2.0; with an overall in-hospital mortality of 1.86%, 
a higher rate than the one presented by Byrd et al in 2002 and that reflects the complex 
comorbid condition of this patient population, especially device-related endocarditis. In 
this study, the all-cause in-hospital mortality rate for the device-related endocarditis 
population was 4.3%, 1.7% for pocket infection and 0.3% for all noninfected patients, 
proving the seriousness of deep advanced and pocket infections. 
Moon et al. (2002), found three independent predictors of the need for laser-assist during 
lead extractions: prolonged implant duration, nonseptic leads and necessary or 
discretionary versus mandatory indications. 
7.3 Femoral and transjugular extraction techniques 
The preferred via for lead extraction is the same transvenous access by which they were 
implanted, usually subclavian, cephalic or axillary veins. However, when removing broken 
or cut leads with free ends and when the primary approach via the implant vein fails, a 
femoral or transjugular access is the procedure of choice. 
The internal jugular transvenous access was described by Mazetti et al. (2008), and, although 
their experience was based only on 18 patients and 22 leads, they achieved a high success 
rate with very few complications. 
Lead extraction using the femoral vein is called “the inferior approach” and probably it is 
the most versatile approach for lead removal. There are two fundamental snaring 
techniques (Belott, 2007): a direct approach in which, once the lead is grabbed with a snare, 
an attempt is made to remove the lead by traction; and a two-step process, by first pulling 
either the proximal or distal end of the lead into the inferior vena cava and secondly, snaring 
the free end and pulling it for its removal. There are many tools for femoral lead extraction; 
the more advanced one is the Byrd Femoral Work Station (Cook Vascular Inc., Leechburg, 
PA). 
Recently (Fischer et al., 2009), it has been described a simple and safe technique of 
transfemoral lead snaring to assist lead extraction and maintain vascular access in the 
setting of venous occlusion, when the distal lead tip pulls free of the myocardium before an 
extraction sheath is passed beyond the point of venous obstruction. 
Finally, both the transjugular and transfemoral approaches have the same potential 
complications of cardiac or vascular perforations. 
7.4 Surgical lead removal and other techniques 
An open heart surgical approach for lead removal should be limited to two scenarios: 
1. Patients with significant retained hardware after percutaneous removal failure. 
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2. Lead vegetations greater than 2 cm in diameter, because of concern of pulmonary 
embolism with percutaneous procedures. This is not a definitive indication because 
there is some experience in transvenous lead extraction with large vegetations without 
precipitating a pulmonary embolism or, even having evidence of it, neither survival nor 
length of hospital stay has been affected by this complication (Meier-Ewert et al., 2003). 
In some cases, a combined technique is the best treatment option. Removal of the distal end 
of the lead by sternotomy and cardiopulmonary bypass due to the presence of large 
vegetations; and a simultaneous percutaneous procedure for extraction of the proximal end, 
due to severe fibrosis around the lead at the venous system, that precluded its traction from 
the atrium. 
Although the currently recommended treatment for pacemaker infection is complete 
removal, both surgery and percutaneous techniques are complex and of very high risk in 
some patients with many comorbidities, in these cases, less invasive techniques have been 
applied at some centers: 
- Closed irrigation system (Hurst et al., 1986), they treated 19 patients for infected or 
eroded permanent pacemaker pockets with local debridement and insertion of a closed 
irrigation system using a solution of tyloxapol and tobramycin. Successful eradication 
of the infection, without complete replacement of the pacemaker system, was achieved 
in all cases. 
- Placement of an antibiotic-releasing envelope to treat an infected pacemaker pocket: only 
one case report has been described in the literature (Lopez, 2010), with good results. 
- Vacuum-assisted system for pacemaker infection: Satsu & Onoe (2010) describe the 
application of vacuum-assisted therapy for treating four patients with infected 
permanent pacemaker with good results. 
7.5 Selection of percutaneous lead extraction technique in permanent transvenous 
pacemaker infections 
Extraction of recently implanted cardiac rhythm devices (less than one year) is commonly a 
safe and easy procedure which consists in pulse generator removal and direct lead traction. 
However, chronically implanted leads become encapsulated by fibrotic attachments along 
any length of the lead where there is contact with the vein, valve or endocardial structures. 
In these cases, percutaneous lead extraction has become the preferred method to remove 
leads with a rate of success in centers with a high-volume case load of 95-97% and high rates 
of resolution of infection. On the other side, these procedures are associated with 
complications rates between 0 and 11% and involve significant risks such as cardiac 
tamponade, hemothorax, pulmonary embolism, lead migration, pneumonia and death. 
Every of these previous described techniques remain useful and its employment depends on 
the indication and the experience of each center, but there are some recent reviews that may 
be of interest in selecting one or another technique. They are summarized in next table 
(Table 4). Anyway, it is important to emphasize that operator experience is vital in 
determining success as familiarity of a wide array of techniques will increase the likelihood 
of uncomplicated extraction. 
Mathur et al. (2003), made a retrospective analysis of various conventional techniques for 
lead extraction, obtaining good results and a low complication rate. They conclude that the 
only independent predictor associated with successful lead extraction with these techniques 
was a shorter dwell time. Success rates for leads in situ for greater than six years 
considerably decreased in their study. 
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Reference Techniques Results Complications 






158 leads extracted in 80 
patients: 
- Simple traction 16.4% 
- Locking stylet 6.1% 
- Telescoping sheath 67.3% 
- Transfemoral approach 
6.1% 
- Thoracotomy 4.8% 
Success at 1st procedure 87.7%
 - Cephalic approach 90% 
 - Transfemoral approach 56%
 - Thoracotomy 75% 
Complete lead removal 86.7%
Lead remnants 7.3% 
Complete lead remaining 
6.1% 
Deaths - 0 
Tamponade - 1 
Stroke - 1 
Pulmonary embolism - 1 
Significant bleeding 12% 
Centella et al 
Retrospective 
analysis of their 
experience 
1989-2006 
314 leads extracted in 187 
patients: 
-Symple traction 44 leads 
-Telescoping sheath 34 
patients 
-Electrosurgical sheath 80 
patients 
Complete extraction 96.8% 
48 patients required a second 
technique for lead remnant 
removal 
Deaths - 1 
Tamponade - 1 
Sepsis – 1 
Pulmonary embolism – 1 
Severe tricuspid 
insufficiency – 1 
Rusanov et al 
Retrospective 






 - Simple traction 
 - Locking stylet 
 - Telescoping sheath 
Open surgical approach 
11.2% 
 - No CPB 4.2% 
 - CPB 6.3% 
Complete extraction 86.2% 
Partial success (<4cm 
retained) 9.2% 
Failure to extract (>4cm 
retained) 4.6% 
Pneumothorax – 2 
(surgical approach) 
Persistent infection – 1 
(percutaneous) 









161 leads implanted for at 
least 6 months in 120 
patients: 
 - 84 leads extracted with 
radiofrequency sheaths 
 - 77 leads extracted with 
telescoping sheaths 
Radiofrequency extraction: 
 - Complete success 93% 
 - Partial success 7% 
Standard extraction: 
 - Complete success 73% 
 - Partial success 14% 
Pulmonary embolism – 2 
Sepsis – 3 
Blood transfusion 
requirement – 3 
No procedure-related 
deaths 




301 patients with 465 leads: 
 - laser extraction: 244 leads 
 -  non-laser: 221 leads 
Complete extraction: 
 - laser 94% 
 - non-laser 64% 
Partial extraction: 
 - laser 2.5% 
 - non-laser 1.8% 
Failure: 
 - laser 3.3% 
 - non-laser 34% 
Clinical success: 
 - laser 94.8% 
 - non-laser 95.9% 
Tamponade – 2 (laser) 
Hemothorax – 1 (laser) 
Valve damage – 1 (laser) 
Procedure-related death – 
1 (laser) 




450 consecutive lead 
extractions: 
 - 354 laser-assisted 
 - 96 radiofrequency-assisted
Procedure time lower in 
radiofrequency group 
Fluoroscopy time reduced in 
radiofrequency group 
No complications in 
radiofrequency group 
Two deaths in laser group 
Success rates comparables 
in both groups 
Table 4. Contemporary reviews of different transvenous lead extraction techniques. 
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In the same manner, Centella et al. (2007) revised their experience with percutaneous lead 
extraction between 1989-2006, using conventional techniques and electrosurgical sheaths. A 
statistically significant relation is observed between younger patients and major 
complication development, as well as with endocarditis being the indication for lead 
removal. 
Rusanov et al. (2010), describe a single operator experience with percutaneous and open 
surgical techniques for lead removal in 143 endocardial leads. Complete radiographic 
success was achieved for 131 leads with a low rate of major complications. They also 
describe an interesting multistage procedure for patients with purulent wounds: first they 
exteriorize the generator and irrigate and débride the pocket while initiate or continue 
antibiotherapy. In a second stage, when wound cultures are negative, they perform lead 
extraction with a caudal approach. They refer an accelerated wound healing with this 
technique. 
Neuzil et al. (2010) performed a prospective randomized study comparing conventional 
telescoping sheaths lead extraction results with electrosurgical sheaths one. They obtained 
statistically significant differences in success rates between both techniques, in favour of the 
electrosurgical system. They also observed a significant reduction in the time of traction 
with this technique. 
Another prospective randomized study is the PLEXES study (Wilkoff et al., 1999), which 
compares lead extraction results using conventional or laser techniques. Extraction efficacy 
was significantly higher in patients randomized to laser-assisted removal, with shorter 
mean procedure duration. Complication rates were not significantly different between both 
groups, with an incidence in the laser group below 2%. 
Verma & Wilkoff (2004) performed a retrospective review of 450 lead extractions in their 
institution and concluded that electrosurgical sheath appeared to have success rates 
comparable to laser sheath; although there was a selection bias because laser had been 
selected for more challenging lead extraction cases. Based on their experience, they 
recommend the use of radiofrequency sheaths, especially in patients at higher risk of 
complications; and they employ laser techniques as first option for cases requiring 
extraction of multiple leads, defibrillator leads, older implantation date ones and in 
occluded veins. 
Regarding to the removal of infected leads, there are some data suggesting that leads 
associated with systemic sepsis may be easier to extract with little effort (Moon et al., 2002) 
and that infected leads that are difficult to remove and require electrosurgical or laser 
sheaths, are unlikely to be infected at their endocardial tip with some reported data 
suggesting that tip-only retentions at incomplete extractions do not develop recurrence of 
infection and do well without another intervention requirement (Kratz & Toole, 2010). 
Finally, there is a short experience in relation to coronary sinus lead extraction. In many 
cases, this leads are extracted with simple traction but there are some reports of laser sheath 
employment for coronary sinus lead removal. 
8. Conclusion 
According to the increasing use of cardiac implantable electrophysiological devices, 
associated infectious complications are increasing, so that the most common essential 
indication for lead extraction remains infected systems. This can be a life-threatening 
complication associated with significant morbidity and mortality and its management 
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Significant bleeding 12% 
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-Telescoping sheath 34 
patients 
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48 patients required a second 
technique for lead remnant 
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Severe tricuspid 
insufficiency – 1 
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 - No CPB 4.2% 
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Complete extraction 86.2% 
Partial success (<4cm 
retained) 9.2% 
Failure to extract (>4cm 
retained) 4.6% 
Pneumothorax – 2 
(surgical approach) 
Persistent infection – 1 
(percutaneous) 









161 leads implanted for at 
least 6 months in 120 
patients: 
 - 84 leads extracted with 
radiofrequency sheaths 
 - 77 leads extracted with 
telescoping sheaths 
Radiofrequency extraction: 
 - Complete success 93% 
 - Partial success 7% 
Standard extraction: 
 - Complete success 73% 
 - Partial success 14% 
Pulmonary embolism – 2 
Sepsis – 3 
Blood transfusion 
requirement – 3 
No procedure-related 
deaths 




301 patients with 465 leads: 
 - laser extraction: 244 leads 
 -  non-laser: 221 leads 
Complete extraction: 
 - laser 94% 
 - non-laser 64% 
Partial extraction: 
 - laser 2.5% 
 - non-laser 1.8% 
Failure: 
 - laser 3.3% 
 - non-laser 34% 
Clinical success: 
 - laser 94.8% 
 - non-laser 95.9% 
Tamponade – 2 (laser) 
Hemothorax – 1 (laser) 
Valve damage – 1 (laser) 
Procedure-related death – 
1 (laser) 




450 consecutive lead 
extractions: 
 - 354 laser-assisted 
 - 96 radiofrequency-assisted
Procedure time lower in 
radiofrequency group 
Fluoroscopy time reduced in 
radiofrequency group 
No complications in 
radiofrequency group 
Two deaths in laser group 
Success rates comparables 
in both groups 
Table 4. Contemporary reviews of different transvenous lead extraction techniques. 
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In the same manner, Centella et al. (2007) revised their experience with percutaneous lead 
extraction between 1989-2006, using conventional techniques and electrosurgical sheaths. A 
statistically significant relation is observed between younger patients and major 
complication development, as well as with endocarditis being the indication for lead 
removal. 
Rusanov et al. (2010), describe a single operator experience with percutaneous and open 
surgical techniques for lead removal in 143 endocardial leads. Complete radiographic 
success was achieved for 131 leads with a low rate of major complications. They also 
describe an interesting multistage procedure for patients with purulent wounds: first they 
exteriorize the generator and irrigate and débride the pocket while initiate or continue 
antibiotherapy. In a second stage, when wound cultures are negative, they perform lead 
extraction with a caudal approach. They refer an accelerated wound healing with this 
technique. 
Neuzil et al. (2010) performed a prospective randomized study comparing conventional 
telescoping sheaths lead extraction results with electrosurgical sheaths one. They obtained 
statistically significant differences in success rates between both techniques, in favour of the 
electrosurgical system. They also observed a significant reduction in the time of traction 
with this technique. 
Another prospective randomized study is the PLEXES study (Wilkoff et al., 1999), which 
compares lead extraction results using conventional or laser techniques. Extraction efficacy 
was significantly higher in patients randomized to laser-assisted removal, with shorter 
mean procedure duration. Complication rates were not significantly different between both 
groups, with an incidence in the laser group below 2%. 
Verma & Wilkoff (2004) performed a retrospective review of 450 lead extractions in their 
institution and concluded that electrosurgical sheath appeared to have success rates 
comparable to laser sheath; although there was a selection bias because laser had been 
selected for more challenging lead extraction cases. Based on their experience, they 
recommend the use of radiofrequency sheaths, especially in patients at higher risk of 
complications; and they employ laser techniques as first option for cases requiring 
extraction of multiple leads, defibrillator leads, older implantation date ones and in 
occluded veins. 
Regarding to the removal of infected leads, there are some data suggesting that leads 
associated with systemic sepsis may be easier to extract with little effort (Moon et al., 2002) 
and that infected leads that are difficult to remove and require electrosurgical or laser 
sheaths, are unlikely to be infected at their endocardial tip with some reported data 
suggesting that tip-only retentions at incomplete extractions do not develop recurrence of 
infection and do well without another intervention requirement (Kratz & Toole, 2010). 
Finally, there is a short experience in relation to coronary sinus lead extraction. In many 
cases, this leads are extracted with simple traction but there are some reports of laser sheath 
employment for coronary sinus lead removal. 
8. Conclusion 
According to the increasing use of cardiac implantable electrophysiological devices, 
associated infectious complications are increasing, so that the most common essential 
indication for lead extraction remains infected systems. This can be a life-threatening 
complication associated with significant morbidity and mortality and its management 
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represents a difficult challenge for cardiology, cardiac surgery and infectious diseases 
specialists. 
Although we dispose of a wide range of antibiotics to face pacemaker infections, the 
treatment of choice in device-related infections requires its complete removal. Considering 
that are healthcare-related infections, an increasing number of episodes caused by 
multiresistant microorganism strains is expected, so a better knowledge of the role of new 
antimicrobials is mandatory. We also need to investigate which is the appropriate duration 
of antibiotic therapy as well as the optimal time for a new device implantation. 
Nowadays, there are many surgical tools to remove infected leads with high success rates. 
This sort of techniques must be performed at tertiary referral centers with a high volume 
demand on these procedures and with a cardiac surgeon as the primary operator or aware 
of the procedure at least. With a well-structured team and the availability of different 
surgical lead extraction techniques, the rate of major complications is very low. 
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represents a difficult challenge for cardiology, cardiac surgery and infectious diseases 
specialists. 
Although we dispose of a wide range of antibiotics to face pacemaker infections, the 
treatment of choice in device-related infections requires its complete removal. Considering 
that are healthcare-related infections, an increasing number of episodes caused by 
multiresistant microorganism strains is expected, so a better knowledge of the role of new 
antimicrobials is mandatory. We also need to investigate which is the appropriate duration 
of antibiotic therapy as well as the optimal time for a new device implantation. 
Nowadays, there are many surgical tools to remove infected leads with high success rates. 
This sort of techniques must be performed at tertiary referral centers with a high volume 
demand on these procedures and with a cardiac surgeon as the primary operator or aware 
of the procedure at least. With a well-structured team and the availability of different 
surgical lead extraction techniques, the rate of major complications is very low. 
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1. Introduction   
Since the initial use of prosthetic heart valves, the use of cardiac prosthesis and implantable 
devices has revolutionized the therapeutic options available to patients (de Oliveira et 
al.,2009). Cardiac Permanent PaceMakers (PPMs) have been implanted since the early 1960s. 
Over the past 50 years there have been tremendous advances in both the design of the 
device and the software employed. In the mid 1960s, transvenous leads were developed that 
could be inserted through a vein and thence into the heart, thus preventing the need for a 
thoracotomy. The development of ‘active fixation’ leads ensured a better contact with the 
endocardium and the presence of a steroid eluting tip helped to reduce any inflammation 
that might result. The introduction of the lithium iodine battery has dramatically increased 
the battery life to well over ten years. Radiofrequency programming became available in the 
1970s, allowing simple adjustments to be made to pacemaker’s settings without the need for 
surgery. Today, permanent pacemakers and ICD (Implantable Cardiac Defibrillator), 
together with any adjustments, can be completed within minutes using a portable computer. 
Information regarding events such as periods of bradycardia, tachycardia or ventricular 
fibrillation can be stored within the memory of the device and accessed by the specialist 
during the routine checkup. To maintain atrio-ventricular synchrony, dual chamber pacing 
was then introduced. Moreover, in the late 1990s, pacemaker technology had improved to 
the extent that it became possible to increase the pacing rate to match the patient’s activity 
level (Allen et al., 2007). 
A wide range of cardiac implantable electronic devices (CIEDs) are now available, including 
ICDs and cardiac resynchronization systems. PPMs are commonly used in patients with 
atrioventricular conduction block, sick sinus syndrome, and symptomatic sinus 
bradycardia, whereas ICDs target primarily patients at risk for life-threatening ventricular 
arrhythmias.  
Since clinical trials have consistently demonstrated the ability of the ICD to reduce 
mortality in selected patients with moderate-to-severe left ventricular systolic 
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ICDs and cardiac resynchronization systems. PPMs are commonly used in patients with 
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Since clinical trials have consistently demonstrated the ability of the ICD to reduce 
mortality in selected patients with moderate-to-severe left ventricular systolic 
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dysfunction, the indications for CIEDs have expanded dramatically and the rate of 
implantation has greatly rosen. A recent analysis showed that rate of implantation in US 
between 1997 and 2004 rose by 19% and 60% for PPMs and ICDs, respectively. 
Approximately 70% of device recipients were 65 years of age or older, and more than 75% 
of them had one or more coexisting illnesses. The rate of ICD implantation has increased 
in the elderly (70 to 79 years of age) and very elderly (80 years of age or older). The 2001 
World Survey found that in developed countries, between 20% and 35% of CIED 
recipients were more than 80 years old. The National Hospital Discharge Survey found a 
49% increase in the number of new CIED implantations, including both PPMs and ICDs. 
In 2003, although the absolute number of PPMs implantations was higher than that of 
ICDs (180284 versus 57436 implanted devices) most of the increase in CIED device 
implantation was due to ICD implantations (160% and 31% increases in ICD and PPM 
implantations, respectively) (Baddour et al., 2010). 
Despite their unquestioned clinical importance and diffusion, CIEDs may be linked to 
several complications, including infections, and the consequences of them may be 
catastrophic. Therefore, development of strategies for the prevention of device associated 
infections is crucial (Borer et al., 2004).  
The reported rate of infection after implantation of permanent endocardial devices ranges 
between 0.13% and 12.6%, depending on definition. The wide use of CIEDs and increasing 
age of patients set the stage for higher role of associated infections and related 
hospitalizations increased of about 3-fold (Baddour et al., 2010). Moreover, the cost of 
treating device-associated infections may be enormous, thus leading to increased healthcare 
expenses (Borer et al., 2004). Precise data regarding the actual healthcare burden of CIED 
infections are not available. The financial impact is due to multiple factors, including the 
costs of device removal, cost of new device (which would be required in the majority of 
patients) and costs related to cardiac and other medical evaluations, diagnostic procedures, 
surgical interventions for infected device removal, medical therapy, and increased length of 
stay in intensive care unit (Baddour et al., 2010). 
2. Epidemiology of CIED associated infections   
CIED infections have been recognized as a source of major comorbidity since the early 
1970s. In earlier years, the rates of PPM infection ranged widely between 0.13% and 
19.9%. Although most infections have been limited to the pocket, frank PPM endocarditis 
accounted for approximately 10% of PPM infections. The decreased size of ICDs allowed 
implantation without thoracotomy. Initially, abdominal implantation with tunneling was 
required. Subsequently, the entire device could be implanted prepectorally; with these 
less extensive operations the infection rate lowered to less than 7%. In a study on all ICD 
primary implantations, replacements, and revisions at a single center, there were 21 ICD-
related infections (1.2%) among 1700 procedures. Among 959 patients with long-term 
follow-up, the infection rate was 3.2% with abdominal and 0.5% with pectoral systems 
respectively (Mela et al., 2001). However, globally, the rate of CIED infection has been 
increasing. Cabell et al. reported that the rate of cardiac device infections (PPMs, ICDs, 
valves, and ventricular assist devices) increased from 0.94 to 2.11 per 1000 patients 
between 1990 and 1999, a 124% increase during the study period. The rate of frank 
endocarditis was relatively unchanged (0.26 and 0.39 cases/1000 patients, respectively) 
(Cabell et al., 2004). These findings were similar to that analyzed in Olmsted County, 
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Minnesota, from 1975 to 2004. A total of 1524 patients were included with a total person-
time follow-up of 7578 years. The incidence of CIED infection was 1.9/1000 device years 
(95% confidence interval [CI] 1.1 to 3.1), with an incidence of pocket infection alone of 
1.37/1000 device-years (95% CI 0.62 to 0.75) and an incidence of pocket infection with 
bloodstream infection or device-related endocarditis of 1.14/1000 device-years (95% CI 
0.47 to 2.74) (Uslan et al., 2007). Notably, the cumulative probability of CIED infection was 
higher among patients with ICDs than among those with PPMs. The National Hospital 
Discharge Survey similarly showed that between 1996 and 2003, the number of 
hospitalizations for CIED infections increased 3.1-fold (2.8-fold for PPMs and 6.0-fold for 
ICDs). The numbers of CIED infection–related hospitalizations increased out of 
proportion to rates of new device implantation. Moreover, CIED infection increased the 
risk of in-hospital death by more than 2-fold (Voigt et al., 2006). 
3. Definition and clinical presentation  
CIED pocket infection is defined on the ground of signs and symptoms of local infection 
associated with microbiological confirmation based on results of cultures of 
intraoperatively collected fluid samples, explanted CIED, or purulent discharge from the 
pocket site. CIED infection can present as acute or chronic syndromes that can be both 
early or tardive. In the early, acute form, the short time elapsed between device 
implantation and occurrence of infection may prompt the diagnosis. In chronic and 
tardive infections there is often a delay between the onset of symptoms and the diagnosis. 
This may be due to the fact that CIED-related infections are not routinely considered in 
the differential diagnosis. In other cases, possible clues to the diagnosis are ignored. 
Clinical manifestations of pacemaker infection are linked to the portion of the device 
involved. Moreover, signs and symptoms may be limited to the insertion pocket or be 
systemic or absent altogether (Cacoub et al,. 1998). 
A CIED-related infection is considered nosocomial when occurs 48 hours after admission 
and is not incubating at the time of admission. Infection of CIED is regarded as health care 
associated if patient received intravenous therapy at home, attended an outpatient 
hemodialysis center in the previous 30 days, was hospitalized in an acute care hospital for 2 
days in the 90 days before admission, or resided in a nursing home or long-term care 
facility. In contrast, CIED-related infection is recognized as community acquired if it does 
not fit the above definitions (Tablan et al., 2003).  
3.1 Clinical presentation 
In the vast majority of cases, local inflammation of the generator-pocket site is present, 
including erythema (34%), pain (32%), swelling (21%), warmth (11.5%), and drainage 
through a fistulous or poorly healed incision (25%). In most severe cases cutaneous erosion 
(23%) with percutaneous exposure of the generator and/or leads may be seen. All these 
signs can be associated or not with bacteremia (Cacoub et al,. 1998). These local changes 
usually prompt medical attention. Some patients present with systemic symptoms that 
include malaise, fatigue, anorexia, or decreased functional capacity. Sometimes isolated 
local symptoms occurr without fever. Chua et al. reported the presence of localized signs 
without systemic involvement in 69% (88 of 123) of patients, a combination of local and 
systemic signs and symptoms in 20% (25 of 123), and systemic signs and symptoms alone in 
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Minnesota, from 1975 to 2004. A total of 1524 patients were included with a total person-
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tardive infections there is often a delay between the onset of symptoms and the diagnosis. 
This may be due to the fact that CIED-related infections are not routinely considered in 
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associated if patient received intravenous therapy at home, attended an outpatient 
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not fit the above definitions (Tablan et al., 2003).  
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including erythema (34%), pain (32%), swelling (21%), warmth (11.5%), and drainage 
through a fistulous or poorly healed incision (25%). In most severe cases cutaneous erosion 
(23%) with percutaneous exposure of the generator and/or leads may be seen. All these 
signs can be associated or not with bacteremia (Cacoub et al,. 1998). These local changes 
usually prompt medical attention. Some patients present with systemic symptoms that 
include malaise, fatigue, anorexia, or decreased functional capacity. Sometimes isolated 
local symptoms occurr without fever. Chua et al. reported the presence of localized signs 
without systemic involvement in 69% (88 of 123) of patients, a combination of local and 
systemic signs and symptoms in 20% (25 of 123), and systemic signs and symptoms alone in 
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11% (13 of 123) of patients (Chua et al., 2000).  In implanted patients with unexplained fever 
CIED associated endocarditis should be ruled out. In CIED recipient isolated bacteremia 
pro,t medical investigation to rolu out endocarditis. Pacemaker endocarditis should be 
considered in all patients with cardiac pacemakers and chronic fever, recurrent bronchitis, 
pulmonary infection, and recurrent or persistent pocket infection (Cacoub et al., 1998; Klug 
et al., 1997). In some patients, involvement of lungs may be evident, including pleural 
effusions, pneumonia, pulmonary abscess, recurrent pulmonary embolism. Recurrent 
bronchitis is evident in 32% to 43% of patients with pacemaker endocarditis. A serious 
complication of pacemaker infection is generator or lead erosion through the skin. This can 
be the consequence of primary infection or can be the result of pressure on the overlying 
tissue, resulting in erosion and subsequent contamination. Erosion has been noted to be 
more common after elective pacemaker replacement than initial implantation (Harcombe et 
al., 1998). Other rare conditions associated to CIED infections are thrombosis of a vein where 
leads were in place (subclavian vein or superior vena cava), symptomatic pulmonary 
embolism, septic arthritis, vertebral, sternal or femoral osteomyelitis, splenic, brain, liver 
and perinephric abscess (Sohail et al., 2007a). 
4. Pathophysiology  
4.1 Etiology 
In patients with pacemaker infection bacterial pathogens can be found in blood or 
pacemaker pockets. Pacemaker’s hardware can be colonized as well. The most common 
pathogens in pocket infections are skin flora, and, specifically, Staphylococcus aureus and 
coagulase-negative staphylococci, including Staphylococcus epidermidis. Rarely, enteric 
Gram-negative bacilli can be found. Repeated cultures and percutaneous aspirates should 
help make the distinction between normal skin flora and pathogenic culture isolates 
(Gandelman at al., 2007).  
Staphylococcal species cause most of CIED infections and account for 60%-80% of cases in 
most reported series (Fig.1). A variety of coagulase-negative Staphylococcus (CoNS) species 
have been described a causative agents of CIED infections. CoNS are a common cause of 
microbiological specimen contamination, and thus, repeated isolation of the same species of 
CoNS with an identical antibiotic susceptibility pattern is advisable to be diagnostic. 
Polymicrobial infection sometimes involves more than one species of CoNS. The prevalence 
of oxacillin resistance among staphylococcal strains has varied among studies ranging from 
4 to 22% (Sohail et al., 2007a; Viola et al., 2010). 
Several factors are responsible for the higher propensity of Staphylococci to cause CIED 
infections. Staphylococci are frequent colonizer of human skin and contamination of CIED 
generator, electrode leads or pocket tissue at the time of implantation is the predominant 
mechanism for the majority of the pocket infections. Staphylococci express on their 
membranes several adherence factors that enable them to bind the foreign materials and 
establish chronic infection. In addition, these organisms are capable of producing biofilm on 
the device surface which helps them to evade host defences and limit antimicrobial 
penetration. Finally, Staphylococci are the predominant pathogens responsible for 
secondary catheter-related bloodstream infections as they can seed the intravenous leads 
during an episode of bacteremia.    
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Corynebacterium species, Propionibacterium acnes, Gram-negative bacilli, including 
Pseudomonas aeruginosa, and Candida species account for a minority of CIED infections. 
Fungi other than Candida and nontuberculosis mycobacteria are rarely responsible for CIED 
infection (Sohail et al., 2010).  
The microorganisms that cause CIED infections may be acquired either endogenously from 
the skin of patients or exogenously from the hospital environment. An association has been 
found between the presence of preaxillary skin flora and the pathogens isolated from 
pacemaker infection. Although low concentrations of methicillin-resistant CoNS have been 
detected in patients with no previous healthcare contact and no recent antibiotic exposure, a  
CIED infection due to multidrug-resistant staphylococci suggests that a healthcare 
environment is the site where infection was acquired (Da Costa et al., 1998a).  
Pacemaker endocarditis usually presents with bacterial growth in both blood and 
hardware cultures. Although there is no uniform agreement regarding the rate of positive 
blood cultures in pacemaker endocarditis, S. epidermidis and S. aureus occur most 
frequently. Other pathogens include Corynebacterium sp., Pseudomonas aeruginosa, and 
Aspergillus niger. In one study, polymicrobial infections were found in 18.1% (Cacoub et 
al., 1998).  
 
 
Fig. 1. Microbiology of CIED infection. Modified from Baddour et al., 2010. 
4.2 Pathogenesis 
The generator is placed within a surgically created space known as pocket. Electrode 
leads are attached to the generator and travel within the venous system to the right heart. 
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leads are attached to the generator and travel within the venous system to the right heart. 
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Pacemaker infection can be limited to the superficial portion of the pocket and leads or 
involve deeper intravascular and intracardiac components. The latter is known as 
pacemaker endocarditis. Among patients with pacemaker endocarditis, vegetations can 
occur on the tricuspid valve, the electrodes, and the right atrial or ventricular 
endocardium.  
The pocket may become infected at the time of implantation, during subsequent surgical 
manipulation, or if the generator or subcutaneous electrodes erode the overlying skin. In 
this latter case, erosion can also occur as a secondary event due to underlying infection. 
Pacemaker endocarditis can be linked to several factors, including pacemaker lead 
contamination during placement, spread of the organisms along the wires from the 
superficial component, or hematogenous seeding of the intravascular electrodes and wires 
during a bacteriemic episode. While Gram-posivie bacteriamias can cause CIED infections, 
hematogenous seeding of a CIED is unlikely to occur in cases of Gram-negative bacteremia. 
The disruption of the physiologic blood flow through the tricuspid valve often caused by a 
pacing lead passing through the valve and associated regurgitation may contribute to 
pacemaker infection. Microbial adherence to endothelium has been shown to increase in 
areas of high shear turbulence (Baddour et al., 2010).  
CIED infection is the result of the interaction between the device, the microbe, and the host.  
4.2.1 Devices factors  
Initial adhesion of bacteria to the device is mediated by physico-chemical properties of the 
plastic surface, such as hydrophobicity, surface tension, and electrostatic charge.  
Factors like the nature of plastic polymer, irregularity of its surface, and its shape, can all 
affect bacterial adherence to the device. Plastic polymers that encase medical devices, as well 
as the pathogens that adhere to them, are hydrophobic. An irregularly surfaced device 
favours microbial adherence more than a smoothed surfaced one. When this physiochemical 
interaction exists, the risk of CEID infection is related to subsequent invasive manipulation 
of the device and may be linked to a limited experience of the physician performing the 
procedure (Darouiche, 2001).   
4.2.2 Microbial factors  
Bacteria, particularly Gram-positive cocci, can adhere to and be engulfed by endothelial cells 
that lie on endothelialized lead after a certain period of time. This is thought to be an 
important mechanism of device infection by the hematogenous route.  
Microbial adherence may be linked also to interactions of bacterial surface with proteins on 
device’s surface. CoNS may adhere directly to plastic polymers of the surface of the device 
via fimbria-like surface protein structures or via a capsular polysaccharide (Veenstra et al., 
1996). Bacteria may also adhere to host matrix proteins that coat the surface of an implanted 
device. Host extracellular matrix proteins include fibrinogen, fibronectin, and collagen that 
are layered on implanted biomaterials. None of the major virulence factors or toxins of S 
Aureus have been found in CoNS, and it seems clear that the development and persistence 
of CoNS infections, which are so often associated with foreign materials, are due to different 
mechanisms, such as microbiological adherence. On the contrary, Staphylococci have a 
variety of surface adhesins that allow the pathogen to establish a focus of infection.  
 
Subsequent accumulation of bacteria on the device’s surface requires the production of 
polysaccharide intercellular adhesin, which is strongly linked to with the staphylococcal cell 
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surface and mediates cell-to-cell adhesion. The layers of bacteria on the surface of an 
implanted device are encased in this extracellular slime and constitute a biofilm. Biofilm is 
defined as a surface-associated community of one or more microbial species that are firmly 
attached to each other and the solid surface and are encased in an extracellular polymeric 
matrix that holds the biofilm together. Bacteria in a biofilm are more resistant to antibiotics 
and host defences, perhaps as a result of the dense extracellular matrix that protects the 
microbes included in the interior of the community (Lazăr & Chifiriuc, 2010). When a free-
floating bacterial cell enters the biofilm, it undergoes a phenotypic shift, in which expression 
of large groups of genes is up-regulated. Phenotypic variation is thought to support the 
persistence of infection due to staphylococci in a biofilm that coats the surface of a CIED. 
Small colony variants are phenotypes that have caused CIED infections and harbor several 
characteristics that are thought to enhance the survival of staphylococci either in a biofilm or 
in endothelial cells covering the device, including resistance to certain antibiotics (Baddour 
et al., 1990; Boelens et al., 2000). 
4.3 Risk factors 
Several studies have identified host or procedural factors that may be associated with CIED 
infections.  
Among the host factors, the strongest association is between renal failure and risk of CIED 
infection. Risk of device infection appears to be particularly high in patient with end-stage 
renal failure who are undergoing chronic hemodialysis via an implanted central catheter. 
These patients are at risk of recurrent bacteremia from their dialysis catheter and subsequent 
secondary seeding of the tranvenous device leads or pulse generator. Renal failure is also 
associated with immune dysfunction that further increases the odd of CIED infections in 
these patients (Bloom et al.,2006). 
Anticoagulant therapy with warfarin has also been linked to a higher risk of CIED 
infection. Precise reasons for this association are unclear but are likely related to the 
increased risk of pocket hematoma, which may lead to delayed wound healing or need for 
surgical drainage in some cases. Reopening the pocket to drain a large hematoma 
increases the risk of pocket contamination with skin flora and subsequent CIED infection 
(Lekkerkerker et al., 2009).  
Use of immunosuppressive medications, especially long term corticosteroids therapy, has 
also been identified as a risk factor for CIED infections (Sohail et al., 2007b).  
Procedure-related factors may also play an important role in the development of CIED 
infections. In a prospective cohort of 6319 patients receiving CIED implantation in 44 
medical centers, Klug et al. identified 42 patients who developed CIED infection during 1 
year of follow-up. Factors associated with an increased risk of infection included fever 
within 24 hours before implantation, use of preprocedural temporary pacing, and early 
reintervention. Implantation of a new system compared with partial or complete system 
replacement and use of periprocedural antimicrobial prophylaxis were both associated with 
a lower risk of infection (Klug et al., 2007). There is evidence that perioperative antimicrobial 
prophylaxis is associated with a reduction in CIED infections (Bertaglia et al., 2006; Da Costa 
et al., 1998b; de Oliveira et al., 2009).  
Other small studies suggest that pectoral transvenous device placement is associated with 
significantly lower rates of CIED infection than those implanted abdominally or by 
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thoracotomy. Thus, the use of a pectoral approach is not only less invasive but also appears 
to confer an ancillary benefit of lower infection risk (Mela et al., 2001). 
Physician experience in CIED implantation may also play a role in the rate of subsequent 
CIED infection. In a study of Medicare administrative data, Al-Khatib et al. found a 
significantly higher risk of ICD infection within 90 days of device implantation in patients 
whose device was placed by physicians in the lowest quartile of implantation volume. Rates 
of mechanical complications at 90 days were also higher for lower-volume physicians (Al-
Khatib et al., 2005). 
5. Diagnosis  
5.1 Clinical and microbiological diagnosis 
In all patients with suspected CIED infection diagnosis is linked to both local and systemic 
signs of inflammation associated to positive microbiological culture of the skin pocket or 
other materials. Signs and symptoms of systemic inflammation include malaise, fever with 
or without chill, leucocytosis and, in most severe cases, hypotension. A new onset valvular 
murmur suggests CIED endocarditis. Local signs of infection include redness and oedema 
and pain of the skin pocket. 
Definitive diagnosis of CIED infection is linked to microbiological cultures. Usually, samples 
are taken from the generator pocket. Alternatively, once the device has been removed, 
samples from lead tips may be cultured to identify the causative organism and support a 
diagnosis of CIED infection. Gram staining, anaerobic and aerobic bacterial cultures, should 
all be performed. If the initial Gram stain is negative, both tissue and the lead tip should be 
cultured for fungi and mycobacteria. Percutaneous aspiration of the device pocket is not 
recommended because of its low diagnostic accuracy and the theoretical risk of introducing 
microorganisms into the pocket site or spreading germ into the blood stream. 
Contamination of leads may also occur at the time of their extraction throught a contamined 
skin pocket; this may explain some of the positive lead-tip cultures found in patients 
without systemic manifestation and with negative blood cultures. If a CIED-related 
endocarditis is suspected, at least two sets of blood cultures should be obtained before 
starting any antimicrobial therapy. Positive blood cultures, particularly due to 
staphylococcal species, provide a strong clue that the clinical syndrome is due to CIED 
infection (Baddour et al., 2010).  
5.2 Instrumental diagnosis 
5.2.1 Transthoracic and transesophageal echocardiography 
Endocarditis is clinically confirmed when valvular or lead neostructures consistent  
with vegetations are detected on echocardiography, or if the Duke criteria for  
infective endocarditis are met (Table 1)(Klug et al., 1997, Durak et al. 1994). Vegetation is 
defined as an oscillating intracardiac mass which can be seen on the electrodes, the  
leads or the cardiac valve leaflets. To be diagnostic, vegetation should be noted in more 
than one echocardiographic plane (Klug et al., 1997; Sanfilippo et al., 1991; Victor et al., 
1999). Both transtoracic echocardiography (TTE) and transesophageal echocardiography 
(TEE) may be employed, even though TEE is more accurate and is the actual gold 
standard.  
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Definite infective endocarditis 
Pathological criteria 
Microorganisms: demonstrated by culture or histology in vegetation, in a vegetation 
that has embolized, or in intracardiac abscess, or demonstrated by culture of the lead 
Clinical criteria  
Two major criteria, or one major and three minor criteria, or five minor criteria 
 Major criteria 
  Positive blood culture for infective endocarditis 
  Typical microorganisms for infective endocarditis from two separate 
  blood cultures 
  Streptococcus viridans, Streptococcus bovis, HACEK group, or 
  Community-acquired Staphylococcus aureus or enterococci, in the 
  absence of a primary focus, or 
  Persistently positive blood culture, defined as microorganism  
  consistent with infective endocarditis from 
  Blood cultures drawn >12 hours apart, or 
  All of three or a majority of four or more separate blood cultures, 
  with first and last drawn at least 1 hour apart 
  Evidence of endocardial involvement: 
  Positive echocardiogram for infective endocarditis: 
  Oscillating intracardiac mass on PM leads or on the endocardial 
  structure in contact with PM leads 
  Abscess in contact with PM leads 
 Minor criteria 
  Fever >38°C 
  Vascular phenomena: arterial embolism, septic pulmonary infarcts, 
  mycotic aneurysm, intracranial hemorrhage, Janeway lesions 
  Immunologic phenomena: glomerulonephritis, Osler nodes, Roth 
  spots 
  Echocardiogram: consistent with infective endocarditis but not 
  meeting major criterion as noted previously (sleevelike appearance) 
  Microbiological evidence: positive blood culture but not meeting 
  major criterion as noted previously 
Table 1. Diagnostic criteria for infective endocarditis. Modified from Durak et al., 1994. 
TTE is not helpful in ruling out a diagnosis of lead-related endocarditis, particularly in 
adults, due to its poor sensitivity. Moreover, patients can develop both right-sided (lead-
related) and left-sided endocarditis. Actually, sensitivity of TTE for left-sided and for 
perivalvular extension of infection is lower than TEE. On the contrary several indirect 
echocardiographic features of endocarditis may be better seen with TEE. They include 
pericardial effusion, ventricular dysfunction or dyssynchrony, and pulmonary vascular 
pressure estimations. TEE may be not always available and can be discomfortable for the 
patients. For these reasons, even if TEE rapresents the gold standard for the diagnosis of 
CIED infections, and is recommended for the initial diagnosis, TTE can be used during the 
course of patient’s illness for additional studies or follow-up. It is important to underlyine 
that an echocardiographyc image of a mass adherent to the lead may be a sterile thrombus 
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thoracotomy. Thus, the use of a pectoral approach is not only less invasive but also appears 
to confer an ancillary benefit of lower infection risk (Mela et al., 2001). 
Physician experience in CIED implantation may also play a role in the rate of subsequent 
CIED infection. In a study of Medicare administrative data, Al-Khatib et al. found a 
significantly higher risk of ICD infection within 90 days of device implantation in patients 
whose device was placed by physicians in the lowest quartile of implantation volume. Rates 
of mechanical complications at 90 days were also higher for lower-volume physicians (Al-
Khatib et al., 2005). 
5. Diagnosis  
5.1 Clinical and microbiological diagnosis 
In all patients with suspected CIED infection diagnosis is linked to both local and systemic 
signs of inflammation associated to positive microbiological culture of the skin pocket or 
other materials. Signs and symptoms of systemic inflammation include malaise, fever with 
or without chill, leucocytosis and, in most severe cases, hypotension. A new onset valvular 
murmur suggests CIED endocarditis. Local signs of infection include redness and oedema 
and pain of the skin pocket. 
Definitive diagnosis of CIED infection is linked to microbiological cultures. Usually, samples 
are taken from the generator pocket. Alternatively, once the device has been removed, 
samples from lead tips may be cultured to identify the causative organism and support a 
diagnosis of CIED infection. Gram staining, anaerobic and aerobic bacterial cultures, should 
all be performed. If the initial Gram stain is negative, both tissue and the lead tip should be 
cultured for fungi and mycobacteria. Percutaneous aspiration of the device pocket is not 
recommended because of its low diagnostic accuracy and the theoretical risk of introducing 
microorganisms into the pocket site or spreading germ into the blood stream. 
Contamination of leads may also occur at the time of their extraction throught a contamined 
skin pocket; this may explain some of the positive lead-tip cultures found in patients 
without systemic manifestation and with negative blood cultures. If a CIED-related 
endocarditis is suspected, at least two sets of blood cultures should be obtained before 
starting any antimicrobial therapy. Positive blood cultures, particularly due to 
staphylococcal species, provide a strong clue that the clinical syndrome is due to CIED 
infection (Baddour et al., 2010).  
5.2 Instrumental diagnosis 
5.2.1 Transthoracic and transesophageal echocardiography 
Endocarditis is clinically confirmed when valvular or lead neostructures consistent  
with vegetations are detected on echocardiography, or if the Duke criteria for  
infective endocarditis are met (Table 1)(Klug et al., 1997, Durak et al. 1994). Vegetation is 
defined as an oscillating intracardiac mass which can be seen on the electrodes, the  
leads or the cardiac valve leaflets. To be diagnostic, vegetation should be noted in more 
than one echocardiographic plane (Klug et al., 1997; Sanfilippo et al., 1991; Victor et al., 
1999). Both transtoracic echocardiography (TTE) and transesophageal echocardiography 
(TEE) may be employed, even though TEE is more accurate and is the actual gold 
standard.  
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perivalvular extension of infection is lower than TEE. On the contrary several indirect 
echocardiographic features of endocarditis may be better seen with TEE. They include 
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pressure estimations. TEE may be not always available and can be discomfortable for the 
patients. For these reasons, even if TEE rapresents the gold standard for the diagnosis of 
CIED infections, and is recommended for the initial diagnosis, TTE can be used during the 
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or infected vegetation and it is impossible to distinguish between the two with 
echocardiography. Masses that are detected in patients without positive blood cultures or 
other signs of infection are likely to sterile vegetation (thrombus).  In addition, the failure to 
visualize a mass adherent to a lead with TEE does not exclude lead infection. Thus, even 
when vegetation is demonstrated, differential diagnosis may be difficult if microbiological 
culture are not positive. Clear guidelines for CIED infection diagnosis are lacking. Based on 
clinical practice and expert opinion, a summary of recommendations for diagnosis of CIED 
infections is provided in Table 2.  
 
Class I 
1. All patients should have at least 2 sets of blood cultures drawn at the initial evaluation 
before initiation of antimicrobial therapy. (Level of Evidence: C) 
2. Generator-pocket tissue Gram’s stain and culture and lead-tip culture should be 
obtained when the CIED is explanted. (Level of Evidence: C)
3. Patients with suspected CIED infection who either have positive blood cultures or who 
have negative blood cultures but have had recent antimicrobial therapy before blood 
cultures were obtained should undergo TEE for CIED infection or valvular endocarditis. 
(Level of Evidence: C) 
4. All adults suspected of having CIED-related endocarditis should undergo TEE to 
evaluate the left-sided heart valves, even if transthoracic views have demonstrated lead-
adherent masses. In pediatric patients with good views, transthoracic echocardiography 
may be sufficient. (Level of Evidence: B)
 
Class IIa 
Patients should seek evaluation for CIED infection by cardiologists or infectious disease 
specialists if they develop fever or bloodstream infection for which there is no initial 
explanation. (Level of Evidence: C) 
 
Class III 
Percutaneous aspiration of the generator pocket should not be performed as part of the 
diagnostic evaluation of CIED infection. (Level of Evidence: C) 
Table 2. Recommendations for Diagnosis of CIED Infection and Associated Complications. 
Modified from Baddour et al., 2010. 
5.2.2 Positive Emission Tomography (PET) 
Infection staging and identification of other septic locations may be very important in order 
to monitor treatment efficacy before any re-implantation. It might be useful to assess the 
extension of infectious disease (staging) in these patients by non-invasive whole-body 
imaging, and Fluoro-18 desoxyglucose (18F-FDG) PET is a potential candidate for this 
purpose. The use of 18F-FDG PET imaging in inflammatory processes is related to the high 
affinity of inflammatory cells such as neutrophils, lymphocytes and macrophage for 18F-
FDG. 18F-FDG PET shows high diagnostic accuracy when infection affects the box of 
generator but is slightly less reliable when the leads are involved. Globally, sensitivity and 
specificity are optimal for box infection even if mild physiological uptake may be seen in 
normal cases. Physiologically, a slight 18F-FDG uptake may be observed around the box 
even in not infected patients, particularly in the area of the muscle interface. However, 
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uptake around the box is much higher in case of infection. Leads infection represents a 
different challenge. The size of the leads and the size of the vegetation are both very small 
and may easily be below the theoretical resolution of the PET system. For leads, sensitivity 
and specificity are lower, and diagnosis is based upon visualization of mild focal uptake 
along the leads. Interpretation of negative cases should be cautious, particularly if patients 
have received prolonged antibiotherapy (Bensimhon et al., 2010). 
6. Prevention  
The significant morbidity and mortality associated with device infections and the need for 
device removal make prevention of infections extremely important. Prevention of CIED 
infection can be addressed before, during, and after device implantation. Before implanting 
intravascular devices, it is important to ensure that patients do not have clinical signs of 
infection. In this case definitive implantation should be posponed after the resolution of 
infection. Once CIEDs are implanted, both pharmacological and non pharmacological 
strategies can be adopted in order to reduce risk of infection. 
6.1 Pharmacological strategies 
A meta-analysis of 7 randomized studies on 2023 patients examining the impact of systemic 
antibiotics on the risk of pacemaker-related infections suggested that systemic antibiotic 
prophylaxis significantly reduces the incidence of serious infective complications after 
pacemaker implantation (Da Costa et al., 1998b). A following observational study was 
performed to assess the safety and long-term efficacy of a simple scheme of antibiotic 
prophylaxis, and to identify the predictors of long-term infective complications in patients 
undergoing pacemaker implantation or replacement. This study showed the efficacy of a 
single dose of cefazolin in preventing infective complications (Bertaglia et al., 2006). Finally 
a prospective, randomized, double-blinded, placebo-controlled trial was developed to 
determine whether prophylactic antibiotic administration reduces the incidence of infection 
related to device implantation was. This double blinded study included 1000 consecutive 
patients who presented for primary device implantation or generator replacement 
randomized in a 1:1 fashion to prophylactic antibiotics or placebo. Intravenous 
administration of 1 g of cefazolin or placebo was done immediately before the procedure. 
Follow-up was performed at 10 days and 1, 3, and 6 months after discharge. The primary 
end point was any evidence of infection at the surgical incision (pulse generator pocket), or 
systemic infection related to the procedure. The safety committee interrupted the trial after 
649 patients were enrolled because of a significant difference in favor of the antibiotic arm 
and concluded that antibiotic prophylaxis significantly reduces infectious complications in 
patients undergoing implantation of pacemakers or cardioverter-defibrillators (de Oliveira 
et al., 2009). Most experts continue to advocate a first-generation cephalosporin, such as 
cefazolin, as prophylaxis agent. Although not generally recommended, some authors 
advocate the use of vancomycin, particularly in centers where oxacillin resistance among 
staphylococci is high. If vancomycin is used, then it should be administered 90 to 120 
minutes before the procedure. Vancomycin also represents an alternative to a first-
generation cephalosporin in patients who are allergic to cephalosporins (Sohail et al., 2007b). 
In patients who are allergic to both cephalosporins and vancomycin, daptomycin and 
linezolid are alternative agents for prophylaxis. Antibiotic prophylaxis is also recommended 
if subsequent invasive manipulation of the CIED is required. Currently, there are no data to 
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or infected vegetation and it is impossible to distinguish between the two with 
echocardiography. Masses that are detected in patients without positive blood cultures or 
other signs of infection are likely to sterile vegetation (thrombus).  In addition, the failure to 
visualize a mass adherent to a lead with TEE does not exclude lead infection. Thus, even 
when vegetation is demonstrated, differential diagnosis may be difficult if microbiological 
culture are not positive. Clear guidelines for CIED infection diagnosis are lacking. Based on 
clinical practice and expert opinion, a summary of recommendations for diagnosis of CIED 
infections is provided in Table 2.  
 
Class I 
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obtained when the CIED is explanted. (Level of Evidence: C)
3. Patients with suspected CIED infection who either have positive blood cultures or who 
have negative blood cultures but have had recent antimicrobial therapy before blood 
cultures were obtained should undergo TEE for CIED infection or valvular endocarditis. 
(Level of Evidence: C) 
4. All adults suspected of having CIED-related endocarditis should undergo TEE to 
evaluate the left-sided heart valves, even if transthoracic views have demonstrated lead-
adherent masses. In pediatric patients with good views, transthoracic echocardiography 
may be sufficient. (Level of Evidence: B)
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Patients should seek evaluation for CIED infection by cardiologists or infectious disease 
specialists if they develop fever or bloodstream infection for which there is no initial 
explanation. (Level of Evidence: C) 
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Percutaneous aspiration of the generator pocket should not be performed as part of the 
diagnostic evaluation of CIED infection. (Level of Evidence: C) 
Table 2. Recommendations for Diagnosis of CIED Infection and Associated Complications. 
Modified from Baddour et al., 2010. 
5.2.2 Positive Emission Tomography (PET) 
Infection staging and identification of other septic locations may be very important in order 
to monitor treatment efficacy before any re-implantation. It might be useful to assess the 
extension of infectious disease (staging) in these patients by non-invasive whole-body 
imaging, and Fluoro-18 desoxyglucose (18F-FDG) PET is a potential candidate for this 
purpose. The use of 18F-FDG PET imaging in inflammatory processes is related to the high 
affinity of inflammatory cells such as neutrophils, lymphocytes and macrophage for 18F-
FDG. 18F-FDG PET shows high diagnostic accuracy when infection affects the box of 
generator but is slightly less reliable when the leads are involved. Globally, sensitivity and 
specificity are optimal for box infection even if mild physiological uptake may be seen in 
normal cases. Physiologically, a slight 18F-FDG uptake may be observed around the box 
even in not infected patients, particularly in the area of the muscle interface. However, 
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uptake around the box is much higher in case of infection. Leads infection represents a 
different challenge. The size of the leads and the size of the vegetation are both very small 
and may easily be below the theoretical resolution of the PET system. For leads, sensitivity 
and specificity are lower, and diagnosis is based upon visualization of mild focal uptake 
along the leads. Interpretation of negative cases should be cautious, particularly if patients 
have received prolonged antibiotherapy (Bensimhon et al., 2010). 
6. Prevention  
The significant morbidity and mortality associated with device infections and the need for 
device removal make prevention of infections extremely important. Prevention of CIED 
infection can be addressed before, during, and after device implantation. Before implanting 
intravascular devices, it is important to ensure that patients do not have clinical signs of 
infection. In this case definitive implantation should be posponed after the resolution of 
infection. Once CIEDs are implanted, both pharmacological and non pharmacological 
strategies can be adopted in order to reduce risk of infection. 
6.1 Pharmacological strategies 
A meta-analysis of 7 randomized studies on 2023 patients examining the impact of systemic 
antibiotics on the risk of pacemaker-related infections suggested that systemic antibiotic 
prophylaxis significantly reduces the incidence of serious infective complications after 
pacemaker implantation (Da Costa et al., 1998b). A following observational study was 
performed to assess the safety and long-term efficacy of a simple scheme of antibiotic 
prophylaxis, and to identify the predictors of long-term infective complications in patients 
undergoing pacemaker implantation or replacement. This study showed the efficacy of a 
single dose of cefazolin in preventing infective complications (Bertaglia et al., 2006). Finally 
a prospective, randomized, double-blinded, placebo-controlled trial was developed to 
determine whether prophylactic antibiotic administration reduces the incidence of infection 
related to device implantation was. This double blinded study included 1000 consecutive 
patients who presented for primary device implantation or generator replacement 
randomized in a 1:1 fashion to prophylactic antibiotics or placebo. Intravenous 
administration of 1 g of cefazolin or placebo was done immediately before the procedure. 
Follow-up was performed at 10 days and 1, 3, and 6 months after discharge. The primary 
end point was any evidence of infection at the surgical incision (pulse generator pocket), or 
systemic infection related to the procedure. The safety committee interrupted the trial after 
649 patients were enrolled because of a significant difference in favor of the antibiotic arm 
and concluded that antibiotic prophylaxis significantly reduces infectious complications in 
patients undergoing implantation of pacemakers or cardioverter-defibrillators (de Oliveira 
et al., 2009). Most experts continue to advocate a first-generation cephalosporin, such as 
cefazolin, as prophylaxis agent. Although not generally recommended, some authors 
advocate the use of vancomycin, particularly in centers where oxacillin resistance among 
staphylococci is high. If vancomycin is used, then it should be administered 90 to 120 
minutes before the procedure. Vancomycin also represents an alternative to a first-
generation cephalosporin in patients who are allergic to cephalosporins (Sohail et al., 2007b). 
In patients who are allergic to both cephalosporins and vancomycin, daptomycin and 
linezolid are alternative agents for prophylaxis. Antibiotic prophylaxis is also recommended 
if subsequent invasive manipulation of the CIED is required. Currently, there are no data to 
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support the administration of postoperative antibiotic therapy, and this is not recommended 
because of the risk of drug adverse events, selection of drug-resistant organisms, and costs 
(Baddour et al., 2010).  
6.2 Non pharmacological strategies 
Several preventive measures are recommended in combination with prophylactic 
antibiotics. Using a strictly aseptic technique during implantation is of paramount 
importance, including surgical scrubbing, use of standard operating room, facemasks, caps, 
and sterile gowns and gloves, and the use of sterile, dry gauze pads to cover surgical 
incisions (Voet et al., 1999). Other preventive strategies include to limit the duration of 
temporary pacing to the shortest time and to limit the number of people in the room during 
the procedure to those absolutely necessary. Prevention of hematoma during the procedure 
is important, and several interventions have been used, although there are no data to 
support their use (Lekkerkerker et al., 2009). This can be achieved by meticulous 
cauterization of bleeding sites and packing the pocket with antibiotic-soaked sponges to 
provide tamponade while leads are being placed. The application of topical thrombin may 
be helpful, particularly in anticoagulated patients. Irrigation of the pocket is useful to 
remove debris and may reveal persistent bleeding that could lead to a pocket hematoma. In 
addition, irrigation with an antimicrobial-containing solution for pocket cleansing has been 
used. Use of monofilament suture for closure of the subcuticular layer may avoid superficial 
postoperative cellulitis. A compressive dressing applied 12-24 hours after skin closure may 
further decrease the risk of hematoma formation. In the immediate postoperative period, 
recent data indicate that low-molecular-weight heparin predisposes to hematoma formation 
and should be avoided (Robinson et al., 2009). A hematoma should be evacuated only when 
there is increased tension on the skin. Needle aspiration should otherwise be avoided 
because of the risk of introducing skin flora into the pocket and subsequent development of 
infection. Finally, routine ambulatory care follow-up after CIED placement to detect early 
infectious complications has been performed in many centers and this is actively 
recommended (Deuling et al., 2009). 
7. Therapy  
7.1 Conservative treatment 
Optimal management of CIED infection depends on the clinical presentation and causative 
pathogen. Conservative treatment with antibiotics alone without removal of the device may 
be sufficient in patients with local signs without sepsis, endocarditis or skin erosion. Seven 
to ten days of antibiotic therapy with an oral agent with activity against staphylococci is 
reasonable (Gandelman et al., 2007).  
7.2 Device removal 
Complete removal of all hardware is the recommended treatment for patients with 
established CIED infection or sepsis (Chua et al., 2000; Sohail et al., 2007a). This includes 
cases in which a localized pocket infection occurs in the absence of signs of systemic 
infection. Complete removal of hardware is needed because infection relapse rates due to 
retained hardware are high (Field et al., 2007). Erosion of any part of the CIED should imply 
contamination of the entire system, including the intravascular portion of leads, and 
complete device removal should be performed. Complete CIED removal should be 
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performed when patients undergo valve replacement or repair for infective endocarditis, 
because the CIED could serve as a nidus for relapsing infection and subsequent seeding of 
the surgically treated heart valve. An epicardial system should be considered if a new CIED 
is required after valve surgery with initial CIED removal. Device removal is also 
recommended in those patients with S. aureus bacteremia with clinical or echocardiographic 
evidence of CEID infection, un-explained bacteremia, or relapsing bacteremia after antibiotic 
treatment (Chamis et al., 2001).  
7.2.1 Approach to hardware removal 
Two techniques for removing pacemaker systems are currently available: invasive 
thoracotomy and percutaneous extraction. The choice of the less invasive percutaneous 
technique is usually based on time elapsed from implantation, vegetation size, absence of 
vegetation on the tricuspid valve, and the general conditions of the patient. Percutaneous 
lead extraction has become the preferred method for removal of CIED hardware. However, 
these procedures involve significant risks, including cardiac tamponade, hemothorax, 
pulmonary embolism, lead migration, and death, even in experienced hands. Thus, the 
performance of these procedures should be limited to centers with the appropriate facilities 
and training, including the presence of immediate availability of cardiothoracic surgery to 
provide backup in the event of complications. In high-volume centers, percutaneous lead 
removal can be accomplished relatively safely with a high rate of success (Jones et al., 2008). 
A primary surgical approach to lead removal in patients with CIED infection should be 
limited to patients who have significant retained hardware after one attempt at 
percutaneous removal. Another scenario in which a preference for surgical lead removal has 
been advocated is in patients with lead vegetations >2 cm in diameter, because of concerns 
about the risk of pulmonary embolism with percutaneous lead extraction. Experience 
suggests, however, that percutaneous removal in patients with large vegetations can be 
done without precipitating a clinically apparent pulmonary embolism. Until additional data 
are available, decisions regarding percutaneous versus surgical removal of leads with 
vegetations larger than 2 cm in diameter should be individualized and based on a patient’s 
clinical parameters and the extractor’s evaluation (Field et al., 2007; Gandelman et al., 2007; 
Sohail et al., 2007a).  
Antimicrobial therapy is adjunctive in patients with CIED infection, and complete device 
removal should not be delayed, regardless of timing of initiation of antimicrobial therapy. 
Selection of the appropriate antimicrobial agent should be based on identification and in 
vitro susceptibility testing results. Because most infections are due to staphylococcal species, 
treatment agent should be effective against those germs. In case of oxacillin resistant 
infections is suspected, vancomycin should be administered initially as empirical antibiotic 
coverage until microbiological results are known. Patients with infections due to oxacillin-
susceptible staphylococcal strains can be given cefazolin or nafcillin alone with 
discontinuation of vancomycin. Vancomycin should be continued in patients who are not 
candidates for betalactam antibiotic therapy and those with infections due to oxacillin-
resistant staphylococci. Compared with Gram-positive infections, Gram-negative and fungi 
are less frequently isolated and empiric coverage against those microorganisms is not 
routinely indicated; it should be started after microbiological identification has been 
performed.  
Pathogen identification and in vitro susceptibility testing can be used to guide treatment in 
patients with nonstaphylococcal CIED infections. When microbiological culture are 
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support the administration of postoperative antibiotic therapy, and this is not recommended 
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the procedure to those absolutely necessary. Prevention of hematoma during the procedure 
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used. Use of monofilament suture for closure of the subcuticular layer may avoid superficial 
postoperative cellulitis. A compressive dressing applied 12-24 hours after skin closure may 
further decrease the risk of hematoma formation. In the immediate postoperative period, 
recent data indicate that low-molecular-weight heparin predisposes to hematoma formation 
and should be avoided (Robinson et al., 2009). A hematoma should be evacuated only when 
there is increased tension on the skin. Needle aspiration should otherwise be avoided 
because of the risk of introducing skin flora into the pocket and subsequent development of 
infection. Finally, routine ambulatory care follow-up after CIED placement to detect early 
infectious complications has been performed in many centers and this is actively 
recommended (Deuling et al., 2009). 
7. Therapy  
7.1 Conservative treatment 
Optimal management of CIED infection depends on the clinical presentation and causative 
pathogen. Conservative treatment with antibiotics alone without removal of the device may 
be sufficient in patients with local signs without sepsis, endocarditis or skin erosion. Seven 
to ten days of antibiotic therapy with an oral agent with activity against staphylococci is 
reasonable (Gandelman et al., 2007).  
7.2 Device removal 
Complete removal of all hardware is the recommended treatment for patients with 
established CIED infection or sepsis (Chua et al., 2000; Sohail et al., 2007a). This includes 
cases in which a localized pocket infection occurs in the absence of signs of systemic 
infection. Complete removal of hardware is needed because infection relapse rates due to 
retained hardware are high (Field et al., 2007). Erosion of any part of the CIED should imply 
contamination of the entire system, including the intravascular portion of leads, and 
complete device removal should be performed. Complete CIED removal should be 
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performed when patients undergo valve replacement or repair for infective endocarditis, 
because the CIED could serve as a nidus for relapsing infection and subsequent seeding of 
the surgically treated heart valve. An epicardial system should be considered if a new CIED 
is required after valve surgery with initial CIED removal. Device removal is also 
recommended in those patients with S. aureus bacteremia with clinical or echocardiographic 
evidence of CEID infection, un-explained bacteremia, or relapsing bacteremia after antibiotic 
treatment (Chamis et al., 2001).  
7.2.1 Approach to hardware removal 
Two techniques for removing pacemaker systems are currently available: invasive 
thoracotomy and percutaneous extraction. The choice of the less invasive percutaneous 
technique is usually based on time elapsed from implantation, vegetation size, absence of 
vegetation on the tricuspid valve, and the general conditions of the patient. Percutaneous 
lead extraction has become the preferred method for removal of CIED hardware. However, 
these procedures involve significant risks, including cardiac tamponade, hemothorax, 
pulmonary embolism, lead migration, and death, even in experienced hands. Thus, the 
performance of these procedures should be limited to centers with the appropriate facilities 
and training, including the presence of immediate availability of cardiothoracic surgery to 
provide backup in the event of complications. In high-volume centers, percutaneous lead 
removal can be accomplished relatively safely with a high rate of success (Jones et al., 2008). 
A primary surgical approach to lead removal in patients with CIED infection should be 
limited to patients who have significant retained hardware after one attempt at 
percutaneous removal. Another scenario in which a preference for surgical lead removal has 
been advocated is in patients with lead vegetations >2 cm in diameter, because of concerns 
about the risk of pulmonary embolism with percutaneous lead extraction. Experience 
suggests, however, that percutaneous removal in patients with large vegetations can be 
done without precipitating a clinically apparent pulmonary embolism. Until additional data 
are available, decisions regarding percutaneous versus surgical removal of leads with 
vegetations larger than 2 cm in diameter should be individualized and based on a patient’s 
clinical parameters and the extractor’s evaluation (Field et al., 2007; Gandelman et al., 2007; 
Sohail et al., 2007a).  
Antimicrobial therapy is adjunctive in patients with CIED infection, and complete device 
removal should not be delayed, regardless of timing of initiation of antimicrobial therapy. 
Selection of the appropriate antimicrobial agent should be based on identification and in 
vitro susceptibility testing results. Because most infections are due to staphylococcal species, 
treatment agent should be effective against those germs. In case of oxacillin resistant 
infections is suspected, vancomycin should be administered initially as empirical antibiotic 
coverage until microbiological results are known. Patients with infections due to oxacillin-
susceptible staphylococcal strains can be given cefazolin or nafcillin alone with 
discontinuation of vancomycin. Vancomycin should be continued in patients who are not 
candidates for betalactam antibiotic therapy and those with infections due to oxacillin-
resistant staphylococci. Compared with Gram-positive infections, Gram-negative and fungi 
are less frequently isolated and empiric coverage against those microorganisms is not 
routinely indicated; it should be started after microbiological identification has been 
performed.  
Pathogen identification and in vitro susceptibility testing can be used to guide treatment in 
patients with nonstaphylococcal CIED infections. When microbiological culture are 
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available, a de-escalation approach should be considered in order to minimize the 
development of antimicrobial resistances (De Gaudio et al., 2010). There are no clinical trial 
data to define the optimal duration of antimicrobial therapy for CIED infections, regardless 
of the extent of infection, or to determine when conversion to an oral agent is appropriate 
once complete device removal has been achieved. Factors that influence duration of therapy 
include the extent of device infection, the causative organism, the persistence of positive 
blood cultures, and associated complications such as valvular involvement, septic 
thrombophlebitis, or osteomyelitis. Blood cultures should be obtained from all patients after 
device removal. Therapy can be switched to an oral regimen once susceptibility results are 
known if there is an oral agent available that is active against the pathogen and the infected 
CIED has been removed. At least two weeks of parenteral therapy are recommended after 
removal of an infected device and for patients with bloodstream infection. Patients with 
sustained (>24 hours) positive blood cultures despite CIED removal and appropriate 
antimicrobial therapy should receive parenteral therapy for at least 4 weeks, even if TEE is 
negative for valvular vegetations.  
7.2.2 Hardware reimplantation 
It is important to assess the need for new device placement in any patient with an infected 
CIED. Based of available data, one third to one half of patients will not require new CIED 
placement. There are several factors, including reversal of the pathological processes that 
precipitated the need for CIED implantation and lack of appropriate clinical indications, that 
may obviate the need for new CIED placement (Sohail et al., 2007b). Adequate debridement 
and control of infection at all sites, both at the generator site and metastatic, if present, must 
be achieved before new device placement (Baddour et al., 2010). Removal of infected 
hardware should not be attempted until a careful assessment of a new implantation strategy 
has been performed, particularly in patients with pacemakers for complete heart block and 
resynchronization therapy devices. When implantation of a new device is necessary, it 
should be performed on the counterlateral side if possible to avoid relapsing device 
infection. If this is not possible, a transvenous lead can be tunneled to a device placed 
subcutaneously in the abdomen. Implantation is usually postponed to allow for resolution 
of infection, but patients who are CIED dependent represent a challenge, because they 
cannot be discharged with a temporary pacemaker. Active-fixation leads attached to pacing 
generators or defibrillators are now being used as a bridge until PPM implantation is 
deemed appropriate. Use of active-fixation leads connected to external devices permits 
earlier mobilization of patients dependant on cardiac stimulators and has been associated 
with a reduced risk of pacing-related adverse events, including lead dislocation, and local 
infection (Braun et al., 2006). 
Optimal timing of device replacement is unknown. There have been no prospective trials 
that examined timing of new device replacement and risk of relapsing infection; however, 
several investigators recommend waiting for blood cultures to be negative before a new 
device is placed (Gandelman et al., 2007; Sohail et al., 2007a) 
8. Conclusions  
Currently, 3 million implanted cardiac pacing systems and 180000 implantable cardioverter-
defibrillators exist worldwide. The rate of device implantations is increasing due to the 
aging of the general population and the development of new indications. Although 
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conferring obvious benefits, the use of these implantable devices is associated with some 
complications. Infections must be considered as a serious and potentially fatal complication.  
The clinical presentation of device infection ranges from superficial wound infection to 
frank device-related endocarditis.  
The incidence of infection related to pacemakers varies from 0.13% to 19.9% in prospective 
and retrospective studies. Serious complications, such as endocarditis and sepsis, may occur 
in 0.5% of patients. In addition, infectious complications have a significant economic impact 
to health care systems due to the high cost of treatment. 
Data to guide treatment of patients with this condition are limited. However, the consensus 
from the published literature recommends prompt and complete device removal, combined 
with antimicrobial therapy of appropriate duration. Conservative treatment without 
explantation of all hardware is frequently unsuccessful. Given the progressive rise in 
antimicrobial-resistant bacteria in general, and gram-positive pathogens in particular, 
treatment of cardiovascular infections is likely to become more difficult in the future. 
Finally, because a substantial number of patients may no longer require such devices, 
reimplantation should be done only after the continued need for such therapy has been 
reassessed.   
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The clinical presentation of device infection ranges from superficial wound infection to 
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The incidence of infection related to pacemakers varies from 0.13% to 19.9% in prospective 
and retrospective studies. Serious complications, such as endocarditis and sepsis, may occur 
in 0.5% of patients. In addition, infectious complications have a significant economic impact 
to health care systems due to the high cost of treatment. 
Data to guide treatment of patients with this condition are limited. However, the consensus 
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with antimicrobial therapy of appropriate duration. Conservative treatment without 
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treatment of cardiovascular infections is likely to become more difficult in the future. 
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1. Introduction 
The Chapter was constructed to offer the recommended tactics of clinical practice in 
radiation oncology, since pacemaker patients generally maintain their implanted 
pacemaker throughout their cancer treatment. Recent improvements to the functionality 
and stability of implantable pacemakers involve changes for greater battery power 
consumption efficiency as well as radiation hardened electrical circuits. Manufacturers 
have also pursued MRI-compatibility for these devices with some success. While such 
newer models of pacemakers are similar in construction to previously marketed devices, 
even for the recent MRI-compatible designs currently in clinical trials, there is increased 
interest now with regard to radiation therapy dose effects when a device is near or 
directly in the field of radiation. This manuscript provides the radiation safety 
precautions clinically incorporated for the management of patients having implantable 
pacemakers with a required need for radiation therapy. It provides guidance and current 
recommendations for the cardiac physician, radiation oncologist and medical physicist 
prior to and during radiation delivery.  
The Chapter first details extensively the concepts of CT imaging, computerized treatment 
planning, and dose aim analysis with mock treatments. The later sections deal with current 
research observations from investigators concerned with the consequences of using different 
modalities of treatment and imaging for a patient having a pacemaker implanted. These 
sections include novel research on electronic device instability induced by x-rays, neutrons, 
and proton beams as well as radiation from radioactive material. The recent advancement of 
technology for magnetic resonance imaging and its limitations are also provided. This 
Chapter should provide a sound basis for comprehension of the complex nature of dealing 
with a patient having a pacemaker, while requiring continual treatment for cancer care after 
their implant. It is also a significant educational source for the detailed research on device 
interactions presented. 
2. Radiation oncology methods  
It is not a common occurrence for radiation oncologists to be referred a patient having a 
cardiac pacemaker implanted. At a clinic operating up to 60 patients per day with two 
radiation oncologists, only two patients may be referred to them for consultation in any 
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calendar year. However, when faced with the dilemma of how to treat such a patient, the 
radiation oncologist often finds one of their greatest challenges. Not only do they have to 
determine the best chances of survival for the patient given their type of disease, 
classification, staging, and current physiological status, but they also have to be aware of the 
possible harm to the stationary pacemaker when the prescribed amount of radiation is 
directed at the patient. Treatments most commonly performed for cancer patients involve 
radiation originating from external beam particle accelerators. Many of these machines are 
capable of emitting x-ray radiation in the clinical energy range of 6-18 MV and at dose-rates1 
of 6 Gy/min. Figure 1 shows a commonly used particle accelerator found in a Radiation 






Fig. 1. Varian Medical Systems (Palo Alto, CA) Clinac® model Trilogy particle accelerator 
[Varian Medical Systems, Inc. - All rights reserved] 
                                                 
1 The gray (Gy) is the International System of Units standard unit for absorbed dose, defined as the 
absorption of 1 Joule of ionizing radiation by 1 kilogram of matter (i.e. human tissue or water). It is 
equivalent to 100 cGy or 100 rads. 
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The radiation oncology community practice guidelines used when dealing with radiation safety 
issues for patients that have a pacemaker implanted are those published by the American 
Association of Physicists in Medicine (AAPM) through Task Group-45 (Marbach et al., 1994). 
Now seventeen years later, much of the electronics in pacemakers have been reengineered. 
Therefore, designs and mechanisms addressed in that literature are now outdated. While the 
newly formed AAPM Task Group-2032 is actively researching to update and recreate a new 
guidance document, pacing specialists, radiation oncologists and medical physicists struggle to 
determine standards to these issues clinically. Even the effect of simple computerized 
tomography (CT) scanning on pacemakers is not well defined (Solan et al., 2004). 
Nearly all radiation oncology treatments are performed in the accompaniment of a CT scan of 
the patient’s anatomy. This is something that most cancer centers have within their 
department. Although the CT scan is not intended to diagnose the patient, the three-
dimensional data may be utilized within planning computers to simulate the intended 
delivery of dose to the patient before they are actually treated with radiation. Such computers, 
referred to as treatment planning systems, contain radiation data measured by the medical 
physicist from the particle accelerator. By applying the radiation measurements at the various 
depths in water, and for the various beam aperture sizes that can be used, one may be able to 
visualize the distribution of dose overlay on the patient’s CT scan. It is this preliminary 
dosimetric simulation that the radiation oncologist uses to determine the intended plan for 
treating the targeted cancer. The ability to predict the consequential dose distribution is 
important to assist in the predetermination of excessive doses to pacemakers as well.  
There are two important issues concerning pacemakers in radiation oncology. First, does the 
treatment planning system model the dose to the pacemaker accurately? In general, incident 
radiation has three possible directional pathways to travel when directed at an object. It can 
pass directly through the device with some blocking affects (attenuation), it can bounce 
backward (back-scattering), or it can ricochet outward (side-scattering) from it. Research has 
proven that treatment planning systems underestimate all three of these interactions for 
metallic structures. Under the most standard geometry, the amount of radiation blocked by 
the pacemaker and scattered from it were determined to be less when calculated by 
computer then when measured with ionization detectors.  
Specifically, for a selection of pacemaker generators investigated over a span of 2 years 
identically from Medtronic (Gossman, et al., 2010, 2011) (Adapta model ADDR01, Versa 
model VEDR01, Sensia model SEDR01, and Enpulse2 model E2DR01) as well as those from 
Boston Scientific (Gossman, 2011) (Altrua 60 EL model S606 and Altrua 60 model S603) 
attenuation results varied between computer and measurement up to a maximum 
disagreement of 5.3%. Actual measurements revealed attenuation ranges for all devices to 
be significant with respect to normal tissue at -6.4% to -15.9% at 6 MV and -5.2% to -9.4% at 
18 MV respectively. Back-scattering and side-scattering were of the least consequence of the 
three. Back-scattering results were shown to range from 0.0-2.8% at 6 MV and 0.0-3.4% at 18 
MV, whereas side-scattering ranged from 0.0-2.5% at 6 MV and 0.0-5.7% at 18 MV. 
Electrode leads exhibit similar affects in altering the distribution of dose used 
therapeutically, although at less drastic levels. In these studies, marginally significant 
attenuation dose changes were observed only for electrode leads and connector ports, at less 
                                                 
2 This author is a member of the American Association of Physicists in Medicine (AAPM) Task Group-203 
on the Management of Radiotherapy Patients with Implanted Cardiac Pacemakers and Defibrillators. 
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than 3.1% for Boston Scientific (Gossman, 2011) devices (LD CV Acuity Spiral Up lead 
model 4593, Fineline II Sterox EZ lead model 4469, and Fineline II Sterox lead model 4457) 
and 3.8% for a Medtronic (Gossman et al., 2010, 2011) lead (Single wire lead model 5076-
85CM) similarly. Scattering was determined to be negligible for either set of leads. 
As a result of those publications, medical physicists have noted that the viability of 
computer modeling is heavily dependent upon the mathematical algorithms used. Still, the 
measured results forecast a concern as to the accuracy of computer approximations when 
electronics are included within the calculation matrix. This is true even when the pacemaker 
is not directly irradiated. Dose calculations compute dose throughout the anatomy of the 
patient regardless of whether or not the beam path projects through it. This leaves the 
radiation oncologist with no alternative recourse than to rely heavily on the medical 
physicist to best approximate treatment planning system results, while understanding from 
this published research that dosimetric results may be underestimated. 
To enable treatment modeling on computer, the patient must first undergo a CT scan. These 
image data provide anatomical information specific to the patient in three dimensions. The CT 
is instrumental to be able to plan for the angle and size of the radiation beam prior to delivering 
radiation. Irradiation for imaging in this modality can result in pacemaker oversensing, 
although these effects are predominantly transient (McCollough et al., 2007; Yamaji et al., 2006). 
As explained in one group, benign problems are discovered when either there is a trigger for 
non-physiologic tracking that results in inappropriate rapid-paced ventricular rates, or perhaps 
when extra senses simulate an atrial arrhythmia that inducing a false detection and delivery of an 
unnecessary atrial antitachycardia pacing therapy. However, oversensing did cause inhibition 
of pacing in some tests. This delay is important if the heart resorts back to the same problematic 
functionality, putting them at risk for asystole. The researchers proved that dynamic CT 
scanning without table movement should not be employed. They further demonstrated that it is 
appropriate to consider situations in the future with other imaging modalities, in review of 
possible effects that may produce clinically important risks (White, 2008).   
The material of the pacemaker can cause imaging limitations for the radiation oncologist using 
CT scans as well. Research has shown that the digitally reconstructed radiograph of a patient 
having a pacemaker implanted often contains artifacts which could lead to errant computer 
calculations if not corrected properly by a qualified medical physicist (Gossman 2010, 2011a, 
2011b). These artifacts show up as non-uniform lines that obscure normal tissue anatomy. 
Closer analysis of these artifacts lead to marked observations that the Hounsfield units (HU) 
assigned by the convoluted reconstructor of the CT scanner at locations not containing the 
pacemaker actually have metallic values of upwards of 3000-8000 HU. At physical locations 
where no metallic pacemaker is present, normal tissues values in its immediate vicinity 
typically registers values more near to 0-250 HU. As these values are directly related to the 
density of the material, it is not appropriate to scan such a patient using the “normal HU 
range” which extends from -1000 HU (air) to 0 HU (water) and upward to +1000 HU (dense 
bone: 900 mg/cm3). Rather, it is recommended to use the “extended HU range” (Coolens & 
Childs, 2003) to account for these very high density metals. Incorrect HU scaling for locations 
around the pacemaker will happen no matter what. These must be corrected in the treatment 
planning process. Medical physicists refer to this process as contouring with Boolean 
operation. Planning system software used should have the capability of permitting manual 
reassignment of HU values as a solution. An example of this correction is shown in Figure 2.  
 




Fig. 2. General Electric (Fairfield, CT) CT scanner model LightSpeed RT® digital 
reconstructed radiograph in the coronal plane detailing a Medtronic ICP Adapta® model 
ADDR01 in water; (Left) with unavoidable artifact distortion and (Right) following 
appropriate manual Hounsfield unit correction 
Treatment planning system dose calculations should also be conducted with care. Only  
the best algorithms should be employed to handle dose distributions around pacemakers 
and any other high density device (Gossman et al., 2009), such as electrode leads for that 
matter.  
While some calculation algorithms provide only results assuming the entire patient  
is comprised of water density, this is not true for a real patient. Instead, the algorithm 
chosen by the medical physicist should be one which performs results with heterogeneity 
density correction throughout the entirety of the patient’s anatomy. In this manner, as 
radiation passes through the body and hits the pacemaker, a more accurate depiction of 
dose will result from the computer having calculated consequential scattering and 
attenuation from it. Likewise, a more accurate dose will result when radiation passes 
through local organs which have their own unique density. As an aid to the radiation 
oncologist, where both algorithm tools are available, the medical physicist should provide 
results with the pacemaker’s density computed as metal, and with it assigned as water as a 
second plan (Reft et al, 2003). Then, the differences between the two plans can illustrate for 
the radiation oncologist observable consequence of having the pacemaker in the calculated 
dose region. The treatment plan modeling described is exhibited in Figure 3.  
The second issue concerning the irradiation of pacemakers in radiation oncology are the 
consequential malfunctions and damage that a device might incur if irradiated. In clinical 
practice pacemakers should be placed outside of the unshielded beam as recommended by 
the AAPM3 (1). It should be well understood that even though a radiation therapy beam 
aperture can be adjusted in shape to not aim radiation directly at the pacemaker, radiation 
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appropriate manual Hounsfield unit correction 
Treatment planning system dose calculations should also be conducted with care. Only  
the best algorithms should be employed to handle dose distributions around pacemakers 
and any other high density device (Gossman et al., 2009), such as electrode leads for that 
matter.  
While some calculation algorithms provide only results assuming the entire patient  
is comprised of water density, this is not true for a real patient. Instead, the algorithm 
chosen by the medical physicist should be one which performs results with heterogeneity 
density correction throughout the entirety of the patient’s anatomy. In this manner, as 
radiation passes through the body and hits the pacemaker, a more accurate depiction of 
dose will result from the computer having calculated consequential scattering and 
attenuation from it. Likewise, a more accurate dose will result when radiation passes 
through local organs which have their own unique density. As an aid to the radiation 
oncologist, where both algorithm tools are available, the medical physicist should provide 
results with the pacemaker’s density computed as metal, and with it assigned as water as a 
second plan (Reft et al, 2003). Then, the differences between the two plans can illustrate for 
the radiation oncologist observable consequence of having the pacemaker in the calculated 
dose region. The treatment plan modeling described is exhibited in Figure 3.  
The second issue concerning the irradiation of pacemakers in radiation oncology are the 
consequential malfunctions and damage that a device might incur if irradiated. In clinical 
practice pacemakers should be placed outside of the unshielded beam as recommended by 
the AAPM3 (1). It should be well understood that even though a radiation therapy beam 
aperture can be adjusted in shape to not aim radiation directly at the pacemaker, radiation 
                                                 
3 The AAPM is a scientific and medical organization with society membership affiliation to the American 
Institute of Physics. Publications include the scientific “Medical Physics Journal”, technical reports, and 
symposium proceedings. 
 
Aspects of Pacemakers – Functions and Interactions in Cardiac and Non-Cardiac Indications 
 
150 
will also penetrate the shielding of the head of the particle accelerator that shapes the beam 
(transmission), resulting in imperceptible and possibly significant dose to the pacemaker. 
 
 
Fig. 3. Treatment plan dose distributions in the axial plane at 6 MV x-rays involving the 
Boston Scientific ICP Altrua® 60 EL model S606 in water; (Top) with no density correction 
and (Bottom) following appropriate heterogeneity correction 
Some radiation will also scatter from the patient to the pacemaker as back-scatter and side-
scatter. Under geometrical conditions where the pacemaker is out of the direct radiation beam 
although near a field edge, which is defined within the beam profile where the intensity falls-
off laterally, as much as 80% of the intended dose to the target structure can be given. Even if 
the directed beam is adjusted to just barely keep the pacemaker out of the field, it can very 
easily absorb a significant amount of dose prescribed to a tumor that is not intended for the 
generator. The variation of dose across the irradiated field is shown in Figure 4. Inspecting the 
dose profile shape, one will notice that the relative dose within the beam is very symmetric in 
shape and flat. A closer inspection reveals that between the 80% and 20% relative dose, the 
intensity decreases dramatically away from the center of the radiation beam. This distal off-
axis region on each side of the scan axis is called the penumbra. This is considered to be out of 
the ideal treatment intensity, since therapeutic dose is not well controlled in this region.  
Still further away from the penumbra, the dose continues to be present, although continually 
diminishing. This area constitutes the scattering of radiation outward, which resembles  
the aperture transmission as well as the scatter caused by the patient or phantom media.  
The plot provided is the definitive proof that a pacemaker can get a significant dose, even if it 
is not placed directly within the field intended to target the tumor. By definition, penumbral 
doses of up to 80% can be registered, while scattering doses can range of up to 20% as shown. 
Depending on how close the beam is to the pacemaker, there can be significant escalations in 
the absorbed dose to it. 
 




Fig. 4. Beam profile for a square aperture in water from 6 MV x-rays of the particle accelerator 
With these facts, the medical physicist needs to pay close attention to the dose given to the 
pacemaker over the entire course of treatment.  
As an example, let’s consider an early stage non-small cell lung cancer prescribed to receive a 
low dose boost of 20 Gy over 10 fractional days of treatment. If we assume the pacemaker can 
only tolerate 2 Gy of radiation from the particle accelerator in accordance with the current 
guidelines of the AAPM (Marbach et al., 1994) and assume a single beam is assigned with a 
profile represented in Figure 4 with a plan for treatment such that the pacemaker is 2.0 cm 
away from the field, then theoretically we would see a scattered relative dose of nearly 11% 
possibly being absorbed by it. Each fractional dose prescribed to the tumor is scheduled to 
receive 2 Gy. Although 11% of this dose is small at only 0.22 Gy, the total dose after all 10 
fractions yields a pacemaker total dose of 2.2 Gy. This is beyond the specified limit of 2 Gy. 
Therefore, the medical physicist will need to incorporate more beams with various oblique 
angles to avoid contribution of dose to the pacemaker.  
A second example details the concern for an implantable cardioverter-defibrillator (ICD) 
similarly placed too close to the field as presented in Figure 5. It illustrates what is often 
experienced with pacemakers in this treatment planning process, similar to an ICP. Three 
beams are oriented at different angles to target a tumor in the example patient’s right lung. 
The first beam is directed anterior at 180. The second beam is directed to the tumor at a left 
anterior oblique angle of 250. Then, the third beam is angled with a left posterior oblique 
angle of 310. At 180 the AP beam passes through the generator. At 250 the LAO beam is 
directed such that the device is within the penumbra region of the beam. At 250 in this 
example, the LPO resulting geometry leaves the generator out of the field of radiation in the 
scatter region only. The beams-eye-view of each radiation field is shown in Figure 6 with the 
tumor and generator contoured for illustration. The proximity of the generator to the beam 
aperture is well observed in each example. Figure 7 provides the dosimetric results for the 
mock treatment in terms of a dose-volume histogram. Each scenario is analyzed in Table 1. 
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Fig. 5. Mock treatment projected beam paths in the axial view for a patient having the St. 
Jude Medical (St. Paul, MN) ICD Atlas® model V-242 implanted 
 




Fig. 6. Mock treatment beams-eye-views for a patient having the St. Jude Medical (St. Paul, 
MN) ICD Atlas® model V-242 implanted 
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Fig. 7. Mock treatment dose-volume histogram resulting dose to the pacemaker for a patient 
having the St. Jude Medical (St. Paul, MN) ICD Atlas® model V-242 implanted 
 










Percentage Dose on 
Entire Volume 
AP 90% 3%  
 50% 7%  
 30% 60%  
 10% 405% 443% 
    
LAO 90% 2%  
 50% 3%  
 30% 4%  
 10% 6% 225% 
    
LPO 90% 1%  
 50% 2%  
 30% 3%  
 10% 4% 8% 
Table 1. Dose-volume histogram results for the mock treatment detailing absorbed dose to 
the ICD from radiation 
Looking at the maximum percentage dose absorbed by the generator for the example of a 
patient scheduled for 2 Gy in 10 fractions with an overall dose of 20 Gy, only the LPO beam 
yielded satisfactory results of dose to the generator, as it was in the scatter region outside of 
the direct radiation field and the penumbra. At a maximum dose of 8% of that 20 Gy 
prescription, the resulting dose to the electronics of the device is 1.6 Gy. This is the only 
beam arrangement that satisfies the 2 Gy recommendation. The medical physicist could 
benefit from the application of a variety of different beams at different angles. Using this 
approach, the dose absorbed to the device will be spread out over the entire surface rather 
than one directed device volume, resulting in less maximum percentage dose. 
This is the definitive dilemma for the medical physicist and radiation oncologist. Some 
diseases may be best suited for a simple 2-field technique. An anterior-posterior opposed 
field technique is the likely tactic approached for a small lung tumor medially located. In 
this example with a patient lying supine on the treatment couch, an anterior-to-posterior 
beam aimed from the patient’s chest to their back, and a posterior-to-anterior beam aimed 
through their back up through their chest may only be assigned. With the pacemaker having 
been implanted in the anterior chest wall of the patient, it then resides not only in the field 
of the entering anterior beam, but also in the field of the posterior field about to exit upward 
through the chest. These APPA beams are likely of little use now given the radiation 
tolerance limitations of the pacemaker as shown in the example. 
Instead, oblique angles should be considered (Riley et al., 2004) as shown. The radiation 
oncologist will now have to concentrate their awareness of the limitations of dose to the 
pacemaker as well as the elevated doses that will now be incurred by all these other organs 
resultantly (Gullane, 1991), while insuring the pacemaker is considerably away from the 
radiation field edge.  
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The practice of irradiating pacemakers beyond levels recommended by society-based 
entities and manufacturers is discouraged. Many researchers have sought out to investigate 
the consequences of extensive irradiation to pacemakers in order to test their susceptibility 
to induced operation changes that is unwanted. For such testing, researchers often place the 
devices directly in the path of the beam. However, the approach is safely conducted when 
the generator is implanted into a phantom environment, thus removing concerns for patient 
radiation safety as well as needs for clinical trials. Further, with devices tested directly in the 
path of the beam, the total time for irradiation is much less than if it were placed out of the 
field, to arrive at the same cumulative dose for testing. Numerous issues were discovered by 
researchers. These will now be summarized here. 
3. X-ray radiation 
A large pacemaker study was performed (Mouton et al., 2002) incorporating a batch of 96 
used pacemakers to test the influence of radiotherapy and the electromagnetic field. Several 
dose-rates (from 0.05 to 8 Gy/min) where used to yield pacemaker cumulative doses 
ranging from 6.2 Gy to 120 Gy. According to this group, approximately 15% of the 
irradiated pacemakers showed an important failure under 5 Gy. Below 2 Gy, the results 
indicated failure occurrences to drop by 9% although still present. There maintained the 
observance of important defects noted at cumulative doses of merely 0.15 Gy. 
Later, a smaller study (Hurkmans et al., 2005) was initiated involving 19 new pacemakers 
having radiation delivered directly to each in fractional increments up to doses of 120 Gy 
while being monitored. Results for pacing pulse tests included 25% amplitude deviations 
in 5 devices, a complete loss of signal in 7 devices, and 30-50% pulse duration decreases. 
Pacing frequency tests revealed inhibitions during irradiation for 8 devices. Sensing 
thresholds changed more than 25% for 2 devices with no recovery. Telemetry capability 
was lost entirely for 3 devices. Battery problems were exhibited in 5 devices. Lead 
impedance changes were seen in nearly all devices. Finally, although 5 devices did not 
show any error, 7 lost output completely. With the exception of one device, which showed 
its point of failure at 20 Gy, all other devices could withstand a dose of 90 Gy or more 
before it reached a point of failure.  
Devices differ in their susceptibility to radiation interference and damage (Yerra & Reddy, 
2007). The effect on the device is cumulative, depending on the total dose to the device. 
There was no safe threshold observed in either study, validating the concerns of the AAPM 
(Marbach et al., 1994). 
4. Electromagnetic interference 
Forty-five irradiated patients implanted with a heart rhythm device was prospectively 
investigated in an 8 years span (Ferrara, 2010) to identify any relationship between the 
various types of devices with the electric and magnetic fields produced near the linear 
accelerator. An analysis of radiation damage to pacemakers, depending on the geometric 
and dosimetric characteristics of the radiation beams was carried out. There were no 
discovered problems with the devices due to the interaction with the electromagnetic fields. 
Acute (3 cases) and late (2 cases) cardiac events were observed only in 5 patients who 
underwent treatment, but with no dysfunction observed in any pacemaker for 
electromagnetic interference (EMI).  
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5. Neutron radiation 
Neutrons are created in interactions involving high energy x-rays or high energy protons. 
Most proton beams can produce a knock-out neutron. However, neutrons can only be 
produced by x-ray beams operating above 8.04 MV. The flux of thermal neutrons created by 
an 18 MV x-ray beam of a radiotherapy linear accelerator has been observed to have caused 
a high rate of soft errors in integrated circuits that contain 10B compounds (Wilkinson et al., 
2005). These memory-loss effects can be removed entirely if 6 MV x-rays are used 
alternatively. 
6. Proton radiation 
Investigations on proton beam radiation therapy with implanted cardiac pacemaker 
function have been studied in at least one group (Oshiro et al., 2008). After a phantom study 
confirmed the safety of proton therapy in patients with cardiac pacemakers, 8 patients were 
treated using proton therapy to a total tumor dose of 33-77 Gy in dose fractions of 2.2–6.6 
Gy. Although all pulse generators remained outside the treatment field, 4 patients had 
pacing leads in the radiation field. All patients were monitored by means of 
electrocardiogram during treatment, and pacemakers were routinely examined before and 
after proton therapy. The phantom study could not distinguish between proton dose and 
neutron scatter dose contributions on pacemaker generators. However, device functionality 
observances were well documented. In the study, changes in heart rate occurred in 2 
patients. Proton therapy can result in pacemaker malfunctions that manifest as changes in 
pulse rate and pulse patterns. Minor malfunctions of implanted cardiac pacemakers 
occurred in 25% of patients receiving relatively high dose-rate proton therapy. Therefore,  it 
was recommended that patients with cardiac pacemakers should be monitored by means of 
electrocardiogram during proton therapy. 
7. Brachytherapy 
Limited research can be found with regard to radiation induced effects on pacemakers from 
sealed source radioactive material. This is mainly due to the large variety of types and 
energies of radiation that is emitted by all the different radionuclides available. Heavier 
emissions, such as alpha particles, beta particles and electrons each have mass. Therefore, 
they have no ability to penetrate the metal casing of the pacemaker. However, gamma 
radiation may pass through the device entirely, depending on the energy of the photon 
being considered. Some brachytherapy sources emit kilovoltage photons, whereas others 
emit megavoltage energies. In general for electronics, the greater the mass and energy of the 
incident radiation, the greater the likelihood for it to interact with metallic components that 
affect pacemaker functionality.  
The limited research involving brachytherapy sources are also due to their intensity of 
emission. The radioactivity of a source is dependent on the stability of the atom and the 
quantity of emissions per unit time increment when it decays.. Most radiation oncology 
sources have relatively low activity concentrations. Consequently, radioactive material for 
human use generally does not deliver as high a dose-rate as a particle accelerator. Still, 
one such investigation was found (Abner et al., 2002). Intravascular brachytherapy has 
been used for more than 10 years to treat restenosis within the heart. The doses imparted 
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electrocardiogram during treatment, and pacemakers were routinely examined before and 
after proton therapy. The phantom study could not distinguish between proton dose and 
neutron scatter dose contributions on pacemaker generators. However, device functionality 
observances were well documented. In the study, changes in heart rate occurred in 2 
patients. Proton therapy can result in pacemaker malfunctions that manifest as changes in 
pulse rate and pulse patterns. Minor malfunctions of implanted cardiac pacemakers 
occurred in 25% of patients receiving relatively high dose-rate proton therapy. Therefore,  it 
was recommended that patients with cardiac pacemakers should be monitored by means of 
electrocardiogram during proton therapy. 
7. Brachytherapy 
Limited research can be found with regard to radiation induced effects on pacemakers from 
sealed source radioactive material. This is mainly due to the large variety of types and 
energies of radiation that is emitted by all the different radionuclides available. Heavier 
emissions, such as alpha particles, beta particles and electrons each have mass. Therefore, 
they have no ability to penetrate the metal casing of the pacemaker. However, gamma 
radiation may pass through the device entirely, depending on the energy of the photon 
being considered. Some brachytherapy sources emit kilovoltage photons, whereas others 
emit megavoltage energies. In general for electronics, the greater the mass and energy of the 
incident radiation, the greater the likelihood for it to interact with metallic components that 
affect pacemaker functionality.  
The limited research involving brachytherapy sources are also due to their intensity of 
emission. The radioactivity of a source is dependent on the stability of the atom and the 
quantity of emissions per unit time increment when it decays.. Most radiation oncology 
sources have relatively low activity concentrations. Consequently, radioactive material for 
human use generally does not deliver as high a dose-rate as a particle accelerator. Still, 
one such investigation was found (Abner et al., 2002). Intravascular brachytherapy has 
been used for more than 10 years to treat restenosis within the heart. The doses imparted 
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to a pacemaker from intraluminal brachytherapy sources was calculated to be less than 
0.01 Gy for 89Sr as compared to 0.74 Gy for 192Ir, maximally. Both were deemed non-
consequential by the investigators, since no patient induced side effects were noted in the 
clinical study. 
8. Magnetic resonance imaging 
The presence of a cardiac pacemaker had been a strict FDA (Ahmed & Shellock, 2001; U.S. 
FDA, 1988) contraindication for patients undergoing a magnetic resonance imaging (MRI) 
procedure for pacemaker dependent patients since 2000. According to estimates, 50-75 
percent of patients worldwide with implanted cardiac devices are expected to need an MRI 
scan during the lifetime of their devices (Kalin & Stanton, 2005). Consequences with the use 
of non-FDA approved devices as determined in computer modeling, in vitro testing, animal 
in vivo studies and clinical trials include a considerable list of concerns (Kalin & Stanton, 
2005; Bassen & Mendoza, 2009; Roguin et al, 2004). These include: thermal injury to the 
myocardium and endocardium from electrode radiofrequency absorption heating of the 
electrode tip causing thermal tissue damage locally. Other consequences include induced 
voltage in leads that couple with pacing electrodes to trigger unwanted stimulation or 
sustained tachycardia, electrical in-operation, conductivity of the pacemaker case, vibration 
of the device, and a static magnetic field  forcing of translation or rotation of the device or 
lead. 
Recently, the U.S. FDA (U.S. FDA, 2011) relaxed their position with the advancement of an 
MRI compatible pacemaker; the Medtronic model Revo MRI™. The device may only be used 
with the associated CapSureFix MRI™ SureScan leads that are FDA approved for use in the 
MRI environment. The pacemaker may only be prescribed for certain patients under specific 
conditions. This comes after a few years of experience with a similar device outside of the 
United States. The Medtronic model EnRhythm had been approved since 2009 in Europe 
and is the first pacing system approved for MRI acquisition anywhere (Kalin & Stanton, 
2005). 
9. Summary 
The following are a summary of the recommendations for medical physicists and radiation 
oncologists to consider for implantable pacemakers and cardioverter defibrillators when 
continuing care for a patient having a pacemaker implanted in the treatment planning 
process. 
Recommendations for treatment planning: 
i. Only conduct computed tomography scanning using the commissioned extended 
Hounsfield unit range when using these scans for computer modeled dose delivery 
simulation calculations. 
ii. Incorporate known implant device outer dimension information provided by the 
manufacturer in assisting manual contouring of the device in simulation software. 
iii. Remove all streaking artifacts local to the pacemaker implant device that may cause the 
resulting calculation to be inaccurate. 
iv. Position reference points for computer prescriptions away from all high density areas.  
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v. Use algorithms for calculation that minimally have three dimensional convolution 
superposition capabilities for most accuracy in determining dose with high density 
implants. 
vi. Avoid directly aiming radiation through the pacemaker through the pacemaker and 
provide a considerable margin away from the field edge so that it is away from the 
penumbra region. 
vii. Facilitate both homogeneous and heterogeneous calculations while comparing the 
differences observed for a better understanding of the magnitude and direction of 
profile shifts in the isodose distribution. 
viii. Review published research on treatment planning system inaccuracies involving these 
devices. 
Recommendations for treatment & imaging: 
i. Particulate radiation at low energies, such as those from brachytherapy sealed sources, 
generally cannot penetrate the casing of a pacemaker and will therefore likely not be of 
any considerable cause of device malfunction, unless they are adjacent to high dose-rate 
afterloader devices containing 192Ir at high activity. 
ii. With proven consequences resulting with higher dose-rates for x-ray radiation, the 
smallest clinical dose-rate should be utilized.  
iii. X-ray radiations at 6 MV energy are preferred over higher energies, since lower 
nominal x-ray energies and those from radioactive material brachytherapy sources will 
avoid neutron production and their consequences.  
iv. Proton and neutron radiations have indicated the ability to induce malfunctions in 
similar to x-rays. Proton irradiation is known to create secondary neutrons, which can 
interact heavily with devices containing 10B compounds. All such patients should be 
monitored with an electrocardiogram before and after treatment. 
v. EMI changes have yet to be verified in the research referenced.  
vi. Cumulative dose testing has shown no real absolute threshold for a safe dose to the 
pacemaker. However, the least dose possible should be considered strongly as the 
suitable plan for treatment. This is consistent with the ALARA standard; “As low as 
reasonably achievable.” 
Finally, consultation with the implanting pacing specialist, radiation oncologist and 
medical physicist should always be obtained for each patient, aside of the initial 
preparation for such cases, in an attempt to devise an in-house quality assurance protocol 
addressing timelines for assessing patient and device status during all imaging and 
radiation therapy procedures. As a general precaution for situations that arise beyond 
material presented here, it is strongly recommended that the clinician contact the 
manufacturer about the specific model in question, while referring to the most recent 
investigative research and updated formal guidance from the AAPM Task Group-203, 
which is now pending.  
10. References 
Abner AL, Meskell P, Carrozza J, et al. (2002). Dose to cardiac pacemakers and implanted 
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1. Introduction 
In the upper urinary tract, the mechanisms by which urine is transported from the kidney to 
the bladder remain little understood. For the last 35 years, it has been thought that 
pyeloureteric autorhythmicity arises in specialized electrically active atypical smooth 
muscle cells (SMC) that have many of the morphological and electrical features of cardiac 
sino-atrial cells and are predominantly located in the proximal regions of the ureteropelvic 
junction (UPJ). However, increasing evidence indicates that ICC-like cells (ICC-LC), 
displaying many of the morphological features of intestinal ICC and immuno-reactivity to 
antibodies raised against the c-Kit proto-oncogene, are present in the UPJ of a number of 
mammals. These cells are c-Kit-positive in upper urinary tract (UUT) of mouse and Human, 
c-kit-negative in guinea pig (Lang JR et al 2006.) c-Kit immuno-reactivity also appears 
developmentally at the same time of coordinated unidirectional peristaltic contractions in 
mouse embryonic ureters in organ culture. Moreover, the development of the ureteric 
structure and peristaltic contractions in organ colture can be prevented upon exposure to 
the c-Kit antibody, ACK45 (David SG et al 2005), suggesting that ICC-LC play a crucial role 
in promoting pyeloureteric peristalsis. 
ICCs were first described by Ramon Y Cajal in 1893 as primitive neurons in the 
gastrointestinal system (GIS) (Lang JR et al 2006; Cajal SR 1893). Infact, ICCs were firstly 
found in relation to the Auerbach plexus, but also in the submucosal plexus and between 
the muscle layers. Moreover, mice with spontaneous mutations of the c-kit genes, and that 
are deficient in ICCs, lack spontaneous slow waves in the intestine and display 
uncoordinated peristalsis (Streuker et al 2003). Further investigations revealed that ICCs 
play a role as pacemaker cells, between neurons and smooth muscle cells, are originally 
derived from the mesenchymal tissue, and are responsible for conduction of the slow wave 
electrical potential for peristaltic movements (Sanders KM 1996). Local decreases in or a lack 
of c-kit immunoreactivity on ICCs in the gut have been detected in Hirschsprungs’s disease, 
infantile hypertrophic pyloric stenosis, and slow transmission constipation. Recently, 
mucosal ICC were reported at the human ureteropelvic junction (UPJ), the submucosal and 
muscolar layers of the rat vase deferents, between the stroma of smooth muscle layers and 
glandular layers of guinea pig prostate, between the smooth muscle fibers and neurons of 
guinea pig bladder and in the rabbit urethra (Solari V et al 2003). Also in the UUT, ICCs 
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have shown to be responsible for initiating, coordinating and producing ureteropelvic 
peristaltic movements at the intercaliceal area, providing the passage of urine from the 
caliceal system through the ureter to the bladder (Sergeant et al 2000).  
Several studies have been performed in uni-calyceal mammals as mouse, dog, rat, guinea pig 
and rabbit as well in multi-calyceal species such as human and pig. In multi-calyceal mammals 
minor calyces combine to form several major calyces, which fuse together to form the renal 
pelvis. In the isolated pig renal pelvis, small amplitude contractile and electrical activity 
originates at the border of the major and minor calyces. Upon injection of saline into the upper 
calyx, these peristaltic waves propagate through the lower calyces to the renal pelvis and the 
UPJ. During periods of low urine production only a few of the muscle contractions in the renal 
pelvis travel through to the ureter (Morita T et al 1981). With higher rates of diuresis, 
transmission improves until there is a one-to-one propagation of all contractions to the ureter 
(Constantinou CE et al 1974, 1976). The ureter in human and pig displays spontaneous 
contractions in vitro. In contrast the ureter in dog, rabbit, pig and rat contracts spontaneously in 
vitro only in the presence of excitatory agonists (Morita T et al 1986; Patacchini R et al 1998) or 
if the renal pelvis is left attached (Golenhofen K et al 1973; Gosling JA et al 1971; Lang RJ et al 
2001). In both uni-calyceal and multi-calyceal mammals, circumferentially cut strips of muscle 
wall dissected from the same region contract at the same frequency. However contraction 
frequency decreases with distance from the renal fornix as strips are dissected from the middle 
and lower calyces, renal pelvis and UPJ (Gosling JA et al 1971; Hannapel J et al 1978; Zhang Y 
& Lang RJ 1994). Thus researchers have located the primary pacemaker in the most proximal 
calyceal regions of the renal pelvis. 
2. Ultrastructure of the upper urinary tract (UUT) 
A compact layer of epithelial cells (mucous membrane) lines the lumen on the full length of 
the UUT stand, on a lamina propria of varying thickness containing collagen fibrils, 
myofibroblasts, as well as numerous small blood vessels and unmyelinated axon bundles. A 
layer of smooth muscle cells (SMC) surrounds the lamina propria. In the most proximal 
inter-renal regions of attachment of the UUT to the renal fornix, the pelvi-calyceal junction, 
cells are arranged in an open network, with large areas of intervening connective tissue. In 
the renal pelvis, SMC are arranged in small randomly oriented bundles, which create a 
plexiform layer of interconnecting bundles, separated by areas of connective tissue. In 
contrast the muscle wall of the ureter is arranged into an inner circular and an outer 
longitudinal layer of closely pace SMC. Surrounding these layers the adventitia is made up 
of connective tissue and fibroblasts and containing blood vessels, nerve bundles and 
lymphatic vessels (Notley RG 1978).  
3. Atypical, typical smooth muscle and ICC-like cells in the UUT 
Two types of smooth muscle cells within the muscle wall of the UUT have been identified 
under the light and electron microscope: 'atypical' and 'typical' SMC (Gosling JA & Dixon JS 
1972,1974). A third population of electrically-active cells has been described in the UUT in 
human and many mammals (Lang RJ et al 2001; Gosling JA & Dixon JS 1974) which may 
well play a fundamental role in pyeloureteric autorythmicity. 
Atypical SMCs have an irregular morphology and a non-specific cholinesterase. They have 
been described as long thin cells, having a small nucleus and being irregularly-shaped due to 
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the presence of many long branching processes. Their contractile myofilaments are arranged in 
bundles which are separated by large areas of cytoplasm containing Golgi cisternae, granular 
endoplasmic reticulum and small mitochondria occupying 3% of cell sectional area (Klemm 
MF et al 1999; Gosling JA & Dixon JS 1972) . They form areas of close apposition with each 
other and with typical SMC, these appositions being separated by long portions of naked 
membrane. In uni-calyceal kidneys, atypical SMC were firstly described as forming a discrete 
layer which begins at the pelvi-calyceal junction and continues the length of the renal pelvis to 
the UPJ (Dixon JS & Gosling JA 1970; Gosling JA & Dixon JS 1970,1971). In the rat and guinea 
pig, atypical SMC represent 22% and 80%, respectively, of the SMC present in the pelvi-
calyceal junction. (Lang RJ et al 2001; Gosling JA & Dixon JS 1974)  
In multi-calyceal kidneys, 'atypical' SMC alone form the muscle coat of each minor calyx. A 
thin sheet of loosely-arranged atypical SMC extends between the minor calyces creating an 
open network near the point of attachment to the kidney (Gosling JA & Dixon JS 1972,1974; 
Dixon JS & Gosling JA 1973,1982), the space between cells being filled with collagen-rich 
connective tissue and axon bundles (Lang RJ et al 2001; Klemm MF et al 1999; Dixon JS & 
Gosling JA 1970). A gradual thickening of the wall of the UUT of all mammals with distance 
from the pelvi-calyceal junction indicates the increasing presence of 'typical' SMC.  
'Typical' SMC are described as long spindle-shaped cell, filled by contractile filament and 
surrounded by a continuous basal lamina and containing a large round/oval shaped 
nucleus and generally grouped into bundles. In the pig 'typical' SMC are evident in the 
major calyx, renal pelvis and ureter (Gosling JA & Dixon JS 1974 ; Dixon JS & Gosling JA 
1970) . In the guinea pig and rat, typical SMC represent 78–83% and >98% of the SMC in the 
proximal renal pelvis and UPJ, respectively. The relative proportion of contractile-filament 
rich typical SMC and atypical SMC has been shown by immuno-staining sections of the 
pelvi-calyceal junction (P-CJ), renal pelvis (RP) and ureter for α smooth muscle actin, and it 
has been reported that the intensity of immuno-reactivity for α smooth muscle actin 
increases along the length of the UUT (Lang RJ et al 2001; Gosling JA & Dixon JS 1974).  
ICC-like cells (ICC-LC) are the recently described population of electrically- active cells in 
the UUT (Lang RJ et al 2001; Gosling JA & Dixon JS 1974) and they seem to play a 
fundamental role in pyeloureteric autorythmicity. Under the electron microscope, these cells 
are stellate in appearance, the cytoplasmic area containing an oval-shaped nuclear region, 
numerous mitochondria (4% of cell sectional area), well-developed Golgi apparatus, but no 
contractile filaments or immuno-reactivity to α smooth muscle actin. The plasma membrane 
of these cells also displays a discontinuous basal lamina and numerous calveolae. These 
interstitial cells form close appositions both 20nm and adherens junctions, with themselves 
(80% of cells) and SMC. Thus these cells display many of the morphological features used to 
distinguish ICC, from fibroblasts within the wall of the intestinal tract (Huizinga JD et al 
1997; Huizinga JD 2005). In the guinea-pig UUT, ICC-LC lay within in the lamina propria of 
the pelvi-calyceal region and the renal pelvis and do not form close associations (<30nm) 
with nerve bundles, nor they were identified in the ureter (Gosling JA & Dixon JS 1974). 
These cells are also immunoreactive to antibodies raised against c-kit proto oncogene, a 
member of the receptor-tyrosine kinase family. Several studies described ICC-LC in UUT. 
Solari et al. described that c-kit positive cells in human UPJ had a fusiform cell body with 2 
distinct dendrites (Solari et al 2003), Pezzone et al. described c-kit positive cells in the mouse 
UUT as being stellate in appearance (Pezzone MA et al 2003). Networks of these c-kit 
positive cells were located adjacent to the inner longitudinal muscle layer and between the 
inner and outer SMC layers (Solari et al 2003, Pezzone MA et al 2003).  
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Fig. 1. Ureteral wall showing both the urothelium layer and a portion of smooth muscle 
layer (A) (H&H, Original magnification 125x) CD117 immunostaining displaying a 
cytoplasmic immunopositive Cajal cells in subepithelial (B), smooth muscle layer (C) and 
adventitial (D) sites (arrows), together with some mast-cells (Original magnification 250x) 
There is general agreement that the number of these c-kit positive cells was greatest in the 
proximal renal pelvis and decreased with distance from the UPJ (Thompson CB 1995, 
Metzger R et al 2004, Pezzone MA et al 2003). Differences in technologies and antibodies 
used when fixing and staining preparations have been evoked to explain the variation of c-
kit staining observed between species by different laboratories (Sleator W 1955, Pezzone MA 
et al 2003). Double labelling experiments have discounted the possibility that these c-kit-
positive cells are mast cells, fibroblasts or macrophages (Metzger R et al 2004).  
It is becoming clear that ICC and ICC-like cells in various urogenital and intestinal tissues 
can also be divided into a number of subpopulations on the basis of their immuno-reactivity 
or -negativity to c-kit, vimentin, actin filaments, ion channel populations (Lang RJ et al 2001; 
Gosling JA & Dixon JS 1974), receptors (Van der AaF et al 2004) and gap junction subunits. 
In human and less frequently pig, another population of 'vertically-orientated' c-kit positive 
spindle shape cells was present between the basal cells of the transitional epithelium 
(Metzger R 2004). The number of these radially arranged c-kit positive cells was greatest in 
the intermediate ureter and lowest in the renal pelvis. The role of these c-kit positive cells 
remains little unknown but it is interesting that these cells are present in an area that is 
richly innervated by sensory nerves suggesting that these ICC may be acting as an 
intermediate between the afferent innervation and the urothelium and maybe they are 
responsible even for initiating, coordinating and producing ureteropelvic peristaltic 
movements at the intercaliceal area, providing the passage of urine from the caliceal system 






Pacemakers in the Upper Urinary Tract 169 
4. Pacemaking in the UUT and electrical recordings 
Pressure recordings and intracellular and extracellular electrophysiological investigations 
have established that every peristaltic contraction of the renal pelvis and ureter is preceded 
by a complex ‘ureteric’ or ‘driven’ action potential. Driven action potentials have a time 
course consisting of an initial slow membrane depolarization followed by a single or 
multiple rapidly-rising spike(s), which partially repolarize to a plateau phase (100ms to > 1s 
in duration) followed by a second repolarization to an afterhyperpolarization which decays 
back to the resting membrane potential (Sleator W et al 1955, Shuba MF 1977).  
It has been also established that the probability of recording ureteric or 'driven' action 
potentials increased with distance from the renal fornix, from 75% of cells in the proximal 
renal pelvis to 89% in the distal renal pelvis and 100% of cells in the ureter. This gradient of 
recording action potentials with distance is due to an increasingly more negative membrane 
potential and a decreasing frequency of action potential discharge with distance from the 
renal fornix.  
Atipical SMC and ICC-LC are described as pacemakers cells, essential for the induction and 
propagation of contractile electrical pulse.  
Atypical SMC seems to be essential pacemaker cells of pelviureteric peristalsis. Investigators 
have envisaged that autorhythmicity within the upper urinary tract involves a ‘chain of 
coupled linear oscillators’ with the most proximal oscillator firing at the highest frequency, 
The decreasing presence of ‘atypical’ SMC with distance from the papillate base has been 
correlated with the decreasing frequency of contraction. 
Atypical SMC have higher frequency (8-15 min-1) transient potentials of a simple waveform, 
those potentials are frequently (83% of cells) recorded in short “atypical” SMC (90–230μm in 
length) in the pelvi-calyceal junction of the guinea pig renal pelvis (Patacchini R et al 1998; 
Klemm MF et al 1999; Seki N et al 1990, Tsuchida S et al 1992). These transient potentials were 
recorded less frequently in the proximal renal pelvis (10% of recordings) and never in the 
ureter (Lang RJ et al 2001; Gosling JA & Dixon JS 1974). High frequency transient potentials 
and driven action potentials in the renal pelvis and ureter have been demonstrated by research 
groups, to be abolished by nifedipine, suggesting that Ca2+ entry through voltage gated L-
type Ca2+ channels is essential in the initiation, maintenance or propagation of these electrical 
events. This model implies that the intrinsic frequency of pacemaking atypical SMC decreases 
with distance from the papilla base which would require morphologically similar cells having 
different expression profiles of voltage- and Ca2+-activated ion channels and pacemaking 
apparatus as their location increases with distance from the papilla. 
Diuresis also has an important role in ureter peristalsis. It has been suggested that diuresis 
to distend the muscle wall which increases, in an unknown manner, the ‘coupling’ of the 
pacemaker regions in the longitudinal direction until the highest frequency oscillator in the 
proximal regions entrains the oscillators in the distal regions of the renal pelvis. 
Furthermore simultaneous extracellular recordings from numerous sites on the sheep renal 
pelvis have revealed that only one pacemaker region on the pelvi-calyceal border is active at 
any one time and that the pathway of conduction might meander throughout the renal 
pelvis. The site of the pacemaker signal on the pelvi-calyceal border can shift spontaneously, 
conduction delays or block of the wave of excitation can occur at any point or time 
(Lammers WJ et al 1996). These observations do not support the concept of summation of 
subthreshold pacemaker activity. Rather it suggests that one pacemaker region in the 
proximal portion of the UUT dominates to drive neighbouring regions and that conduction 
 
Aspects of Pacemakers – Functions and Interactions in Cardiac and Non-Cardiac Indications 168 
      
 
      
Fig. 1. Ureteral wall showing both the urothelium layer and a portion of smooth muscle 
layer (A) (H&H, Original magnification 125x) CD117 immunostaining displaying a 
cytoplasmic immunopositive Cajal cells in subepithelial (B), smooth muscle layer (C) and 
adventitial (D) sites (arrows), together with some mast-cells (Original magnification 250x) 
There is general agreement that the number of these c-kit positive cells was greatest in the 
proximal renal pelvis and decreased with distance from the UPJ (Thompson CB 1995, 
Metzger R et al 2004, Pezzone MA et al 2003). Differences in technologies and antibodies 
used when fixing and staining preparations have been evoked to explain the variation of c-
kit staining observed between species by different laboratories (Sleator W 1955, Pezzone MA 
et al 2003). Double labelling experiments have discounted the possibility that these c-kit-
positive cells are mast cells, fibroblasts or macrophages (Metzger R et al 2004).  
It is becoming clear that ICC and ICC-like cells in various urogenital and intestinal tissues 
can also be divided into a number of subpopulations on the basis of their immuno-reactivity 
or -negativity to c-kit, vimentin, actin filaments, ion channel populations (Lang RJ et al 2001; 
Gosling JA & Dixon JS 1974), receptors (Van der AaF et al 2004) and gap junction subunits. 
In human and less frequently pig, another population of 'vertically-orientated' c-kit positive 
spindle shape cells was present between the basal cells of the transitional epithelium 
(Metzger R 2004). The number of these radially arranged c-kit positive cells was greatest in 
the intermediate ureter and lowest in the renal pelvis. The role of these c-kit positive cells 
remains little unknown but it is interesting that these cells are present in an area that is 
richly innervated by sensory nerves suggesting that these ICC may be acting as an 
intermediate between the afferent innervation and the urothelium and maybe they are 
responsible even for initiating, coordinating and producing ureteropelvic peristaltic 
movements at the intercaliceal area, providing the passage of urine from the caliceal system 






Pacemakers in the Upper Urinary Tract 169 
4. Pacemaking in the UUT and electrical recordings 
Pressure recordings and intracellular and extracellular electrophysiological investigations 
have established that every peristaltic contraction of the renal pelvis and ureter is preceded 
by a complex ‘ureteric’ or ‘driven’ action potential. Driven action potentials have a time 
course consisting of an initial slow membrane depolarization followed by a single or 
multiple rapidly-rising spike(s), which partially repolarize to a plateau phase (100ms to > 1s 
in duration) followed by a second repolarization to an afterhyperpolarization which decays 
back to the resting membrane potential (Sleator W et al 1955, Shuba MF 1977).  
It has been also established that the probability of recording ureteric or 'driven' action 
potentials increased with distance from the renal fornix, from 75% of cells in the proximal 
renal pelvis to 89% in the distal renal pelvis and 100% of cells in the ureter. This gradient of 
recording action potentials with distance is due to an increasingly more negative membrane 
potential and a decreasing frequency of action potential discharge with distance from the 
renal fornix.  
Atipical SMC and ICC-LC are described as pacemakers cells, essential for the induction and 
propagation of contractile electrical pulse.  
Atypical SMC seems to be essential pacemaker cells of pelviureteric peristalsis. Investigators 
have envisaged that autorhythmicity within the upper urinary tract involves a ‘chain of 
coupled linear oscillators’ with the most proximal oscillator firing at the highest frequency, 
The decreasing presence of ‘atypical’ SMC with distance from the papillate base has been 
correlated with the decreasing frequency of contraction. 
Atypical SMC have higher frequency (8-15 min-1) transient potentials of a simple waveform, 
those potentials are frequently (83% of cells) recorded in short “atypical” SMC (90–230μm in 
length) in the pelvi-calyceal junction of the guinea pig renal pelvis (Patacchini R et al 1998; 
Klemm MF et al 1999; Seki N et al 1990, Tsuchida S et al 1992). These transient potentials were 
recorded less frequently in the proximal renal pelvis (10% of recordings) and never in the 
ureter (Lang RJ et al 2001; Gosling JA & Dixon JS 1974). High frequency transient potentials 
and driven action potentials in the renal pelvis and ureter have been demonstrated by research 
groups, to be abolished by nifedipine, suggesting that Ca2+ entry through voltage gated L-
type Ca2+ channels is essential in the initiation, maintenance or propagation of these electrical 
events. This model implies that the intrinsic frequency of pacemaking atypical SMC decreases 
with distance from the papilla base which would require morphologically similar cells having 
different expression profiles of voltage- and Ca2+-activated ion channels and pacemaking 
apparatus as their location increases with distance from the papilla. 
Diuresis also has an important role in ureter peristalsis. It has been suggested that diuresis 
to distend the muscle wall which increases, in an unknown manner, the ‘coupling’ of the 
pacemaker regions in the longitudinal direction until the highest frequency oscillator in the 
proximal regions entrains the oscillators in the distal regions of the renal pelvis. 
Furthermore simultaneous extracellular recordings from numerous sites on the sheep renal 
pelvis have revealed that only one pacemaker region on the pelvi-calyceal border is active at 
any one time and that the pathway of conduction might meander throughout the renal 
pelvis. The site of the pacemaker signal on the pelvi-calyceal border can shift spontaneously, 
conduction delays or block of the wave of excitation can occur at any point or time 
(Lammers WJ et al 1996). These observations do not support the concept of summation of 
subthreshold pacemaker activity. Rather it suggests that one pacemaker region in the 
proximal portion of the UUT dominates to drive neighbouring regions and that conduction 
 
Aspects of Pacemakers – Functions and Interactions in Cardiac and Non-Cardiac Indications 170 
block is a dynamic process and modulated by a number of factors such as wall stress or the 
hormonal/neurotransmitter/prostaglandin milieu. These mechanisms may explain the 
conduction block between the renal pelvis and the ureter evident in vivo under conditions of 
low urine production which is relieved during periods of increased diuresis.  
ICC-LC have been described as a population of active cells which may well be responsible 
for additional autorythmicity. A number of investigators have demonstrated that ICC-LC 
form close appositions with themselves and with neighboring typical and atypical SMC, 
suggesting electrical connectivity and conduction. 
Intracellular microelectrode impalements have been made from the serosal surface of the 
pelvi-calyceal junction and renal pelvis of the guinea pig and it has been that 11–17% of cells 
fired spontaneous action potentials with a distinctive time course consisting of a single spike 
followed by a quiescent plateau and a rapid repolarization. (Klemm MF et al 1999). 
In the guinea pig UUT contractions occur regularly from a stable baseline at a frequency (4–
7 min) essentially similar to the frequency of driven action potential discharge and lower 
than the frequency of discharge of transient potentials ( Zhang Y et al 1994; Lang RJ et al 
2002). Spontaneous transient potentials arise in atypical SMC and propagate to 
neighbouring typical SMC and ICC-like cells, triggering driven and intermediate action 
potentials, respectively. 
The mechanisms involved in the generation and propagation of pacemaker potentials in 
SMC display considerable variation between tissues and species. 
In conclusion, except for the very proximal regions of the UTT and distal ureteric regions, it 
looks that two populations of pacemaker cells, atypical SMC and ICC-LC, are present in any 
portion of UUT and that the drive of each pacemaker system on any typical SMC bundle 
varies with distance from the papilla base. Importantly, to the best of our knowledge, there 
aren’t any pharmacological agents at present that selectively identify, block or activate the 
drive of either pacemaker system. Although c-kit antibody binding to unfixed tissues allows 
for the identification and selective recording from c-kit-positive ICC-LC, there are no vital 
stains selective for atypical SMC or c-kit-negative ICC-LC to allow a similar targeted 
examination of their influence on muscle wall contractility. Anyway, a complete 
electrophysiological and pharmacological profile of c-kit- positive/negative ICC-LC and 
atypical SMC at the single cell level and the establishment of any species differences or 
changes in properties might be crucial before the development of a complete model of UPJ 
autorhythmicity.  
The renal pelvis and ureter represent a functional system with myogenic excitation, generation 
and conduction. The coordination between renal pelvis and ureteral peristalsis is an important 
part of the hydrodynamics of the upper urinary tract. Contraction waves arising from the 
upper and urinary tract, and propagation may require the direct involvement of ICCs, which 
are the pacemaker cells in SMC. As in gastrointestinal motility, ICCs may have a significant 
role in the propagation, coordination and modulation of UUT peristalsis. As in the 
gastrointestinal tract damage, several studies have been done to identify a possible 
pathogenetic factor of altered ICC in genitourinary disease as primary vesicoureteral reflux, 
congenital ureteropelvic junction obstruction and primary obstructive megaureter. 
5. Congenital ureteropelvic junction obstruction 
Congenital ureteropelvic junction (UPJ) obstruction is the most common cause of neonatal 
hydronephrosis with a frequency of 1/1,000 to 2,000 newborns. Previous and recent studies 
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showed abnormal innervation patterns and abnormalities of smooth muscle or collagen in 
UPJ cases, including absent or deficient muscle and muscular malorientation, suggesting a 
basis for disordered function and obstruction (Solari V et al 2003).  
The renal pelvis and ureter represent a functional system with myogenic excitation, 
generation and conduction. The coordination between renal pelvis and ureteral peristalsis is 
an important part of the hydrodynamics of the upper urinary tract. Contraction waves 
arising from the upper urinary tract, and propagation may require the direct involvement of 
ICCs, which are the pacemaker cells in smooth muscle. As described, ICCs may have a 
significant role in the propagation, coordination and modulation of ureteropelvic peristalsis. 
Decreased expression of c-kit positive ICCs in UPJ obstruction may cause the failure of 
transmission of peristaltic waves across the UPJ, resulting in the failure of urine to be 
propelled from the renal pelvis into the ureter in UPJ obstruction. Solari et al (Solari V et al 
2003) examined the status of UPJ innervation using immunohistochemistry with 
antiperipherin antibody (type III intermediate filament, a specific marker for peripheral 
neurons, and nerve fibers). Peripherin immunoreactive nerve fibers were markedly 
decreased in obstructed UPJ samples. So in patients with UPJ obstruction there is not only 
defective intramuscular innervation of UPJ, but also altered distribution of ICCs, which are 
coordinators of peristaltic activity. The lack or deficient expression of ICCs in the UPJ may 
lead to defective generation of pacemaker activity, thus, causing peristaltic activity 
dysfunction. 
The lack or absence of c-kit positive ICCs in obstructed UPJ specimens suggests that this 
might be responsible for motility disturbance of the upper ureter. The possible link between 
absent ICCs and other features reported in obstructed UPJ cases, such as neuronal depletion 
in the muscle layers, justify additional studies. Further investigations of ICCs are still 
necessary to understand better the pacemaker mechanism in the human upper urinary tract 
and the unknown etiology of the failure of spontaneous contractions to propel urine from 
the renal pelvis through the ureter in patients with UPJ obstruction.  
6. Primary vesico-ureteral reflux 
Primary vesico-ureteral reflux (VUR) is thought to be caused by a congenital structural 
deficiency of the trigonal vesico-ureteral junction (VUJ) due to maturational abnormalities. 
The VUJ represents the boundary line between the low-pressure upper urinary tract and the 
high variable pressure of the lower urinary tract. It protects the upper tract from reflux 
using active and passive antireflux mechanisms. The most common explanation of a 
competent valve mechanism is passive compression of the roof of the intravesical ureter 
against the underlying detrusor. The length of the intravesical ureter relative to its diameter 
seems to be the crucial point supporting the ‘passive’ reflux defence mechanism (Arena S. et 
al 2007). The ‘active’ antireflux system is due to the contraction of the longitudinal muscle 
coat of the VUJ. Active shortening of the longitudinal muscle layer of the transmural and 
submucosal ureterer areas ejects the bolus of urine into the bladder lumen. 
Reductions of the total smooth muscle mass or defective configurations creating insufficient 
or uncoordinated contractions are accompanied by a decrease in the neuronal supply or 
aganglionosis. Predominantly in the upper urinary tract, coordinated peristalsis is essential 
to propel urine from the renal pelvis down to the bladder in a unidirectional way. Those 
peristaltic waves are generated in the renal pelvis and the proximal ureter by pacemaker 
cells. Functional and structural alterations of ureteric ends seem to impair the active valve 
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looks that two populations of pacemaker cells, atypical SMC and ICC-LC, are present in any 
portion of UUT and that the drive of each pacemaker system on any typical SMC bundle 
varies with distance from the papilla base. Importantly, to the best of our knowledge, there 
aren’t any pharmacological agents at present that selectively identify, block or activate the 
drive of either pacemaker system. Although c-kit antibody binding to unfixed tissues allows 
for the identification and selective recording from c-kit-positive ICC-LC, there are no vital 
stains selective for atypical SMC or c-kit-negative ICC-LC to allow a similar targeted 
examination of their influence on muscle wall contractility. Anyway, a complete 
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atypical SMC at the single cell level and the establishment of any species differences or 
changes in properties might be crucial before the development of a complete model of UPJ 
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Decreased expression of c-kit positive ICCs in UPJ obstruction may cause the failure of 
transmission of peristaltic waves across the UPJ, resulting in the failure of urine to be 
propelled from the renal pelvis into the ureter in UPJ obstruction. Solari et al (Solari V et al 
2003) examined the status of UPJ innervation using immunohistochemistry with 
antiperipherin antibody (type III intermediate filament, a specific marker for peripheral 
neurons, and nerve fibers). Peripherin immunoreactive nerve fibers were markedly 
decreased in obstructed UPJ samples. So in patients with UPJ obstruction there is not only 
defective intramuscular innervation of UPJ, but also altered distribution of ICCs, which are 
coordinators of peristaltic activity. The lack or deficient expression of ICCs in the UPJ may 
lead to defective generation of pacemaker activity, thus, causing peristaltic activity 
dysfunction. 
The lack or absence of c-kit positive ICCs in obstructed UPJ specimens suggests that this 
might be responsible for motility disturbance of the upper ureter. The possible link between 
absent ICCs and other features reported in obstructed UPJ cases, such as neuronal depletion 
in the muscle layers, justify additional studies. Further investigations of ICCs are still 
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and the unknown etiology of the failure of spontaneous contractions to propel urine from 
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The VUJ represents the boundary line between the low-pressure upper urinary tract and the 
high variable pressure of the lower urinary tract. It protects the upper tract from reflux 
using active and passive antireflux mechanisms. The most common explanation of a 
competent valve mechanism is passive compression of the roof of the intravesical ureter 
against the underlying detrusor. The length of the intravesical ureter relative to its diameter 
seems to be the crucial point supporting the ‘passive’ reflux defence mechanism (Arena S. et 
al 2007). The ‘active’ antireflux system is due to the contraction of the longitudinal muscle 
coat of the VUJ. Active shortening of the longitudinal muscle layer of the transmural and 
submucosal ureterer areas ejects the bolus of urine into the bladder lumen. 
Reductions of the total smooth muscle mass or defective configurations creating insufficient 
or uncoordinated contractions are accompanied by a decrease in the neuronal supply or 
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cells. Functional and structural alterations of ureteric ends seem to impair the active valve 
 
Aspects of Pacemakers – Functions and Interactions in Cardiac and Non-Cardiac Indications 172 
mechanism of the VUJ, causing VUR (Schwentner C et al 2005). Several studies have shown 
that the reducing of the total smooth muscle fascicles or a defective configuration creating 
insufficient or uncoordinated contractions are accompanied by a loss of c-kit-positive ICCs 
at the VUJ. Manometric findings on refluxing ureteric units (RUs) showed changed 
manometric patterns. In fact, the pressures recorded in the VUJ in the control and patients 
with VUR fluctuated rhythmically from a basal pressure to a high pressure during 
peristalsis (Pmax). While in RUs affected by grade I to III VUR the waves were rhythmic, the 
manometric profile in grade IV and V VUR was an arrhythmic or ‘silent’ pattern, with 
typical bicuspid spikes in the manometric record. Moreover, the basal and maximum 
pressure were negatively correlated with the grade of VUR (Arena S. et al 2007).  
The variable and inconsistent pressures of the peristaltic waves, and the irregular wave 
rhythm, are likely to result in disturbed urine transport along the distal part of RUs, while 
the silent ureter might represent an advanced stage of ureteric arrhythmia, suggesting a 
more damaged ureter resembling a ureteric arrhythmic state. 
Histological and histochemical findings showed a varied extent of change in intravesical RU 
tracts, e.g. muscle disarrangement and atrophy, and increased interstitial fibrosis. It has been 
reported a significant correlation between the grades of VUR and smooth muscle lesions, in 
according with Gearhart et al. (Gosling JA 1995) who reported a degree of smooth muscle 
deterioration and more collagen deposition in dilated refluxing ureters than in normal ureters. 
Moreover, Oswald et al. (Oswald J et al 2004) reported a replacement of muscle bundles by 
connective tissue, leading to ureteric rigidity. It is patent that a defect of the longitudinal 
muscle coat implies an impairment of the contraction of the ureteric muscular layer, 
producing VUR. In fact, both the ostial valve contraction and ureteric peristalsis support an 
‘active’ antireflux mechanism (Oswald J et al 2003). A significant decrease in c kit- positive 
ICCs, common tissue regulators in assisting peristalsis, has been described. It is not clear 
why depletion of c-kit-expressing ICCs occurs in RU ends. Interestingly, mammalian ICCs 
derive from smooth muscle progenitors, whose differentiation is independent of neural 
crest-derived cell lines (Wu JJ et al 2000). In RU there is a grade-correlated defect of muscle 
cells, among which c-kit-positive ICCs differentiate inside the ureteric ending, so that the 
loss of c-kit-positive ICCs might be a consequence of the disruption of muscle cells. 
Alternatively, as mesenchymal cells, surrounding the mesonephric duct, differentiate into 
the ureteric inner layer of smooth muscle cells, the delayed elongation of the Wolffian duct 
endings might be a pathogenetic event for muscular and subsequent ICC defects in VUR. 
Thus, the late maturation of ureteric ends is coherent with a possible spontaneous resolution 
of VUR, after postnatal remodelling of the VUJ, as shown for the pathogenesis of primary 
megaureter (Nicotina PA et al 1997). Loss of c-kit-positive ICCs could be also secondary to 
ureteric trauma during episodes of VUR, as reported in the proximal segment of obstructed 
fetal bowel (Khen N et al 2004). Consistently it is acknowledged that that mechanical stress 
can affect the expression of development genes, providing evidence that molecular signals 
are not the only forces that are involved in modelling the developing embryo. 
In conclusion, RU ends share muscle disarrangement and fibrosis, dysfunction of the ostial 
valve and impairment of basal VUJ pressure, impairing significantly peristaltic waves. It’s 
shown that the density of c-kit-positive ICCs in VUR negatively correlated with the grade of 
VUR and positively with Pmax , implying qualitative and quantitative alterations of 
peristaltic waves in VUR. These observations underline the assumption that VUR is related 
to an inadequately active mechanism, but further investigations are needed to clarify the 
origin of architectural lesions and the absence of c-kit- positive ICCs. 
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7. Congenital primary obstructive megaureter 
Congenital megaureter is a term used in many cases of urinary tract dilation detected before 
and after birth (Shokeir AA et al 2000). In children, the ureteral diameter is usually not >5 
mm, and when it is >7 mm, it could be considered a megaureter (Angerri O et al 2007). 
The studies by Payabvash et al. (Payabvash S et al 2007) and Kajbafzadeh et al. (Kajbafzadeh 
AM et al 2006) revealed that the proportion of muscular content in the ureteral wall of an 
obstructed vesicoureteral junction is significantly lower than that in normal specimens. Lee 
et al. (Lee BR et al 1992) suggested that active and passive biomechanical wall properties, as 
well as morphologic parameters, such as decreased smooth muscle and increased collagen 
content are likely to change in various pathologic situations, including the obstructed 
megaureter. It has been suggested that abnormal peristalsis might have potentially 
contributed to the development of both obstructive and the increased collagen of the dilated 
ureter might be responsible for the abnormal peristalsis. 
 
 
Fig. 2. Electromanometric ureteral findings in unilateral congenital megaureter: the upper 
track shows an impaired peristalsis in all ureteral parts as compared with contralateral ureter 
that has normal peristalsis . The post operative findings show only respiratory waves in the 
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mechanism of the VUJ, causing VUR (Schwentner C et al 2005). Several studies have shown 
that the reducing of the total smooth muscle fascicles or a defective configuration creating 
insufficient or uncoordinated contractions are accompanied by a loss of c-kit-positive ICCs 
at the VUJ. Manometric findings on refluxing ureteric units (RUs) showed changed 
manometric patterns. In fact, the pressures recorded in the VUJ in the control and patients 
with VUR fluctuated rhythmically from a basal pressure to a high pressure during 
peristalsis (Pmax). While in RUs affected by grade I to III VUR the waves were rhythmic, the 
manometric profile in grade IV and V VUR was an arrhythmic or ‘silent’ pattern, with 
typical bicuspid spikes in the manometric record. Moreover, the basal and maximum 
pressure were negatively correlated with the grade of VUR (Arena S. et al 2007).  
The variable and inconsistent pressures of the peristaltic waves, and the irregular wave 
rhythm, are likely to result in disturbed urine transport along the distal part of RUs, while 
the silent ureter might represent an advanced stage of ureteric arrhythmia, suggesting a 
more damaged ureter resembling a ureteric arrhythmic state. 
Histological and histochemical findings showed a varied extent of change in intravesical RU 
tracts, e.g. muscle disarrangement and atrophy, and increased interstitial fibrosis. It has been 
reported a significant correlation between the grades of VUR and smooth muscle lesions, in 
according with Gearhart et al. (Gosling JA 1995) who reported a degree of smooth muscle 
deterioration and more collagen deposition in dilated refluxing ureters than in normal ureters. 
Moreover, Oswald et al. (Oswald J et al 2004) reported a replacement of muscle bundles by 
connective tissue, leading to ureteric rigidity. It is patent that a defect of the longitudinal 
muscle coat implies an impairment of the contraction of the ureteric muscular layer, 
producing VUR. In fact, both the ostial valve contraction and ureteric peristalsis support an 
‘active’ antireflux mechanism (Oswald J et al 2003). A significant decrease in c kit- positive 
ICCs, common tissue regulators in assisting peristalsis, has been described. It is not clear 
why depletion of c-kit-expressing ICCs occurs in RU ends. Interestingly, mammalian ICCs 
derive from smooth muscle progenitors, whose differentiation is independent of neural 
crest-derived cell lines (Wu JJ et al 2000). In RU there is a grade-correlated defect of muscle 
cells, among which c-kit-positive ICCs differentiate inside the ureteric ending, so that the 
loss of c-kit-positive ICCs might be a consequence of the disruption of muscle cells. 
Alternatively, as mesenchymal cells, surrounding the mesonephric duct, differentiate into 
the ureteric inner layer of smooth muscle cells, the delayed elongation of the Wolffian duct 
endings might be a pathogenetic event for muscular and subsequent ICC defects in VUR. 
Thus, the late maturation of ureteric ends is coherent with a possible spontaneous resolution 
of VUR, after postnatal remodelling of the VUJ, as shown for the pathogenesis of primary 
megaureter (Nicotina PA et al 1997). Loss of c-kit-positive ICCs could be also secondary to 
ureteric trauma during episodes of VUR, as reported in the proximal segment of obstructed 
fetal bowel (Khen N et al 2004). Consistently it is acknowledged that that mechanical stress 
can affect the expression of development genes, providing evidence that molecular signals 
are not the only forces that are involved in modelling the developing embryo. 
In conclusion, RU ends share muscle disarrangement and fibrosis, dysfunction of the ostial 
valve and impairment of basal VUJ pressure, impairing significantly peristaltic waves. It’s 
shown that the density of c-kit-positive ICCs in VUR negatively correlated with the grade of 
VUR and positively with Pmax , implying qualitative and quantitative alterations of 
peristaltic waves in VUR. These observations underline the assumption that VUR is related 
to an inadequately active mechanism, but further investigations are needed to clarify the 
origin of architectural lesions and the absence of c-kit- positive ICCs. 
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It was observed that apoptosis was significantly increased in the primary obstructive 
megaureter compared with the refluxing one. Kim et al. (Kim HG et al 2006) suggested that 
cell proliferation and apoptosis might play an important role in the pathogenesis of the 
obstructive megaureter. In fact, apoptosis of myocytes in the obstructive megaureter might 
affecr peristalsis. According to Kim et al. (Kim HG et al 2006) peak proliferation is noted 
during the early stage and apoptosis during the late stage of obstruction in animal models of 
obstructive ureter. We also hypothesized that the number of ICC-like cells, which are known 
to play an important role in peristalsis as a pacemaker of smooth muscle contraction, might 
be altered. As regards, it has been observed a normal distribution of ICCs in both the 
circular and longitudinal muscle layers of the dilated segments of patients affected by 
congenital primary megaureter, while a severe muscle hypoplasia and significant less of 
ICCs occurred in the longitudinal muscle layer of the restricted part of primary obstructive 
megaureter. Differently, a normal distribution of peripherin positive fibres was present in 
both the dilated and restricted ureteral segments (Arena F et al 2007).  
Because megaureter is also a congenital disease with abnormal peristalsis, it has been 
hypothesized that the alterations in the number or function of ICC cells might induce 
discoordination between the signals of the nervous system and smooth muscle, causing 
abnormal peristalsis and, eventually, resulting in the development of ureteral dilation.  
In contrast, a comparison between primary refluxing and obstructive magaureters showed 
that the number of c-kit-positive cells was clearly different between the obstructive and 
refluxing megaureters, with the latter having significantly fewer ICC-like cells than the 
former. Studies of mice with mutations leading to defects in the development of c-kit 
positive ICC populations have shown that without pacemakers, the coordination of smooth 
muscle contractions is lost.(Brading AF et al 2005). 
Torihashi et al (Torihashi S et al 1999) reported that when c-kit receptors were blocked 
during development, the ICCs almost entirely disappeared from the small intestine. 
However, this loss of ICCs was not accounted for using assays for cell death, and closer 
examination revealed that the remaining ICCs developed ultrastructural features similar to 
those of smooth muscle cells. According to Burns (Burns AJ 2007) an inherent plasticity 
between ICCs and smooth muscle cells is regulated by c-kit signaling. c-kit signaling might 
be necessary for the maintenance and further development of ICC-like cells before and after 
birth, accounting for the spontaneous improvement of such conditions with time in some 
cases. According to the study by Mei et al (Mei F et al 2009) the ICC number is reduced after 
intestinal ischemic injury but makes a dramatic recovery. However, ischemic injury can lead 
to apoptosis of the ICCs, smooth muscle cells, and enteric neurons. Therefore, the higher c-
kit expression in obstructive megaureters as compared to refluxing ureter might have been 
preceded by a reduction in ICC-like cells after ischemic injury, such as in the intestines, and 
the remaining increased apoptosis of smooth muscle cells might be the cause of the ureteral 
dysfunction. 
8. Conclusions 
ICC-LC are present in the UUT of a number of mammals and they have a crucial role in 
promoting pyeloureteric peristalsis. Studies showed that ICC-LC are responsible for 
initiating, coordinating and producing ureteropelvic peristaltic movements at the 
intercaliceal area, providing the passage of urine from the caliceal system through the ureter 
to the bladder. In conclusion, as well as in some gastrointestinal diseases (Hirschsprungs’s 
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disease, infantile hypertrophic pyloric stenosis, slow transmission constipation), a local 
decrease or a lack of c-kit immunoreactivity ICCs-LC may be involved in dysfunctional 
disease of urinary tract as primary vesicoureteral reflux, congenital ureteropelvic junction 
obstruction and primary obstructive megaureter. 
9. Abbreviations 
ACK:   c-kit antibodies 
GIS:   gastrointestinal system 
ICC:   interstitial cajal cells 
ICC-LC:  ICC-like cells  
P-CJ:   pelvi-calyceal junction  
RP:   renal pelvis  
RUs:   refluxing ureteric units 
SMC:   smooth muscle cell 
UPJ:   ureteropelvic junction 
UTT:  upper urinary tract 
VUR:   Primary vesico-ureteral reflux  
VUJ:   trigonal vesico-ureteral junction  
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It was observed that apoptosis was significantly increased in the primary obstructive 
megaureter compared with the refluxing one. Kim et al. (Kim HG et al 2006) suggested that 
cell proliferation and apoptosis might play an important role in the pathogenesis of the 
obstructive megaureter. In fact, apoptosis of myocytes in the obstructive megaureter might 
affecr peristalsis. According to Kim et al. (Kim HG et al 2006) peak proliferation is noted 
during the early stage and apoptosis during the late stage of obstruction in animal models of 
obstructive ureter. We also hypothesized that the number of ICC-like cells, which are known 
to play an important role in peristalsis as a pacemaker of smooth muscle contraction, might 
be altered. As regards, it has been observed a normal distribution of ICCs in both the 
circular and longitudinal muscle layers of the dilated segments of patients affected by 
congenital primary megaureter, while a severe muscle hypoplasia and significant less of 
ICCs occurred in the longitudinal muscle layer of the restricted part of primary obstructive 
megaureter. Differently, a normal distribution of peripherin positive fibres was present in 
both the dilated and restricted ureteral segments (Arena F et al 2007).  
Because megaureter is also a congenital disease with abnormal peristalsis, it has been 
hypothesized that the alterations in the number or function of ICC cells might induce 
discoordination between the signals of the nervous system and smooth muscle, causing 
abnormal peristalsis and, eventually, resulting in the development of ureteral dilation.  
In contrast, a comparison between primary refluxing and obstructive magaureters showed 
that the number of c-kit-positive cells was clearly different between the obstructive and 
refluxing megaureters, with the latter having significantly fewer ICC-like cells than the 
former. Studies of mice with mutations leading to defects in the development of c-kit 
positive ICC populations have shown that without pacemakers, the coordination of smooth 
muscle contractions is lost.(Brading AF et al 2005). 
Torihashi et al (Torihashi S et al 1999) reported that when c-kit receptors were blocked 
during development, the ICCs almost entirely disappeared from the small intestine. 
However, this loss of ICCs was not accounted for using assays for cell death, and closer 
examination revealed that the remaining ICCs developed ultrastructural features similar to 
those of smooth muscle cells. According to Burns (Burns AJ 2007) an inherent plasticity 
between ICCs and smooth muscle cells is regulated by c-kit signaling. c-kit signaling might 
be necessary for the maintenance and further development of ICC-like cells before and after 
birth, accounting for the spontaneous improvement of such conditions with time in some 
cases. According to the study by Mei et al (Mei F et al 2009) the ICC number is reduced after 
intestinal ischemic injury but makes a dramatic recovery. However, ischemic injury can lead 
to apoptosis of the ICCs, smooth muscle cells, and enteric neurons. Therefore, the higher c-
kit expression in obstructive megaureters as compared to refluxing ureter might have been 
preceded by a reduction in ICC-like cells after ischemic injury, such as in the intestines, and 
the remaining increased apoptosis of smooth muscle cells might be the cause of the ureteral 
dysfunction. 
8. Conclusions 
ICC-LC are present in the UUT of a number of mammals and they have a crucial role in 
promoting pyeloureteric peristalsis. Studies showed that ICC-LC are responsible for 
initiating, coordinating and producing ureteropelvic peristaltic movements at the 
intercaliceal area, providing the passage of urine from the caliceal system through the ureter 
to the bladder. In conclusion, as well as in some gastrointestinal diseases (Hirschsprungs’s 
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disease, infantile hypertrophic pyloric stenosis, slow transmission constipation), a local 
decrease or a lack of c-kit immunoreactivity ICCs-LC may be involved in dysfunctional 
disease of urinary tract as primary vesicoureteral reflux, congenital ureteropelvic junction 
obstruction and primary obstructive megaureter. 
9. Abbreviations 
ACK:   c-kit antibodies 
GIS:   gastrointestinal system 
ICC:   interstitial cajal cells 
ICC-LC:  ICC-like cells  
P-CJ:   pelvi-calyceal junction  
RP:   renal pelvis  
RUs:   refluxing ureteric units 
SMC:   smooth muscle cell 
UPJ:   ureteropelvic junction 
UTT:  upper urinary tract 
VUR:   Primary vesico-ureteral reflux  
VUJ:   trigonal vesico-ureteral junction  
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Role of Pacing in Neurally Mediated Syncope 
Vikas Kuriachan and Robert Sheldon 
Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta,  
Canada 
1. Introduction 
Neurally mediated syncope syndromes involve autonomic reflexes causing bradycardia 
and/or hypotension resulting in a transient loss of consciousness(Brignole et al., 2004). 
These episodes can result in injuries and emotional stress. Recurrent vasovagal syncope can 
have a significant detrimental effect on the quality of life comparable to chronic disease 
patients with chronic back pain or rheumatoid arthritis(Linzer et al., 1991; Rose, Koshman, 
Spreng, & Sheldon, 2000). Hence management strategies have targeted vasodepression and 
bradycardia. Pacing has been a tempting solution that treats the cardioinhibitory response.  
2. Vasovagal syncope 
Vasovagal syncope is one of the common causes of syncope and a common reason for 
emergency room encounters(Savage, Corwin, McGee, Kannel, & Wolf, 1985). Vasovagal 
syncope is seen in younger patients and the reflex may have triggers such as sight of blood, 
venipuncture, or prolonged standing(Brignole et al., 2004). Some patients may have a 
prodrome of nausea and diaphoresis prior to loss of consciousness due to hypotension and/or 
bradycardia. Usually the syncopal episode last less than a minute but accompanying nausea, 
diaphoresis, and pallor can last longer. Many patients do not have a prodrome sufficiently 
long upon which to act, and therefore are unable to use preventive techniques such as 
counterpressure maneuvers or sitting/lying down to avoid or minimize a full episode. Unlike 
patients with cardiac or neurologic cause for syncope, patients with vasovagal syncope have 
no increased risk of cardiovascular morbidity or mortality (Soteriades et al., 2002). Hence in 
patients with vasovagal syncope preventing injury and maintaining a good quality of life are 
the primary goals for management(Kuriachan & Sheldon, 2008). 
3. Initial pacing studies for vasovagal syncope 
Bradycardia has long been recognized as a component of vasovagal syncope(Sharpey-Schafer, 
1956). In recent years, bradycardia was seen during tilt table test studies in patients with 
vasovagal syncope during the induced episodes(Mosqueda-Garcia et al., 1997). Bradycardic 
problems have also been detected by pacemaker and implantable loop recorders during clinic 
episodes of vasovagal syncope(Krahn, Klein, & Yee, 1997). This suggested that pacing could 
prevent vasovagal syncope by treating the bradycardia component. This was initially looked 
at in patients with tilt table induced syncope associated with bradycardia(Fitzpatrick, 
Theodorakis, Ahmed, Williams, & Sutton, 1991). These patients underwent repeat tilt table test 
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with temporary pacing. This prevented syncope in over half the patients although they still 
experienced vasovagal symptoms and presyncope. The results of this study should also be 
interpreted with caution since repeated tilt table testing can have a training effect and may 
reduce syncopal episodes(Reybrouck, Heidbuchel, Van De Werf, & Ector, 2002). Also the 
hemodynamic changes seen on tilt table induced syncopal episodes may not correlate with 
clinical episodes(Menozzi et al., 1993).  
Initial observational studies seemed to show benefit with pacing as a treatment for 
vasovagal syncope(Sheldon, Koshman, Wilson, Kieser, & Rose, 1998; Petersen et al., 1994; 
Benditt et al., 1997). These initial studies were mainly a sequential design, with no placebo 
group, and included highly symptomatic patients, who received a pacemaker. Open label 
studies then followed which also showed impressive results with pacing. The North 
American Vasovagal Pacemaker Study (VPS) randomized 54 vasovagal syncope patients to 
a pacemaker or optimal medical treatment(Connolly, Sheldon, Roberts, & Gent, 1999a). 
Impressive results, as shown in Figure 1, were seen with 19/27 in the medical treatment 
group and only 6/27 in the pacemaker arm having one or more recurrences of syncope. The 
Vasovagal Syncope International Study (VASIS) randomized 42 syncope patients with 
cardioinhibitory responses on tilt table testing to pacemaker or medical therapy(Sutton et 
al., 2000). Again, an impressive reduction in syncope was seen, with only 5% in the 
pacemaker group and 61% in the medical therapy having syncope recurrence. Another open 
label study, Syncope Diagnosis and Treatment Study (SYDAT), randomized 93 syncope 
patients to a pacemaker or atenolol(Ammirati, Colivicchi, & Santini, 2001). This also showed 
a significant reduction in syncope with pacing (4.3%) versus atenolol (26%). Hence initial 
observational and open-label studies suggest a significant reduction in syncope recurrence 
with pacing with up to 87% relative risk reduction(Sud et al., 2007a; Connolly, Sheldon, 
Roberts, & Gent, 1999b). Summaries of the observational and randomized open-label pacing 
studies in vasovagal syncope are shown in Table 1. 
 
 
Fig. 1. Kaplan-Meier plot of time to first recurrence in VPS I of the 27 patients with 
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VVS = vasovagal syncope, CSS = carotid sinus syncope, ppm = pacemaker 
Table 1. Summary of major open-label and observational studies for pacing in vasovagal 
syncope 
4. Pacemaker programming 
Various pacemaker settings have been tried in patients with vasovagal syncope. In general 
dual chamber (AV sequential) pacing is preferred, since both sinus and atrioventricular 
nodal function can be affected during a vasovagal episode. DDD pacing was compared to 
VVI and to sensing only (ODO) in 12 children with vasovagal syncope and found both 
modes of pacing to prevent syncope(McLeod, Wilson, Hewitt, Norrie, & Stephenson, 1999). 
All 12 were implanted with dual chamber pacemakers. Then programmed to ODO, VVI, 
and DDD with rate drop response for four month periods. Parents and patients were 
blinded to the pacemaker mode. Physician analyzing the results were blinded to patient and 
pacemaker mode. Even though both pacing modes prevented syncope, DDD was better 
than VVI for reducing presyncopal events.  
Rate-changing programming has also been examined including rate hysteresis, rate 
smoothing, and rate drop response. The goals of these programming strategies are to treat the 
bradycardia and also to compensate for the hypotensive/vasodepressive response. Rate 
hysteresis triggers pacing at a higher rate when the intrinsic heart rate falls below a preset rate. 
Rate smoothing prevents sudden changes in heart rate by pacing when there is an abrupt drop 
in intrinsic heart rate even in just 1-2 beats. (This is also used in patients with atrial fibrillation.) 
Rate drop response, the most sophisticated of the three, results in high rate pacing for a few 
minutes when a drop in native heart rate is detected. This hopes to achieve pacing support that 
can overcome bradycardia and hypotension. Rate response programming has been used in 
many syncope studies including VPS and VPS II. One study compared DDD with rate drop 
response to DDI with rate hysteresis in vasovagal syncope(Ammirati et al., 1998). This study 
randomized 20 vasovagal syncope patients with cardioinhibitory response during tilt testing 
to rate drop response or rate hysteresis. During the 17 month follow up, no patients with rate 
drop response had syncope but 3 of 8 in the rate hysteresis group had recurrence of syncope. 
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with temporary pacing. This prevented syncope in over half the patients although they still 
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Hence rate drop response was found to be more effective. Recent studies have also looked at 
closed loop stimulation (CLS). In closed loop stimulation variation of intracardiac impedance 
is tracked every beat, so that contractility changes can be detected in the early phase (prior to 
changes in heart rate) of a vasovagal episode and dual chamber pacing is activated(Occhetta, 
Bortnik, Audoglio, & Vassanelli, 2004a), as shown in Figure 2. This early initiation of pacing is 
believed to not only treat the bradycardic response that may follow but also overcome the 
transient hypotension. The INVASY trial randomized 55 patients with vasovagal syncope and 
positive tilt test to a CLS pacemaker or DDI and found CLS to be effective in preventing 
syncope over two-year follow-up period(Occhetta et al., 2004a). None of the patients had 
recurrences of syncope while in a CLS mode. However both groups had a reduction in syncope, 
likely due to a placebo effect. The recently completed, but not published, SCANSYNC study 
also used CLS pacing, described below. A preceding single blind cross-over study of 23 
patients used a microaccelerator-equipped ventricular pace/sense leads (Sorin Biomedica, 
Saluggia, Italy) with a sensor at the tip that measures peak endocardial acceleration that 
correlates with measurements of left ventricular contractility(Deharo et al., 2003). This study 
compared standard DDI pacing to a rate adaptive (DDDR) specialized pacing system with a 
microaccelerometer in the right ventricular lead to detect myocardial contractivity. Both 
modalities were found to decrease syncopal episodes; in addition, the contractility-driven 
DDDR might have an additive benefit to conventional DDI pacing (Deharo et al., 2003).  
 
 
Fig. 2. Autonomic nervous system (ANS) monitors cardiac output (CO) via the mean arterial 
blood pressure (MABP). Cardiac output is a product of heart rate (HR) and stroke volume 
(SV). Myocardial contraction dynamics are monitored and changes detected early on by the 
closed loop stimulation pacemaker. Which enables the CLS pacemaker to provide heart rate 
changes help improve cardiac output. Figure taken from 
http://www.biotronik.com/en/in/1088 (c) Biotronik. Reproduced with permission from 
BIOTRONIK 
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5. Randomized, double blind studies comparing active pacing to sensing 
only 
The great success of the initial studies raised the possibility a placebo effect with implant of 
a pacemaker for treatment of vasovagal syncope. Hence the first randomized, multicenter, 
double blinded study was designed and completed. VPS II, in which all 100 patients 
received pacemakers but were randomized to dual chamber pacing with rate drop sensing 
or sensing only(Connolly et al., 2003). After six months of follow up, there was no significant 
benefit with pacing and showed a 40% cumulative risk of syncope in the sensing group and 
31% in the pacing group. This was also confirmed in a smaller study that included 29 
patients with recurrent tilt-induced vasovagal syncope and one relapse after tilt testing 
(SYNPACE)(Raviele et al., 2004). In this study, patients all received a pacemaker and then 
were randomized to pacing or no pacing. Results of the first interim analysis and VPS II 
stopped this trial prematurely. They were unable to show a benefit with active pacing in 
preventing syncope. 
A recent meta-analysis examined the role of pacing in vasovagal syncope(Sud et al., 2007b). 
Nine randomized trials were looked at in the meta-analysis, which included open label, 
single blind, and double blind trials. Interestingly, in contrast to open label trials, blinded 
trials for pacing in vasovagal syncope do not show a benefit, even in patients with marked 
cardioinhibitory response on tilt table testing(Sud et al., 2007a). Therefore, a cardioinhibitory 
response on tilt table testing probably is neither an appropriate surrogate marker for pacing 
studies, nor can it be used to predict patients who might respond to pacing.. The authors of 
the meta-analysis described that the benefits seen in open label, unblinded trials as being 
due to an expectation effect, by both patients and physicians. The authors of this meta-
analysis synthesized a unique comparison between “inactive” pacing and no treatment and 










Study Arms Results 
VPS II (2003) 100 Double blind randomized No 
Rate drop pacing vs 
ODO 
Pacing did not 





randomized Yes DDD rate drop vs ODO 
Pacing did not 
reduce risk of 
syncope 





No Contractility driven DDDR vs DDI 
Both reduced 
syncope. Contractility 
driven may be better 
than DDI 




Yes DDD-CLS compared to DDI 
Both reduced 
syncope. CLS pacing 
seems to be better 
than DDI. 
Mcleod et al. 
(1999) 12 
Double blind 
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Fig. 3. Odds ratios comparing active cardiac pacing versus no therapy, “inactive” pacing 
versus active pacing, and a synthesized “inactive” versus no therapy. Line at OR 1.0 
indicates no difference between the two groups. Estimates to the left of 1 represent 
treatment is better and estimates to the right represent control is better. Hence the bottom 
comparison represents the “expectation” effect. Figure from Sud et al 2007.  
6. Placebo effect in pacing for vasovagal syncope 
The placebo effect can be powerful and may be due to expectation effects of patients and 
health care providers, conditioning effects in patients, along with biases in patient assessment 
and reporting(Olshansky, 2007). Patients who receive pacemakers, due to the expense and 
invasive nature of the treatment, may be more willing to consider it as being a beneficial 
treatment for their problems. Healthcare workers who are involved in the care of these 
patients may not be conscious of biases they are exhibiting in assessment and reporting, and 
may also apparently observe a benefit from an ineffective intervention. Conversely those 
patients who did not receive pacemakers in studies may be disappointed and more inclined to 
report symptoms. Similar situations have also been encountered in the past with hypertrophic 
cardiomyopathy, where pacing was initially thought to improve functional status in open label 
studies(Nishimura et al., 1997). Similarly, atrial pacing was first reported to reduce atrial 
fibrillation, stroke, and death in patients with pacemakers(Gillis et al., 1999; Connolly et al., 
2000). However, randomized, controlled studies did not show the benefits that were seen in 
the open label studies in any of these situations(Gillis et al., 1999; Connolly et al., 2000; 
Nishimura et al., 1997). Hence interpretation of studies in pacing that are not randomized, 
double blind, placebo-controlled should be done with caution since there may be important 
placebo effects. The vasodepressor and cardioinhibitory components may vary in each patient 
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with different episodes and 50% to 83% of syncopal episodes may not have a cardioinhibitory 
component(Sheldon & Connolly, 2003). This may also explain why pacing does not seem to be 
of benefit in vasovagal syncope. Pacing alone may not be enough to overcome vasodepression.  
7. Ongoing studies 
Although the two blinded randomized trials are small (VPS II and SYNPACE), it seems 
pacing may not benefit most patients with vasovagal syncope. The ISSUE 2 study reported 
392 patients with recurrent syncope and an implantable loop recorder (ILR)(Brignole et al., 
2006). Specific treatment was then given to 53 patients based on the monitoring findings, of 
whom 47 received a pacemaker for asystole and 6 received anti-tachycardia treatments. A 
marked decrease in syncopal episodes was noted in the group that received specific 
treatment. In the 53 patients receiving specific treatment, the 1-year syncope recurrence rate 
was 10% compared to 41% in the patients without specific treatment. However the study is 
limited by lack of blinding and having only a minority of patients receiving specific 
treatment. To overcome the limitation of ISSUE 2, the ISSUE 3 study was designed 
(Brignole, 2007). Patients found to have asystolic pauses associated with syncope on ILR 
monitoring were randomized to pacemaker On or Off. This is a multicenter, randomized, 
placebo-controlled, prospective study of patients with a documented pause during syncope 
on an implantable loop recorder and then randomized to a pacemaker with pacing or only 
sensing. ISSUE 3 has finished recruitment and is now in the follow-up phase. The results of 
this study will help to clarify whether pacing may be of benefit in vasovagal syncope 
patients with prolonged asystolic pauses. As mentioned previously, initial studies also 
suggest that using a closed loop pacing (CLS) that detects contractility may be able to detect 
a neurocardiogenic episode early and provide pacing support better than a rate drop 
system(Kanjwal, Karabin, Kanjwal, & Grubb, 2010; Occhetta, Bortnik, & Vassanelli, 2003; 
Occhetta, Bortnik, Audoglio, & Vassanelli, 2004b). A randomized, prospective, double blind, 
cross over study (SCANSYNC) compared active (CLS pacing) to passive (VVI 30) pacing in 
patients with recurrent vasovagal syncope has been completed and is awaiting publication. 
8. Other treatment options in vasovagal syncope 
Other treatments for vasovagal syncope have also had similar findings with open label and 
observational studies showing benefit but double blind, randomized studies showing minimal 
benefit or no difference from placebo(Kuriachan, Sheldon, & Platonov, 2008). In patients with 
an identifiable prodrome there may be some benefit to using physical counterpressure 
maneuvers (PCM) which are safe and cost free(van et al., 2006). The maneuvers used are 
usually leg crossing with tensing of abdominal, buttock, and lower extremity muscles and/or 
gripping hands while abducting both arms. These maneuvers should be tried as first line 
treatments in patients with vasovagal syncope and an identifiable prodrome. Ensuring 
adequate volume repletion is important with salt and fluid intake. Various medications have 
also been studied, including beta-blockers, selective serotonin re-uptake inhibitors (SSRI), 
Fludrocortisone, and Midodrine. In general, no clear benefit has thus far been seen from 
studies with beta-blockers, SSRIs, and fludrocortisone(Kuriachan & Sheldon, 2008). The POST 
II study is comparing fludrocortisone to placebo in a randomized, double blind fashion and is 
in the follow-up phase (Raj, Rose, Ritchie, & Sheldon, 2006). Midodrine, a peripherally acting 
alpha-agonist, does seem to have some benefit in adults and children. Frequent dosing and 
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some side effects, such as supine hypertension, may limits its use(Kuriachan et al., 2008). POST 
IV will be a double blind, randomized, placebo controlled study comparing midodrine to 
placebo in patients with vasovagal syncope. 
The initial management approach to a patient with vasovagal syncope should include 
education about the condition, reassurance, and dietary intake (particularly salt and fluid). 
PCM should be taught to patients with a prodrome. If they still have frequent recurrent 
symptoms then medications attempts should be made. Pacing should be reserved as a last 
resort and ideally in patients documented with asystole during their syncopal episodes. A 
frank and open discussion should be held with the patient about the limited benefit that has 
been seen in studies for medications and pacing. Refer to Figure 4 for management 
approach for vasovagal syncope. 
 
 
Fig. 4. Pyramid scheme of treatment for vasovagal syncope. All patients should receive the 
basic interventions as appropriate. Currently limited evidence for medications and pacing, 
hence use should be limited in very select patients who have significant, recurrent episodes 
after the basic interventions. 
9. Carotid sinus hypersensitivity 
Carotid sinus hypersensitivity and association with syncope have been known for many 
years. Carotid sinus hypersensitivity (CSH) is defined as a fall in systolic BP > 50mmHg 
and/or asystolic pause > 3 seconds with carotid sinus massage. Carotid sinus syndrome is 
when CSH is associated with spontaneous syncope that can be reproduced with carotid 
sinus massage(CSM). Carotid sinus syncope tends to happen in elderly men and the 
prevalence increases with cardiovascular, cerebrovascular, and neurodegenerative 
disease(Claesson, Kristensson, Edvardsson, & Wahrborg, 2007). A fall from syncope can 
result in significant injuries given the older age of this patient population. Although there is 
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limited evidence, carotid sinus syncope has been believed to occur in the context head 
turning movements that may cause pressure on the carotid, such as shoulder checking in a 
car with shoulder seat belt putting pressure or wearing a tight collar. 
It is important to differentiate carotid sinus hypersensitivity from carotid sinus syndrome. A 
positive carotid sinus massage was noted in 32% of patients having an angiogram who had 
no history of carotid sinus syncope(Brown, Maloney, Smith, Haritzler, & Ilstrup, 1980). 
Asymptomatic carotid sinus hypersensitivity may be common in the elderly. Carotid sinus 
reflex helps with hemodynamic regulation. The vagal efferent signals increases cardiac 
vagal input resulting in lowering heart rate and peripheral vasodilation lowering blood 
pressure(LOWN & LEVINE, 1961). Hence an abnormal reflex can cause significant changes 
in blood pressure and heart rate which decreases brain perfusion and results in syncope. 
10. Carotid sinus massage 
Various protocols have been used for carotid sinus massage (Brignole et al., 2001). In one 
method, the carotid artery is firmly massaged at the anterior margin of the 
sternocleidmastoid at the cricoids cartilage level for up to 5 seconds, while the patient is in a 
supine position. If the first side does not yield a positive result then CSM is performed on 
the other side. Asystolic pause > 3 seconds (sinus pause or at times due to AV block), fall in 
BP > 50mmHg, and development of symptoms are necessary for a truly positive test. 
Abnormal responses can also be seen in patients with a history of spontaneous syncope. 
Some protocols use longer duration of massage to reproduce spontaneous symptoms, as 
well as both supine and upright positions (ensure patient safety in upright position). Heart 
rate changes can be readily seen on cardiac monitoring but a blood pressure drop is difficult 
to document without invasive monitoring (not usually practical) or noninvasive continuous 
digital plethysmography. CSM is contraindicated in patients with carotid bruits or history of 
prior stroke/TIA, due to concerns that the CSM may result in carotid plaque disruption and 
embolization resulting in a cerebrovascular event. Studies have looked at the safety of CSM, 
totaling over 5000 patients and found complication rates in the 0.1 – 0.2% range, of which 
most were transient neurological symptoms and full recovery was made except in two 
patients(Munro et al., 1994; Davies & Kenny, 1998).  
11. Pacing studies in carotid sinus syncope 
One of the first studies in carotid sinus syncope reported 70 patients with CSH and syncope, 
and found pacing to be very effective(Morley et al., 1982a). Subsequently a second study 
assessed 56 consecutive patients with CSH and syncope who had received no treatment (13 
patients), anticholinergic medications (20), and pacemaker implant (23). In this study, 
pacing was effective in preventing syncope but a high rate of spontaneous remission was 
also observed(Sugrue et al., 1986). Another study with 21 patients, in which 13 received 
pacemakers, found only minimal benefit with pacing(Huang, Ezri, Hauser, & Denes, 1988). 
However, none of the patients with pacemakers had recurrences of syncope and only one 
patient had recurrence in the no pacemaker group of eight patients, demonstrating a very 
low recurrence rate even without receiving treatment. Other observational studies also 
found benefits from pacing and are listed in Table 3(Brignole et al., 1991; Brignole, Menozzi, 
Lolli, Sartore, & Barra, 1988).Hence some benefit was observed with pacing in CSH and 
syncope in the initial studies, but there were high rates of spontaneous remission.  
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Since many elderly patients who have syncope may not remember the details of the event and 
prodrome, they may present with a non-accidental fall. Hence it was thought that in many 
elderly patients, carotid sinus syncope might be responsible for non-accidental falls. This was 
first examined in the SAFE-PACE trial(Kenny et al., 2001). This open-label study included 175 
consecutive patients over the age of 50 with non-accidental falls attending an accident and 
emergency facility. Those with carotid sinus hypersensitivity were randomized to rate drop 
dual chamber pacemaker or standard treatment. Paced patients were significantly less likely to 
fall (odds ratio 0.42) and reduced injurious event by 70%. SAFE-PACE 2 was a double blind, 
randomized study done to assess this(Daniel, Steen, Seifer, & Kenny, 2010). 141 patients with 
unexplained falls and cardioinhibitory carotid sinus hypersensitivity were randomized to a 
rate responsive pacemaker or implantable loop recorder. No significant reduction was seen in 
the pacemaker group, but this small sample size led to an underpowered study. Again, due to 
concerns of the open-label nature of the initial SAFE-PACE, a randomized study was 
conducted in which 25 patients received pacemakers but was randomized to pacemaker On 
(DDD) or Off (ODO)(Parry, Steen, Bexton, Tynan, & Kenny, 2009). This was a double blind 
study with a cross over design. There was a mean of 3.48 falls in the ODO mode and 4.04 in 
the DDD mode. Survival analysis showed no significant differences in time to first fall between 
the two groups (Figure 5). Hence no benefit was seen with pacing in this group for fall 
reduction. Further supporting the placebo effect in this study was the fall reduction that was 
seen in both groups, pacemaker On or Off, in the first six months after implant. However, this 
study was underpowered and should be interpreted with caution. Hence the initial impressive 
benefits seen in SAFE-PACE may be due to a placebo effect similar to the open-label vasovagal 
pacing studies.  
 
 
Fig. 5. Survival analysis (treating each group as independent samples) showed no significant 
differences in time to first fall between DDD and ODO modes. P=0.57. Figure from Parry et 
al. 2009. 
 
Role of Pacing in Neurally Mediated Syncope 
 
189 
Study (year) Number of Patients Methodology Study Arms Results 
Sugrue et al. (1986) 56 Observational 
13 no treatment  23 
pacemaker   20 
anticholinergics 
Pacing was effective 
but high rate of 
spontaneous 
remission 
Morley et al. (1982) 70 Observational 
54 patients VVI  13 
patients DVI  18 
patients DDD    
89% asymptomatic 
with pacing 
Huang et al. (1988 ) 21 Observational 13 with pacemaker 8 with no implant 
Pacing found to be 
beneficial. However 
only one patient had 
recurrence (in no 
pacer group) 
Brignole et al. (1991) 60 Observational Crossover 
26 with DDD   34 
with VVI 
DDD found to have 
less symptoms 
overall 
Brignole et al.(1988) 35 Observational 
19 no implant    11 




SAFEPACE 1 (2001) 175 Open label 87 with pacemaker 88 no implant 
Pacing reduced falls 
and minimal 
reduction of syncope 
SAFEPACE 2 (2010) 141 Double blind 71 with pacemaker 70 with loop recorder 
No significant 
reduction in falls 
seen 
Parry et al. (2009) 25 Double blind Crossover 
25 DDD and 
crossover to ODO 
Pacing had no effect 
of falls 
Table 3. Pacing studies in context of Carotid Sinus Hypersensitivity, Syncope, and Falls. 
Although only a few small studies have shown benefit, pacing has generally been felt to be 
beneficial in this condition, especially in elderly patients with a predominantly 
cardioinhibitory response to CSM and present with symptoms suggestive of carotid sinus 
syncope(Brignole, Menozzi, Lolli, Bottoni, & Gaggioli, 1992; Morley et al., 1982b; Claesson et 
al., 2007; Moya et al., 2009). Management should also include volume repletion and 
recommendations on avoiding situations that may cause syncope, such as tight collars and 
ties. Volume expanders and vasopressors may also be helpful but usually are limited due to 
problems with heart failure and hypertension that is common in the elderly population. 
12. Conclusion 
Initial steps in the management of vasovagal syncope should include education about the 
diagnosis and reassurance. Patients should be instructed on liberal intake of salt and fluid. 
Counterpressure maneuvers should be taught to patients with a prodrome. If they still have 
frequent recurrent symptoms, then medications attempts should be made. Pacing should be 
reserved as a last resort and ideally in patients documented with asystole during their 
syncopal episodes. For patients with carotid sinus syncope, pacing should be considered. 
Additional management should also include volume repletion and recommendations on 
avoiding situations that may cause syncope. 
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Outstanding steps forward were made in the last decades in terms of identification of 
endogenous pacemakers and the exploration of their controllability. New “artifical” 
devices were developed and are now able to do much more than solely pacemaking of 
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various organ systems were examined. In addition, various areas of application and the 
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